,Generic Name,Orphan Designation,Designation Date,Designation Status,drug_qid,inchi,indication,doid,hpo,ordo,mesh,indication_qid_doid,indication_qid_ordo,indication_qid_mesh
0,"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid",Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy,03/31/2003,Designated/Withdrawn,Q27088744,ZVVCSBSDFGYRCB-UHFFFAOYSA-N,serious adverse events associated with vascular leak syndrome caused by interleukin-2 therapy,,,,,,,
1,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",Treatment of Stage IIB through Stage IV malignant melanoma,02/01/2008,Designated/Withdrawn,,,stage iib through stage iv malignant melanoma,,,,,,,
2,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",Treatment of cholangiocarcinoma,01/10/2008,Designated/Withdrawn,,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
3,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",Treatment of pancreatic cancer,01/10/2008,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
4,"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester",Treatment of Fragile X syndrome,10/12/2011,Designated,Q6589598,ZFPZEYHRWGMJCV-ZHALLVOQSA-N,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
5,"(1,3)-ÃŸ-D-glucan synthesis inhibitor",Treatment of invasive Aspergillus infections,08/22/2016,Designated,,,invasive aspergillus infections,,,,,,,
6,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate",Treatment of pancreatic cancer,06/05/2013,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
7,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate",Treatment of soft tissue sarcoma,03/09/2012,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
8,"(1OR)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile",Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer,06/23/2015,Designated,,,anaplastic lymphoma kinase (alk)-positive or ros1-positive non-small cell lung cancer,,,,,,,
9,"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-",Treatment of vaso-occlusive crisis in patients with sickle cell disease.,02/17/2009,Designated,,,vaso-occlusive crisis in patients with sickle cell disease,,,,,,,
10,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",Treatment of T-cell non-Hodgkin's lymphoma,01/29/2004,Designated,,,t-cell non-hodgkin's lymphoma,,,,,,,
11,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",Treatment of acute lymphoblastic leukemia,08/13/2004,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
12,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride","Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia",08/10/2004,Designated,,,"chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult t-cell leukemia, and hairy cell leukemia",,,,,,,
13,"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate",Treatment of acute myeloid leukemia,01/19/2010,Designated/Withdrawn,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
14,"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride",Treatment of infantile spasms,09/15/2010,Designated,,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
15,"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane",Treatment of progressive supranuclear palsy,06/23/2014,Designated,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
16,"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride",Treatment of Rett Syndrome.,05/18/2016,Designated,Q27252594,FEQOLYDPQKHFTD-UHFFFAOYSA-N,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
17,(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide),Treatment of multiple myeloma,11/29/2016,Designated,Q27258687,VLIUIBXPEDFJRF-UHFFFAOYSA-N,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
18,"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)",Treatment of systemic sclerosis.,10/14/2015,Designated,Q27258840,RGYQPQARIQKJKH-UHFFFAOYSA-N,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
19,"(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate",Treatment of retinitis pigmentosa,12/02/2010,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
20,"(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)",Treatment of Leber congential amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.,12/02/2010,Designated,,,leber congential amaurosis (lca) due to inherited mutations in rpe65 (encoding the protein retinal pigment epithelial protein 65) or lrat (encoding the enzyme lecithin:retinol acyltransferase)genes,,,,,,,
21,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",Treatment of primary biliary cirrhosis,10/31/2012,Designated,,XULSCZPZVQIMFM-IPZQJPLYSA-N,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
22,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",Treatment of progressive familial intrahepatic cholestatis,10/31/2012,Designated,,XULSCZPZVQIMFM-IPZQJPLYSA-N,progressive familial intrahepatic cholestatis,,,,,,,
23,(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide,"Prevention of acute rejection following kidney, heart, and liver transplantation",01/10/2005,Designated,,,"acute rejection following kidney, heart, and liver transplantation",,,,,,,
24,"(3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide mono(4-methylbenzenesulfonate) monohydrate",Treatment of liposarcoma,02/13/2017,Designated,,WPJOGWGXMTUHPW-CIPNXXNHSA-N,liposarcoma,http://purl.obolibrary.org/obo/DOID_3382,http://purl.obolibrary.org/obo/HP_0012034,http://www.orpha.net/ORDO/Orphanet_69078,D008080,Q1827425,,Q18556954
25,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",Treatment of chronic myelogenous leukemia.,03/18/2011,Designated,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
26,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",Treatment of pancreatic cancer,03/18/2011,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
27,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019",Treatment of Glioma,03/18/2011,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
28,"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne",Treatment of multiple myeloma,04/30/2014,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
29,"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",Treatment of Fragile X Syndrome.,12/09/2015,Designated,,HWSLMIXAPNOWGU-AWEZNQCLSA-N,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
30,"(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate",Treatment of Gaucher disease,09/11/2014,Designated,Q27274745,YFHRCLAKZBDRHN-MRXNPFEDSA-N,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
31,"(3S)-1-azabicylo[2.2.2]oct-3yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate",Treatment of Fabry's disease,08/26/2014,Designated,,,fabry's disease,http://purl.obolibrary.org/obo/DOID_14499,,,D000795,Q615645,,Q615645
32,"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine",Treatment of tuberculosis,07/05/2007,Designated,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
33,"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid",Treatment of patients undergoing solid organ transplantation.,08/19/2003,Designated,,,patients undergoing solid organ transplantation,,,,,,,
35,"(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate",Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA,09/18/2015,Designated,,WQDBPGWQDBPVQZ-NBCXFSEXSA-N,pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (jia) ilar categories excluding systemic jia,,,,,,,
36,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",Treatment of alagille syndrome,09/04/2013,Designated,,,alagille syndrome,http://purl.obolibrary.org/obo/DOID_9245,,http://www.orpha.net/ORDO/Orphanet_52,D016738,Q1544408,,Q1544408
37,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",Treatment of primary sclerosing cholangitis,09/04/2013,Designated,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
38,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",Treatment of primary biliary cirrhosis,09/04/2013,Designated,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
39,"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime",Treatment malignant glioma,11/29/2002,Designated/Withdrawn,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
40,"(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride",Treatment of erythromelalgia,01/30/2017,Designated,Q27268497,HEPUBAGOKRIZEO-PPPUBMIESA-N,erythromelalgia,http://purl.obolibrary.org/obo/DOID_9240,,http://www.orpha.net/ORDO/Orphanet_1956,D004916,Q524353,,Q524353
41,"(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride",Treatment of trigeminal neuralgia,07/24/2013,Designated,,,trigeminal neuralgia,http://purl.obolibrary.org/obo/DOID_12098,http://purl.obolibrary.org/obo/HP_0100661,http://www.orpha.net/ORDO/Orphanet_221091,D014277,Q1132120,,Q1132120
42,"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide",Treatment of ovarian cancer,04/14/2016,Designated,,XNLCCACCEOWFNQ-OSPRVTPDSA-N,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
43,(6-maleimidocaproyl)hydrazone of doxorubicin,Treatment of soft tissue sarcoma,06/29/2011,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
45,"(6aR, 10aR)-3-(1â€™,1â€™-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",Treatment of cystic fibrosis.,10/13/2015,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
46,"(6aR, 10aR)-3-(1Ã¢Â¿Â¿,1Ã¢Â¿Â¿-dimethylheptyl)-ÃŽÂ¿8-tetrahydro-cannabinol-9-carboxylic acid",Treatment of systemic sclerosis,06/10/2015,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
48,"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid",Prevention of post-operative complications of aortic anuerysm surgical repair,12/08/2004,Designated,,,post-operative complications of aortic anuerysm surgical repair,,,,,,,
49,(E)-Nâ€™-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate,Treatment of Ewing's sarcoma.,01/12/2017,Designated,,JIPBQMGGMHCGBW-CWUUNJJBSA-N,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
50,"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)",Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients,04/21/2016,Designated,,,pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients,,,,,,,
51,(monomethoxypolyethylene glycol) recombinant adenosine deaminase,Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency,03/19/2015,Designated,,,adenosine deaminase deficiency in patients with severe combined immunodeficiency,,,,,,,
52,"(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt",Treatment of adrenocortical carcinoma,03/09/2012,Designated,,,adrenocortical carcinoma,http://purl.obolibrary.org/obo/DOID_3948,http://purl.obolibrary.org/obo/HP_0006744,http://www.orpha.net/ORDO/Orphanet_1501,D018268,Q918285,,Q918285
53,"(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide",Treatment of cystic fibrosis,04/24/2014,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
54,(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt,Treatment of idiopathic pulmonary fibrosis,04/15/2011,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
55,"(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea",Treatment of gastric neuroendocrine tumors (gastric NETs).,05/12/2016,Designated,,GPEYTRIZYSZRRK-MHZLTWQESA-N,gastric neuroendocrine tumors (gastric nets),,,,,,,
56,"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate",Treatment of cystic fibrosis,01/25/2017,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
57,"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",Treatment of pulmonary tuberculosis.,07/12/2007,Designated,Q15408413,XDAOLTSRNUSPPH-XMMPIXPASA-N,pulmonary tuberculosis,http://purl.obolibrary.org/obo/DOID_2957,,,D014397,Q18555243,,Q18555243
58,"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",Treatment of multiple myeloma,05/05/2008,Designated/Withdrawn,Q27292463,WDVGRPCSLPVWKC-VROLVAQFSA-N,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
59,"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",Treatment of small cell lung cancer.,12/19/2007,Designated,Q27292463,WDVGRPCSLPVWKC-VROLVAQFSA-N,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
60,"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",Treatment of chronic lymphocytic leukemia,12/19/2007,Designated/Withdrawn,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
61,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",Treatment of cholangiocarcinoma.,11/19/2015,Designated,,OLDWOVJAXRWCGT-FBHGDYMESA-N,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
62,(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide,Treatment of circadian rhythm sleep disorders in blind people with no light perception,10/03/2001,Designated,Q6460405,RKHCTAKUYDTFHE-QMMMGPOBSA-N,circadian rhythm sleep disorders in blind people with no light perception,,,,,,,
63,(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide,Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients,07/03/2003,Designated,,RGIOSHFEERMCPG-VIFPVBQESA-N,neuroleptic-induced tardive dyskinesia in schizophrenia patients,,,,,,,
64,"(RS)-baclofen, naltrexone and D-sorbitol",Treatment of Charcot-Marie-Tooth disease type 1A,03/17/2014,Designated,,,charcot-marie-tooth disease type 1a,http://purl.obolibrary.org/obo/DOID_0110148,,http://www.orpha.net/ORDO/Orphanet_101081,,Q27677640,,
65,"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",Treatment of acute myeloid leukemia,11/05/2014,Designated,Q27236818,KXMZDGSRSGHMMK-VWLOTQADSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
66,"(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2"",4"",5"",7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride",Treatment of hepatocellular carcinoma,10/06/2010,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
67,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",Treatment of pemphigus vulgaris,01/26/2015,Designated,,QUMWKKVIZAIAHU-LBPRGKRZSA-N,pemphigus vulgaris,,,http://www.orpha.net/ORDO/Orphanet_704,D010392,,,Q1483214
68,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",Treatment of epidermolysis bullosa acquisita,01/05/2017,Designated,,QUMWKKVIZAIAHU-LBPRGKRZSA-N,epidermolysis bullosa acquisita,http://purl.obolibrary.org/obo/DOID_4313,,http://www.orpha.net/ORDO/Orphanet_46487,D016107,Q3726860,Q3726860,Q3726860
69,"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium",Treatment of pulmonary arterial hypertension,11/17/2014,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
70,(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one,Treatment of follicular lymphoma,08/01/2013,Designated,Q27077129,SJVQHLPISAIATJ-ZDUSSCGKSA-N,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
71,"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid",Treatment of chronic iron overload in patients with transfusion-dependent anemias,02/04/2009,Designated,,,chronic iron overload in patients with transfusion-dependent anemias,,,,,,,
72,(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride,Treatment of Stage IIb through Stage IV BRAF mutant melanoma,06/24/2013,Designated,,DKGYQCPFBWFTHM-FSRHSHDFSA-N,stage iib through stage iv braf mutant melanoma,,,,,,,
73,"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide",Treatment of Waldenstrom macroglobulinemia.,10/22/2015,Designated,Q23668732,WDENQIQQYWYTPO-IBGZPJMESA-N,waldenstrom macroglobulinemia,,http://purl.obolibrary.org/obo/HP_0005508,,D008258,,,Q4118092
74,"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide",Treatment of mantle cell lymphoma.,09/21/2015,Designated,Q23668732,WDENQIQQYWYTPO-IBGZPJMESA-N,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
75,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",Treatment of inherited mitochondrial respiratory chain diseases,11/17/2014,Designated,Q27896091,HVFWCHDZDIRYBZ-MQZJHDQISA-N,inherited mitochondrial respiratory chain diseases,,,,,,,
76,"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",Treatment of Hodgkin lymphoma,04/29/2015,Designated,Q27254856,RSIWALKZYXPAGW-NSHDSACASA-N,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
77,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydroprazolo[1,5-a]pyrimidine-3-carboxamide",Treatment of mantle cell lymphoma.,06/23/2016,Designated,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
78,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",Treatment of Waldenstrom's macroglobulinemia,06/29/2016,Designated,,RNOAOAWBMHREKO-QFIPXVFZSA-N,waldenstrom's macroglobulinemia,,,,D008258,,,Q4118092
79,"(S)-7-(1acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",Treatment of chronic lymphocytic leukemia.,07/20/2016,Designated,,RNOAOAWBMHREKO-QFIPXVFZSA-N,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
80,"(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester",Treatment of pulmonary arterial hypertension (PAH).,10/06/2015,Designated,,TZSZZENYCISATO-WIOPSUGQSA-N,pulmonary arterial hypertension (pah),,,,,,,
81,"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate",Treatment of soft tissue sarcoma.,08/31/2015,Designated,,PXHANKVTFWSDSG-QLOBERJESA-N,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
82,(S)-perillyl alcohol temozolomide,Treatment of glioma,11/12/2014,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
83,(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor),Treatment of acute sensorineural hearing loss,03/28/2006,Designated,,,acute sensorineural hearing loss,,,,,,,
84,"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide",Treatment of diffuse large B-cell lymphoma,05/14/2014,Designated,,FDGUOHZQGBFFTA-RJRFIUFISA-N,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
85,1 8-(p[131I]-iodophenyl)octadecyl phosphocholine,Treatment of multiple myeloma,12/03/2014,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
86,"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one",Treatment of erythromelalgia,11/19/2012,Designated,,NEBUOXBYNAHKFV-UHFFFAOYSA-N,erythromelalgia,http://purl.obolibrary.org/obo/DOID_9240,,http://www.orpha.net/ORDO/Orphanet_1956,D004916,Q524353,,Q524353
87,"1,2:5,6-Dianhdrogalactitol, NSC-132313",Treatment of malignant gliomas,01/31/2012,Designated,,,malignant gliomas,,,,D005910,,,Q18556612
88,"1,2:5,6-dianhydrogalactitol",Treatment of medulloblastoma.,03/10/2016,Designated,,,medulloblastoma,http://purl.obolibrary.org/obo/DOID_0050902,http://purl.obolibrary.org/obo/HP_0002885,http://www.orpha.net/ORDO/Orphanet_616,D008527,Q1333608,,Q18556102
89,"1,2:5,6-dianhydrogalactitol",Treatment of ovarian cancer.,04/19/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
90,"1,5-(Butylimino)-1,5 dideoxy,D-glucitol",Treatment of Fabry's disease.,05/12/1998,Designated,,,fabry's disease,http://purl.obolibrary.org/obo/DOID_14499,,,D000795,Q615645,,Q615645
91,"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate",Treatment of hormone refractory prostate carcinoma.,01/18/2000,Designated/Withdrawn,Q27265739,RCBJUJRVBGYTEO-UHFFFAOYSA-N,hormone refractory prostate carcinoma,,,,,,,
92,"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one",Treatment of frontotemporal dementia.,04/06/2016,Designated,,XWMHYQATSBWUNT-UHFFFAOYSA-N,frontotemporal dementia,http://purl.obolibrary.org/obo/DOID_9255,http://purl.obolibrary.org/obo/HP_0002145,http://www.orpha.net/ORDO/Orphanet_282,D057180,Q18592,Q18592,
93,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,Treatment of acute myelogenous leukemia,06/24/2010,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
94,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,Treatment of myelodysplastic syndrome,06/24/2010,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
95,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,Treatment of status epilepticus,07/07/2016,Designated,,TZOWVYPYWJLZTK-IMTBSYHQSA-N,status epilepticus,http://purl.obolibrary.org/obo/DOID_1824,http://purl.obolibrary.org/obo/HP_0002133,,D013226,Q980709,,Q980709
98,"1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]carbamoyl}- 2-pyridyl) piperidine-4-caboxylic acid Monomaleate",Treatment of idiopathic thrombocytopenic purpura,09/01/2011,Designated,,,idiopathic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_8924,http://purl.obolibrary.org/obo/HP_0001973,,D016553,Q638729,,Q638729
99,"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide",Treatment of multiple myeloma,07/08/2015,Designated,,RDALZZCKQFLGJP-UHFFFAOYSA-N,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
101,"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)",Treatment of acute myelogenous leukemia,07/28/2011,Designated/Withdrawn,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
102,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,Treatment of systemic sclerosis,03/31/2015,Designated,Q27896056,OQDQIFQRNZIEEJ-UHFFFAOYSA-N,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
103,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,Treatment of acute myeloid leukemia,11/12/2009,Designated,Q27453557,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
104,"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene",Treatment of poliovirus infection.,01/09/2012,Designated,Q27259647,XXMDDBVNWRWNCW-UHFFFAOYSA-N,poliovirus infection,,,,,,,
105,10 synthetic peptides targeting 5 tumor asociated antigens,Treatment of non-small cell lung cancer in patients expressing HLA-A2,01/23/2013,Designated,,,non-small cell lung cancer in patients expressing hla-a2,,,,,,,
106,111Indium pentetreotide,Treatment of somatostatin receptor positive neuroendocrine tumors.,06/10/1999,Designated,,,somatostatin receptor positive neuroendocrine tumors,,,,,,,
107,12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21),Treatment of pancreatic cancer,06/07/2011,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
108,131-I-8H9 monoclonal antibody,Treatment of neuroblastoma,08/29/2016,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
109,131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I,Treatment of Acute Myeloid Leukemia (AML),03/28/2016,Designated,,,acute myeloid leukemia (aml),,,,,,,
110,14-amino acid peptide derived from wound growth factor,Prevention of delayed graft function in renal transplant recipients,08/05/2010,Designated/Withdrawn,,,delayed graft function in renal transplant recipients,,,,,,,
111,14-amino acid peptide derived from wound growth factor,Treatment of delayed graft function in renal transplant recipients,08/16/2010,Designated/Withdrawn,,,delayed graft function in renal transplant recipients,,,,,,,
112,17 amino acid peptide,Prevention of ischemia reperfusion injury in the lung during lung tranplantation,01/29/2010,Designated,,,ischemia reperfusion injury in the lung during lung tranplantation,,,,,,,
113,17-a-hydroxyprogesterone caporate (oral formulation),Prevention of preterm birth in women with a singleton pregnancy,06/01/2015,Designated,,,preterm birth in women with a singleton pregnancy,,,,,,,
114,17-allylamino-17-demethoxygeldanamycin (17-AGG),Treatment of chronic myelogenous leukemia,09/03/2004,Designated,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
115,177-LU-DOTA-GlyGlyNle-CycMSHhex,Treatment of Stage IIB through IV malignant melanoma,04/16/2015,Designated,,,stage iib through iv malignant melanoma,,,,,,,
116,177Lu-tetraxetan-tetulomab,Treatment of Follicular Lymphoma,05/14/2014,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
119,"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",Treatment of spinal and bulbar muscular atrophy,02/17/2016,Designated,,,spinal and bulbar muscular atrophy,,,,D020966,,,Q18558067
120,2 dimethylbutyrate,Treatment of beta thalassemia,06/18/2008,Designated,,,beta thalassemia,http://purl.obolibrary.org/obo/DOID_12241,,,D017086,Q3616632,,Q3616632
121,"2',3',5'-tri-o-acetyluridine",Treatment of mitochondrial disease,01/13/2003,Designated/Withdrawn,,,mitochondrial disease,,,http://www.orpha.net/ORDO/Orphanet_68380,D028361,,Q935710,Q935710
122,2'-3'-dideoxyadenosine,Treatment of aquired immunodeficiency syndrome.,07/21/1987,Designated/Withdrawn,,,aquired immunodeficiency syndrome,,,,,,,
124,2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide,Treatment of acromegaly,05/10/2016,Designated,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
125,2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3',Treatment of amyotrophic lateral sclerosis,10/31/2012,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
126,"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)",Treatment of systemic light chain (AL) amyloidosis.,03/09/2012,Designated,,,systemic light chain (al) amyloidosis,,,,,,,
127,"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-",Treatment of congenital adrenal hyperplasia (CAH),01/15/2015,Designated,,,congenital adrenal hyperplasia (cah),,,,,,,
128,2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate,Treatment of Charcot-Marie Tooth disease.,09/10/2015,Designated,,WEXITTWZMLUGNU-UHFFFAOYSA-N,charcot-marie tooth disease,,,,,,,
129,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",Treatment of idiopathic pulmonary fibrosis.,09/21/2010,Designated,Q27258840,RGYQPQARIQKJKH-UHFFFAOYSA-N,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
130,2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,Treatment of acute myeloid leukemia.,01/29/2010,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
131,2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,Treatment of hepatocellular carcinoma,07/01/2014,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
132,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,Treatment of multiple myeloma.,12/22/2008,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
133,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt,Treatment of ovarian carcinoma,03/18/2009,Designated,,,ovarian carcinoma,http://purl.obolibrary.org/obo/DOID_4001,,,,Q18556145,,
134,"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate",Treatment of pancreatic cancer,01/26/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
135,"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate",Treatment of mulitple myeloma and associated bone resorption,12/02/2003,Designated,Q27294619,WWCRKTZNNINNOT-SPIKMXEPSA-N,mulitple myeloma and associated bone resorption,,,,,,,
136,"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate",Treatment of carcinoid tumors,09/18/2006,Designated,Q27294619,WWCRKTZNNINNOT-SPIKMXEPSA-N,carcinoid tumors,,http://purl.obolibrary.org/obo/HP_0100570,,D002276,,,Q1734755
137,"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline",Treatment of acute myeloid leukemia,06/01/2015,Designated,,NIRXBXIPHUTNNI-UHFFFAOYSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
138,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide,Treatment of cystic fibrosis,05/13/2015,Designated,,XRPSUWYWZUQALB-UHFFFAOYSA-N,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
139,"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate",Treatment of cystic fibrosis,08/15/2003,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
140,2-0-desulfated heparin,Treatment of cystic fibrosis.,09/17/1993,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
141,"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride",Prevention of graft versus host disease.,10/06/2015,Designated,Q27258209,MYIFLDFUXIHOCJ-UHFFFAOYSA-N,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
142,2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate,Treatment of invasive aspergillosis,10/26/2016,Designated,,,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
143,2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate,Treatment of coccidioidomycosis,11/03/2016,Designated,,,coccidioidomycosis,http://purl.obolibrary.org/obo/DOID_13450,,http://www.orpha.net/ORDO/Orphanet_228123,D003047,Q868137,,Q868137
144,2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate,Treatment of invasive candidiasis,10/19/2016,Designated,,,invasive candidiasis,,,,D058365,,,
145,2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate,"Treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)",11/02/2016,Designated,,,"invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)",,,,,,,
147,2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride,Treatment of spinocerebellar ataxia.,05/18/2016,Designated,,ZRZLEMQBDKNTLJ-UHFFFAOYSA-N,spinocerebellar ataxia,,,,D020754,,,Q899726
148,2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide,Treatment of hepatocellular carcinoma,02/17/2012,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
149,2-chloroethyl-3-sarcosinamide-1-nitrosourea,Treatment for malignant gliomas,08/03/2001,Designated,Q27274664,,malignant gliomas,,,,D005910,,,Q18556612
150,2-chloroethyl-3-sarcosinamide-1-nitrosourea,Treatment for malignant glioma,11/15/2001,Designated,Q27274664,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
151,"2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate",Treatment of Ebola virus disease,09/18/2015,Designated,,RWWYLEGWBNMMLJ-YSOARWBDSA-N,ebola virus disease,http://purl.obolibrary.org/obo/DOID_4325,,http://www.orpha.net/ORDO/Orphanet_319218,D019142,Q51993,,Q8064876
152,2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde,Treatment of sickle cell disease (SCD).,12/29/2015,Designated,,FWCVZAQENIZVMY-UHFFFAOYSA-N,sickle cell disease (scd),,,,,,,
153,2-hydroxypropyl-B-cyclodextrin,"Treatment of Niemann Pick disease, type C.",02/18/2013,Designated,,,"niemann pick disease, type c",,,,D052556,,,Q2067267
154,2-iminobiotin,Treatment of perinatal asphyxia.,02/24/2009,Designated,Q27094295,,perinatal asphyxia,,,,,,,
155,2-methoxyestradiol,Treatment of multiforme glioblastoma,06/16/2006,Designated/Withdrawn,Q4596897,,multiforme glioblastoma,,,,,,,
156,2-methoxyestradiol,Treatment of pulmonary arterial hypertension,04/11/2005,Designated,Q4596897,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
157,2-methoxyestradiol,Treatment of multiple myeloma,07/10/2001,Designated/Withdrawn,Q4596897,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
158,2-methoxyestradiol,Treatment of ovarian cancer,04/04/2005,Designated/Withdrawn,Q4596897,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
159,"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate",Treatment of anal cancer,04/09/2015,Designated,,,anal cancer,http://purl.obolibrary.org/obo/DOID_14110,,,D001005,Q484827,,Q18556540
160,"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole",Treatment of hepatocellular carcinoma.,08/27/2008,Designated,Q254296,MJIHNNLFOKEZEW-UHFFFAOYSA-N,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
161,"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide",Treatment of nuclear protein in testis (NUT) midline carcinoma.,09/29/2015,Designated,,,nuclear protein in testis (nut) midline carcinoma,,,,,,,
162,"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate",Treatment of acute myeloid leukemia,07/16/2014,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
163,2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide,Treatment of malignant melanoma stages IIb through IV.,12/18/2007,Designated,,,malignant melanoma stages iib through iv,,,,,,,
164,2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid,Treatment of Huntington's disease.,06/02/2014,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
165,2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid,Treatment of patients with systemic sclerosis,05/14/2013,Designated,,,patients with systemic sclerosis,,,,,,,
166,2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,Treatment of patients with Frederickson Type I or V hyperlipoproteinemia,04/15/2015,Designated,,,patients with frederickson type i or v hyperlipoproteinemia,,,,,,,
167,2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,Treatment of primary biliary cholangitis,11/07/2016,Designated,,,primary biliary cholangitis,,,http://www.orpha.net/ORDO/Orphanet_186,,,Q1072420,
168,2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,Treatment of homozygous familial hypercholesterolemia (HoFH),03/18/2015,Designated,,,homozygous familial hypercholesterolemia (hofh),,,,,,,
169,2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,Treatment of acute myeloid leukemia,01/19/2010,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
170,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",Treatment of glioblastoma multiforme.,06/16/2015,Designated,,ZLJZDYOBXVOTSA-XMMPIXPASA-N,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
171,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",Treatment of malignant melanoma stages IIB to IV.,06/23/2015,Designated,,ZLJZDYOBXVOTSA-XMMPIXPASA-N,malignant melanoma stages iib to iv,,,,,,,
172,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",Treatment of ovarian cancer.,06/16/2015,Designated,,ZLJZDYOBXVOTSA-XMMPIXPASA-N,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
173,"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid",Treatment of pulmonary arterial hypertension,08/28/2014,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
174,20-mer complementary to Akt mRNA,Treatment of stomach cancer,12/10/2004,Designated,,,stomach cancer,http://purl.obolibrary.org/obo/DOID_10534,http://purl.obolibrary.org/obo/HP_0012126,,D013274,Q189588,,Q189588
175,20-mer oligonucleotide complementary to Akt mRNA,Treatment of ovarian cancer,12/01/2004,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
176,20-mer oligonucleotide complementary to Akt mRNA,Treatment of glioblastoma,12/08/2004,Designated,,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
177,20-mer oligonucleotide complementary to Akt mRNA,Treatment of pancreatic cancer,12/08/2004,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
178,20-mer oligonucleotide complementary to Akt mRNA,Treatment of renal cell carcinoma,12/01/2004,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
179,225Ac-lintuzumab,Treatment of acute myelogenous leukemia,11/25/2014,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
180,"24,25 dihydroxycholecalciferol",Treatment of uremic osteodystrophy.,02/27/1987,Designated,,,uremic osteodystrophy,,,,,,,
181,"2S,4R ketoconazole",Treatment of endogenous Cushing's syndrome,03/09/2012,Designated,,,endogenous cushing's syndrome,,,,,,,
182,"3'-azido-2',3'dideoxyuridine",Treatment of acquired immunodeficiency syndrome.,11/20/1989,Designated/Withdrawn,Q27286725,ZSNNBSPEFVIUDS-SHYZEUOFSA-N,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
183,"3,4 diaminopyridine and choline bitartrate",Treatment of Lambert-Eaton myasthenic syndrome,04/30/2010,Designated,,SIAFMJAUTCHNQW-UHFFFAOYSA-O,lambert-eaton myasthenic syndrome,http://purl.obolibrary.org/obo/DOID_0050214,,http://www.orpha.net/ORDO/Orphanet_43393,D015624,Q1756898,,Q1756898
184,"3,4-diaminopyridine",Treatment of Lambert-Eaton myasthenic syndrome.,12/18/1990,Designated,Q411707,OYTKINVCDFNREN-UHFFFAOYSA-N,lambert-eaton myasthenic syndrome,http://purl.obolibrary.org/obo/DOID_0050214,,http://www.orpha.net/ORDO/Orphanet_43393,D015624,Q1756898,,Q1756898
185,"3,5,3'-triiodothyroacetate","Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.",09/20/2000,Designated,,,"well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland",,,,,,,
186,"3,5-diiodothyropropionic acid",Treatment of Allan-Herndon-Dudley syndrome,05/14/2013,Designated,Q27252433,,allan-herndon-dudley syndrome,http://purl.obolibrary.org/obo/DOID_0050631,,http://www.orpha.net/ORDO/Orphanet_59,,Q4731121,Q4731121,
187,"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",Treatment of von Hippel-Lindau disease.,03/23/2000,Designated,,,von hippel-lindau disease,http://purl.obolibrary.org/obo/DOID_14175,,http://www.orpha.net/ORDO/Orphanet_892,D006623,Q741315,,Q741315
188,"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",Treatment of Kaposi's sarcoma.,09/11/1998,Designated,,,kaposi's sarcoma,http://purl.obolibrary.org/obo/DOID_8632,http://purl.obolibrary.org/obo/HP_0100726,,D012514,Q725345,,Q725345
189,"3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",Treatment of fibrodysplasia ossificans progressiva.,07/14/2015,Designated,,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
190,"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",Treatment of fibrodysplasia ossificans progressiva.,07/14/2015,Designated,,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
191,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",Treatment of diffuse large B-cell lymphoma,09/19/2016,Designated,,BVJRNKXVSYLNFD-UHFFFAOYSA-N,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
192,"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione",Treatment of glioblastoma,03/29/2016,Designated,,FARXPFGGGGLENU-UHFFFAOYSA-N,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
193,"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid",Treatment of cystic fibrosis,03/02/2010,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
194,3-aminopropyl-butyl phosphinic acid,Treatment of succinic semialdehyde dehydrogenase deficiency.,12/13/2016,Designated,Q27075900,ONNMDRQRSGKZCN-UHFFFAOYSA-N,succinic semialdehyde dehydrogenase deficiency,http://purl.obolibrary.org/obo/DOID_0060175,,http://www.orpha.net/ORDO/Orphanet_22,,Q2823333,Q2823333,
195,3-bromopyruvate,Treatment of pancreatic cancer,04/29/2014,Designated,Q27073726,PRRZDZJYSJLDBS-UHFFFAOYSA-M,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
196,3-bromopyruvate,Treatment of liver and intrahepatic bile duct cancer,03/05/2013,Designated,Q27073726,PRRZDZJYSJLDBS-UHFFFAOYSA-M,liver and intrahepatic bile duct cancer,,,,,,,
197,3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone,Treatment of Rett syndrome,10/25/2013,Designated,Q5423588,WAAXKNFGOFTGLP-UHFFFAOYSA-N,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
198,3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride,Treatment of behavioral abnormalities associated with fragile X syndrome.,07/28/2008,Designated,,,behavioral abnormalities associated with fragile x syndrome,,,,,,,
199,3-pentylbenzenacetic acid sodium salt,Treatment of idiopathic pulmonary fibrosis.,02/11/2015,Designated,,CNSJWSLXKSJQFE-UHFFFAOYSA-M,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
200,3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid,Prevention of acute attacks of angioedema in individuals with hereditary angioedema,12/23/2014,Designated,Q27291314,TUWMKPVJGGWGNL-UHFFFAOYSA-N,acute attacks of angioedema in individuals with hereditary angioedema,,,,,,,
201,3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride,Treatment of retinopathy of prematurity,01/17/2017,Designated,,MGVVVBJYSKDOKM-UHFFFAOYSA-N,retinopathy of prematurity,http://purl.obolibrary.org/obo/DOID_13025,,http://www.orpha.net/ORDO/Orphanet_90050,D012178,Q1423087,,Q1423087
202,3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt,Treatment of idiopathic pulmonary fibrosis,01/25/2017,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
203,"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate",Treatment of Proteus Syndrome.,11/09/2015,Designated,,,proteus syndrome,http://purl.obolibrary.org/obo/DOID_13482,,http://www.orpha.net/ORDO/Orphanet_744,D016715,Q281115,Q281115,Q281115
204,"4, 5 dibromorhodamine methyl ester",Treatment of diffuse large B-cell lymphoma,10/30/2008,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
205,"4, 5 dibromorhodamine methyl ester",Treatment of follicular lymphoma,10/30/2008,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
207,"4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt",Treatment of hepatocellular carcinoma.,04/18/2011,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
208,"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol",Treatment of Angelman syndrome.,09/06/2016,Designated,Q4130924,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,angelman syndrome,http://purl.obolibrary.org/obo/DOID_1932,,http://www.orpha.net/ORDO/Orphanet_120365,D017204,Q535364,,Q535364
209,"4,5-dibromorhodamine 123",Treatment of chronic myelogenous leukemia,04/10/2003,Designated/Withdrawn,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
210,"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one",Treatment of malignant glioma.,04/27/2009,Designated/Withdrawn,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
211,4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl),Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.,10/11/2006,Designated,,,chronic functional vomiting to include functional vomiting and cyclic vomiting syndrome,,,,,,,
212,4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl,Treatment of Huntington's disease.,12/12/2005,Designated,Q27287263,YGRHOYQMBLLGEV-UHFFFAOYSA-N,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
213,4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid,Prevention of scarring post ab externo glaucoma surgery,03/24/2015,Designated,,TYORCOLIIIUMSE-UHFFFAOYSA-N,scarring post ab externo glaucoma surgery,,,,,,,
214,"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",Treatment of diffuse large B-cell lymphoma.,03/27/2014,Designated,Q23671272,LQBVNQSMGBZMKD-UHFFFAOYSA-N,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
215,"4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride",Treatment of fibrodysplasia ossificans progressiva,04/15/2013,Designated,,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
216,"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one",Treatment of congenital long QT syndrome,05/04/2015,Designated,Q27077170,YNUAEEJQYHYLMS-UHFFFAOYSA-N,congenital long qt syndrome,,,http://www.orpha.net/ORDO/Orphanet_768,,,,
217,"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one",Treatment of pancreatic cancer.,09/23/2014,Designated,,QLLGKCJUPWYJON-HLTSFMKQSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
218,"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone",Treatment of hepatocellular carcinoma.,08/22/2007,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
219,4-Aminopyridine,Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome,12/14/2005,Designated,Q27454555,NUKYPUAOHBNCPY-UHFFFAOYSA-N,functional motor and sensory deficits from guillain-barre syndrome,,,,,,,
220,4-aminosalicylic acid,Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.,12/13/1989,Designated,Q229924,WUBBRNOQWQTFEX-UHFFFAOYSA-N,mild to moderate ulcerative colitis in patients intolerant to sulfasalazine,,,,,,,
221,4-aminosalicylic acid,Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease,04/26/2006,Designated,Q229924,WUBBRNOQWQTFEX-UHFFFAOYSA-N,acute flares in pediatric patients with ileo-cecal crohn's disease,,,,,,,
222,"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione",Treatment of progressive supranuclear palsy,10/13/2009,Designated/Withdrawn,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
223,"4-cholest-en-3-one, oxime",Treatment of amyotrophic lateral sclerosis,12/01/2005,Designated/Withdrawn,,QNTASHOAVRSLMD-GYKMGIIDSA-N,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
224,4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride,Treatment of acute myeloid leukemia,07/20/2006,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
225,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",Treatment of cerebral cavernous malformation.,09/29/2015,Designated,,,cerebral cavernous malformation,http://purl.obolibrary.org/obo/DOID_0060669,,,D020786,Q28020303,,
226,4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide,Treatment of Chagas disease.,01/11/2017,Designated,,,chagas disease,http://purl.obolibrary.org/obo/DOID_12140,,http://www.orpha.net/ORDO/Orphanet_3386,D014355,Q649558,,Q649558
227,4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide,Treatment of pancreatic cancer.,11/02/2010,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
228,"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",Treatment of retinitis pigmentosa,02/08/2016,Designated,,ISXCNDQRTAJCDE-VOTSOKGWSA-N,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
229,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",Treatment of patients with Duchenne Muscular Dystrophy.,11/18/2015,Designated,,KPOXJHIAEVDHMU-WXXKFALUSA-N,patients with duchenne muscular dystrophy,,,,,,,
230,4-[131I]iodo-L-phenylalanine,Treatment of glioma.,01/04/2011,Designated,Q27263179,PZNQZSRPDOEBMS-WPUCPVGPSA-N,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
232,"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol",Treatment of chronic myeloid leukemia,10/04/2011,Designated,,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
233,"4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt",Treatment of Philadelphia chromosome positive chronic myeloid leukemia,09/03/2009,Designated,Q27247608,ARPBZBAWXAVDCE-UHFFFAOYSA-N,philadelphia chromosome positive chronic myeloid leukemia,,,,,,,
234,"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol",Treatment of idiopathic pulmonary fibrosis,09/23/2011,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
236,"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",Treatment of Acute Myeloid Leukemia,05/19/2014,Designated,Q27287480,TVTXCJFHQKSQQM-LJQIRTBHSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
238,5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+,Treatment of diffuse large B-cell lymphoma.,03/31/2015,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
240,"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine",Treatment of pancreatic cancer,12/07/2009,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
241,5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin,Treatment of osteosarcoma (bone cancer),06/15/2007,Designated,,,osteosarcoma (bone cancer),,,,,,,
242,"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)",Treatment of malignant gliomas,10/11/2006,Designated/Withdrawn,,,malignant gliomas,,,,D005910,,,Q18556612
243,"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride",Treatment of pancreatic cancer,08/20/2003,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
244,"5,6-dihydro-5-azacytidine",Treatment of malignant mesothelioma.,05/11/1992,Designated,Q27236168,LJIRBXZDQGQUOO-KVTDHHQDSA-N,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
245,"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",Treatment of Huntington's disease,09/04/2014,Designated,,VSRSUNAZJQGYCB-UHFFFAOYSA-N,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
246,"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one",Prevention of acute radiation syndrome,06/18/2007,Designated,Q415957,TZBJGXHYKVUXJN-UHFFFAOYSA-N,acute radiation syndrome,,,,D054508,,,Q275459
247,"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate",Treatment of pulmonary arterial hypertension,10/21/2010,Designated/Withdrawn,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
248,"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride",Treatment of progressive supranuclear palsy.,04/18/2011,Designated,Q27265266,FVWAMONNJGNNHY-UHFFFAOYSA-N,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
249,"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine",Treatment of primary central nervous system lymphoma.,11/21/2016,Designated,Q27088437,ADGGYDAFIHSYFI-UHFFFAOYSA-N,primary central nervous system lymphoma,,http://purl.obolibrary.org/obo/HP_0030069,http://www.orpha.net/ORDO/Orphanet_46135,,,,
250,"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide",Treatment pulmonary arterial hypertension,01/15/2015,Designated,,,arterial hypertension,,,,,,,
251,5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole,Treatment of Duchenne Muscular Dystrophy,11/22/2011,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
253,5-aza-2'-deoxycytidine,Treatment of acute leukemia.,08/03/1987,Designated,Q1181878,XAUDJQYHKZQPEU-KVQBGUIXSA-N,acute leukemia,http://purl.obolibrary.org/obo/DOID_12603,http://purl.obolibrary.org/obo/HP_0002488,,,Q976388,,
254,"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one",Treatment of thalassemia,02/16/2017,Designated,,,thalassemia,http://purl.obolibrary.org/obo/DOID_10241,,,D013789,Q185137,,Q185137
255,5-hydroxymethyl-2-furfuraldehyde,Treatment of sickle cell disease,05/26/2006,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
256,5-imino-13-deoxydoxorubicin HCl,Treatment of soft tissue sarcoma,12/31/2015,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
257,5-iodo-2-pytimidinone-2'-deoxyribose,Treatment of malginant glioma,05/26/2006,Designated,,,malginant glioma,,,,,,,
258,"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol",Treatment of MELAS syndrome,03/13/2008,Designated,Q407329,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,melas syndrome,http://purl.obolibrary.org/obo/DOID_3687,,,D017241,Q2666433,,Q2666433
259,"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine",Treatment of spinal muscular atrophy,08/25/2009,Designated,Q27282418,MNLHFGXIUJNDAF-UHFFFAOYSA-N,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
260,5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine,Treatment of malignant mesothelioma,02/10/2015,Designated/Withdrawn,Q27089164,QYBGBLQCOOISAR-UHFFFAOYSA-N,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
261,"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one",Treatment of active tuberculosis,12/05/2016,Designated,,XZISSTDXPBUCJA-DYESRHJHSA-N,active tuberculosis,,,,,,,
264,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",Treatment of Rett syndrome,11/03/2016,Designated,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
265,"6,8-bis-benzylsulfanyl-octanoic acid",Treatment of acute myeloid leukemia.,08/22/2011,Designated,Q27276958,ZYRLHJIMTROTBO-UHFFFAOYSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
266,"6,8-bis-benzylsulfanyl-octanoic acid",Treatment of pancreatic cancer,02/06/2006,Designated,Q27276958,ZYRLHJIMTROTBO-UHFFFAOYSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
267,"6,8-bis-benzylsulfanyl-octanoic acid",Treatment of myelodysplastic syndrome,09/26/2013,Designated,Q27276958,ZYRLHJIMTROTBO-UHFFFAOYSA-N,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
268,"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one",Treatment of sickle cell disease,09/04/2014,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
269,"6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate",Treatment of chronic lymphocytic leukemia,04/14/2014,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
270,"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride",Treatment of pulmonary arterial hypertension (WHO Group 1),11/09/2016,Designated,,GMTQOJSRMVAFIF-UHFFFAOYSA-N,pulmonary arterial hypertension (who group 1),,,,,,,
271,"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",Treatment of mucopolysaccharidosis type 1 (MPS I),10/18/2016,Designated,,,mucopolysaccharidosis type 1 (mps i),,,,,,,
272,6-alpha-ethylchenodeoxycholic acid,Treatment of primary sclerosing cholangitis,04/09/2008,Designated,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
273,6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide,Treatment of stage IIb-IV melanoma,10/15/2013,Designated,,,stage iib-iv melanoma,,,,,,,
274,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one",Treatment of Netherton syndrome,06/18/2015,Designated,,,netherton syndrome,http://purl.obolibrary.org/obo/DOID_0050474,,http://www.orpha.net/ORDO/Orphanet_634,D056770,Q9390284,Q9390284,Q9390284
276,6-hydroxymethylacylfulvene,Treatment of histologically confirmed advanced or metastatic pancreatic cancer.,04/06/1999,Designated/Withdrawn,,,histologically confirmed advanced or metastatic pancreatic cancer,,,,,,,
277,6-mercaptopurine oral liquid,Treatment of acute lymphoblastic leukemia in the pediatric population,12/07/2009,Designated,,,acute lymphoblastic leukemia in the pediatric population,,,,,,,
278,"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole",Treatment of cholangiocarcinoma,05/11/2016,Designated,Q27292488,UZJVBXKFBQNDTQ-UHFFFAOYSA-N,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
279,"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one",Treatment of sickle cell disease (SCD),01/31/2017,Designated,,,sickle cell disease (scd),,,,,,,
280,"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine",Treatment of multiple myeloma,06/12/2014,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
281,"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide",Treatment of glioblastoma multiforme (GBM).,02/11/2016,Designated,,,glioblastoma multiforme (gbm),,,,,,,
282,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate",Treatment of diffuse large B-cell lymphoma,02/14/2017,Designated,,ZVPYVZMKBQYKQG-ZVWHLABXSA-N,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
283,"6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione",Treatment of symptomatic obstructive hypertrophic cardiomyopathy,04/27/2016,Designated,,RLCLASQCAPXVLM-NSHDSACASA-N,symptomatic obstructive hypertrophic cardiomyopathy,,,,,,,
285,7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester,Treatment of gliomas.,06/15/2011,Designated,,,gliomas,,,,D005910,,,Q18556612
286,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl",Treatment of glioblastoma.,06/23/2016,Designated,,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
287,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL",Treatment of mantle cell lymphoma (MCL),02/07/2017,Designated,Q27896336,HKBXPCQCBQFDML-UHFFFAOYSA-N,mantle cell lymphoma (mcl),,,,,,,
288,7-ethyl-10-hydroxycamptothecin (EHC),Treatment of small cell lung cancer.,04/13/2016,Designated,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
289,"8 Cyclopentyl 1,3-dipropylxanthine",Treatment of cystic fibrosis.,03/24/1997,Designated/Withdrawn,Q5280076,FFBDFADSZUINTG-UHFFFAOYSA-N,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
290,8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one,Treatment of glioblastoma multiforme,01/21/2015,Designated,Q27294013,YEAHTLOYHVWAKW-UHFFFAOYSA-N,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
292,"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride",Treatment of ovarian cancer.,09/03/2009,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
293,"9,10-dimethoxy-5,6-dihydro-[1,3] dioxolo[4,5-g]isoquinolino[3,2-alpha]isoquinolin-7-ium(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyhexadecahydro-1H-cyclopenta[alpha]",Treatment of primary sclerosing cholangitis,08/29/2016,Designated,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
294,"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester",Treatment of Friedreich's Ataxia,05/23/2016,Designated,,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
295,9-cis-retinoic acid,Prevention of retinal detachment due to proliferative vitreoretinopathy.,01/02/1997,Designated/Withdrawn,Q3611854,,retinal detachment due to proliferative vitreoretinopathy,,,,,,,
296,9-nitro-20-(S)-camptothecin,Treatment of pediatric HIV infection/AIDS,05/15/2001,Designated,,,pediatric hiv infection/aids,,,,,,,
297,9-nitro-20-(S)-camptothecin,Treatment of pancreatic cancer.,09/16/1996,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
298,90Y-DOTA-tyr3-Octreotide,Treatment of neuroendocrine tumors,01/20/2016,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
299,90Y-hPAMA4,Treatment of pancreatic cancer,01/29/2004,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
300,a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy,Treatment of Stage II to IV invasive cervical carcinoma,04/29/2014,Designated,,,stage ii to iv invasive cervical carcinoma,,,,,,,
301,A-dmDT390-bisFv(UCHT1),Treatment of cutaneous T-cell lymphoma,10/09/2014,Designated,,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
302,a-Galactosidase A,Treatment of Fabry's disease,01/21/2003,Designated,,,fabry's disease,http://purl.obolibrary.org/obo/DOID_14499,,,D000795,Q615645,,Q615645
303,A10 & AS2-1 Antineoplaston,Treatment for patients with brain stem glioma,09/03/2004,Designated,,,patients with brain stem glioma,,,,,,,
304,"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1",Treatment of choroideremia due to mutations in the human choroideremia gene (CHM),09/12/2013,Designated,,,choroideremia due to mutations in the human choroideremia gene (chm),,,,,,,
305,AAV-G6Pase vector,Treatment of glycogen storage disease type Ia,03/11/2013,Designated,,,glycogen storage disease type ia,,,,,,,
306,abagovomab,Treatment of epithelial ovarian cancer,11/25/2003,Designated/Withdrawn,Q3603118,,epithelial ovarian cancer,,,,,,,
307,abatacept,Treatment of type 1 diabetes mellitus patients with residual beta cell function,05/30/2013,Designated,Q2697833,,type 1 diabetes mellitus patients with residual beta cell function,,,,,,,
308,ABCA4 DNA nanoparticles,Treatment of Stargardt Macular Degeneration,10/28/2015,Designated,,,stargardt macular degeneration,,,,,,,
309,abeotaxane inhibitor of microtubules,Treatment of pediatric neuroblastoma.,04/18/2011,Designated,,,pediatric neuroblastoma,,,,,,,
310,abeotaxane inhibitor of microtubules,Treatment of gliomas,10/07/2011,Designated,,,gliomas,,,,D005910,,,Q18556612
311,Abetimus,Treatment of lupus nephritis.,07/28/2000,Designated,Q4667244,,lupus nephritis,http://purl.obolibrary.org/obo/DOID_0080162,,,D008181,Q1621830,,Q1621830
312,Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac,Treatment of paroxysmal nocturnal hemoglobinuria,04/20/2014,Designated,,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
313,acadesine,Treatment of chronic lymphocytic leukemia,03/03/2011,Designated,Q4671562,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
314,acadesine,Treatment of multiple myeloma,05/04/2011,Designated,Q4671562,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
315,acamprosate,Treatment of fragile X syndrome,03/25/2013,Designated,Q337668,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
316,aceneuramic acid,Treatment of hereditary inclusion body myopathy,09/23/2011,Designated,Q27120624,,hereditary inclusion body myopathy,http://purl.obolibrary.org/obo/DOID_3429,,,,Q1848471,,
317,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide,Treatment of acute myeloid leukemia.,11/24/2015,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
318,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide,Treatment of pancreatic cancer.,02/18/2011,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
319,acetyl-l-carnitine,Treatment of Fragile X syndrome,07/24/2012,Designated,Q311992,GJTJQSPLLQWKMB-SECBINFHSA-N,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
320,acetyl-l-carnitine (ALC),Treatment of Rett syndrome,03/18/2011,Designated,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
324,Aconiazide,Treatment of tuberculosis.,06/20/1988,Designated/Withdrawn,Q15633956,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
325,ActRIIB-IgG1),Treatment of Duchenne muscular dystrophy,08/16/2010,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
326,acyclovir,Treatment of herpetic keratitis.,05/03/2016,Designated,Q147101,,herpetic keratitis,,,http://www.orpha.net/ORDO/Orphanet_137586,D016849,,,Q5743641
327,acyclovir,Treatment of herpetic keratitis,09/16/2010,Designated/Withdrawn,Q147101,,herpetic keratitis,,,http://www.orpha.net/ORDO/Orphanet_137586,D016849,,,Q5743641
328,acyclovir,Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2,12/13/2010,Designated,Q147101,,acute herpetic keratitis caused by herpes simplex virus type 1 and 2,,,,,,,
329,Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus,Treatment of ovarian cancer,03/17/2014,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
330,adalimumab,Treatment of pediatric patients with ulcerative colitis,05/11/2011,Designated,Q348260,,pediatric patients with ulcerative colitis,,,,,,,
331,adalimumab,Treatment of juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,Q348260,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
332,adalimumab,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),05/13/2015,Designated/Approved,Q348260,,moderate to severe hidradenitis suppurativa (hurley stage 2 and hurley stage 3 disease),,,,,,,
333,adalimumab,Treatment of pediatric Crohn's disease.,10/19/2006,Designated/Approved,Q348260,,pediatric crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,,,,Q1472,,
334,adalimumab,"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis",05/13/2014,Designated/Approved,Q348260,,"non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis",,,,,,,
335,adalimumab,Treatment of Behcet's disease,07/10/2014,Designated,Q348260,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
336,aden-associated virus vector serotype 9 expressing human a-L-iduronidase,Treatment of mucopolysaccharidosis Type I (MSP I).,09/29/2015,Designated,,,mucopolysaccharidosis type i (msp i),,,,,,,
337,adeno associated viral vector containing human ARSB gene,Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome),03/17/2011,Designated,,,mucopolysaccharidosis type vi (mps vi; maroteaux-lamy syndrome),,,,,,,
338,adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome),05/06/2013,Designated,,,mucopolysaccharidosis type iiia (sanfilippo type a syndrome),,,,,,,
339,adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene,Treatment of hemophilia B,03/14/2014,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
340,Adeno-associated vector expressing the human lipoprotein lipase protein,Treatment of lipoprotein lipase deficiency,05/21/2007,Designated,,,lipoprotein lipase deficiency,,,,D008072,,,Q2349695
341,adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH),Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome,11/18/2015,Designated,,,mucopolysaccharidosis type iiia or sanfilippo type a syndrome,,,,,,,
342,adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA,Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.,03/16/2016,Designated,,,cln2 disease (neuronal ceroid lipofuscinosis (ncl)) caused by tpp1 deficiency,,,,,,,
343,adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX,Treatment of hemophilia B.,09/21/2015,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
344,adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene,treatment of retinitis pigmentosa,12/13/2012,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
345,adeno-associated viral vector containing modified U11 snRNA,Treatment of Duchenne muscular dystrophy.,09/15/2010,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
348,adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene,Treatment of Leber Hereditary Optic Neuropathy,11/20/2013,Designated,,,leber hereditary optic neuropathy,http://purl.obolibrary.org/obo/DOID_705,,http://www.orpha.net/ORDO/Orphanet_104,D029242,Q1262161,,Q1262161
349,Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.,Treatment of Duchenne muscular dystrophy.,08/31/2016,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
350,Adeno-associated viral vector expressing human acid alpha glucosidase gene,Treatment of Pompe disease,03/20/2007,Designated,,,pompe disease,,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,,,Q1365789
351,adeno-associated viral vector expressing human retinoschisin-1 gene,Treatment of X-linked juvenile retinoschisis (XLRS).,05/21/2007,Designated,,,x-linked juvenile retinoschisis (xlrs),,,,,,,
352,Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor,Treatment of homozygous familial hypercholesterolemia,01/31/2012,Designated,,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
353,adeno-associated viral vector expressing the human vascular endothelial growth factor gene,"Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated",12/31/2015,Designated,,,"critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated",,,,,,,
354,adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene,Treatment of choroideremia,11/05/2014,Designated,,,choroideremia,http://purl.obolibrary.org/obo/DOID_9821,http://purl.obolibrary.org/obo/HP_0001139,http://www.orpha.net/ORDO/Orphanet_180,D015794,Q2397009,,Q2397009
355,adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene,Treatment of retinitis pigmentosa,01/25/2017,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
356,Adeno-associated viral vector serotype 5 containing human ABCA4 gene,Treatment of Stargardt's disease.,09/30/2008,Designated/Withdrawn,,,stargardt's disease,,,,,,,
357,adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),12/27/2012,Designated,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
358,adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene,Treatment of catecholaminergic polymorphic ventricular tachycardia,10/02/2014,Designated,,,catecholaminergic polymorphic ventricular tachycardia,http://purl.obolibrary.org/obo/DOID_0060674,,http://www.orpha.net/ORDO/Orphanet_3286,,Q28024493,,
359,adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene,Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations,03/18/2015,Designated,,,inherited retinal dystrophy due to biallelic rpe65 gene mutations,,,,,,,
360,Adeno-associated viral-based vector cystic fibrosis gene therapy,Treatment of cystic fibrosis.,02/15/1995,Designated/Withdrawn,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
361,adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase,Treatment of GM1 gangliosidosis,01/30/2017,Designated,,,gm1 gangliosidosis,,,http://www.orpha.net/ORDO/Orphanet_354,D016537,,,Q5513690
362,Adeno-associated virus delivered transgene of follistatin,Treatment of inclusion body myositis,09/19/2016,Designated,,,inclusion body myositis,http://purl.obolibrary.org/obo/DOID_3429,,http://www.orpha.net/ORDO/Orphanet_611,D018979,Q1848471,,Q1848471
363,Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX),Treatment of hemophilia B,09/01/2016,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
364,adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene,Treatment of mucopolysaccharidosis type I (MPS I),01/09/2017,Designated,,,mucopolysaccharidosis type i (mps i),,,,,,,
365,adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene,Treatment of spinal muscular atrophy,09/30/2014,Designated,,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
366,adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene,Treatment of mucopolysaccharidosis type II (Hunter syndrome).,07/16/2015,Designated,,,mucopolysaccharidosis type ii (hunter syndrome),,,,,,,
367,Adeno-associated virus serotype rh10 vector encoding the human factor IX gene,Treatment of hemophilia B.,08/25/2015,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
368,adeno-associated virus transgene of follistatin,Treatment of Duchennes and Becker's muscular dystrophy,11/19/2012,Designated,,,duchennes and becker's muscular dystrophy,,,,,,,
369,adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS),Treatment of X-linked retinoschisis,11/16/2015,Designated,,,x-linked retinoschisis,http://purl.obolibrary.org/obo/DOID_0060763,,http://www.orpha.net/ORDO/Orphanet_792,D041441,Q28065568,Q3458131,Q1049881
370,adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII,Treatment of Hemophilia A.,02/29/2016,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
371,adeno-associated virus vector serotype 9 expressing human sulfamidase,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).,06/01/2011,Designated,,,mucopolysaccharidosis type iiia (sanfilippo a syndrome),,,,,,,
374,Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase,"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)",03/03/2011,Designated,,,"myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)",,,,,,,
375,Adenoviral vector expressing Herpes simplex virus thymidine kinase gene,Treatment of malignant brain tumors,06/17/2005,Designated,,,malignant brain tumors,,,,,,,
377,Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex,Treatment of malignant glioma.,07/23/2015,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
378,adenovirus associated viral vector serotype 5 containing the human RPE65 gene,Treatment of Leber congenital amaurosis,03/10/2016,Designated,,,leber congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,http://www.orpha.net/ORDO/Orphanet_65,D057130,Q1811132,Q1811132,Q1811132
379,adenovirus associated viral vector serotype 5 containing the RPGR gene,Treatment of retinitis pigmentosa,11/29/2016,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
380,adenovirus associated viral vector serotype 8 containing the human CNGB3 gene,Treatment of achromatopsia due to mutations in the CNGB3 gene.,03/10/2016,Designated,,,achromatopsia due to mutations in the cngb3 gene,,,,,,,
381,adenovirus containing a human FAS-c gene,Treatment of malignant glioma,04/02/2012,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
382,"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma",Treatment of glioma,10/01/2014,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
383,Adenovirus encoding the recombinant CD40 ligand,Treatment of stage IIb through IV melanoma.,04/19/2016,Designated,,,stage iib through iv melanoma,,,,,,,
384,"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)",Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC),09/04/2014,Designated,,,human papillomavirus (hpv)-associated head and neck squamous cell carcinoma (hnscc),,,,,,,
385,adenovirus vaccine encoding reduced expression in immortalized cell protein,Treatment of mesothelioma,07/14/2015,Designated,,,mesothelioma,,,,D008654,,,Q18555143
386,adenovirus-associated viral vector serotype 5 containing the human pde6B gene,Treatment of retinitis pigmentosa due to pde6B gene mutations,07/05/2016,Designated,,,retinitis pigmentosa due to pde6b gene mutations,,,,,,,
387,Adenovirus-based vector Factor VIII complementary DNA to somatic cells,Treatment of hemophilia A.,12/15/1999,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
388,ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides,Treatment of renal cell carcinoma in HLA-A*2 positive patients,09/28/2012,Designated/Withdrawn,,,renal cell carcinoma in hla-a*2 positive patients,,,,,,,
389,adult adherent bone marrow-derived multipotent stem cells,"Treatment of MPS-1, including Hurler syndrome",07/06/2012,Designated,,,"mps-1, including hurler syndrome",,,,,,,
390,adult hemogenic endothelial cells,Treatment of aplastic anemia,05/27/2015,Designated,,,aplastic anemia,http://purl.obolibrary.org/obo/DOID_12449,http://purl.obolibrary.org/obo/HP_0001915,http://www.orpha.net/ORDO/Orphanet_182040,D000741,Q846316,,Q846316
391,ADXS11-001,Treatment of HPV-positive associated anal cancer,08/12/2013,Designated,,,hpv-positive associated anal cancer,,,,,,,
392,aerosolized beractant,Treatment of respiratory distress syndrome,03/11/2013,Designated,,,respiratory distress syndrome,,,,,,,
393,Aerosolized pooled immune globulin,Treatment of respiratory syncytial virus lower respiratory tract disease.,01/03/1989,Designated/Withdrawn,,,respiratory syncytial virus lower respiratory tract disease,,,,,,,
394,AEZS-108 (LHRH-agonist linked to doxorubicin),Treatment of ovarian cancer,04/30/2010,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
395,afamelanotide,Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),02/04/2016,Designated,Q410794,,cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),,,,,,,
396,afamelanotide,Treatment of erythropoietic porphyrias,07/17/2008,Designated,Q410794,,erythropoietic porphyrias,,,,D017092,,,Q1759389
397,afamelanotide,Treatment of solar urticaria,12/11/2009,Designated,Q410794,,solar urticaria,,,http://www.orpha.net/ORDO/Orphanet_97230,,,Q959383,
398,afamelanotide,Treatment of familial benign chronic pemphigus (Hailey-Hailey disease),05/14/2014,Designated,Q410794,,familial benign chronic pemphigus (hailey-hailey disease),,,,,,,
399,afatinib,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,12/03/2012,Designated/Approved,Q4688818,,epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc),,,,,,,
400,afatinib,Treatment of malignant brain and central nervous system tumors,06/04/2014,Designated,Q4688818,,malignant brain and central nervous system tumors,,,,,,,
401,afatinib,Treatment of non-small cell lung cancer with squamous histology.,08/03/2015,Designated/Approved,Q4688818,,non-small cell lung cancer with squamous histology,,,,,,,
402,aganirsen,Prevention of corneal graft rejection.,11/07/2016,Designated,Q15633943,,corneal graft rejection,,,,,,,
403,AI-RSA,Treatment of autoimmune uveitis.,10/08/1992,Designated/Withdrawn,,,autoimmune uveitis,,,,,,,
404,Albendazole,"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.",01/18/1996,Designated/Approved,Q411629,,"neurocysticercosis due to taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis",,,,,,,
405,Albendazole,Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).,01/17/1996,Designated/Approved,Q411629,,hydatid disease (cystic echinococcosis due to e. granulosus larvae or alveolar echinococcosis due to e. multilocularis larvae),,,,,,,
406,Albuterol,Prevention of paralysis due to spinal cord injury,03/12/2002,Designated,Q410358,,paralysis due to spinal cord injury,,,,,,,
408,Aldesleukin,Treatment of metastatic melanoma.,09/10/1996,Designated/Approved,Q20801763,,metastatic melanoma,,,,,,,
409,Aldesleukin,Treatment of metastatic renal cell carcinoma.,09/14/1988,Designated/Approved,Q20801763,,metastatic renal cell carcinoma,,,,,,,
410,Aldesleukin,Treatment of primary immunodeficiency disease associated with T-cell defects.,03/22/1989,Designated,Q20801763,,primary immunodeficiency disease associated with t-cell defects,,,,,,,
411,Aldesleukin,Treatment of acute myelogenous leukemia.,07/31/1998,Designated/Withdrawn,Q20801763,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
412,aldoxorubicin,Treatment of small cell lung cancer,09/24/2014,Designated,Q27275099,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
413,aldoxorubicin,Treatment of glioblastoma multiforme,09/24/2014,Designated,Q27275099,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
414,aldoxorubicin,Treatment of ovarian cancer,09/24/2014,Designated,Q27275099,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
415,alectinib,Treatment of ALK-positive non-small cell lung cancer,01/27/2015,Designated/Approved,Q21099132,,alk-positive non-small cell lung cancer,,,,,,,
417,alemtuzumab,Treatment of chronic lymphocytic leukemia.,10/20/1997,Designated/Approved,Q420164,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
418,alendronate,Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older,03/31/2003,Designated/Withdrawn,Q420057,,osteogenesis imperfecta in pediatric patients 4 years of age and older,,,,,,,
419,Alendronate disodium,Treatment of the bone manifestations of Gaucher disease,02/13/2001,Designated,,,the bone manifestations of gaucher disease,,,,,,,
421,Alfentanil,Treatment of painful HIV-associated neuropathy,08/09/2005,Designated,Q176533,,painful hiv-associated neuropathy,,,,,,,
422,alfimeprase,Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention,09/20/2012,Designated,,,st-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention,,,,,,,
423,algenpantucel-L,Treatment of pancreatic cancer.,10/21/2010,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
426,alicaforsen,Treatment of pouchitis.,06/24/2008,Designated,Q17147922,,pouchitis,,,,D019449,,,
427,alisertib,Treatment of small cell lung cancer,07/12/2013,Designated,Q15633917,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
428,alisertib,Treatment of peripheral T-cell lymphoma,05/14/2012,Designated/Withdrawn,Q15633917,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
429,Alitretinoin,Treatment of acute promyelocytic leukemia,04/10/1992,Designated,Q3611854,,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
430,Alitretinoin,Treatment of AIDS-related Kaposi's sarcoma.,03/24/1998,Designated/Approved,Q3611854,,aids-related kaposi's sarcoma,,,,,,,
431,"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid",Treatment of retinitis pigmentosa,05/21/2014,Designated,Q423345,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
432,allantoin,Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa,11/21/2002,Designated,Q409804,,skin blistering and erosions associated with inherited epidermolysis bullosa,,,,,,,
433,allogeneic cardiosphere-derived cells,Treatment of Duchenne Muscular Dystrophy,04/21/2015,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
435,allogeneic Epstein-Barr virus cytotoxic T lymphocytes,Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.,02/04/2016,Designated,,,epstein-barr virus-positive post-transplant lymphoproliferative disorders,,,,,,,
439,allogeneic ex-vivo expanded placental adherent stromal cells,Treatment of thromboangiitis obliterans (Buerger's disease),08/22/2011,Designated,,,thromboangiitis obliterans (buerger's disease),,,,,,,
440,allogeneic ex-vivo expanded placental adherent stromal cells,Treatment of Aplastic Anemia,02/18/2013,Designated,,,aplastic anemia,http://purl.obolibrary.org/obo/DOID_12449,http://purl.obolibrary.org/obo/HP_0001915,http://www.orpha.net/ORDO/Orphanet_182040,D000741,Q846316,,Q846316
441,allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells,Treatment of acute myeloid leukemia,04/20/2016,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
442,allogeneic hematopoietic stem cell,"Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.",02/02/2010,Designated,,,"of transplant related mortality (trm, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation",,,,,,,
443,Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix,Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis,04/03/2009,Designated,,,arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis,,,,,,,
444,allogeneic human islets of Langerhans,Treatment of Brittle Type 1 Diabetes,02/01/2017,Designated,,,brittle type 1 diabetes,,,,,,,
445,Allogeneic human retinal pigment epithelial cells on gelatin microcarriers,Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.,07/18/1997,Designated/Withdrawn,,,hoehn and yahr stage 3 and 4 parkinson's disease,,,,,,,
446,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,Treatment of Amyotrophic Lateral Sclerosis,01/17/2014,Designated/Withdrawn,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
447,Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture,Treatment of pancreatic cancer,06/13/1997,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
448,Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor,Treatment of retinitis pigmentosa,09/01/2004,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
450,allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor,Treatment of macular telangiectasia type 2 (MacTel),07/24/2012,Designated,,,macular telangiectasia type 2 (mactel),,,,,,,
451,allopregnanolone,Treatment of status epilepticus,04/20/2014,Designated,Q18352362,,status epilepticus,http://purl.obolibrary.org/obo/DOID_1824,http://purl.obolibrary.org/obo/HP_0002133,,D013226,Q980709,,Q980709
452,allopregnanolone,"Treatment of Neimann-Pick disease, type C",07/12/2013,Designated,Q18352362,,"neimann-pick disease, type c",,,,,,,
456,allosteric activator of the red blood cell-specific form of pyruvate kinase,Treatment of pyruvate kinase deficiency,03/24/2015,Designated,,,pyruvate kinase deficiency,,,,,,,
457,alpha melanotropin,Treatment of chronic beryllium disease,09/02/2010,Designated,,,chronic beryllium disease,,,http://www.orpha.net/ORDO/Orphanet_133,,,,
458,alpha-1 proteinase inhibitor (human),Treatment of patients with recent onset (<15 years)with Type 1A diabetes mellitus with residual beta-cell function,07/28/2011,Designated,,,patients with recent onset (<15 years)with type 1a diabetes mellitus with residual beta-cell function,,,,,,,
459,alpha-1 proteinase inhibitor (human),Treatment of graft versus host disease,10/23/2014,Designated,,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
460,Alpha-1-acid glycoprotein,Treatment of cocaine overdose,03/05/2004,Designated/Withdrawn,,,cocaine overdose,,,,,,,
461,Alpha-1-acid glycoprotein,Treatment of tricyclic antidepressant poisoning,03/17/2004,Designated/Withdrawn,,,tricyclic antidepressant poisoning,,,,,,,
463,Alpha-galactosidase A,Treatment of Fabry's disease.,07/20/1990,Designated,,,fabry's disease,http://purl.obolibrary.org/obo/DOID_14499,,,D000795,Q615645,,Q615645
464,Alpha-galactosidase A,Treatment of alpha-galactosidase A deficiency (Fabry's disease).,06/17/1991,Designated,,,alpha-galactosidase a deficiency (fabry's disease),,,,,,,
466,Alpha-melanocyte stimulating hormone,Prevention and treatment of intrinsic acute renal failure due to ischemia.,08/19/1997,Designated,,,treatment of intrinsic acute renal failure due to ischemia,,,,,,,
467,Alpha-tocopherol quinone,Treatment of inherited mitochondrial respiratory chain diseases,03/28/2006,Designated,,,inherited mitochondrial respiratory chain diseases,,,,,,,
468,alpha-tocotrienol quinone,Treatment of inherited mitochondrial respiratory chain diseases.,10/21/2010,Designated,,,inherited mitochondrial respiratory chain diseases,,,,,,,
469,alpha1 proteinase inhibitor (human),Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.,01/29/2010,Designated,,,emphysema secondary to congenital alpha1-antitrypsin deficiency,,,,,,,
470,Alpha1-antitrypsin(human),Treatment of bronchiectasis,04/03/2008,Designated,,,bronchiectasis,http://purl.obolibrary.org/obo/DOID_9563,http://purl.obolibrary.org/obo/HP_0002110,,D001987,Q32778,,Q32778
472,alpha1-proteinase inhibitor (human),Treatment of cystic fibrosis,02/20/2009,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
474,alpha1-proteinase inhibitor (human),Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.,03/03/2015,Designated,,,type 1 diabetes mellitus patients with residual beta-cell function,,,,,,,
475,alpha1-proteinase inhibitor (human),Treatment of cystic fibrosis,04/06/2012,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
477,Alpha1-Proteinase Inhibitor (Human),Treatment of cystic fibrosis,09/01/2004,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
478,Alprostadil,"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.",10/20/1993,Designated/Withdrawn,Q579348,,"severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated",,,,,,,
479,alteplase,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,01/27/2003,Designated,Q19606349,,intraventricular hemorrhage associated with intracerebral hemorrhage,,,,,,,
480,altiratinib,Treatment of glioblastoma multiforme.,08/19/2014,Designated,Q27074416,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
481,Altretamine,Treatment of advanced adenocarcinoma of the ovary.,02/09/1984,Designated/Approved,Q415242,,advanced adenocarcinoma of the ovary,,,,,,,
482,alvocidib,Treatment of acute myeloid leukemia,04/21/2014,Designated,Q4063441,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
484,Amantadine HCl,Treatment of levodopa-induced dyskinesia,07/20/2015,Designated,,,levodopa-induced dyskinesia,,,,,,,
485,Amantadine hydrochloride,Treatment of levodopa-induced dyskinesia,04/09/2015,Designated,Q27105739,,levodopa-induced dyskinesia,,,,,,,
486,amatuximab,Treatment of mesothelioma,09/28/2012,Designated,Q4740637,,mesothelioma,,,,D008654,,,Q18555143
487,ambrisentan,Treatment of pulmonary arterial hypertension,07/16/2004,Designated/Approved,Q410789,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
488,ambrisentan,Treatment of idiopathic pulmonary fibrosis,12/23/2009,Designated/Withdrawn,Q410789,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
489,ambrisentan/tadalafil fixed combination,Treatment of pulmonary arterial hypertension,08/22/2016,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
490,ambroxol,Treatment of Gaucher disease,06/29/2011,Designated,Q221637,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
491,amifampridine phosphate,Treatment of congenital myasthenic syndromes,03/03/2015,Designated,Q27270515,,congenital myasthenic syndromes,,,,D020294,,,Q3508800
492,amifampridine phosphate,Treatment of myasthenia gravis,08/31/2016,Designated,Q27270515,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
493,amifampridine phosphate,Treatment of Lambert-Eaton Myasthenic Syndrome,11/12/2009,Designated,Q27270515,,lambert-eaton myasthenic syndrome,http://purl.obolibrary.org/obo/DOID_0050214,,http://www.orpha.net/ORDO/Orphanet_43393,D015624,Q1756898,,Q1756898
497,Amifostine,Treatment of myelodysplastic syndromes.,10/04/1999,Designated,Q251698,,myelodysplastic syndromes,,,,D009190,,,Q954625
501,Amiloride HCl solution for inhalation,Treatment of cystic fibrosis.,07/18/1990,Designated/Withdrawn,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
503,aminolevulinic acid hydrochloride,Treatment of esophageal dysplasia,03/20/2007,Designated,Q27291473,BYAFJYYQCWOTAX-UHFFFAOYSA-N,esophageal dysplasia,,,,,,,
504,Aminosalicylate sodium,Treatment of Crohn's disease.,04/06/1993,Designated/Withdrawn,Q27288525,RIIVZTGVYKPDON-UHFFFAOYSA-M,crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,http://purl.obolibrary.org/obo/HP_0100280,,D003424,Q1472,,Q18553712
505,Aminosalicylic acid,Treatment of tuberculosis infections,02/19/1992,Designated/Approved,Q229924,NBGAYCYFNGPNPV-UHFFFAOYSA-N,tuberculosis infections,,,,,,,
506,Aminosidine,Treatment of Mycobacterium avium complex.,11/15/1993,Designated,Q415625,,mycobacterium avium complex,http://purl.obolibrary.org/obo/DOID_2755,,,D015269,Q6946984,,
507,Aminosidine,Treatment of tuberculosis.,05/14/1993,Designated,Q415625,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
508,Aminosidine,Treatment of visceral leishmaniasis (kala-azar).,09/09/1994,Designated,Q415625,,visceral leishmaniasis (kala-azar),,,,,,,
509,aminosidine,Treatment of visceral leishmaniasis,03/29/2005,Designated,Q415625,,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
510,Amiodarone,Treatment of incessant ventricular tachycardia.,08/17/1993,Designated,Q410061,,incessant ventricular tachycardia,,,,,,,
512,amitriptyline and ketamine,Treatment of postherpetic neuralgia,01/19/2010,Designated,,,postherpetic neuralgia,,,,D051474,,,
513,ammonium 21-tungsto-9-antimoniate,Treatment of acquired immunodeficiency syndrome.,07/17/1985,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
514,Ammonium tetrathiomolybdate,Treatment of Wilson's disease.,01/31/1994,Designated,,,wilson's disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
515,ammonium tetrathiomolybdate,Treatment of idiopathic pulmonary fibrosis,05/05/2008,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
516,"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)",Treatment of acquired immunodeficiency syndrome.,11/09/1987,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
517,Amonafide L-malate,Treatment of acute myeloid leukemia,12/20/2006,Designated/Withdrawn,Q27282993,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
518,amphotericin B,Treatment of visceral leishmaniasis.,09/15/2010,Designated,Q412223,,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
519,Amphotericin B inhalation powder,"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies",12/15/2005,Designated,,,"pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies",,,,,,,
520,Amphotericin B lipid complex,Treatment of invasive coccidioidomycosis.,05/06/1996,Designated/Withdrawn,,,invasive coccidioidomycosis,,,,,,,
521,Amphotericin B lipid complex,Treatment of invasive protothecosis.,08/21/1996,Designated/Withdrawn,,,invasive protothecosis,,,,,,,
522,Amphotericin B lipid complex,Treatment of invasive fungal infections.,12/05/1991,Designated/Approved,,,invasive fungal infections,,,,D000072742,,,
523,Amphotericin B lipid complex,Treatment of invasive zygomycosis.,05/06/1996,Designated/Withdrawn,,,invasive zygomycosis,,,,,,,
524,Amphotericin B lipid complex,Treatment of invasive candidiasis.,06/27/1996,Designated/Withdrawn,,,invasive candidiasis,,,,D058365,,,
525,Amphotericin B lipid complex,Treatment of invasive sporotrichosis.,09/23/1996,Designated/Withdrawn,,,invasive sporotrichosis,,,,,,,
526,amrubicin,Treatment of small cell lung cancer,03/10/2008,Designated/Withdrawn,Q4748723,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
527,Amsacrine,Treatment of acute adult leukemia.,12/07/1984,Designated/Withdrawn,Q2784004,,acute adult leukemia,,,,,,,
528,"Amyl nitrite, sodium nitrite, sodium thiosulfate",Treatment of cyanide poisoning,12/18/2006,Designated,,NZZNWYYTFHPOOS-UHFFFAOYSA-L,cyanide poisoning,,,http://www.orpha.net/ORDO/Orphanet_466670,,,,
529,amylopectin,Treatment of glycogen storage disease types Ia and Ib,03/24/2015,Designated,,,glycogen storage disease types ia and ib,,,,,,,
530,an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco),Treatment of hemophilia B,12/22/2011,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
531,ANA-conjugated dactunomycin nanoemulsion,Treatment of Ewing sarcoma,07/07/2015,Designated,,,ewing sarcoma,http://purl.obolibrary.org/obo/DOID_3369,http://purl.obolibrary.org/obo/HP_0012254,http://www.orpha.net/ORDO/Orphanet_319,D012512,Q18555397,,Q18555397
532,Anagrelide,Treatment of essential thrombocythemia.,01/27/1988,Designated/Approved,Q27124246,,essential thrombocythemia,http://purl.obolibrary.org/obo/DOID_2224,,http://www.orpha.net/ORDO/Orphanet_3318,D013920,Q18555037,Q18555037,Q18555037
533,Anagrelide,Treatment of thrombocytosis in chronic myelogenous leukemia.,07/14/1986,Designated,Q27124246,,thrombocytosis in chronic myelogenous leukemia,,,,,,,
534,Anagrelide,Treatment of polycythemia vera.,06/11/1985,Designated,Q27124246,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
535,anakinra,Treatment of cryopyrin-associated periodic syndromes,08/19/2010,Designated/Approved,Q415411,,cryopyrin-associated periodic syndromes,,,,D056587,,,Q1835481
538,Anaritide acetate,Treatment of patients with acute renal failure.,08/27/1992,Designated/Withdrawn,,,patients with acute renal failure,,,,,,,
539,Anatibant,Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome,04/15/2005,Designated,Q27074461,,patients having experienced a severe traumatic brain injury (glasgow coma scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome,,,,,,,
543,anfibatide,Treatment of thrombotic thrombocytopenic purpura.,03/10/2016,Designated,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
544,Angiotensin (1-7),Treatment of LAMA2-related muscular dystrophy,02/08/2016,Designated,,,lama2-related muscular dystrophy,,,,,,,
545,angiotensin (1-7),Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor,08/30/2013,Designated,,,patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (cd34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor,,,,,,,
546,Angiotensin (1-7),Treatment of recessive dystrophic epidermolysis bullosa (RDEB).,09/01/2016,Designated,,,recessive dystrophic epidermolysis bullosa (rdeb),,,,,,,
547,Angiotensin (1-7),Treatment of limb-girdle muscular dystrophy,11/26/2013,Designated,,,limb-girdle muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11724,http://purl.obolibrary.org/obo/HP_0006785,http://www.orpha.net/ORDO/Orphanet_263,D049288,Q1531322,Q1531322,Q1531322
548,angiotensin (1-7)[A(1-7)],Treatment of Duchenne muscular dystrophy,07/25/2013,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
549,Angiotensin 1-7,Treatment of neutropenia associated with autologous bone marrow transplantation.,02/16/2000,Designated,Q27074464,,neutropenia associated with autologous bone marrow transplantation,,,,,,,
550,Angiotensin 1-7,Treatment of myelodysplastic syndrome,08/03/2001,Designated,Q27074464,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
552,angiotensin 1-7,Treatment of sarcoma.,01/29/2010,Designated,Q27074464,,sarcoma,http://purl.obolibrary.org/obo/DOID_1115,http://purl.obolibrary.org/obo/HP_0100242,,D012509,Q223911,,Q18975788
553,Angiotensin-(1-7),Treatment of pulmonary arterial hypertension.,09/13/2011,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
554,anisina,Treatment of neuroblastoma.,07/14/2015,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
555,anlotinib hydrochloride,Treatment of ovarian cancer,12/31/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
556,antagonist of the complement 5a receptor,Treatment of atypical hemolytic uremic syndrome,11/17/2014,Designated,,,atypical hemolytic uremic syndrome,,,,D065766,,,Q17165460
557,antagonist of the complement 5a receptor,"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.",06/02/2014,Designated,,,"anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or wegener's granulomatosis), microscopic polyangiitis, and churg-strauss syndrome",,,,,,,
558,"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9",Treatment of Waldenstrom's macroglobulinemia,12/23/2014,Designated,,,waldenstrom's macroglobulinemia,,,,D008258,,,Q4118092
559,anthrax immune globulin,Treatment of inhalation anthrax disease,09/03/2009,Designated/Withdrawn,,,inhalation anthrax disease,,,http://www.orpha.net/ORDO/Orphanet_247257,,,,
560,anthrax immune globulin (human),Treatment of inhalational anthrax,07/29/2008,Designated/Approved,,,inhalational anthrax,,,http://www.orpha.net/ORDO/Orphanet_247257,,,,
562,anti human Nogo-A human monoclonal antibody,Treatment of acute spinal cord injury,10/20/2008,Designated,,,acute spinal cord injury,,,,,,,
564,anti-Beta1 integrin monoclonal antibody,Treatment of ovarian cancer,01/13/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
565,Anti-Beta1 integrin monoclonal antibody,Treatment of glioblastoma,08/07/2014,Designated,,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
566,"anti-CD23 IgG1, kappa monoclonal antibody",Treatment of chronic lymphocytic leukemia,02/12/2003,Designated/Withdrawn,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
567,anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein,Treatment of graft versus host disease,09/13/2013,Designated,,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
568,anti-CD30 Fc engineered humanized monoclonal antibody,Treatment of Hodgkin lymphoma,12/02/2008,Designated,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
569,Anti-CD45 monoclonal antibodies,Prevention of acute graft rejection of human organ transplants.,09/10/1990,Designated/Withdrawn,,,acute graft rejection of human organ transplants,,,,,,,
570,Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201),Treatment of pancreatic cancer,05/21/2003,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
573,Anti-EphA1 monoclonal antibody conjugated to mcMMAF,Treatment of ovarian cancer,07/27/2009,Designated/Withdrawn,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
574,Anti-eTau Humanized IgG4 Monoclonal Antibody,Treatment of Progressive Supranuclear Palsy,05/13/2015,Designated,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
575,anti-HER2 bispecific antibody,Treatment of ovarian cancer,05/18/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
576,Anti-HER2 bispecific antibody,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",02/06/2017,Designated,,,"gastric cancer, including cancer of the gastroesophageal junction",,,,,,,
577,anti-HER2 bispecific antibody drug conjugate,Treatment of ovarian cancer,07/06/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
580,anti-interleukin 21 (NNC0114-0006) in combination with liraglutide,Treatment of Type I Diabetes Mellitus with residual beta cell function.,01/12/2017,Designated,,,type i diabetes mellitus with residual beta cell function,,,,,,,
582,anti-nogo-A monoclonal antibody,Treatment of amyotrophic lateral sclerosis,07/07/2009,Designated/Withdrawn,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
583,anti-sense oligonucleotide consisting of 2ÃƒÂ¿Ã†Â¿ÃƒÂ¿Ã¢Â¿Â¿ÃƒÂ¿Ã¢Â¿Â¿ÃƒÂ¿Ã‚Â¢ÃƒÂ¿Ã†Â¿ÃƒÂ¿Ã‚Â¢ÃƒÂ¿Ã‚Â¢ÃƒÂ¢Ã¢Â¿Â¿Ã‚Â¬ÃƒÂ¿Ã‚Â¡ÃƒÂ¿Ã¢Â¿Â¿ÃƒÂ¿Ã‚Â¬ÃƒÂ¿Ã†Â¿ÃƒÂ¿Ã‚Â¢ÃƒÂ¿Ã‚Â¢ÃƒÂ¢Ã¢Â¿Â¿Ã‚Â¬ÃƒÂ¿Ã‚Â¾ÃƒÂ¿Ã¢Â¿Â¿ÃƒÂ¿Ã‚Â¢0-Me RNA with a phosphorothioate backbone,Treatment of cystic fibrosis,09/23/2013,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
584,anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody,Treatment of pancreatic cancer,08/29/2016,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
586,"anti-T-lymphocyte immune globulin, rabbit",Prevention of graft versus host disease (GVHD),03/26/2010,Designated,,,graft versus host disease (gvhd),,,,,,,
588,Anti-tap-72 immunotoxin,Treatment of metastatic colorectal adenocarcinoma.,03/06/1987,Designated/Withdrawn,,,metastatic colorectal adenocarcinoma,,,,,,,
589,"anti-TCR murine monoclonal antibody (MAb, type IgM)",Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function,06/07/2010,Designated,,,patients 16 years of age and younger with immune-mediated t1dm and preserved pancreatic beta cell function,,,,,,,
590,"anti-TCR murine monoclonal antibody (MAB, type IgM)",Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age,01/12/2011,Designated,,,pediatric multiple sclerosis in patients less than or equal to 16 years of age,,,,,,,
591,Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131,Treatment of primary malignant brain tumors,10/04/2005,Designated,,,primary malignant brain tumors,,,,D001932,,,Q18554460
592,anti-thymocyte Globulin (rabbit),Treatment of myelodysplastic syndrome,09/06/2000,Designated/Withdrawn,Q20801777,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
594,Anti-thymocyte serum,"Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.",06/02/1993,Designated,,,"allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation",,,,,,,
595,anti-tumor necrosis factor (TNF) polyclonal antibody (bovine),Treatment of pediatric ulcerative colitis (0 through 16 years of age),11/17/2014,Designated,,,pediatric ulcerative colitis (0 through 16 years of age),,,,,,,
596,Anti-von Willebrand Aptamer,Treatment of thrombotic thrombocytopenic purpura,04/09/2008,Designated/Withdrawn,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
597,antiangiogenic components extracted from marine cartilage,Treatment of renal cell carcinoma,10/16/2002,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
598,Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E,Treatment of ovarian cancer,07/29/2014,Designated/Withdrawn,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
599,antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E,Treatment of gastric cancer,07/21/2014,Designated/Withdrawn,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
600,Antiepilepsirine,Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.,03/23/1989,Designated,,,drug resistant generalized tonic-clonic epilepsy in children and adults,,,,,,,
601,Antihemophilic factor (human),Treatment of von Willebrand's disease,01/05/1996,Designated/Approved,,,von willebrand's disease,http://purl.obolibrary.org/obo/DOID_12531,,,D014842,Q709360,,Q709360
604,Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent,Treatment of hemophilia A,04/29/2009,Designated/Withdrawn,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
605,"antihemophilic factor (recombinant), Fc fusion protein",Treatment of hemophilia A,11/23/2010,Designated/Approved,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
606,"antihemophilic factor (recombinant), porcine sequence",Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII,03/16/2004,Designated/Approved,,,prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor viii,,,,,,,
607,"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized",Treatment of patients with von Willebrand's disease,10/16/1992,Designated/Approved,,,patients with von willebrand's disease,,,,,,,
609,Antimelanoma Antibody XMMME-001-RTA,Treatment of stage III melanoma not amenable to surgical resection.,11/14/1984,Designated/Withdrawn,,,stage iii melanoma not amenable to surgical resection,,,,,,,
610,antimesothelin-ADC (antibody drug conjugate),Treatment of mesothelioma,07/05/2012,Designated,,,mesothelioma,,,,D008654,,,Q18555143
611,"antineoplaston A10, antineoplaston AS2-1",Treatment of gliomas,11/21/2008,Designated,,,gliomas,,,,D005910,,,Q18556612
612,antinuclear antibody conjugated liposomal doxorubicin,Treatment of Ewing's sarcoma.,02/03/2015,Designated,,,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
614,Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA,Treatment of acute myeloid leukemia,04/15/2005,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
615,antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA],Treatment for renal cell carcinoma,03/12/2003,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
616,antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA,Treatment of Leber's congenital amaurosis.,05/25/2016,Designated,,,leber's congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
617,Antisense oligonucleotide directed against connexin43,Treatment of persistent corneal epithelial defects,04/27/2009,Designated,,,persistent corneal epithelial defects,,,,,,,
618,antisense oligonucleotide inhibitor of the expression of superoxide dismutase 1 gene,Treatment of amyotrophic lateral sclerosis,09/19/2016,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
619,antisense oligonucleotide targeted to human transthyretin (TTR) mRNA,Treatment of familial amyloid polyneuropathy,07/24/2012,Designated,,,familial amyloid polyneuropathy,http://purl.obolibrary.org/obo/DOID_0050638,,,D028227,Q2844603,,
620,Antisense oligonucleotide targeted to the huntingtin protein,Treatment of Huntington's disease,12/29/2015,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
621,antisense oligonucleotide targeting the U isoform of SNP rs362307,Treatment of Huntington's disease (prodromal stage Huntington's disease and diagnosed Huntington's disease),06/16/2016,Designated,,,huntington's disease (prodromal stage huntington's disease and diagnosed huntington's disease),,,,,,,
626,Antivenin crotaline (pit-viper) equine immune F(ab)2),Treatment of envenomation by Crotaline snakes,01/29/2004,Designated/Approved,,,envenomation by crotaline snakes,,,,,,,
627,"Antivenin, crotalidae polyvalent immune Fab (ovine)",Treatment of envenomations inflicted by North American crotalid snakes.,01/12/1994,Designated/Approved,,,envenomations inflicted by north american crotalid snakes,,,,,,,
628,Antivenom (crotalidae) purified (avian),Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.,02/12/1991,Designated,,,envenomation by poisonous snakes belonging to the crotalidae family,,,,,,,
629,antroquinonol,Treatment of acute myeloid leukemia,04/30/2015,Designated,Q27133859,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
630,antroquinonol,Treatment of pancreatic cancer,01/21/2015,Designated,Q27133859,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
631,antroquinonol,Treatment of hepatocellular carcinoma,07/23/2015,Designated,Q27133859,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
632,aphidicolin,Treatment of Ebola virus infection,04/20/2016,Designated,Q414000,,ebola virus infection,,,,D019142,,,Q8064876
633,apolipoprotein E mimetic peptide,Treatment of homozygous familial hypercholesterolemia,12/03/2012,Designated,,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
634,Apomorphine,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,07/17/1995,Designated,Q269111,,the on-off fluctuations associated with late-stage parkinson's disease,,,,,,,
636,Apomorphine HCl,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,04/22/1993,Designated/Approved,Q27114230,,the on-off fluctuations associated with late-stage parkinson's disease,,,,,,,
638,apremilast,Treatment of Behcet's disease,01/17/2013,Designated,Q2858961,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
640,AQ-13 (4-aminoquinoline analog),Treatment of malaria,09/12/2008,Designated,,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
641,Arcitumomab,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",05/10/1996,Designated/Withdrawn,Q637504,,"localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma",,,,,,,
642,Arenegyr,Treatment of malignant pleural mesothelioma,08/22/2008,Designated,,,malignant pleural mesothelioma,http://purl.obolibrary.org/obo/DOID_7474,,,,Q18557602,,
643,Arginine butyrate,Treatment of beta-hemoglobinopathies and beta-thalassemia.,04/07/1992,Designated,Q27280766,HTWPXGKLFMPZHG-WCCKRBBISA-N,beta-hemoglobinopathies and beta-thalassemia,,,,,,,
644,Arginine butyrate,Treatment of sickle cell disease and beta thalassemia.,05/25/1994,Designated/Withdrawn,Q27280766,HTWPXGKLFMPZHG-WCCKRBBISA-N,sickle cell disease and beta thalassemia,,,,,,,
645,arimoclomol,Treatment of amyotrophic lateral sclerosis,03/29/2005,Designated,Q4790694,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
646,arimoclomol citrate,"Treatment of Neimann-Pick disease, type C",01/13/2015,Designated,Q27287107,,"neimann-pick disease, type c",,,,,,,
647,aripiprazole,Treatment of Tourette's syndrome,01/25/2006,Designated/Approved,Q411188,,tourette's syndrome,,,,D005879,,,Q191779
648,arsenic,"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7",11/02/2001,Designated,Q21060492,RQNWIZPPADIBDY-UHFFFAOYSA-N,"acute myelocytic leukemia subtypes m0, m1, m2, m4, m5, m6 and m7",,,,,,,
649,Arsenic trioxide,Treatment of acute promyelocytic leukemia.,03/03/1998,Designated/Approved,Q26841209,,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
650,Arsenic trioxide,Treatment of chronic lymphocytic leukemia,05/13/2003,Designated,Q26841209,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
651,arsenic trioxide,Treatment of liver cancer,06/13/2003,Designated,Q26841209,,liver cancer,http://purl.obolibrary.org/obo/DOID_3571,http://purl.obolibrary.org/obo/HP_0002896,,D008113,Q623031,,Q1671502
652,arsenic trioxide,Treatment of chronic myeloid leukemia,10/18/2001,Designated,Q26841209,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
653,Arsenic trioxide,Treatment of malignant glioma,03/04/2005,Designated,Q26841209,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
654,arsenic trioxide,Treatment of myelodysplastic syndrome.,07/17/2000,Designated,Q26841209,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
655,Arsenic trioxide,Treatment of multiple myeloma.,04/28/2000,Designated,Q26841209,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
656,arsenic trioxide capsule (oral),Treatment of acute promyelocytic leukemia.,11/02/2015,Designated,,,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
659,Artesunate,Treatment of malaria.,07/19/1999,Designated,Q707939,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
660,arylsulfatase A (rhASA),Treatment of metachromatic leukodystrophy,02/27/2008,Designated,,,metachromatic leukodystrophy,http://purl.obolibrary.org/obo/DOID_10581,,http://www.orpha.net/ORDO/Orphanet_512,D007966,Q1120682,Q1120682,Q1120682
661,ascorbic acid,Treatment of Charcot-Marie-Tooth disease type 1A.,05/11/2009,Designated,Q199678,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,charcot-marie-tooth disease type 1a,http://purl.obolibrary.org/obo/DOID_0110148,,http://www.orpha.net/ORDO/Orphanet_101081,,Q27677640,,
662,Ascorbic acid,Treatment of scurvy,08/31/2007,Designated,Q199678,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,scurvy,http://purl.obolibrary.org/obo/DOID_13724,,,D012614,Q163865,,Q163865
663,Asfotase alfa,Treatment of hypophosphatasia,09/12/2008,Designated/Approved,Q22075839,,hypophosphatasia,http://purl.obolibrary.org/obo/DOID_14213,,http://www.orpha.net/ORDO/Orphanet_436,D007014,Q1313510,,Q1313510
664,astuprotimut-R,Treatment of MAGE-A3 positive non-small cell lung cancer,05/29/2009,Designated,,,mage-a3 positive non-small cell lung cancer,,,,,,,
665,astuprotimut-R,Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma,05/29/2009,Designated/Withdrawn,,,mage-a3 positive stages iib to iv malignant melanoma,,,,,,,
666,ataluren,Treatment of spinal muscular atrophy,03/10/2008,Designated,Q753330,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
667,ataluren,Treatment of aniridia,09/01/2015,Designated,Q753330,,aniridia,http://purl.obolibrary.org/obo/DOID_12271,http://purl.obolibrary.org/obo/HP_0000526,http://www.orpha.net/ORDO/Orphanet_77,D015783,Q548719,,Q548719
669,ataluren,Treatment of mucopolysaccharidosis type I,12/10/2014,Designated,Q753330,,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
670,ataluren,Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene,01/10/2005,Designated,Q753330,,muscular dystrophy resulting from premature stop mutations in the dystrohin gene,,,,,,,
671,Atezolizumab,Treatment of small cell lung cancer (SCLC),10/13/2016,Designated,Q20707748,,small cell lung cancer (sclc),,,,,,,
672,Atezolizumab,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",02/13/2017,Designated,Q20707748,,"patients with stage iib, iic, iii, and iv melanoma",,,,,,,
673,atezolizumab,"Treatment of Stage llb, llc, lll and IV melanoma",02/13/2017,Designated,Q20707748,,"stage llb, llc, lll and iv melanoma",,,,,,,
674,Atomoxetine hydrochloride,Treatment of Tourette's Syndrome,08/26/2003,Designated/Withdrawn,Q27225729,,tourette's syndrome,,,,D005879,,,Q191779
675,Atovaquone,Treatment of AIDS associated Pneumocystis Carinii Pneumonia.,09/10/1990,Designated/Approved,Q418179,,aids associated pneumocystis carinii pneumonia,,,,,,,
676,Atovaquone,"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.",08/14/1991,Designated/Approved,Q418179,,"pneumocystis carinii pneumonia (pcp) in high-risk, hiv-infected patients defined by a history of one or more episodes of pcp and/or a peripheral cd4+ (t4 helper/inducer) lymphocyte count less than or equal to 200/mm3",,,,,,,
678,Atovaquone,Treatment and suppression of Toxoplasma gondii encephalitis.,03/16/1993,Designated/Withdrawn,Q418179,,suppression of toxoplasma gondii encephalitis,,,,,,,
679,Atrasentan,Treatment of pediatric nephrotic syndrome,09/29/2016,Designated,Q125083,,pediatric nephrotic syndrome,,,,,,,
680,Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells,Treatment of primary central nervous system malignancies,04/27/2007,Designated,,,primary central nervous system malignancies,,,,,,,
681,auranofin,Treatment of amebiasis,04/30/2010,Designated,Q421230,,amebiasis,http://purl.obolibrary.org/obo/DOID_9181,,,D000562,Q949694,,Q949694
682,autologous adipose derived mesenchymal stromal cells,Treatment of amyotrophic lateral sclerosis,10/22/2014,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
683,autologous adipose tissue derived mesenchymal stem cells,Treatment of Buerger's disease (thromboangiitis obliterans).,05/04/2016,Designated,,,buerger's disease (thromboangiitis obliterans),,,,,,,
684,autologous antigen presenting cells pulsed with autologous tumor Ig idiotype,Treatment of multiple myeloma,04/18/2002,Designated/Withdrawn,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
685,"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",Treatment of adenosine deaminase deficient severe combined immunodeficiency,10/21/2014,Designated,,,adenosine deaminase deficient severe combined immunodeficiency,,,,,,,
686,Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor),Treatment of acute lymphoblastic leukemia (ALL),11/13/2014,Designated,,,acute lymphoblastic leukemia (all),,,,,,,
687,autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc),Treatment of severe combined immune deficiency-X1,01/15/2015,Designated,,,severe combined immune deficiency-x1,,,,,,,
688,Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003),Treatment of Wiskott Aldrich syndrome,04/30/2010,Designated,,,wiskott aldrich syndrome,,,,D014923,,,Q953638
689,autologous CD34+ hematopoietic stem cells tranduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA,Treatment of andrenoleukodystrophy,04/19/2012,Designated,,,andrenoleukodystrophy,,,,,,,
691,autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene,Treatment of B-thalassemia major and intermedia,03/18/2013,Designated,,,b-thalassemia major and intermedia,,,,,,,
692,autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor (CAR) and a truncated epidermal growth factor receptor.,Treatment of chronic lymphocytic leukemia,10/04/2016,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
693,autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor,Treatment of acute lymphoblastic leukemia,09/07/2016,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
694,autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor,Treatment of diffuse large B-cell lymphoma,04/27/2016,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
695,autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia),11/06/2014,Designated,,,acute lymphoblastic leukemia (inclusive of b-cell acute lymphoblastic leukemia),,,,,,,
696,Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein,Treatment of soft tissue sarcoma.,03/28/2016,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
697,autologous CD4+CD25hiFoxP3+regulatory T cells,Prevention of graft rejection following solid organ transplantation,11/19/2013,Designated,,,graft rejection following solid organ transplantation,,,,,,,
698,Autologous cultured endothelial cells on a donor human corneal disk,"Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy",06/01/2007,Designated,,,"fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy",,,,,,,
699,Autologous dendritic cell/tumor antigens,Treatment of glioblastoma multiforme (GBM),09/27/2016,Designated,,,glioblastoma multiforme (gbm),,,,,,,
700,autologous dendritic cells pulsed with allogeneic tumor cell lysate,Treatment of malignant mesothelioma,05/06/2014,Designated,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
701,Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells,Treatment of primary brain malignant cancer,11/29/2002,Designated,,,primary brain malignant cancer,,,,,,,
702,Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose,Treatment of ovarian cancer.,09/13/2010,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
704,Autologous Engineered Skin Substitute,Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.,06/01/2012,Designated,,,hospitalized patients with deep partial and full thickness burns requiring grafting,,,,,,,
705,autologous Epstein-Barr virus specific T-cells,Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.,03/09/2015,Designated,,,epstein-barr virus positive non-hodgkin lymphomas,,,,,,,
706,autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2ÃƒÂ¢Ã¢Â¿Â¬Ã¢Â¿Â¢-deoxycytidine,Treatment of glioblastoma multiforme,09/13/2013,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
707,autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells,Treatment of type 1 diabetes mellitus with residual beta cell function,05/10/2016,Designated,,,type 1 diabetes mellitus with residual beta cell function,,,,,,,
708,autologous genetically modified human dermal fibroblasts,Treatment of dystrophic epidermolysis bullosa.,06/10/2014,Designated,,,dystrophic epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_4959,,http://www.orpha.net/ORDO/Orphanet_303,D016108,Q3589131,,Q3589131
710,"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5",Treatment of chronic graft versus host disease,04/03/2008,Designated,,,chronic graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_99921,,,,
711,Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin,Treatment of Waldenstrom's macroglobulinemia,10/18/2011,Designated,,,waldenstrom's macroglobulinemia,,,,D008258,,,Q4118092
712,autologous neo-uninary conduit,Treatment of bladder dysfunction requiring incontinent urinary diversion.,06/07/2011,Designated,,,bladder dysfunction requiring incontinent urinary diversion,,,,,,,
713,autologous olfactory neural progenitors,Treatment of amyotrophic lateral sclerosis,12/31/2008,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
714,Autologous olfactory neural progenitors,"Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C",02/01/2008,Designated,,,"spinal cord injury patients with asia impairment grades a, b, or c",,,,,,,
715,Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane,Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency,07/14/2005,Designated,,,ocular surface diseases that are characterized by total limbal stem cell deficiency,,,,,,,
716,autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.,Treatment of congenital pseudarthrosis of the tibia,06/30/2016,Designated,,,congenital pseudarthrosis of the tibia,,,,,,,
717,autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor,Treatment of diffuse large B-cell lymphoma.,03/27/2014,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
718,Autologous stromal vascular cell fraction from adipose tissue (central facitily processed),Treatment of impaired hand function due to systemic sclerosis,11/09/2016,Designated,,,impaired hand function due to systemic sclerosis,,,,,,,
720,autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,Treatment of chronic lymphocytic leukemia,03/14/2014,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
721,autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,Treatment of chronic lymphocytic leukemia.,04/20/2016,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
722,autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,Treatment of follicular lymphoma.,04/25/2016,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
723,Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,Treatment of acute lymphoblastic leukemia. (ALL).,04/20/2016,Designated,,,acute lymphoblastic leukemia. (all),,,,,,,
724,autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,Treatment of mantle cell lymphoma.,04/28/2016,Designated,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
725,autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,Treatment of primary mediastinal B-cell lymphoma.,04/20/2016,Designated,,,primary mediastinal b-cell lymphoma,,,,,,,
726,autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen,Treatment of multiple myeloma,05/11/2016,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
727,"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line",Treatment of glioblastoma,05/06/2015,Designated,,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
728,autologous tumor-derived gp96 heat shock protein-peptide complex,Treatment of renal cell carcinoma,05/10/2002,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
729,autologous tumor-derived gp96 heat shock protein-peptide complex,Treatment of metastatic melanoma,07/11/2002,Designated,,,metastatic melanoma,,,,,,,
730,autologous umbilical cord blood,Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury,07/24/2012,Designated,,,pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury,,,,,,,
731,autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene,Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.,08/26/2009,Designated,,,severe combined immunodeficiency due to adenosine deaminase deficiency,,,http://www.orpha.net/ORDO/Orphanet_277,,,,
732,Autolymphocyte therapy,Treatment of renal cell carcinoma.,07/12/1994,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
733,avicin d,Treatment of multiple myeloma,03/24/2015,Designated,Q27264310,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
734,aviptadil,Treatment of pulmonary arterial hypertension,02/22/2005,Designated,Q4828930,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
735,axitinib,Treatment of pancreatic cancer,05/31/2007,Designated/Withdrawn,Q4830631,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
737,Azacitidine,Treatment of acute myeloid leukemia,06/18/2008,Designated,Q416451,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
738,Azathioprine,Treatment of oral manifestations of graft-versus-host disease.,09/14/1999,Designated,Q18939,,oral manifestations of graft-versus-host disease,,,,,,,
741,Azurin-p28,Treatment of glioma,12/02/2015,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
742,B Lymphocyte Stimulator,Treatment of common variable immunodeficiency (CVID),02/21/2001,Designated/Withdrawn,,,common variable immunodeficiency (cvid),,,,,,,
743,Bacillus Calmette-Guerin vaccine,Treatment of stage IIb through IV metastatic melanoma,08/09/2006,Designated,,,stage iib through iv metastatic melanoma,,,,,,,
744,Bacillus subtilis oxalate decarboxylase,Treatment of pediatric hyperoxaluria,02/29/2016,Designated,,,pediatric hyperoxaluria,,,,,,,
745,Bacitracin,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,03/13/1984,Designated,Q424319,,antibiotic-associated pseudomembranous enterocolitis caused by toxins a and b elaborated by clostridium difficile,,,,,,,
746,baclofen,Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.,12/16/1991,Designated,Q413717,,intractable spasticity due to multiple sclerosis or spinal cord injury,,,,,,,
747,Baclofen,Treatment of spasticity associated with cerebral palsy.,09/26/1994,Designated,Q413717,,spasticity associated with cerebral palsy,,,,,,,
748,baclofen,Treatment of dystonia,12/02/2003,Designated,Q413717,,dystonia,http://purl.obolibrary.org/obo/DOID_543,http://purl.obolibrary.org/obo/HP_0001332,,D004421,Q906492,,Q906492
749,baclofen,Treatment of complex regional pain syndrome.,10/28/2015,Designated,Q413717,,complex regional pain syndrome,http://purl.obolibrary.org/obo/DOID_3223,,http://www.orpha.net/ORDO/Orphanet_83452,,Q1066311,,
750,baclofen,"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).",11/10/1987,Designated/Approved,Q413717,,"intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)",,,,,,,
751,bacterium Bacteroides thetaiotaomicron,Treatment of active Crohn's disease in the pediatric population,09/26/2013,Designated,,,active crohn's disease in the pediatric population,,,,,,,
752,Balsalazide disodium,Treatment of pediatric patients with ulcerative colitis,08/12/2005,Designated/Approved,Q27126501,,pediatric patients with ulcerative colitis,,,,,,,
753,Bardoxolone,Treatment of pancreatic cancer,08/06/2008,Designated,Q27074871,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
754,bardoxolone,Treatment of pulmonary arterial hypertension,03/30/2015,Designated,Q27074871,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
756,basimglurant,Treatment of Fragile X Syndrome,03/09/2012,Designated,Q18209947,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
757,BCL-005 (fused (hybrid) melanoma-dendritic cells),Treatment of stage IIb to IV melanoma in HLA-A2 positive patients,10/21/2010,Designated/Withdrawn,,,stage iib to iv melanoma in hla-a2 positive patients,,,,,,,
758,beclomethasone,Treatment of pediatriac patients with ulcerative colitis,03/04/2009,Designated,,,pediatriac patients with ulcerative colitis,,,,,,,
759,"beclomethasone 17,21-dipropionate",Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation,07/24/2009,Designated,,,gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation,,,,,,,
760,"beclomethasone 17,21-dipropionate",Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,11/19/2012,Designated,,,death following a potentially lethal dose of total body irradiation during or after a radiation disaster,,,,,,,
761,"beclomethasone 17,21-dipropionate",Prevention of gastrointestinal graft-versus-host disease,08/28/2001,Designated,,,gastrointestinal graft-versus-host disease,,,,,,,
762,"beclomethasone 17,21-diproprionate",Treatment of pediatric patients with Crohn disease.,12/18/2007,Designated,,,pediatric patients with crohn disease,,,,,,,
764,"bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol",Treatment of active tuberculosis,01/10/2005,Designated/Approved,,,active tuberculosis,,,,,,,
766,Belinostat,Treatment of peripheral T-cell lymphoma (PTCL).,09/03/2009,Designated/Approved,Q4882925,,peripheral t-cell lymphoma (ptcl),,,,,,,
767,beloranib,Treatment of Prader-Willi syndrome,01/15/2013,Designated/Withdrawn,Q4884554,,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
768,bendamustine for 50 ml admixture,Treatment of chronic lymphocytic leukemia,07/02/2014,Designated/Approved,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
769,bendamustine for 50ml admixture,"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)",07/02/2014,Designated/Approved,,,"follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoma tissue (malt), and nodal marginal zone lymphoma (collectively indolent b-cell non-hodgkin's lymphoma)",,,,,,,
770,bendamustine hydrochloride,"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)",11/26/2013,Designated/Approved,Q27272066,,"follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoma tissue (malt), and nodal marginal zone lymphoma (collectively indolent b-cell non-hodgkin's lymphoma)",,,,,,,
771,Bendamustine hydrochloride,Treatment of chronic lymphocytic leukemia,08/17/2007,Designated/Approved,Q27272066,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
772,bendamustine hydrochloride with betadex sulfobutyl ether sodium,Treatment of chronic lymphocytic leukemia,09/10/2013,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
773,Bendamustine oral doseage formulation,Treatment of chronic lymphocytic leukemia,11/05/2015,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
774,benznidazole,Treatment of Chagas disease,04/14/2014,Designated,Q425300,,chagas disease,http://purl.obolibrary.org/obo/DOID_12140,,http://www.orpha.net/ORDO/Orphanet_3386,D014355,Q649558,,Q649558
775,benzoate,Treatment of pediatric schizophrenia,07/06/2012,Designated,Q27075054,WPYMKLBDIGXBTP-UHFFFAOYSA-M,pediatric schizophrenia,,,,,,,
777,benzoate/phenylacetate,Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,11/22/1993,Designated/Approved,,,acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle,,,,,,,
781,Beractant,Treatment of neonatal respiratory distress syndrome,02/05/1986,Designated/Approved,,,neonatal respiratory distress syndrome,http://purl.obolibrary.org/obo/DOID_12716,,http://www.orpha.net/ORDO/Orphanet_70587,D012127,Q754348,,
782,Beractant,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",12/20/1993,Designated,,,"full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis",,,,,,,
783,Beraprost,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",04/29/1999,Designated,Q5977854,,"pulmonary arterial hypertension associated with any new york heart association classification (class i, ii, iii, or iv)",,,,,,,
784,beraprost sodium 314d,Treatment of pulmonary arterial hypertension,12/22/2011,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
785,Beta alethine,Treatment of multiple myeloma.,03/24/1997,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
786,Beta alethine,Treatment of metastatic melanoma.,03/24/1997,Designated,,,metastatic melanoma,,,,,,,
787,Betahistine dihydrochloride,Treatment of obesity associated with Prader Willi syndrome,11/08/2007,Designated,,,obesity associated with prader willi syndrome,,,,,,,
788,Betaine,Treatment of homocystinuria.,05/16/1994,Designated/Approved,Q10860583,,homocystinuria,http://purl.obolibrary.org/obo/DOID_9263,http://purl.obolibrary.org/obo/HP_0002156,,D006712,Q994859,,Q994859
789,betamethasone,Treatment of Ataxia Telangiectasia.,10/07/2015,Designated,Q416132,,ataxia telangiectasia,http://purl.obolibrary.org/obo/DOID_12704,,,D001260,Q387082,,Q387082
790,Bethanidine sulfate,Prevention of recurrence of primary ventricular fibrillation.,11/24/1989,Designated/Withdrawn,Q27887005,,recurrence of primary ventricular fibrillation,,,,,,,
791,Bethanidine sulfate,Treatment of primary ventricular fibrillation.,09/20/1988,Designated/Withdrawn,Q27887005,,primary ventricular fibrillation,,,,,,,
793,bevacizumab,Treatment of malignant glioma,05/26/2006,Designated/Approved,Q413299,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
794,bevacizumab,Treatment of pancreatic cancer,10/20/2004,Designated,Q413299,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
795,bevacizumab,Treatment of fallopian tube carcinoma,11/23/2010,Designated/Approved,Q413299,,fallopian tube carcinoma,http://purl.obolibrary.org/obo/DOID_1963,http://purl.obolibrary.org/obo/HP_0030394,,,Q18554948,,
797,bevacizumab,Treatment of Coat's disease,03/10/2016,Designated,Q413299,,coat's disease,,,,,,,
799,bevacizumab,Treatment of hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Q413299,,hereditary hemorrhagic telangiectasia,http://purl.obolibrary.org/obo/DOID_1270,,http://www.orpha.net/ORDO/Orphanet_774,D013683,Q776881,Q776881,Q776881
800,bevacizumab,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,10/13/2009,Designated,Q413299,,melanoma stages iib through iv as part of a combination chemotherapy regimen,,,,,,,
801,bevacizumab,Treatment of renal cell carcinoma,11/06/2003,Designated/Approved,Q413299,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
802,bevacizumab,Treatment of mesothelioma,01/27/2016,Designated,Q413299,,mesothelioma,,,,D008654,,,Q18555143
803,bevacizumab,Treatment of primary peritoneal carcinoma.,11/02/2010,Designated/Approved,Q413299,,primary peritoneal carcinoma,http://purl.obolibrary.org/obo/DOID_1791,http://purl.obolibrary.org/obo/HP_0030406,http://www.orpha.net/ORDO/Orphanet_168829,,Q1816041,Q1816041,
804,Bexarotene,Treatment of cutaneous T-cell lymphoma.,06/18/1999,Designated/Approved,Q418192,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
806,BF2.649 (Pitolisant),Treatment of narcolepsy,05/17/2010,Designated,,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
807,bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine,Treatment of Ewing's sarcoma,10/22/2014,Designated,,,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
808,bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine,Treatment of stage IIB to IV melanoma,02/17/2012,Designated,,,stage iib to iv melanoma,,,,,,,
809,bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine,Treatment of ovarian cancer,04/18/2011,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
810,bifidobacterium infantis 35624,Treatment of pediatric ulcerative colitis,03/24/2008,Designated,,,pediatric ulcerative colitis,,,,,,,
811,bifidobacterium longum infantis 35624,Treatment of pediatric Crohn's disease,01/16/2003,Designated,,,pediatric crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,,,,Q1472,,
812,"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts",Treatment of partial deep dermal and full thickness burn wounds,09/06/2016,Designated,,,partial deep dermal and full thickness burn wounds,,,,,,,
813,Bindarit,Treatment of lupus nephritis.,02/03/1998,Designated,Q27281631,,lupus nephritis,http://purl.obolibrary.org/obo/DOID_0080162,,,D008181,Q1621830,,Q1621830
814,binimetinib,Treatment Stage IIB-IV melanoma.,11/19/2013,Designated,Q19903515,,iib-iv melanoma,,,,,,,
815,binimetinib,Treatment of ovarian cancer,07/31/2014,Designated,Q19903515,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
817,Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL),Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2,02/11/2002,Designated,,,patients with acute liver failure presenting with encephalopathy deteriorating beyond parson's grade 2,,,,,,,
819,Bis(4-fluorophenyl)phenylacetamide,Treatment of sickle cell disease.,03/02/2000,Designated,Q7450628,SCTZUZTYRMOMKT-UHFFFAOYSA-N,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
820,bisantrene HCl,Treatment of acute myeloid leukemia,02/14/2014,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
821,bispecific antibody (monoclonal antibody),Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction,08/08/2013,Designated,,,her2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction,,,,,,,
822,bispecific antibody (monoclonmal antibody),Treatment of HER2-expressing adenocarcinoma of the esophagus,08/08/2013,Designated,,,her2-expressing adenocarcinoma of the esophagus,,,,,,,
824,bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13),Treatment of idiopathic pulmonary fibrosis.,09/14/2011,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
825,bivalent anti-human myostatin adnectin-IgG1,Treatment of duchenne muscular dystrophy,02/10/2015,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
827,Bleomycin,Treatment of pancreatic cancer.,12/20/2010,Designated,Q26998364,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
828,Bleomycin,Treatment of pancreatic cancer.,02/09/1999,Designated,Q26998364,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
829,Bleomycin sulfate,Treatment of malignant pleural effusion.,09/17/1993,Designated/Approved,,,malignant pleural effusion,,,,D016066,,,
830,Blinatumomab,Treatment of chronic lymphocytic leukemia,05/16/2008,Designated,Q410189,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
831,blinatumomab,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",02/06/2006,Designated,Q410189,,"indolent b-cell lymphoma, excluding cll and nhl with cns involvement",,,,,,,
832,blinatumomab,Treatment of prolymphocytic leukemia,05/16/2008,Designated,Q410189,,prolymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1039,,,D015463,Q2112719,,Q2112719
833,blinatumomab,Treatment for hairy cell leukemia.,05/16/2008,Designated,Q410189,,hairy cell leukemia,http://purl.obolibrary.org/obo/DOID_285,,http://www.orpha.net/ORDO/Orphanet_58017,D007943,Q201299,,Q201299
834,blinatumomab,Treatment of acute lymphocytic leukemia,05/16/2008,Designated/Approved,Q410189,,acute lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
835,Bone marrow-derived mononuclear cells,Treatment of thromboangiitis obliterans (Buerger's disease),05/17/2010,Designated,,,thromboangiitis obliterans (buerger's disease),,,,,,,
836,bortezomib,Treatment of mantle cell lymphoma.,05/30/2012,Designated/Approved,Q419319,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
837,bortezomib,Treatment of neurofibromatosis type 2 (NF2),07/05/2016,Designated,Q419319,,neurofibromatosis type 2 (nf2),,,,,,,
838,bortezomib,Treatment of multiple myeloma,01/15/2003,Designated/Approved,Q419319,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
839,bortezomib,Treatment of acute lymphoblastic leukemia,02/03/2015,Designated,Q419319,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
840,bortezomib,Treatment of follicular non-Hodgkin lymphoma,01/04/2011,Designated,Q419319,,follicular non-hodgkin lymphoma,,,,,,,
841,bosentan,Treatment of idiopathic pulmonary fibrosis,09/30/2008,Designated/Withdrawn,Q419769,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
842,Bosentan,Treatment of pulmonary arterial hypertension.,10/06/2000,Designated/Approved,Q419769,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
844,bosutinib,Treatment of chronic myelogenous leukemia,02/24/2009,Designated/Approved,Q894611,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
845,Botulinum toxin type A,Treatment of spasmodic torticollis (cervical dystonia).,08/12/1998,Designated,Q4095199,,spasmodic torticollis (cervical dystonia),,,,,,,
846,Botulinum toxin type A,Treatment of essential blepharospasm.,03/23/1989,Designated,Q4095199,,essential blepharospasm,,,,,,,
847,Botulinum toxin type A,Treatment of strabismus and blepharospasms,03/22/1984,Designated/Approved,Q4095199,,strabismus and blepharospasms,,,,,,,
848,Botulinum toxin type A,Treatment of cervical dystonia.,08/20/1986,Designated/Approved,Q4095199,,cervical dystonia,http://purl.obolibrary.org/obo/DOID_0050840,http://purl.obolibrary.org/obo/HP_0000473,http://www.orpha.net/ORDO/Orphanet_93962,D014103,Q6152510,,
849,Botulinum toxin type A,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,10/20/1999,Designated/Approved,Q4095199,,dynamic muscle contractures in pediatric cerebral palsy patients,,,,,,,
850,Botulinum toxin type A,Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.,09/15/1992,Designated,Q4095199,,synkinetic closure of the eyelid associated with vii cranial nerve aberrant regeneration,,,,,,,
851,Botulinum toxin type A,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.,12/06/1991,Designated,Q4095199,,dynamic muscle contracture in pediatric cerebral palsy patients,,,,,,,
852,Botulinum toxin type B,Treatment of cervical dystonia.,01/16/1992,Designated/Approved,Q15709005,,cervical dystonia,http://purl.obolibrary.org/obo/DOID_0050840,http://purl.obolibrary.org/obo/HP_0000473,http://www.orpha.net/ORDO/Orphanet_93962,D014103,Q6152510,,
853,Botulinum toxin type F,Treatment of spasmodic torticollis (cervical dystonia).,10/24/1991,Designated,,,spasmodic torticollis (cervical dystonia),,,,,,,
854,"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)",Treatment of botulism.,06/29/2011,Designated/Approved,,,botulism,http://purl.obolibrary.org/obo/DOID_11976,,http://www.orpha.net/ORDO/Orphanet_1267,D001906,Q154865,,Q154865
855,Botulism immune globulin,Treatment of infant botulism.,01/31/1989,Designated/Approved,,,infant botulism,http://purl.obolibrary.org/obo/DOID_0050354,,http://www.orpha.net/ORDO/Orphanet_178478,D001906,Q18553252,,Q154865
856,Bovine colostrum,Treatment of AIDS-related diarrhea.,11/19/1990,Designated,,,aids-related diarrhea,,,,,,,
857,"Bovine immunoglobulin concentrate, Cryptosporidium parvum",Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.,03/01/1994,Designated,,,symptomatic relief of cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients,,,,,,,
858,bovine lactoferrin,Prevention of late-onset sepsis in very low birth weight infants,02/19/2015,Designated,,,late-onset sepsis in very low birth weight infants,,,,,,,
859,bovine lactoferrin,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),02/23/2015,Designated,,,necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),,,,,,,
860,Bovine whey protein concentrate,Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.,09/30/1993,Designated,,,cryptosporidiosis caused by the presence of cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent,,,,,,,
861,Branched chain amino acids,Treatment of amyotrophic lateral sclerosis.,12/23/1988,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
862,brentuximab vedotin,Treatment of anaplastic large cell lymphoma,10/23/2008,Designated/Approved,Q422324,,anaplastic large cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050744,,http://www.orpha.net/ORDO/Orphanet_98841,D017728,Q18553446,,
863,brentuximab vedotin,Treatment of enteropathy-associated T-cell lymphoma.,07/07/2016,Designated,Q422324,,enteropathy-associated t-cell lymphoma,,,http://www.orpha.net/ORDO/Orphanet_86880,D058527,,,
864,brentuximab vedotin,Treatment of patients with angioimmunoblastic T-cell lymphoma,09/13/2013,Designated,Q422324,,patients with angioimmunoblastic t-cell lymphoma,,,,,,,
865,brentuximab vedotin,Treatment of Hodgkin's lymphoma,01/30/2007,Designated/Approved,Q422324,,hodgkin's lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
866,brentuximab vedotin,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",04/15/2013,Designated,Q422324,,"patients with peripheral t-cell lymphoma, not otherwise specified",,,,,,,
867,Brentuximab vedotin,Treatment of cutaneous T-cell lymphoma,02/06/2017,Designated,Q422324,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
868,Brentuximab vedotin,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,09/07/2016,Designated,Q422324,,primary cutaneous cd30-positive t-cell lymphoproliferative disorders,,,,,,,
869,brentuximab vedotin,Treatment of mycosis fungoides,11/19/2012,Designated,Q422324,,mycosis fungoides,http://purl.obolibrary.org/obo/DOID_8691,,,D009182,Q1891209,,Q1891209
870,brentuximab vedotin,Treatment of patients with diffuse large B-cell lymphoma.,01/31/2014,Designated,Q422324,,patients with diffuse large b-cell lymphoma,,,,,,,
871,brentuximab vedotin,Treatment of adult T-cell leukemia/lymphoma,05/23/2016,Designated,Q422324,,adult t-cell leukemia/lymphoma,http://purl.obolibrary.org/obo/DOID_0050523,,http://www.orpha.net/ORDO/Orphanet_86875,,Q379054,Q379054,
872,brigatinib,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",04/28/2016,Designated,Q27456393,,"anaplastic lymphoma kinase-positive (alk+), c-ros 1 oncogene positive (ros1+), or epidermal growth factor receptor positive (egfr+) non-small cell lung cancer (nsclc)",,,,,,,
875,Brimonidine,Treatment of anterior ischemic optic neuropathy.,02/07/2000,Designated,Q577377,,anterior ischemic optic neuropathy,http://purl.obolibrary.org/obo/DOID_12010,,,D018917,Q362719,,Q7234207
876,brivanib alaninate,Treatment of hepatocellular carcinoma,03/18/2011,Designated/Withdrawn,Q4971701,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
877,brivaracetam,Treatment of symtomatic myoclonus,10/05/2005,Designated,Q408099,,symtomatic myoclonus,,,,,,,
879,Bromhexine,Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.,05/15/1989,Designated/Withdrawn,Q239778,,mild to moderate keratoconjunctivitis sicca in patients with sjogren's syndrome,,,,,,,
881,Bruton's Tyrosine Kinase (Btk) Inhibitor,Treatment of chronic lymphocytic leukemia (CLL).,05/13/2015,Designated,,,chronic lymphocytic leukemia (cll),,,,,,,
882,Bruton's tyrosine kinase inhibitor,Treatment of chronic lymphocytic leukemia,02/10/2014,Designated/Withdrawn,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
883,bryostatin 1,Treatment of Fragile X Syndrome.,03/31/2015,Designated,Q27160202,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
885,Bucillamine,Treatment of cystinuria,10/22/2015,Designated,Q4982752,,cystinuria,http://purl.obolibrary.org/obo/DOID_9266,http://purl.obolibrary.org/obo/HP_0003131,http://www.orpha.net/ORDO/Orphanet_214,D003555,Q1149046,,Q1149046
887,budesonide,Treatment of patients with eosinophilic esophagitis,12/20/2006,Designated,Q422212,,patients with eosinophilic esophagitis,,,,,,,
890,Buffered Ursodeoxycholic Acid,Treatment of pruritus in patients with Alagille Syndrome,09/03/2004,Designated,,,pruritus in patients with alagille syndrome,,,,,,,
892,bupivacaine hydrochloride,treatment of pain associated with postherpetic neuralgia.,05/31/2016,Designated,Q27887879,,pain associated with postherpetic neuralgia,,,,,,,
893,Buprenorphine hydrochloride,Treatment of opiate addiction in opiate users.,06/15/1994,Designated/Approved,Q27105186,,opiate addiction in opiate users,,,,,,,
894,buprenorphine in combination with naloxone,Treatment of opiate addiction in opiate users,10/27/1994,Designated/Approved,,,opiate addiction in opiate users,,,,,,,
899,Busulfan,Treatment of primary brain malignancies.,07/07/1997,Designated,Q348922,COVZYZSDYWQREU-UHFFFAOYSA-N,primary brain malignancies,,,,,,,
902,butylidenephthalide,Treatment of Malignant Glioma,08/05/2015,Designated,Q27289065,WMBOCUXXNSOQHM-UHFFFAOYSA-N,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
904,Butyrylcholinesterase,Treatment of post-surgical apnea.,09/30/1992,Designated,,,post-surgical apnea,,,,,,,
905,c-myb antisense oligodeoxynucleotide,Treatment of chronic myelogenous leukemia,02/22/2005,Designated/Withdrawn,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
906,C1 esterase inhibitor (human),Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.,08/21/1996,Designated,Q22075742,,prevention of angioedema caused by c1-esterase inhibitor deficiency,,,,,,,
907,C1 esterase inhibitor (human),Treatment of angioedema,07/16/2004,Designated/Approved,Q22075742,,angioedema,http://purl.obolibrary.org/obo/DOID_1558,http://purl.obolibrary.org/obo/HP_0100665,,D000799,Q1129007,,Q1129007
908,C1 esterase inhibitor (Human),Treatment of acute antibody mediated rejection following kidney transplantation,11/30/2016,Designated,Q22075742,,acute antibody mediated rejection following kidney transplantation,,,,,,,
909,C1-esterase inhibitor (recombinant),Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.,02/23/1999,Designated/Approved,,,(acute attacks of) angioedema caused by hereditary or acquired c1-esterase inhibitor deficiency,,,,,,,
910,"C1-esterase-inhibitor, human, pasteurized",Prevention and/or treatment of acute attacks of hereditary angioedema.,10/16/1992,Designated/Approved,,,treatment of acute attacks of hereditary angioedema,,,,,,,
911,C1-inhibitor,"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.",08/30/1990,Designated/Withdrawn,,,"acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures",,,,,,,
912,C1-inhibitor,Treatment of acute attacks of angioedema.,08/30/1990,Designated/Withdrawn,,,acute attacks of angioedema,,,,,,,
913,C20-D3-retinyl acetate,Treatment of Stargardt's disease,09/16/2010,Designated,,,stargardt's disease,,,,,,,
914,C21H27O10P,Treatment of gastric cancer.,03/30/2015,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
915,C24H28N8O7S2,Treatment of diffuse large B-cell lymphoma (DLBCL).,04/02/2015,Designated,,,diffuse large b-cell lymphoma (dlbcl),,,,,,,
916,C66H100N6O27,Treatment of of hepatocellular carcinoma,03/11/2013,Designated,,,of hepatocellular carcinoma,,,,,,,
917,cabozantinib,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",11/29/2010,Designated/Approved,Q795057,,"follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",,,,,,,
918,Caffeine,Treatment of apnea of prematurity.,09/20/1988,Designated/Approved,Q60235,RYYVLZVUVIJVGH-UHFFFAOYSA-N,apnea of prematurity,,,http://www.orpha.net/ORDO/Orphanet_99981,,,,
919,caffeine and sodium benzoate,Treatment of seizure prolongation in patients undergoing electroconvulsive therapy,08/22/2012,Designated,,JWBPVFVNISJVEM-UHFFFAOYSA-M,seizure prolongation in patients undergoing electroconvulsive therapy,,,,,,,
920,Calcitonin salmon nasal spray,Treatment of symptomatic Paget's disease (osteitis deformans).,10/29/1990,Designated/Withdrawn,,,symptomatic paget's disease (osteitis deformans),,,,,,,
921,Calcitonin-human for injection,Treatment of symptomatic Paget's disease (osteitis deformans).,01/20/1987,Designated/Approved,,,symptomatic paget's disease (osteitis deformans),,,,,,,
922,Calcium acetate,Treatment of hyperphosphatemia in end stage renal failure.,12/22/1988,Designated/Approved,Q27126528,VSGNNIFQASZAOI-UHFFFAOYSA-L,hyperphosphatemia in end stage renal failure,,,,,,,
923,Calcium acetate,Treatment of hyperphosphatemia in end stage renal disease.,06/27/1989,Designated,Q27126528,VSGNNIFQASZAOI-UHFFFAOYSA-L,hyperphosphatemia in end stage renal disease,,,,,,,
924,calcium benzoate and risperidone,Treatment of pediatric patients with schizophrenia,12/20/2010,Designated,,,pediatric patients with schizophrenia,,,,,,,
925,Calcium carbonate,Treatment of hyperphosphatemia in patients with end stage renal disease.,06/06/1990,Designated,Q23767,VTYYLEPIZMXCLO-UHFFFAOYSA-L,hyperphosphatemia in patients with end stage renal disease,,,,,,,
929,calfactant,Treatment of acute respiratory distress syndrome (ARDS),09/05/2000,Designated,,,acute respiratory distress syndrome (ards),,,,,,,
930,calfactant,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,06/07/1985,Designated/Approved,,,prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants,,,,,,,
931,camostat,Treatment of chronic pancreatitis,05/18/2011,Designated,Q5026909,,chronic pancreatitis,,http://purl.obolibrary.org/obo/HP_0006280,,D050500,,,Q1996053
932,canakinumab,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,12/05/2013,Designated/Approved,Q3655009,,hyperimmunoglobulinemia d and periodic fever syndrome,,,,D054078,,,Q3043158
933,canakinumab,Treatment of familial mediterranean fever,12/05/2013,Designated/Approved,Q3655009,,familial mediterranean fever,http://purl.obolibrary.org/obo/DOID_2987,,http://www.orpha.net/ORDO/Orphanet_342,D010505,Q1144618,Q1144618,Q1144618
934,canakinumab,Treatment of TNF-receptor associated periodic syndrome (TRAPS),09/04/2012,Designated/Approved,Q3655009,,tnf-receptor associated periodic syndrome (traps),,,,,,,
935,canakinumab,Treatment of cryopyrin-associated periodic syndromes,12/18/2007,Designated/Approved,Q3655009,,cryopyrin-associated periodic syndromes,,,,D056587,,,Q1835481
936,canakinumab,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,09/30/2008,Designated/Approved,Q3655009,,pediatric (age 16 and under) juvenile rheumatoid arthritis,,,,,,,
937,cannabidiol,Prevention of Graft versus Host Disease (GVHD).,07/14/2015,Designated,Q422917,,graft versus host disease (gvhd),,,,,,,
938,cannabidiol,Treatment of infantile spasms,07/23/2015,Designated,Q422917,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
939,cannabidiol,Treatment of tuberous sclerosis complex.,04/19/2016,Designated,Q422917,,tuberous sclerosis complex,,,http://www.orpha.net/ORDO/Orphanet_805,D014402,,,Q1362721
940,cannabidiol,Treatment of infantile spasms,06/13/2016,Designated,Q422917,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
941,cannabidiol,Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age),11/17/2014,Designated,Q422917,,pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age),,,,,,,
942,cannabidiol,Treatment of Fragile X syndrome,02/23/2016,Designated,Q422917,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
943,cannabidiol,Treatment of Graft versus Host Disease,11/29/2016,Designated,Q422917,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
944,cannabidiol,Treatment of Lennox-Gastaut syndrome,06/23/2014,Designated,Q422917,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
945,cannabidiol,Treatment of neonatal hypoxic ischemic encephalopathy,04/22/2015,Designated,Q422917,,neonatal hypoxic ischemic encephalopathy,,,,,,,
946,cannabidiol,Treatment of Dravet syndrome,07/01/2014,Designated,Q422917,,dravet syndrome,http://purl.obolibrary.org/obo/DOID_0060171,,http://www.orpha.net/ORDO/Orphanet_33069,D004831,Q1255956,Q1255956,Q17147280
947,cannabidiol,Treatment of glioma,09/24/2014,Designated,Q422917,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
948,cannabidiol,Treatment of Dravet syndrome.,11/14/2013,Designated,Q422917,,dravet syndrome,http://purl.obolibrary.org/obo/DOID_0060171,,http://www.orpha.net/ORDO/Orphanet_33069,D004831,Q1255956,Q1255956,Q17147280
949,cannabidiol,Treatment of glioblastoma multiforme,08/20/2014,Designated,Q422917,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
950,cannabidiol;,Treatment of Lennox-Gastaut syndrome,02/27/2014,Designated,,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
951,cannabidivarin,Treatment of Rett syndrome,11/30/2016,Designated,Q1104117,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
952,cantharidin,"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa",07/24/2012,Designated,Q410884,,"perforating diseases, including kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa",,,,,,,
953,cantrixil,Treatment of ovarian cancer,04/20/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
954,Caplacizumab,Treatment of thrombotic thrombocytopenic purpura,04/14/2009,Designated,Q5036030,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
955,caprine hyperimmune serum against HIV lysate,Treatment of amyotrophic lateral sclerosis,10/28/2009,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
956,caprine hyperimmune serum against HIV lysate,Treatment of systemic sclerosis,02/14/2014,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
957,Capsaicin,Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis,09/29/2006,Designated,Q273169,,intermetatarsal neuroma (morton's neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis,,,,,,,
958,capsaicin,Treatment of painful HIV-associated neuropathy,05/02/2003,Designated,Q273169,,painful hiv-associated neuropathy,,,,,,,
959,capsaicin,Treatment of erythromelalgia,10/23/2002,Designated,Q273169,,erythromelalgia,http://purl.obolibrary.org/obo/DOID_9240,,http://www.orpha.net/ORDO/Orphanet_1956,D004916,Q524353,,Q524353
960,Capsaicin,Treatment of postherpetic neuralgia.,08/03/2005,Designated,Q273169,,postherpetic neuralgia,,,,D051474,,,
963,carbenoxolone,Treatment of Huntington's Disease,07/02/2014,Designated,Q752861,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
964,carbetocin (nasal spray),Treatment of Prader Willi syndrome,04/11/2014,Designated,,,prader willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,,D011218,Q594013,,Q594013
965,carbon dioxide,Treatment of trigeminal neuralgia,12/17/2015,Designated,Q1997,CURLTUGMZLYLDI-UHFFFAOYSA-N,trigeminal neuralgia,http://purl.obolibrary.org/obo/DOID_12098,http://purl.obolibrary.org/obo/HP_0100661,http://www.orpha.net/ORDO/Orphanet_221091,D014277,Q1132120,,Q1132120
966,carbon monoxide,Treatment of idiopathic pulmonary fibrosis (IPF).,08/16/2016,Designated,Q2025,UGFAIRIUMAVXCW-UHFFFAOYSA-N,idiopathic pulmonary fibrosis (ipf),,,,,,,
968,carbon monoxide,Treatment of sickle cell disease,09/28/2012,Designated,Q2025,UGFAIRIUMAVXCW-UHFFFAOYSA-N,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
969,Carbovir,Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.,12/13/1989,Designated/Withdrawn,Q27225744,,persons with aids and in patients with symptomatic hiv infection and a cd4 count less than 200/mm3,,,,,,,
970,carboxy pyrrolidine hexanoyl pyrrolidine carboxylate,Treatment of AL amyloidosis,02/10/2015,Designated,,PRKOZMYOBGWMTM-UHFFFAOYSA-N,al amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85443,,,,
971,cardiotrophin-1,Prevention of ischemia-reperfusion injury in kidney transplant recipients,10/16/2014,Designated,,,ischemia-reperfusion injury in kidney transplant recipients,,,,,,,
972,cardiotrophin-1,Treatment of acute liver failure,09/13/2011,Designated,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
974,carfilzomib,Treatment of multiple myeloma,01/18/2008,Designated/Approved,Q15366934,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
975,carglumic acid,Treatment of N-acetylglutamate synthetase deficiency.,01/20/1998,Designated/Approved,Q822884,,n-acetylglutamate synthetase deficiency,,,,,,,
976,carglumic acid,Treatment of organic acidemias,06/17/2014,Designated,Q822884,,organic acidemias,,,,,,,
978,carlumab,Treatment of pancreatic cancer,10/24/2006,Designated,Q5043094,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
979,carlumab,Treatment of idiopathic pulmonary fibrosis,11/08/2007,Designated/Withdrawn,Q5043094,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
980,Carmustine,Treatment of intracranial malignancies.,07/03/2000,Designated,Q415869,,intracranial malignancies,,,,,,,
981,Cascara sagrada fluid extract,Treatment of oral drug overdosage to speed lower bowel evacuation.,03/21/1989,Designated,,,oral drug overdosage to speed lower bowel evacuation,,,,,,,
983,Catumaxomab,Treatment of ovarian cancer,06/09/2006,Designated,Q408155,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
984,catumaxomab,Treatment of gastric cancer,07/01/2009,Designated,Q408155,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
985,CD123 x CD3 dual affinity re-targeting (DARTÂ®) protein,Treatment of acute myeloid leukemia (AML),12/22/2016,Designated,,,acute myeloid leukemia (aml),,,,,,,
986,CD4 human truncated 369 AA polypeptide,Treatment of acquired immunodeficiency syndrome.,11/21/1989,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
987,CD40/CD80/CD86 modified autologous dendritic cell therapy,Treatment Type 1 diabetes mellitus patients with residual beta cell function,12/20/2013,Designated,,,1 diabetes mellitus patients with residual beta cell function,,,,,,,
988,CD5-T lymphocyte immunotoxin,Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.,08/27/1987,Designated/Withdrawn,,,graft versus host disease and/or rejection in patients who have received bone marrow transplants,,,,,,,
989,cediranib,Treatment of glioblastoma,12/13/2010,Designated,Q5057052,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
990,Ceftriaxone sodium,Treatment of amyotrophic lateral sclerosis,03/28/2006,Designated,Q27231488,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
991,Celecoxib oral liquid suspension,Treatment of pediatric juvenile idiopathic arthritis,01/05/2017,Designated,,,pediatric juvenile idiopathic arthritis,,,,,,,
992,celiprolol,Treatment of Ehlers-Danlos syndrome,01/05/2015,Designated,Q420586,,ehlers-danlos syndrome,http://purl.obolibrary.org/obo/DOID_13359,,http://www.orpha.net/ORDO/Orphanet_98249,D004535,Q1141499,,Q1141499
993,cell based therapeutic composed of allogeneic donor apoptotic cells,Prevention of graft versus host disease,03/18/2013,Designated,,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
996,cenersen,Treatment of chronic lymphocytic leukemia,02/27/2008,Designated,Q27282015,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
997,cenersen,Treatment of stage IIB through IV melanoma,06/18/2008,Designated,Q27282015,,stage iib through iv melanoma,,,,,,,
998,cenersen,Treatment of acute myeloid leukemia,05/08/2006,Designated,Q27282015,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
999,Centruroides immune F(ab)2,Treatment of scorpion envenomations requiring medical attention.,06/12/2000,Designated/Approved,,,scorpion envenomations requiring medical attention,,,,,,,
1000,ceramide,Treatment of liver cancer,08/08/2016,Designated,Q27147579,,liver cancer,http://purl.obolibrary.org/obo/DOID_3571,http://purl.obolibrary.org/obo/HP_0002896,,D008113,Q623031,,Q1671502
1001,Ceramide trihexosidase/alpha-galactosidase A,Treatment of Fabry's disease.,01/19/1988,Designated/Approved,,,fabry's disease,http://purl.obolibrary.org/obo/DOID_14499,,,D000795,Q615645,,Q615645
1002,cerebrolysin,"Treatment of frontotemporal dementia, including all subvariants",04/05/2016,Designated,,,"frontotemporal dementia, including all subvariants",,,,,,,
1003,ceritinib,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,09/27/2013,Designated/Approved,Q21011233,,patients with non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase(alk)-positive,,,,,,,
1004,cerliponase alfa,Treatment of neuronal ceroid lipofuscinosis type 2,04/01/2013,Designated,,,neuronal ceroid lipofuscinosis type 2,,,,,,,
1008,Cetiedil citrate injection,Treatment of sickle cell disease crisis.,12/22/1988,Designated/Withdrawn,,,sickle cell disease crisis,,,,,,,
1009,cetuximab,Treatment of pancreatic cancer,06/15/2007,Designated/Withdrawn,Q420296,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1010,cetuximab,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,07/03/2000,Designated/Approved,Q420296,,squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,,,,,,,
1011,Chelating agent delivering Holmium-166,Treatment of multiple myeloma.,02/10/1999,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1012,chelmab-y or chelamusab-Y,Treatment of ovarian cancer.,04/24/1990,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1013,chenodeoxycholic acid,Treatment of cerebrotendinous xanthomatosis,02/12/2007,Designated,Q419028,,cerebrotendinous xanthomatosis,http://purl.obolibrary.org/obo/DOID_4810,,http://www.orpha.net/ORDO/Orphanet_120989,D019294,Q2602467,,Q2602467
1014,Chenodeoxycholic acid,Treatment of cerebrotendinous xanthomatosis,01/29/2004,Designated,Q419028,,cerebrotendinous xanthomatosis,http://purl.obolibrary.org/obo/DOID_4810,,http://www.orpha.net/ORDO/Orphanet_120989,D019294,Q2602467,,Q2602467
1016,chenodiol,Treatment of cerebrotendinous xanthomatosis,03/22/2010,Designated,Q419028,,cerebrotendinous xanthomatosis,http://purl.obolibrary.org/obo/DOID_4810,,http://www.orpha.net/ORDO/Orphanet_120989,D019294,Q2602467,,Q2602467
1017,Chimeric (human-murine) G250 IgG monoclonal antibody,Treatment of renal cell carcinoma.,07/24/2000,Designated/Withdrawn,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1018,chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells,Treatment of peripheral T-cell lymphoma,07/28/2016,Designated,,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
1019,chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2,"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)",11/25/2014,Designated,,,"mucopolysaccharidosis iii type b (mps iiib, sanfilippo syndrome type b)",,,,,,,
1020,Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4,Treatment of multiple sclerosis.,06/05/1991,Designated/Withdrawn,,,multiple sclerosis,http://purl.obolibrary.org/obo/DOID_2377,,,D009103,Q8277,,Q8277
1022,chimeric monoclonal antibody against Claudin 6,Treatment of ovarian cancer,03/18/2013,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1023,chimeric monoclonal antibody against claudin-18 splice variant 2,Treatment of pancreatic cancer,09/26/2013,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1024,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),Treatment of Hodgkin's disease,07/18/2003,Designated/Withdrawn,,,hodgkin's disease,,,http://www.orpha.net/ORDO/Orphanet_98293,D006689,,Q209369,Q18557991
1025,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),Treatment of CD30 positive T-cell lymphomas,02/18/2004,Designated/Withdrawn,,,cd30 positive t-cell lymphomas,,,,,,,
1026,chimeric monoclonal antibody to claudin 18 splice variant 2,Treatment of gastric cancer,11/20/2012,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1027,Chimeric monoclonal antibody to mesothelin,Treatment of pancreatic cancer,10/31/2006,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1028,chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain,Treatment of acute myeloid leukemia,04/03/2009,Designated/Withdrawn,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1031,chlorobutanol/propylene glycol/hydrochloric acid,Treatment of patulous eustachian tube,02/18/1997,Designated,,,patulous eustachian tube,http://purl.obolibrary.org/obo/DOID_12358,,,,Q1361850,,
1032,chloropyramine,Treatment of pancreatic cancer,10/22/2010,Designated,Q729863,LSYPVNHPFUQGON-UHFFFAOYSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1033,chloroquine,Treatment of glioblastoma multiforme.,05/20/2015,Designated,Q422438,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1034,chlorotoxin,"Treatment of stage IIb, IIc, III & IV melanoma",12/02/2008,Designated,Q3680957,,"stage iib, iic, iii & iv melanoma",,,,,,,
1035,Chlorotoxin,Treatment of malignant glioma,12/18/2007,Designated,Q3680957,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1037,"cholest-4-en-3-one, oxime",Treatment of spinal muscular atrophy.,02/17/2009,Designated,Q7086437,QNTASHOAVRSLMD-GYKMGIIDSA-N,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
1038,cholic acid,Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism,07/18/2003,Designated/Approved,Q287415,,inborn errors of cholesterol and bile acid synthesis and metabolism,,,,,,,
1039,Choline chloride,"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.",02/10/1994,Designated,Q2964153,SGMZJAMFUVOLNK-UHFFFAOYSA-M,"choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition",,,,,,,
1040,Choline chloride,Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition,07/20/2006,Designated,Q2964153,SGMZJAMFUVOLNK-UHFFFAOYSA-M,treatment of choline deficiency in patients on long-term parenteral nutrition,,,,,,,
1041,choline tetrathiomolybdate,Treatment of Wilson's disease.,08/25/2011,Designated,,,wilson's disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
1043,Chondroitinase,Treatment of patients undergoing vitrectomy.,02/09/1995,Designated/Withdrawn,,,patients undergoing vitrectomy,,,,,,,
1044,chromium picolinate and chromium histidinate,Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age),12/22/2014,Designated,,HCIYFINLGHIASH-BHRFRFAJSA-L,pediatic polycystic ovary syndrome (0 through 16 years of age),,,,,,,
1045,cicletanine hydrochloride,Treatment for pulmonary arterial hypertension.,06/24/2008,Designated/Withdrawn,Q27289519,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1046,cilengitide,Treatment of malignant glioma,05/27/2005,Designated/Withdrawn,Q1091921,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1047,Ciliary neurotrophic factor,Treatment of amyotrophic lateral sclerosis.,01/30/1992,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1048,"Ciliary neurotrophic factor, recombinant human","Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).",05/08/1992,Designated/Withdrawn,,,"motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)",,,,,,,
1049,"Ciliary neurotrophic factor, recombinant human",Treatment of spinal muscular atrophies.,04/02/1992,Designated/Withdrawn,,,spinal muscular atrophies,,,,,,,
1050,cinacalcet,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",04/30/2010,Designated/Approved,Q193978,,"hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",,,,,,,
1051,cinacalcet,Treatment of hypercalcemia in patients with parathyroid carcinoma,05/12/2003,Designated/Approved,Q193978,,hypercalcemia in patients with parathyroid carcinoma,,,,,,,
1052,cinacalcet,Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis,09/07/2016,Designated,Q193978,,secondary hyperparathyroidism (hpt) in pediatric patients with chronic kidney disease receiving dialysis,,,,,,,
1053,Cintredekin Besudotox,Treatment of idiopathic pulmonary fibrosis,04/30/2010,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1056,ciprofloxacin dry powder inhaler,Treatment of non-cystic fibrosis bronchiectasis,04/17/2014,Designated,,,non-cystic fibrosis bronchiectasis,,,,,,,
1057,"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate","Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae",01/19/2010,Designated,,,"malaria caused by plasmodium falciparum, plasmodium vivax, plasmodium ovale, or plasmodium malariae",,,,,,,
1058,Cisplatin,Treatment of anal cancer,09/06/2016,Designated,Q412415,,anal cancer,http://purl.obolibrary.org/obo/DOID_14110,,,D001005,Q484827,,Q18556540
1059,Cisplatin ChemoThin Wafer,"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)",11/03/2015,Designated,,,"anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)",,,,,,,
1060,Cisplatin in liposomal formulation,Treatment of osteosarcoma,03/20/2007,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
1061,Cisplatin/epinephrine,Treatment of squamous cell carcinoma of the head and neck.,04/03/2000,Designated,,,squamous cell carcinoma of the head and neck,http://purl.obolibrary.org/obo/DOID_5520,,,,Q19000571,,
1062,Cisplatin/epinephrine,Treatment of metastatic malignant melanoma.,09/07/2000,Designated,,,metastatic malignant melanoma,,,,,,,
1063,"Citric acid, glucono-delta-lactone and magnesium carbonate",Treatment of renal and bladder calculi of the apatite or struvite variety.,08/28/1989,Designated/Approved,,,renal and bladder calculi of the apatite or struvite variety,,,,,,,
1064,civamide,Treatment of postherpetic neuralgia of the trigeminal nerve,12/09/2002,Designated,,,postherpetic neuralgia of the trigeminal nerve,,,,,,,
1065,civamide,Treatment of postherpetic neuralgia.,02/17/2009,Designated,,,postherpetic neuralgia,,,,D051474,,,
1066,Cladribine,Treatment of acute myeloid leukemia.,07/20/1990,Designated/Withdrawn,Q414030,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1067,Cladribine,Treatment of non-Hodgkin's lymphoma.,04/19/1993,Designated/Withdrawn,Q414030,,non-hodgkin's lymphoma,,,,D008228,,,Q18557998
1068,Cladribine,Treatment of hairy cell leukemia.,11/15/1990,Designated/Approved,Q414030,,hairy cell leukemia,http://purl.obolibrary.org/obo/DOID_285,,http://www.orpha.net/ORDO/Orphanet_58017,D007943,Q201299,,Q201299
1069,cladribine,Treatment of chronic lymphocytic leukemia,12/31/1990,Designated/Withdrawn,Q414030,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1070,cladribine,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,03/19/2015,Designated,Q414030,,neuromyelitis optica and neuromyelitis optica spectrum disorder,,,,,,,
1071,Cladribine,Treatment of the chronic progressive form of multiple sclerosis.,04/19/1994,Designated,Q414030,,the chronic progressive form of multiple sclerosis,,,,,,,
1072,"clarithromycin, rifabutin, clofazimine",Treatment of pediatric Crohn's disease.,04/26/2011,Designated,,,pediatric crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,,,,Q1472,,
1073,Clazosentan,Treatment of cerebral vasospasm following subarachnoid hemorrhage,02/16/2006,Designated,Q1099339,,cerebral vasospasm following subarachnoid hemorrhage,,,,,,,
1074,Clenbuterol,Treatment of Pompe disease (glycogen storage disease type II),01/09/2017,Designated,Q223412,,pompe disease (glycogen storage disease type ii),,,,,,,
1076,Clindamycin,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,10/28/1988,Designated,Q422273,,pneumocystis carinii pneumonia in aids patients,,,,,,,
1077,Clindamycin,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,10/28/1988,Designated,Q422273,,pneumocystis carinii pneumonia associated with aids patients,,,,,,,
1078,Clindamycin hydrochloride,Treatment of sarcoidosis,08/09/2006,Designated,Q27289558,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
1079,clobazam,Treatment of Lennox-Gastaut Syndrome,12/18/2007,Designated/Approved,Q412164,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
1080,clofarabine,Treatment of acute lymphoblastic leukemia,02/07/2002,Designated/Approved,Q5134875,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1081,clofarabine,Treatment of acute myelogenous leukemia,03/14/2002,Designated,Q5134875,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1082,Clofazimine,"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.",06/11/1984,Designated/Approved,Q418611,,"lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum",,,,,,,
1083,clofazimine,Treatment of active tuberculosis,06/25/2014,Designated,Q418611,,active tuberculosis,,,,,,,
1084,Clonazepam,Treatment of hyperekplexia (startle disease).,08/04/1994,Designated,Q407988,,hyperekplexia (startle disease),,,,,,,
1085,Clonazepam Intranasal Spray,Treatment of recurrent acute repetitive seizures,12/19/2007,Designated,,,recurrent acute repetitive seizures,,,,,,,
1087,Clotrimazole,Treatment of Huntington's disease,03/13/2006,Designated,Q413546,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1088,Clotrimazole,Treatment of sickle cell disease.,04/24/1995,Designated,Q413546,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1090,clotrimazole otic solution,Treatment of fungal otitis externa (otomycosis).,05/10/2016,Designated,,,fungal otitis externa (otomycosis),,,,,,,
1091,CNDO-109-activated allogeneic natural killer cells,Treatment of acute myeloid leukemia,06/18/2012,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1094,Coagulation Factor IX (recombinant),Treatment of hemophilia B.,10/03/1994,Designated/Approved,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1097,Coagulation factor VIIa (recombinant),"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",06/18/2004,Designated/Approved,,,"bleeding episodes in patients with hemophilia a or b, with or without inhibitors",,,,,,,
1098,coagulation factor VIIa (recombinant),Treatment of bleeding episodes in Glanzmann's thrombasthenia,06/18/2004,Designated/Approved,,,bleeding episodes in glanzmann's thrombasthenia,,,,,,,
1099,Coagulation factor VIIa (recombinant),Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,07/21/2004,Designated/Approved,,,bleeding episodes in patients with acquired inhibitors to factor viii or factor ix,,,,,,,
1100,Coagulation Factor VIIa (Recombinant),Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,07/16/2004,Designated/Approved,,,bleeding episodes in patients with acquired inhibitors to factor viii or factor ix,,,,,,,
1101,Coagulation Factor VIIa (Recombinant),Treatment of bleeding in patients experiencing intracranial hemorrhage.,10/03/2006,Designated/Withdrawn,,,bleeding in patients experiencing intracranial hemorrhage,,,,,,,
1102,Coagulation factor VIIa (recombinant),Prevention of bleeding episodes in patients with congenital Factor VII deficiency,09/10/2004,Designated/Approved,,,bleeding episodes in patients with congenital factor vii deficiency,,,,,,,
1103,Coagulation factor VIIa (recombinant),Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,06/06/1988,Designated/Approved,,,bleeding episodes in hemophilia a or b patients with inhibitors to factor viii or factor ix,,,,,,,
1104,Coagulation factor VIIa (recombinant),Prevention of bleeding episodes in Glanzmann's thrombasthenia,06/18/2004,Designated,,,bleeding episodes in glanzmann's thrombasthenia,,,,,,,
1105,Coagulation factor VIIa (recombinant),Treatment of bleeding episodes in patients with congenital factor VII deficiency,09/10/2004,Designated/Approved,,,bleeding episodes in patients with congenital factor vii deficiency,,,,,,,
1107,cobimetinib,"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation",01/31/2014,Designated/Approved,Q27162831,,"stage iib, iic, iii, and iv melanoma with brafv600 mutation",,,,,,,
1108,cobiprostone,Treatment of cystic fibrosis,11/14/2002,Designated/Withdrawn,Q27280783,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1110,Coenzyme Q10,Treatment of Huntington's disease,03/05/2001,Designated,Q321285,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1111,coenzyme Q10 and d-alpha-tocopherol,Treatment of Friedreich's Ataxia.,03/14/2011,Designated,,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
1112,Colchicine,Treatment of Behcet's Syndrome,09/25/2007,Designated,Q26998324,,behcet's syndrome,http://purl.obolibrary.org/obo/DOID_13241,,,D001528,Q911427,,Q911427
1113,colchicine,Treatment of familial Mediterranean fever,09/25/2007,Designated/Approved,Q26998324,,familial mediterranean fever,http://purl.obolibrary.org/obo/DOID_2987,,http://www.orpha.net/ORDO/Orphanet_342,D010505,Q1144618,Q1144618,Q1144618
1115,"Colfosceril palmitate, cetyl alcohol, tyloxapol",Treatment of adult respiratory distress syndrome.,01/11/1993,Designated/Withdrawn,,,adult respiratory distress syndrome,http://purl.obolibrary.org/obo/DOID_11394,,,D012128,Q344873,,Q7315912
1117,collagenase clostridium histolyticum,Treatment of advanced (involutional or residual stage) Dupuytren's disease.,05/23/1996,Designated/Approved,Q5145911,,advanced (involutional or residual stage) dupuytren's disease,,,,,,,
1118,collagenase clostridium histolyticum,Treatment of Peyronie's disease.,03/12/1996,Designated/Approved,Q5145911,,peyronie's disease,http://purl.obolibrary.org/obo/DOID_8616,,,D010411,Q874586,,Q874586
1119,"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)",Treatment of hepatocellular carcinoma,10/13/2016,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1120,combination of disulfiram and copper gluconate,Treatment of glioblastoma multiforme.,05/18/2016,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1121,Combination of nivolumab and ipilimumab,Treatment of Stage IIb to Stage IV melanoma,10/09/2014,Designated/Approved,,,stage iib to stage iv melanoma,,,,,,,
1122,combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE),Treatment of soft tissue sarcoma,05/02/2016,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1123,combretastatin A 1 diphosphate,Treatment of acute myelogenous leukemia,11/19/2012,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1124,Combretastatin A4 phosphate,Treatment of ovarian cancer,05/08/2006,Designated,Q5150956,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1125,Combretastatin A4 Phosphate,"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer",07/23/2003,Designated,Q5150956,,"anaplastic thyroid cancer, medullary thyroid cancer, and stage iv papillary or follicular thyroid cancer",,,,,,,
1126,competetive small molecule inhibitor of the enzyme O-GlcNAcase,Treatment of progressive supranuclear palsy.,03/10/2016,Designated,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
1127,complement factor H,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,12/07/2009,Designated/Withdrawn,,,atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,,,,,,,
1128,Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer,Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome),08/06/2013,Designated,,,dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome),,,,,,,
1129,conjugate of human transferrin and a mutant diphtheria toxin (CRM 107),Treatment of malignant tumors of the central nervous system,12/03/2001,Designated,,,malignant tumors of the central nervous system,,,,,,,
1130,conjugated bile acids,Treatment of steatorrhea in patients with short bowel syndrome,07/18/2003,Designated,,,steatorrhea in patients with short bowel syndrome,,,,,,,
1132,copanlisib,Treatment of splenic marginal zone lymphoma,02/07/2017,Designated,Q19903876,,splenic marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050750,,http://www.orpha.net/ORDO/Orphanet_86854,,Q3832900,,
1133,copanlisib,Treatment of extranodal marginal zone lymphoma,02/07/2017,Designated,Q19903876,,extranodal marginal zone lymphoma,,,,,,,
1134,copanlisib,Treatment of follicular lymphoma,02/05/2015,Designated,Q19903876,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1135,copanlisib,Treatment of nodal marginal zone lymphoma,02/07/2017,Designated,Q19903876,,nodal marginal zone lymphoma,,,,,,,
1137,copper histidine,Treatment of Menkes disease,05/14/2012,Designated,Q27271298,UXMNQKKPBFTHMU-JEDNCBNOSA-N,menkes disease,http://purl.obolibrary.org/obo/DOID_1838,,http://www.orpha.net/ORDO/Orphanet_565,D007706,Q639203,,Q639203
1138,Cordycepin,Treatment of TdT-positive acute lymphocytic leukemia,07/05/2007,Designated,Q2256677,,tdt-positive acute lymphocytic leukemia,,,,,,,
1139,corifungin,Treatment of visceral leishmaniasis,07/06/2011,Designated,Q27282614,,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
1140,corifungin,Treatment of amebic meningoencephalitis.,08/22/2011,Designated,Q27282614,,amebic meningoencephalitis,,,,D020808,,,
1142,"Corticotropin-releasing factor, human",Treatment of peritumoral brain edema.,04/06/1998,Designated,,,peritumoral brain edema,,,,,,,
1143,Coumarin,Treatment of renal cell carcinoma.,12/22/1994,Designated,Q111812,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1144,coversin; rEV675,Treatment of paroxysmal nocturnal hemoglobinuria,09/08/2016,Designated,,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1145,Coxsackievirus A21,"Treatment of stage II (T4), stage III, and stage IV melanoma",12/15/2005,Designated,,,"stage ii (t4), stage iii, and stage iv melanoma",,,,,,,
1146,Creatine,Treatment of Huntington's disease,10/11/2005,Designated,Q223600,CVSVTCORWBXHQV-UHFFFAOYSA-N,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1147,creatine,Treatment of amyotrophic lateral sclerosis,02/12/2002,Designated,Q223600,CVSVTCORWBXHQV-UHFFFAOYSA-N,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1148,crenolanib,Treatment of acute myelogenous leukemia,10/31/2012,Designated,Q5184160,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1149,crenolanib,Treatment of soft tissue sarcoma,03/18/2011,Designated,Q5184160,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1150,crenolanib besylate,Treatment of malignant glioma,12/20/2010,Designated,Q27283841,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1151,cridanimod,Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.,01/12/2011,Designated,Q27293702,,progesterone receptor negative endometrial cancer in conjunction with progesterone therapy,,,,,,,
1152,crizotinib,Treatment of neuroblastoma,10/31/2012,Designated,Q5186964,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1153,crizotinib,Treatment of anaplastic large cell lymphoma,09/28/2012,Designated,Q5186964,,anaplastic large cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050744,,http://www.orpha.net/ORDO/Orphanet_98841,D017728,Q18553446,,
1154,crizotinib,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",09/13/2010,Designated/Approved,Q5186964,,"alk-positive, met-positive, or ros-positive non-small cell lung cancer",,,,,,,
1155,Cromolyn sodium,Treatment of mastocytosis.,03/08/1984,Designated/Approved,Q10261779,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
1156,Cromolyn sodium 4% ophthalmic solution,Treatment of vernal keratoconjunctivitis.,07/24/1985,Designated/Approved,,,vernal keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_70476,D003233,,Q4119259,Q18555085
1157,cromolyn sodium for inhalation,Treatment of mastocytosis.,12/09/2015,Designated,,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
1158,Cryptosporidium hyperimmune bovine colostrum IgG concentrate,Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.,12/30/1991,Designated,,,diarrhea in aids patients caused by infection with cryptosporidium parvum,,,,,,,
1159,CT-2584 mesylate,Treatment of malignant mesothelioma.,04/16/1999,Designated/Withdrawn,Q27265739,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
1160,CT-2584 Mesylate,Treatment of adult soft tissue sarcoma.,04/16/1999,Designated/Withdrawn,Q27265739,,adult soft tissue sarcoma,,,,,,,
1161,cultured skin substitute (CSS),Treatment of burns requiring skin grafting.,08/22/2016,Designated,,,burns requiring skin grafting,,,,,,,
1163,cyclic pyranopterin monophosphate (cPMP),Treatment of molybdenum cofactor deficiency type A (MoCD),11/05/2009,Designated,,,molybdenum cofactor deficiency type a (mocd),,,,,,,
1164,"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}","Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis",12/20/2006,Designated,,,"chronic control of non-infectious posterior, intermediate and pan-uveitis",,,,,,,
1165,"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",Treatment of acromegaly,06/24/2013,Designated,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
1166,cyclocreatine,Treatment of creatine transporter deficiency,06/18/2012,Designated,Q27076942,,creatine transporter deficiency,http://purl.obolibrary.org/obo/DOID_0050800,,http://www.orpha.net/ORDO/Orphanet_52503,,Q17084842,Q17084842,
1167,cyclophosphamide,Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant,06/17/2011,Designated,Q27106287,,graft versus host disease following allogeneic hematopoietic stem cell transplant,,,,,,,
1168,cyclophosphamide,Treatment of systemic sclerosis.,06/07/2011,Designated,Q27106287,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1169,Cyclosporin A,Treatment of amyotrophic lateral sclerosis and its variants,10/29/2004,Designated,Q367700,,amyotrophic lateral sclerosis and its variants,,,,,,,
1170,cyclosporine,Treatment of graft-versus-host disease,02/17/2009,Designated,Q367700,,graft-versus-host disease,,,,D006086,,,Q1194520
1173,Cyclosporine,Treatment of acute rejection in patients requiring allogenic lung transplants,11/25/2003,Designated,Q367700,,acute rejection in patients requiring allogenic lung transplants,,,,,,,
1175,Cyclosporine 2% ophthalmic ointment,Treatment of patients at high risk of graft rejection following penetrating keratoplasty,08/01/1991,Designated,,,patients at high risk of graft rejection following penetrating keratoplasty,,,,,,,
1176,cyclosporine A,Treatment of herpes simplex virus stromal keratitis,04/09/2008,Designated,Q367700,,herpes simplex virus stromal keratitis,,,,,,,
1177,cyclosporine A,Prevention of corneal graft rejection,09/30/2008,Designated,Q367700,,corneal graft rejection,,,,,,,
1178,Cyclosporine A,Treatment of vernal keratoconjunctivitis,05/04/2007,Designated,Q367700,,vernal keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_70476,D003233,,Q4119259,Q18555085
1180,Cyclosporine in combination with omega-3 polyunsaturated fatty acids,Prevention of solid organ graft rejection.,12/06/2000,Designated,,,solid organ graft rejection,,,,,,,
1181,Cyclosporine ophthalmic,Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.,11/09/1988,Designated,,,severe keratoconjunctivitis sicca associated with sjogren's syndrome,,,,,,,
1182,cyclosporine; ciclosporin,Treatment of moderate to severe traumatic brain injury.,11/23/2010,Designated,,,moderate to severe traumatic brain injury,,,,,,,
1183,Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III),Treatment of invasive aspergillosis.,12/29/2015,Designated,,,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
1184,Cyproterone acetate,Treatment of severe hirsutism.,10/26/1984,Designated/Withdrawn,Q426185,,severe hirsutism,,,,,,,
1186,cysteamine,Treatment of neuronal ceroid lipofuscinoses (Batten disease),08/06/2008,Designated,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,neuronal ceroid lipofuscinoses (batten disease),,,,,,,
1187,cysteamine,Treatment of Huntington's disease,05/09/2008,Designated,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1188,cysteamine,Treatment of pancreatic cancer,09/11/2013,Designated,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1189,Cysteamine,Treatment of nephropathic cystinosis.,01/25/1991,Designated/Approved,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,nephropathic cystinosis,,,,D003554,,,Q1149042
1190,Cysteamine,Treatment of nephropathic cystinosis.,05/01/1986,Designated,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,nephropathic cystinosis,,,,D003554,,,Q1149042
1191,Cysteamine,Treatment of cystic fibrosis,09/11/2014,Designated,Q617563,UFULAYFCSOUIOV-UHFFFAOYSA-N,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1192,cysteamine enteric coated,Treatment of cystinosis,10/24/2006,Designated/Approved,,,cystinosis,http://purl.obolibrary.org/obo/DOID_1064,,http://www.orpha.net/ORDO/Orphanet_213,D003554,Q1149042,Q1149042,Q1149042
1193,Cysteamine hydrochloride,Treatment of corneal cystine crystal accumulation in cystinosis patients.,08/19/1997,Designated/Approved,Q27280697,OGMADIBCHLQMIP-UHFFFAOYSA-N,corneal cystine crystal accumulation in cystinosis patients,,,,,,,
1194,Cystic fibrosis gene therapy,Treatment of cystic fibrosis.,06/30/1992,Designated/Withdrawn,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1195,Cystic fibrosis Tr gene therapy (recombinant adenovirus),Treatment of cystic fibrosis.,03/09/1995,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1197,Cystic fibrosis transmembrane conductance regulator gene,Treatment of cystic fibrosis.,01/08/1993,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1198,Cytarabine liposomal,Treatment of neoplastic meningitis.,06/02/1993,Designated/Approved,,,neoplastic meningitis,,,,,,,
1199,cytarabine liposome,Treatment of gliomas,01/30/2007,Designated,,,gliomas,,,,D005910,,,Q18556612
1200,Cytarabine:daunorubicin liposome injection,Treatment of acute myeloid leukemia,08/22/2008,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1201,"cytochrome C, flavin mononucleotide and thiamin diphosphate",Treatment of mitochondrial disorders,06/17/2011,Designated,,,mitochondrial disorders,,,,D028361,,,Q935710
1202,cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate,Treatment of pancreatic cancer in combination with ifosfamide,12/17/2014,Designated,,,pancreatic cancer in combination with ifosfamide,,,,,,,
1204,Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes,"Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations",06/03/2005,Designated,,,"clinically significant cytomegalovirus (cmv) viremia, cmv disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations",,,,,,,
1205,Cytomegalovirus immune globulin (human),Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.,08/03/1987,Designated/Approved,,,attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants,,,,,,,
1207,cytomegalovirus specific cytotoxic T lymphocytes,Treatment of cytomegalovirus infection in severely immunocompromised patients,01/05/2017,Designated,,,cytomegalovirus infection in severely immunocompromised patients,,,,,,,
1208,D-mannitol and L-proline,Treatment of Cockayne syndrome,04/20/2009,Designated,,UABMROXHKUBKGO-CMCHIOMNSA-N,cockayne syndrome,http://purl.obolibrary.org/obo/DOID_2962,,http://www.orpha.net/ORDO/Orphanet_132271,D003057,Q914389,,Q914389
1209,d-methadone,Treatment of postherpetic neuralgia,06/02/2016,Designated,,,postherpetic neuralgia,,,,D051474,,,
1210,D-peptide,Treatment of acute myelogenous leukemia,02/04/2011,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1211,D-peptide of the sequence AKRHHGYKRKFH - NH2,Treatment of cystic fibrosis,10/23/2002,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1212,D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate,"Treatment of melanoma, stages IIb through IV",03/19/2009,Designated/Withdrawn,,,"melanoma, stages iib through iv",,,,,,,
1213,D-tagatose,Treatment of Prader-Willi Syndrome,01/19/2017,Designated,Q414089,BJHIKXHVCXFQLS-PQLUHFTBSA-N,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
1214,"d6-tetrabenazine, deutetrabenazine",Treatment of Huntington's Disease,11/05/2014,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1215,D9-ivacaftor,Treatment of cystic fibrosis (CF),01/18/2017,Designated,,,cystic fibrosis (cf),,,,,,,
1216,dabrafenib,Treatment BRAF V600 mutation positive Stage IIB through IV melanoma,01/12/2011,Designated/Approved,Q3011604,,v600 mutation positive stage iib through iv melanoma,,,,,,,
1217,dabrafenib,Treatment of patients with BRAF mutation positive non-small cell lung cancer,10/20/2014,Designated,Q3011604,,patients with braf mutation positive non-small cell lung cancer,,,,,,,
1218,dabrafenib,Treatment of malignant glioma with BRAF V600 mutation,02/08/2016,Designated,Q3011604,,malignant glioma with braf v600 mutation,,,,,,,
1219,dabrafenib and trametinib,Treatment of patients with BRAF mutation positive non-small cell lung cancer.,10/29/2015,Designated,,,patients with braf mutation positive non-small cell lung cancer,,,,,,,
1220,dabrafenib and trametinib,Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.,09/01/2016,Designated,,,patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a braf v600 mutation,,,,,,,
1221,dacetuzumab,Treatment of chronic lymphocytic leukemia,10/06/2005,Designated,Q953025,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1222,dacetuzumab,Treatment of multiple myeloma.,08/13/2004,Designated,Q953025,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1223,Daclizumab,Prevention of acute renal allograft rejection.,03/05/1993,Designated/Approved,Q412920,,acute renal allograft rejection,,,,,,,
1224,dacomitinib,"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.",03/03/2015,Designated,Q17130597,,"non-small cell lung cancer with egfr, her2, her4, or ddr2 mutations",,,,,,,
1225,dalbavancin,Treatment of acute osteomyelitis in children (0 through 16 years of age),03/30/2015,Designated,Q5210237,,acute osteomyelitis in children (0 through 16 years of age),,,,,,,
1227,dantrolene sodium,Treatment of Wolfram Syndrome,02/17/2016,Designated,Q27225695,,wolfram syndrome,http://purl.obolibrary.org/obo/DOID_10632,,http://www.orpha.net/ORDO/Orphanet_3463,D014929,Q1153641,,Q1153641
1228,Dantrolene sodium,Treatment of the neuroleptic malignant syndrome.,12/14/1987,Designated/Withdrawn,Q27225695,,the neuroleptic malignant syndrome,,,,,,,
1229,dantrolene sodium,Treatment of heat stroke,09/25/2012,Designated,Q27225695,,heat stroke,,,,D018883,,,Q1191065
1230,dantrolene sodium suspension for injection,Treatment of malignant hyperthermia syndrome,08/16/2013,Designated/Approved,,,malignant hyperthermia syndrome,,,,,,,
1234,daratumumab,Treatment of multiple myeloma,05/06/2013,Designated/Approved,Q5222113,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1235,daratumumab,Treatment of diffuse large B-cell lymphoma.,11/09/2015,Designated,Q5222113,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1236,daratumumab,Treatment of mantle cell lymphoma.,08/20/2015,Designated,Q5222113,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1237,daratumumab,Treatment of follicular lymphoma,08/06/2015,Designated,Q5222113,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1238,Darinaparsin,Treatment of peripheral T-cell lymphoma.,09/13/2010,Designated,Q27166111,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
1239,Dasatinib,Treatment of chronic myelogenous leukemia,11/28/2005,Designated/Approved,Q27139135,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
1240,Dasatinib,Treatment of Philadelphia-positive acute lymphoblastic leukemia,11/18/2005,Designated/Approved,Q27139135,,philadelphia-positive acute lymphoblastic leukemia,,,,,,,
1241,dasiprotimut-T,Treatment of follicular lymphoma,10/28/2009,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1242,dasiprotimut-T,Treatment of mantle cell lymphoma,06/17/2010,Designated,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1243,daunorubicin citrate liposome,Treatment of acute myeloid leukemia,04/15/2013,Designated/Withdrawn,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1244,Daunorubicin citrate liposome injection,Treatment of patients with advanced HIV-associated Kaposi's sarcoma.,05/14/1993,Designated/Approved,,,patients with advanced hiv-associated kaposi's sarcoma,,,,,,,
1245,Daunorubicin liposomal,Treatment of acute myeloid leukemia,09/05/2008,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1246,davunetide,Treatment of progressive supranuclear palsy.,12/07/2009,Designated,Q27279075,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
1247,DCVAC OvCa,Treatment of ovarian cancer,05/14/2013,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1248,DEAE-rebeccamycin,Treatment of bile duct tumors,03/01/2004,Designated,,,bile duct tumors,,,,,,,
1250,decitabine,Treatment of acute myeloid leukemia,08/04/2006,Designated/Withdrawn,Q1181878,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1251,decitabine,Treatment of chronic myelogenous leukemia.,03/08/1999,Designated/Withdrawn,Q1181878,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
1252,decitabine,Treatment of myelodysplastic syndromes.,03/08/1999,Designated/Approved,Q1181878,,myelodysplastic syndromes,,,,D009190,,,Q954625
1253,decitabine,Treatment of sickle cell anemia,09/09/2002,Designated/Withdrawn,Q1181878,,sickle cell anemia,http://purl.obolibrary.org/obo/DOID_10923,,http://www.orpha.net/ORDO/Orphanet_232,D000755,Q185034,,Q185034
1254,decitabine and tetrahydrouridine,Treatment of sickle cell disease,09/19/2016,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1255,defactinib,Treatment of ovarian cancer,02/12/2015,Designated,Q27077009,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1256,deferasirox,Treatment of chronic iron overload in alpha-thalassemia,02/24/2015,Designated/Approved,Q5251502,,chronic iron overload in alpha-thalassemia,,,,,,,
1257,Deferasirox,Treatment of chronic iron overload in patients with transfusion-dependent anemias,11/21/2002,Designated/Approved,Q5251502,,chronic iron overload in patients with transfusion-dependent anemias,,,,,,,
1258,deferiprone,Treatment of Friedreich's ataxia,07/31/2008,Designated,Q749664,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
1259,deferiprone,Treatment of superficial siderosis,09/01/2011,Designated,Q749664,,superficial siderosis,,,http://www.orpha.net/ORDO/Orphanet_247245,,,,
1260,deferiprone,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,12/12/2001,Designated/Approved,Q749664,,iron overload in patients with hematologic disorders requiring chronic transfusion therapy,,,,,,,
1261,Deferitrin,Treatment of iron overload,04/14/2004,Designated/Withdrawn,Q27289730,,iron overload,,,,D019190,,,
1262,deferoxamine starch conjugate,Treatment of acute iron poisoning,01/28/2005,Designated,,,acute iron poisoning,,,,,,,
1263,deferoxamine starch conjugate,Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.,12/21/1998,Designated,,,chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia,,,,,,,
1264,Defibrotide,Treatment of thrombotic thrombocytopenic purpura.,07/05/1985,Designated,Q3704725,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
1267,deflazacort,Treatment of Duchenne muscular dystrophy,08/16/2013,Designated/Approved,Q779118,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1268,deflazacort,Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.,10/22/2015,Designated,Q779118,,pediatric (0 through 16 years of age) juvenile idiopathis arthritis (jia) international league of associations for rheumatology (ilar) categories excluding systemic jia,,,,,,,
1269,deflazacort,Treatment of Duchenne muscular dystrophy,09/16/2010,Designated,Q779118,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1270,dehydrated alcohol,Treatment of trigeminal neuralgia,03/16/2012,Designated,Q153,,trigeminal neuralgia,http://purl.obolibrary.org/obo/DOID_12098,http://purl.obolibrary.org/obo/HP_0100661,http://www.orpha.net/ORDO/Orphanet_221091,D014277,Q1132120,,Q1132120
1271,dehydrated alcohol,Treatment of hypertrophic obstructive cardiomyopathy,09/11/2013,Designated,Q153,,hypertrophic obstructive cardiomyopathy,http://purl.obolibrary.org/obo/DOID_11984,,,D002312,Q1364270,,Q1364270
1272,Dehydroepiandrosterone,Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.,07/13/1994,Designated/Withdrawn,,,systemic lupus erythematosus (sle) and the reduction in the use of steroids in steroid-dependent sle patients,,,,,,,
1275,Dehydroepiandrosterone sulfate sodium,Treatment of serious burns requiring hospitalization.,01/29/1997,Designated,Q27163028,,serious burns requiring hospitalization,,,,,,,
1276,delta-9-tetrahydrocannibinol and cannabidiol,Treatment of glioma.,12/03/2015,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1277,demcizumab,Treatment of pancreatic cancer,04/30/2014,Designated,Q5255127,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1278,Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12,Treatment of malignant glioma,01/25/2017,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1279,"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha",Treatment of glioblastoma or brain stem glioma,06/07/2010,Designated,,,glioblastoma or brain stem glioma,,,,,,,
1280,dendritic hybrid cell vaccine,Treatment of neuroblastoma,09/23/2011,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1281,"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene",Treatment of soft tissue sarcoma.,01/06/2016,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1282,denileukin diftitox,Treatment of peripheral T-cell lymphoma,04/30/2010,Designated,Q1187179,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
1283,denileukin diftitox,Treatment of cutaneous T-cell lymphoma,07/12/2013,Designated,Q1187179,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1284,denileukin diftitox,Treatment of patients with cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,Q1187179,,patients with cutaneous t-cell lymphoma,,,,,,,
1285,denileukin diftitox,Treatment of peripheral T-cell lymphoma (PTCL),06/29/2011,Designated,Q1187179,,peripheral t-cell lymphoma (ptcl),,,,,,,
1286,denosumab,Treatment of patients with giant cell tumor of bone,12/20/2010,Designated/Approved,Q408283,,patients with giant cell tumor of bone,,,,,,,
1287,denosumab,Treatment of hypercalcemia in malignancy,09/11/2013,Designated/Approved,Q408283,,hypercalcemia in malignancy,,,,,,,
1288,deoxythymidine monophosphate and deoxycytidine monophosphate,Treatment of thymidine kinase 2 deficiency.,07/07/2016,Designated,,IMNAGKZUGSPEQC-IUGOXQOHSA-N,thymidine kinase 2 deficiency,,,,,,,
1289,Dermagraft,Treatment of epidermolysis bullosa,12/13/2010,Designated,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
1290,Deslorelin,Treatment of central precocious puberty.,11/05/1987,Designated,Q5264591,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
1291,Desmoglein 3 synthetic peptide (PI-0824),Treatment of pemphigus vulgaris,10/26/2004,Designated,,,pemphigus vulgaris,,,http://www.orpha.net/ORDO/Orphanet_704,D010392,,,Q1483214
1292,Desmopressin acetate,Treatment of mild hemophilia A and von Willebrand's disease.,01/22/1991,Designated/Approved,Q27126871,,mild hemophilia a and von willebrand's disease,,,,,,,
1293,deutetrabenazine,Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age),01/13/2015,Designated,Q27077026,,tourette syndrome in the pediatric population (defined as 0 through 16 years of age),,,,,,,
1294,dexamethasone intravitreal implant,"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis",09/11/1998,Designated/Approved,,,"non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis",,,,,,,
1295,dexamethasone phosphate,Treatment of corneal graft rejection.,12/02/2008,Designated,Q27137065,,corneal graft rejection,,,,,,,
1296,dexamethasone sodium phosphate encapsulated in autologous erythrocytes,Treatment of ataxia-telangiectasia,07/24/2012,Designated,,,ataxia-telangiectasia,,,http://www.orpha.net/ORDO/Orphanet_100,D001260,,,Q387082
1298,dexpramipexole,Treatment of amyotrophic lateral sclerosis,10/11/2007,Designated,Q5268345,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1300,dexrazoxane,Treatment of anthracycline extravasation during chemotherapy,03/25/2004,Designated/Approved,Q524995,,anthracycline extravasation during chemotherapy,,,,,,,
1301,dexrazoxane hydrochloride,Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines,08/19/2014,Designated,Q27121988,,cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines,,,,,,,
1302,dextran 1,Treatment of cystic fibrosis,03/21/2003,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1303,Dextran 70,Treatment of recurrent corneal erosion unresponsive to conventional therapy.,03/05/1990,Designated,Q28163637,,recurrent corneal erosion unresponsive to conventional therapy,,,,,,,
1304,Dextran and deferoxamine,Treatment of acute iron poisoning.,03/08/1991,Designated,,,acute iron poisoning,,,,,,,
1306,Dextran sulfate sodium,Treatment of aquired immunodeficiency syndrome.,11/19/1987,Designated,,,aquired immunodeficiency syndrome,,,,,,,
1307,dextromethorphan hydrobromide/quinidine sulfate,Treatment of amyotrophic lateral sclerosis (ALS),02/14/2017,Designated,,,amyotrophic lateral sclerosis (als),,,,,,,
1308,DHA-paclitaxel,Treatment of pancreatic cancer,09/25/2001,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1309,DHA-paclitaxel,Treatment of adenocarcinoma of the stomach or lower esophagus,05/01/2003,Designated/Withdrawn,,,adenocarcinoma of the stomach or lower esophagus,,,,,,,
1310,DHA-paclitaxel,Treatment of metastatic malignant melanoma,10/10/2002,Designated/Withdrawn,,,metastatic malignant melanoma,,,,,,,
1311,diacerein,Treatment of epidermolysis bullosa,10/15/2014,Designated,Q413178,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
1313,diannexin,Prevention of ischemia-reperfusion injury in solid organ transplants,10/28/2009,Designated,,,ischemia-reperfusion injury in solid organ transplants,,,,,,,
1317,Diazepam buccal soluble film,"Treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)",11/10/2016,Designated,,,"selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (aed) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)",,,,,,,
1318,diazepam subcutaneous injection,Treatment of acute repetitive seizures.,05/26/2016,Designated,,,acute repetitive seizures,,,,,,,
1320,Diaziquone,Treatment of primary brain malignancies (grade III and IV astrocytomas).,11/10/1983,Designated/Withdrawn,Q27162386,,primary brain malignancies (grade iii and iv astrocytomas),,,,,,,
1321,diazoxide,Treatment of Prader Willi Syndrome,12/03/2012,Designated,Q420009,,prader willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,,D011218,Q594013,,Q594013
1322,diazoxide choline,Treatment of Prader-Willi Syndrome,05/13/2014,Designated,Q27255610,,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
1323,dichlorphenamide,Treatment of primary periodic paralyses,09/02/2010,Designated/Approved,Q3706987,,primary periodic paralyses,,,,,,,
1324,Dideoxyinosine,Treatment of acquired immunodeficiency syndrome.,06/22/1988,Designated/Withdrawn,Q422606,BXZVVICBKDXVGW-NKWVEPMBSA-N,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
1325,Diethyldithiocarbamate,Treatment of AIDS.,04/03/1986,Designated,,LMBWSYZSUOEYSN-UHFFFAOYSA-M,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
1327,Diethylenetriaminepentaacetic acid (DTPA),"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.",04/28/2004,Designated/Approved,,,"patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination",,,,,,,
1328,Diethylnorspermine (DENSPM),Treatment for hepatocellular carcinoma,05/25/2004,Designated/Withdrawn,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1329,diferuloylmethane,Treatment of cystic fibrosis,06/13/2003,Designated,Q312266,VFLDPWHFBUODDF-FCXRPNKRSA-N,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1330,difluprednate,Treatment of endogenous and traumatic anterior uveitis and panuveitis.,09/30/2008,Designated/Approved,Q736113,,endogenous and traumatic anterior uveitis and panuveitis,,,,,,,
1331,digitoxin,Treatment of soft tissue sarcomas,10/18/2001,Designated,Q423890,,soft tissue sarcomas,,http://purl.obolibrary.org/obo/HP_0030448,,D012509,,,Q18975788
1332,digitoxin,Treatment of ovarian cancer,11/02/2001,Designated,Q423890,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1333,digitoxin,Treatment of cystic fibrosis,05/27/2005,Designated,Q423890,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1334,digoxin immune fab (ovine),Treatment of severe preeclampsia and eclampsia,02/03/2012,Designated,Q908009,,severe preeclampsia and eclampsia,,,,,,,
1335,Digoxin immune FAB (Ovine),Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,11/01/1984,Designated/Approved,Q908009,,potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy,,,,,,,
1336,Digoxin immune fab(ovine),"Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.",03/11/1985,Designated,,,"life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia",,,,,,,
1337,dihydroartemisinin and piperaquine,"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale.""",01/08/2007,Designated,,,"uncomplicated malaria caused by ""plasmodium falciparum,"" plasmodium vivax,"" plasmodium malariae,"" or ""plasmodium ovale.""",,,,,,,
1338,Dihydrotestosterone,Treatment of weight loss in AIDS patients with HIV-associated wasting.,02/05/1996,Designated,Q27158453,,weight loss in aids patients with hiv-associated wasting,,,,,,,
1339,dimebon,Treatment of Huntington's Disease.,05/12/2009,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1340,Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP),Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.,11/24/1999,Designated,,,acute graft-versus-host disease in patients undergoing bone marrow transplantation,,,,,,,
1341,dimethyl fumarate,Treatment of Friedreich's Ataxia,09/11/2013,Designated,Q418123,LDCRTTXIJACKKU-ONEGZZNKSA-N,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
1342,Dimethyl sulfoxide,Treatment of cutaneous manifestations of scleroderma.,06/06/1986,Designated/Withdrawn,Q4161663,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,cutaneous manifestations of scleroderma,,,,,,,
1343,Dimethyl sulfoxide,"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.",11/22/1994,Designated,Q4161663,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,"increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available",,,,,,,
1345,Dimethylsulfoxide,Treatment of palmar-plantar erythrodysethesia syndrome.,04/06/1998,Designated,Q407927,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,palmar-plantar erythrodysethesia syndrome,,,,,,,
1347,dinaciclib,Treatment of chronic lymphocytic leukemia.,08/25/2011,Designated,Q15723091,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1348,dinutuximab,Treatment of neuroblastoma,12/20/2010,Designated/Approved,Q21011236,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1349,Dipalmitoylphosphatidylcholine /phosphatidylglycerol,Prevention and treatment of neonatal respiratory distress syndrome.,07/28/1988,Designated,,,treatment of neonatal respiratory distress syndrome,,,,,,,
1350,diphenylcyclopenone,Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU]),06/13/2003,Designated,,,chronic severe forms of alopecia areata (alopecia totalis [at]/alopecia universalis [au]),,,,,,,
1351,Diphenylcyclopropenone gel,Treatment of malignant melanoma stage IIB to IV,04/15/2015,Designated,,,malignant melanoma stage iib to iv,,,,,,,
1352,dipraglurant,Treatment of levodopa-induced dyskinesias,12/29/2015,Designated,Q19596938,,levodopa-induced dyskinesias,,,,,,,
1353,Disaccharide tripeptide glycerol dipalmitoyl,Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.,03/01/1990,Designated,,,pulmonary and hepatic metastases in patients with colorectal adenocarcinoma,,,,,,,
1354,Disodium clodronate,Treatment of hypercalcemia of malignancy.,06/16/1993,Designated,Q27126793,,hypercalcemia of malignancy,,,,,,,
1355,Disodium clodronate tetrahydrate,Treatment of increased bone resorption due to malignancy.,03/05/1990,Designated,,,increased bone resorption due to malignancy,,,,,,,
1356,Disodium silibinin dihemisuccinate,Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).,07/10/1986,Designated/Withdrawn,,,hepatic intoxication by amanita phalloides (mushroom poisoning),,,,,,,
1357,Disufenton sodium,Treatment of glioblastoma multiforme.,08/22/2016,Designated,Q5283598,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1358,"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL",Treatment of glioma.,09/19/2016,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1359,DNA plasmid encoding the acetylcholine receptor,Treatment of myasthenia gravis.,04/18/2011,Designated/Withdrawn,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
1360,DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19,Treatment of ovarian cancer,08/20/2009,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1361,DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor,Treatment of amyotrophic lateral sclerosis,02/06/2014,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1362,DNA plasmid vector expressing eIF5Ak50,Treatment of multiple myeloma.,12/13/2010,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1363,"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)",Treatment of diffuse large B cell lymphoma,07/24/2012,Designated,,,diffuse large b cell lymphoma,,,,,,,
1364,"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)",Treatment of mantle cell lymphoma,07/24/2012,Designated,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1365,DNA plasmid vector expressing human IL-12 gene,Treatment of ovarian cancer.,04/04/2005,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1366,"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2",Treatment of renal cell carcinoma.,04/28/2000,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1368,docosahexaenoic acid,Treatment of sickle cell disease,04/27/2015,Designated,Q423345,DVSZKTAMJJTWFG-UHFFFAOYSA-N,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1369,docosahexaenoic acid,Treatment of short bowel syndrome,06/01/2015,Designated,Q423345,DVSZKTAMJJTWFG-UHFFFAOYSA-N,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
1370,"docosahexaenoic acid, DHA",Treatment of primary sclerosing cholangitis,12/17/2014,Designated,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
1371,docosahexanoic acid-paclitaxel,Treatment of hormone-refractory prostate cancer.,03/05/2001,Designated/Withdrawn,,,hormone-refractory prostate cancer,,,,,,,
1372,dodecafluoropentane emulsion,Treatment of sickle cell disease,02/11/2016,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1374,domperidone,"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",09/02/2011,Designated,Q424238,,"hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",,,,,,,
1375,Doripenem,Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.,07/16/2004,Designated,Q411552,,bronchopulmonary infection in patients with cystic fibrosis who are colonized with pseudomonas aeruginosa or burkholderia cepacia,,,,,,,
1377,double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic,Treatment of Alpha-1 Antitrypsin deficiency,06/09/2015,Designated,,,alpha-1 antitrypsin deficiency,,,,,,,
1378,double stranded RNA which targets the mutated KRAS oncogene,Treatment of pancreatic cancer,01/26/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1379,Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain,Treatment of pancreatic cancer,08/06/2010,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1380,Dovitinib,Treatment of multiple myeloma,10/03/2006,Designated/Withdrawn,Q27077102,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1381,dovitinib,Treatment of adenoid cystic carcinoma,09/26/2013,Designated,Q27077102,,adenoid cystic carcinoma,,,,D003528,,,Q18556510
1382,DOXO-EMCH,Treatment of adenocarcinoma of the pancreas.,04/18/2011,Designated,,,adenocarcinoma of the pancreas,http://purl.obolibrary.org/obo/DOID_4074,,,,Q18556189,,
1383,doxofylline,Treatment of bronchiectasis,02/14/2014,Designated,Q425887,,bronchiectasis,http://purl.obolibrary.org/obo/DOID_9563,http://purl.obolibrary.org/obo/HP_0002110,,D001987,Q32778,,Q32778
1384,doxorubicin,Treatment of hepatocellular carcinoma.,08/25/2009,Designated,Q18936,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1385,doxorubicin,Treatment of cutaneous T-cell lymphoma,04/06/2015,Designated,Q18936,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1386,doxorubicin HCL liposome injection,Treatment of multiple myeloma,12/29/2004,Designated/Approved,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1387,Doxorubicin HCl with pluronic L-61 and pluronic F-127,Treatment of esophageal carcinoma,10/07/2005,Designated,,,esophageal carcinoma,http://purl.obolibrary.org/obo/DOID_1107,http://purl.obolibrary.org/obo/HP_0011459,http://www.orpha.net/ORDO/Orphanet_70482,,Q18553999,,
1388,Doxorubicin liposome,Treatment of ovarian cancer.,11/04/1998,Designated/Approved,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1389,doxorubicin PIHCA nanoparticles,Treatment of hepatocellular carcinoma,03/14/2005,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1390,doxorubicin with pluronics F-127 and L-61,Treatment of gastric cancer,02/20/2008,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1391,DPX-Survivac,Treatment of ovarian cancer.,07/14/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1393,droxidopa,"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.",01/17/2007,Designated/Approved,Q907853,,"neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy",,,,,,,
1394,dry extract from Betulae Cortex (birch bark),Treatment of epidermolysis bullosa,08/07/2014,Designated,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
1396,Duramycin,Treatment of cystic fibrosis.,12/11/1997,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1397,dusquetide,Treatment of macrophage activation syndrome,08/10/2016,Designated,Q27280772,,macrophage activation syndrome,,,http://www.orpha.net/ORDO/Orphanet_158061,D055501,,,
1398,duvelisib,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,04/15/2013,Designated,Q27077129,,chronic lymphocytic leukemia and small lymphocytic lymphoma,,,,,,,
1399,duvoglustat hydrochloride,Treatment of Pompe disease,06/18/2007,Designated,Q27237146,,pompe disease,,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,,,Q1365789
1400,Dynamine,Treatment of Lambert Eaton myasthenic syndrome.,02/05/1990,Designated,,,lambert eaton myasthenic syndrome,,,,D015624,,,Q1756898
1401,Dynamine,Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).,10/16/1991,Designated,,,hereditary motor and sensory neuropathy type i (charcot-marie-tooth disease),,,,,,,
1402,E-selectin antagonist,Treatment of acute myeloid leukemia (AML),05/13/2015,Designated,,,acute myeloid leukemia (aml),,,,,,,
1403,ecallantide,Treatment of angioedema,02/04/2003,Designated/Approved,Q1280166,,angioedema,http://purl.obolibrary.org/obo/DOID_1558,http://purl.obolibrary.org/obo/HP_0100665,,D000799,Q1129007,,Q1129007
1404,"Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4â€™â€™-(pentyloxy)[1,1â€™:4â€™,1â€™â€™-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]",Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.,02/08/2016,Designated,,,candidemia and invasive candidiasis infections caused by susceptible candida spp,,,,,,,
1405,echinomycin,Treatment of acute myeloid leukemia.,05/21/2015,Designated,Q27149203,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1406,echinomycin,Treatment of graft-versus-host disease (GVHD),01/05/2017,Designated,Q27149203,,graft-versus-host disease (gvhd),,,,,,,
1407,echothiophate iodide,Treatment of Stargardt's disease,06/02/2014,Designated,,,stargardt's disease,,,,,,,
1409,ecopipam hydrochloride,Treatment of Tourette's syndrome in children 0-16 years old.,09/29/2010,Designated,Q27262983,,tourette's syndrome in children 0-16 years old,,,,,,,
1410,eculizumab,Treatment of Myasthenia Gravis.,06/12/2014,Designated,Q421617,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
1411,eculizumab,Prevention of delayed graft function after renal transplantation,01/10/2014,Designated,Q421617,,delayed graft function after renal transplantation,,,,,,,
1412,eculizumab,Treatment of paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,Q421617,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1413,eculizumab,Treatment of idiopathic membranous glomerular nephropathy,03/05/2001,Designated,Q421617,,idiopathic membranous glomerular nephropathy,,,,,,,
1414,Eculizumab,Treatment of dermatomyositis,09/21/2000,Designated,Q421617,,dermatomyositis,http://purl.obolibrary.org/obo/DOID_10223,,http://www.orpha.net/ORDO/Orphanet_221,D003882,Q681160,,Q6318950
1415,eculizumab,Treatment of neuromyelitis optica,06/24/2013,Designated,Q421617,,neuromyelitis optica,http://purl.obolibrary.org/obo/DOID_8869,,http://www.orpha.net/ORDO/Orphanet_71211,D009471,Q611458,,Q611458
1416,eculizumab,Treatment of atypical hemolytic uremic syndrome,04/29/2009,Designated/Approved,Q421617,,atypical hemolytic uremic syndrome,,,,D065766,,,Q17165460
1417,eculizumab,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,10/18/2011,Designated,Q421617,,shiga-toxin producing escherichia coli hemolytic uremic syndrome,,,,,,,
1418,edaravone,Treatment of amyotrophic lateral sclerosis,03/12/2015,Designated,Q335099,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1419,edaravone,Treatment of amyotrophic lateral sclerosis,05/12/2015,Designated,Q335099,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1420,Edotreotide,Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors,07/28/2005,Designated,Q908790,,somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors,,,,,,,
1422,Efdispo (tm),Treatment of Ewings Sarcoma.,01/15/2013,Designated,,,ewings sarcoma,http://purl.obolibrary.org/obo/DOID_3369,,,D012512,Q18555397,,Q18555397
1423,Eflornithine,Treatment of anaplastic glioma,09/29/2006,Designated,Q424751,,anaplastic glioma,,,,,,,
1424,eflornithine,Treatment of Familial Adenomatous Polyposis,02/04/2011,Designated,Q424751,,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
1425,eflornithine,Treatment of neuroblastoma,11/23/2010,Designated,Q424751,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1426,eflornithine,Treatment of pancreatic cancer.,12/14/2016,Designated,Q424751,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1427,Eflornithine HCl,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,04/18/1986,Designated/Withdrawn,,,pneumocystis carinii pneumonia in aids patients,,,,,,,
1428,Eflornithine HCl,Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).,04/23/1986,Designated/Approved,,,trypanosoma brucei gambiense infection (sleeping sickness),,,,,,,
1429,eflornithine HCL,Treatment of gastric cancer,04/07/2015,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1430,eflornithine plus sulindac,Treatment of familial adenomatous polyposis,01/22/2013,Designated,,,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
1431,eicosapentaenoic acid,Treatment of familial adenomatous polyposis,03/08/2011,Designated,Q409990,SBHCLVQMTBWHCD-UHFFFAOYSA-N,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
1432,elacytarabine,Treatment of acute myeloid leukemia (AML),06/18/2008,Designated,Q27289866,,acute myeloid leukemia (aml),,,,,,,
1434,Elesclomol,Treatment of metastatic melanoma in combination with paclitaxel,12/18/2007,Designated,Q5359460,,metastatic melanoma in combination with paclitaxel,,,,,,,
1435,eliglustat,Treatment of Type I Gaucher disease,09/17/2008,Designated/Approved,Q21011224,,type i gaucher disease,,,,,,,
1437,elotuzumab,Treatment of multiple myeloma,09/01/2011,Designated/Approved,Q3723645,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1438,eltoprazine HCl,Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.,02/08/2016,Designated,,,levodopa-induced dyskinesia associated with parkinson's disease,,,,,,,
1439,eltrombopag,Treatment of aplastic anemia,11/08/2013,Designated/Approved,Q411588,,aplastic anemia,http://purl.obolibrary.org/obo/DOID_12449,http://purl.obolibrary.org/obo/HP_0001915,http://www.orpha.net/ORDO/Orphanet_182040,D000741,Q846316,,Q846316
1440,eltrombopag,Treatment of idiopathic thrombocytopenia purpura,05/05/2008,Designated/Approved,Q411588,,idiopathic thrombocytopenia purpura,,,,,,,
1441,emixustat,Treatment of Stargardt disease (STGD),01/04/2017,Designated,Q27231516,,stargardt disease (stgd),,,,,,,
1442,emodepside,"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus",09/13/2016,Designated,Q1339032,,"onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus",,,,,,,
1443,emricasan,Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease,11/20/2013,Designated,Q27077178,,liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease,,,,,,,
1444,Enadoline hydrochloride,Treatment of severe head injury.,01/28/1997,Designated,Q27236371,,severe head injury,,,,,,,
1445,enalapril maleate (powder for oral solution),Treatment of hypertension in pediatric patients,01/30/2013,Designated/Withdrawn,,,hypertension in pediatric patients,,,,,,,
1446,Encapsulated porcine islet preparation,Treatment of type I diabetic patients who are already on immunosuppression.,07/05/1995,Designated,,,type i diabetic patients who are already on immunosuppression,,,,,,,
1447,encapsulated spores from fecal microbiota,Treatment of recurrent Clostridium difficile infection (CDI),08/19/2015,Designated,,,recurrent clostridium difficile infection (cdi),,,,,,,
1448,enchochleate amphotericin B,Treatment of visceral leishmaniasis,01/10/2014,Designated,,,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
1449,encochleated amikacin,Treatment of non-tuberculous mycobacteria (NTM) infections,03/03/2016,Designated,,,non-tuberculous mycobacteria (ntm) infections,,,,,,,
1450,encorafenib,Treatment of Stage IIB-IV melanoma positive for BRAF mutation,11/19/2013,Designated,Q15409405,,stage iib-iv melanoma positive for braf mutation,,,,,,,
1451,encorafenib + binimetinib,Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.,11/19/2013,Designated,,,stage iib-iv melanoma positive for the braf mutation,,,,,,,
1452,Endothelin receptor B antagonist,Treatment of malignant melanoma Stages IIB to IV.,01/21/2016,Designated,,,malignant melanoma stages iib to iv,,,,,,,
1453,"enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor","Treatment of invasive Candida infections, including candidemia",05/10/2016,Designated,,,"invasive candida infections, including candidemia",,,,,,,
1454,EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody,Treatment glioblastoma multiforme,02/14/2017,Designated,,,multiforme,,,,,,,
1455,Engineered variant of recombinant human fibroblast growth factor 19,Treatment of primary biliary cirrhosis,02/06/2014,Designated,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
1456,eniluracil,Treatment of hepatocellular carcinoma.,12/15/2005,Designated,Q27094456,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1458,ensituximab,Treatment of pancreatic cancer.,10/21/2010,Designated,Q12182591,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1459,"entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide",Treatment of neuroblastoma,12/22/2014,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1460,enzastaurin,Treatment of diffuse large B-cell lymphoma,03/04/2009,Designated,Q5381479,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1461,Enzastaurin,Treatment of glioblastoma multiforme,09/19/2005,Designated,Q5381479,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1462,epacadostat,Treatment of stage IIB-IV melanoma.,02/11/2016,Designated,Q27077199,,stage iib-iv melanoma,,,,,,,
1465,Epirubicin,Treatment of breast cancer.,09/14/1999,Designated/Approved,Q425122,,breast cancer,http://purl.obolibrary.org/obo/DOID_1612,http://purl.obolibrary.org/obo/HP_0003002,,D001943,Q128581,,Q128581
1466,Epitalon,Treatment of retinitis pigmentosa,09/02/2010,Designated/Withdrawn,Q27285389,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1467,Epoetin alfa,Treatment of anemia associated with HIV infection or HIV treatment.,07/01/1991,Designated/Approved,Q5383794,,anemia associated with hiv infection or hiv treatment,,,,,,,
1468,Epoetin alfa,Treatment of myelodysplastic syndrome.,12/20/1993,Designated,Q5383794,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1469,Epoetin alfa,Treatment of anemia associated with end stage renal disease.,04/10/1986,Designated/Approved,Q5383794,,anemia associated with end stage renal disease,,,,,,,
1470,Epoetin alpha,Treatment of HIV associated anemia related to HIV infection or HIV treatment.,03/07/1989,Designated,,,hiv associated anemia related to hiv infection or hiv treatment,,,,,,,
1471,Epoetin alpha,Treatment of anemia associated with end stage renal disease.,08/27/1987,Designated,,,anemia associated with end stage renal disease,,,,,,,
1472,Epoetin alpha,Treatment of anemia of prematurity in preterm infants.,07/21/1988,Designated/Withdrawn,,,anemia of prematurity in preterm infants,,,,,,,
1473,Epoetin beta,Treatment of anemia associated with end stage renal disease.,10/22/1987,Designated,,,anemia associated with end stage renal disease,,,,,,,
1476,epoprostenol,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,03/22/1999,Designated/Approved,,,secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease,,,,,,,
1477,Epoprostenol,Treatment of primary pulmonary hypertension.,09/25/1985,Designated/Approved,,,primary pulmonary hypertension,http://purl.obolibrary.org/obo/DOID_14557,http://purl.obolibrary.org/obo/HP_0002092,,D065627,Q18554794,,
1478,epratuzumab,Treatment of acute lymphoblastic leukemia,09/30/2008,Designated,Q3730737,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1479,epratuzumab,Treatment of non-Hodgkin's lymphoma,07/13/1998,Designated,Q3730737,,non-hodgkin's lymphoma,,,,D008228,,,Q18557998
1480,Eprodisate,Treatment of secondary amyloidosis,04/06/1999,Designated,Q27265336,,secondary amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85445,,,,
1481,Epstein Barr Virus specific cytotoxic T lymphocytes,Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.,12/27/2006,Designated/Withdrawn,,,treatment of ebv-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant,,,,,,,
1482,Epstein-Barr virus-specific autologous cytotoxic T lymphocytes,Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma),06/12/2014,Designated,,,epstein-barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma),,,,,,,
1483,eptifibatide and iloprost,Treatment of purpura fulminans,04/20/2012,Designated,,,purpura fulminans,http://purl.obolibrary.org/obo/DOID_0060538,,,D055665,Q3410985,,Q3410985
1484,erdosteine,Treatment of bronchiectasis.,12/20/2013,Designated,Q3731252,,bronchiectasis,http://purl.obolibrary.org/obo/DOID_9563,http://purl.obolibrary.org/obo/HP_0002110,,D001987,Q32778,,Q32778
1485,eribulin mesylate,Treatment of soft tissue sarcoma,05/14/2012,Designated/Approved,Q27882076,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1486,Erlotinib Hydrochloride,Treatment of malignant gliomas,07/18/2003,Designated,Q27124083,,malignant gliomas,,,,D005910,,,Q18556612
1488,Erwinia L-asparaginase,Treatment of acute lymphocytic leukemia.,07/30/1986,Designated/Approved,,,acute lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1489,"Erythropoietin (human, recombinant)",Treatment of anemia associated with end stage renal disease.,11/19/1987,Designated/Withdrawn,,,anemia associated with end stage renal disease,,,,,,,
1490,Erythropoietin (recombinant human),Treatment of anemia associated with end stage renal disease.,08/19/1987,Designated,,,anemia associated with end stage renal disease,,,,,,,
1493,Etanercept,Treatment of Wegener's granulomatosis.,04/06/1999,Designated/Withdrawn,Q415343,,wegener's granulomatosis,http://purl.obolibrary.org/obo/DOID_12132,,,D014890,Q1161568,,Q1161568
1496,eteplirsen,Treatment of Duchenne Muscular Dystrophy.,10/23/2007,Designated/Approved,Q5402585,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1497,Ethanol gel,Treatment of congenital venous malformations,03/29/2006,Designated/Withdrawn,,,congenital venous malformations,,,,,,,
1498,Ethanol gel,Treatment of congenital lymphatic malformations,03/13/2006,Designated/Withdrawn,,,congenital lymphatic malformations,,,,,,,
1500,Ethanolamine oleate,"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.",03/22/1984,Designated/Approved,Q6901567,VPHOSDZKGZRSAI-KTKRTIGZSA-N,"patients with esophageal varices that have recently bled, to prevent rebleeding",,,,,,,
1501,"Ethinyl Estradiol, USP",Treatment of Turner's syndrome.,06/22/1988,Designated/Withdrawn,,,turner's syndrome,,,,D014424,,,Q202849
1504,"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate",Treatment of Crohn's disease.,05/13/1998,Designated/Withdrawn,Q27292404,CLQRMSBSMHXMMC-UHFFFAOYSA-N,crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,http://purl.obolibrary.org/obo/HP_0100280,,D003424,Q1472,,Q18553712
1505,Ethyl eicosapentaenoate,Treatment of Huntington's disease.,04/06/2000,Designated,,DTEMJWLYSQBXEL-UHFFFAOYSA-N,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1506,Etidronate disodium,Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,05/02/1991,Designated/Withdrawn,Q27106537,,degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition,,,,,,,
1507,Etidronate disodium,Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.,03/21/1986,Designated/Approved,Q27106537,,hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration,,,,,,,
1508,Etidronate disodium,Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,05/02/1991,Designated/Withdrawn,Q27106537,,degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition,,,,,,,
1509,Etiocholanedione,Treatment of aplastic anemia.,11/03/1995,Designated,Q27096595,,aplastic anemia,http://purl.obolibrary.org/obo/DOID_12449,http://purl.obolibrary.org/obo/HP_0001915,http://www.orpha.net/ORDO/Orphanet_182040,D000741,Q846316,,Q846316
1510,Etiocholanedione,Treatment of Prader-Willi syndrome.,05/07/1996,Designated,Q27096595,,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
1511,etirinotecan pegol,Treatment of ovarian cancer.,04/18/2011,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1512,etrolizumab,Treatment of pediatric patients with ulcerative colitis,08/22/2016,Designated,Q5404888,,pediatric patients with ulcerative colitis,,,,,,,
1513,everolimus,Treatment of hepatocellular carcinoma,07/23/2012,Designated,Q421052,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1514,everolimus,Treatment of diffuse large B-cell lymphoma,06/02/2014,Designated,Q421052,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1515,everolimus,Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma),09/16/2010,Designated/Withdrawn,Q421052,,waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma),,,,,,,
1516,everolimus,Treatment of gastric cancer,05/24/2011,Designated/Withdrawn,Q421052,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1517,everolimus,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",06/08/2009,Designated/Approved,Q421052,,"tuberous sclerosis complex including tsc-associated subependymal giant cell astrocytoma (sega), tsc-associated angiomyolipoma and tsc-associated lymphangioleiomyomatosis (lam)",,,,,,,
1518,everolimus,Treatment of neuroendocrine tumors,02/14/2008,Designated/Approved,Q421052,,neuroendocrine tumors,,,,D018358,,,Q1981276
1521,evolocumab,Treatment of homozygous familial hypercholesterolemia,09/12/2013,Designated/Approved,Q15623825,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
1522,Ex vivo cultured adult human mesenchymal stem cells,Treatment of acute graft versus host disease,12/14/2005,Designated,,,acute graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_99920,,,,
1523,ex vivo cultured human mesenchymal stromal cells,Prevention of graft rejection following solid organ transplantation,05/08/2014,Designated,,,graft rejection following solid organ transplantation,,,,,,,
1524,ex-vivo cultered adult human mesenchymal stem cells,Treatment of Type 1 diabetes patients with residual beta cell function,04/30/2010,Designated,,,type 1 diabetes patients with residual beta cell function,,,,,,,
1525,ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells,Treatment of Amyotrophic Lateral Sclerosis,12/20/2010,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1526,Exemestane,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,09/19/1991,Designated/Approved,Q418819,,advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy,,,,,,,
1527,Exendin 9-39 (Competitive antagonist of glucagon-like peptide-1),Treatment of hyperinsulinemic hypoglycemia,12/08/2016,Designated,,,hyperinsulinemic hypoglycemia,http://purl.obolibrary.org/obo/DOID_13317,http://purl.obolibrary.org/obo/HP_0000825,,,Q1535394,,
1528,exendin-(9-39),Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children,06/01/2011,Designated,,,congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children,,,,,,,
1530,Exon 44 specific phosphorothioate oligonucleotide,Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.,11/05/2009,Designated,,,duchenne muscular dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene,,,,,,,
1531,Exon 45 specific phosphorothioate oligonucleotide,Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45,01/23/2013,Designated,,,duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 45,,,,,,,
1532,Exon 46 specific phosphorothioate oligonucleotide,Treatment of Duchenne muscular dystrophy,11/18/2005,Designated/Withdrawn,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1533,Exon 51 specific phosphorothioate oligonucleotide,Treatment of Duchenne Muscular Dystrophy.,08/25/2009,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1534,Exon 52 specific phosphorothiate oligonucleotide,Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52,01/23/2013,Designated,,,duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 52,,,,,,,
1535,Exon 53 specific antisense morpholino oligonucleotide.,Treatment of Duchenne Muscular Dystrophy,01/12/2017,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1536,exon 53 specific phosphorothioate oligonucleotide,treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53,01/23/2013,Designated,,,duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 53,,,,,,,
1537,Exon 55 specific phosphorothioate oligonucleotide,Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55,01/23/2013,Designated,,,duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 55,,,,,,,
1538,expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS,Treatment of Dystrophic Epidermolysis Bullosa.,08/20/2009,Designated,,,dystrophic epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_4959,,http://www.orpha.net/ORDO/Orphanet_303,D016108,Q3589131,,Q3589131
1539,expanded human allogeneic neural retinal progenitor cells extracted from neural retina,Treatment of retinitis pigmentosa,08/22/2013,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1540,"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass",Treatment of multiple myeloma,05/14/2012,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1541,extract of sorghum bicolor extract,Treatment of sickle cell disease,11/19/2012,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1542,ezatiostat hydrochloride,Treatment of myelodysplastic syndrome,01/09/2013,Designated,Q27276114,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1543,Facilitated DNA Plasmid Vaccine,Treatment of cutaneous T cell lymphoma.,03/08/1995,Designated,,,cutaneous t cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,,,D016410,Q5196687,,Q5196687
1544,factor VIII mimetic bispecific antibody,Treatment of hemophilia A,01/10/2014,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1545,factor XIII concentrate (human),Treatment of congenital factor XIII deficiency,01/16/1985,Designated/Approved,,,congenital factor xiii deficiency,,,http://www.orpha.net/ORDO/Orphanet_331,,,,
1546,"Factor XIII [A2] homodimer, recombinant DNA origin",Treatment of congenital FXIII deficiency,05/21/2003,Designated,,,congenital fxiii deficiency,,,,,,,
1547,"Factor XIII, recombinant",Treatment of congenital factor XIII deficiency.,04/22/1993,Designated/Withdrawn,,,congenital factor xiii deficiency,,,http://www.orpha.net/ORDO/Orphanet_331,,,,
1548,Fampridine,"Treatment of chronic, incomplete spinal cord injury.",06/02/1997,Designated,Q372539,,"chronic, incomplete spinal cord injury",,,,,,,
1549,Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene,Treatment of Fanconi anemia type A patients.,05/02/2016,Designated,,,fanconi anemia type a patients,,,,,,,
1550,farletuzumab,Treatment of ovarian cancer,06/16/2006,Designated,Q3739631,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1551,fecal microbiota,Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease),03/10/2014,Designated,,,recurrent clostridium difficile infection (clostridium difficile gastrointestinal disease),,,,,,,
1552,Felbamate,Treatment of Lennox-Gastaut syndrome.,01/24/1989,Designated/Approved,Q421301,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
1554,Fenobam hydrochloride,Treatment of fragile X syndrome,11/20/2006,Designated,Q27252038,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1555,Fenretinide,Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients,04/07/2010,Designated,Q5443576,,pseudomonas aeruginosa lung infections in cystic fibrosis patients,,,,,,,
1556,fenretinide,Treatment of cutaneous T-cell lymphoma,09/04/2013,Designated,Q5443576,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1557,fenretinide,Treatment of Ewing's sarcoma family of tumors.,02/01/2007,Designated,Q5443576,,ewing's sarcoma family of tumors,,,,,,,
1558,fenretinide,Treatment of peripheral T-cell lymphoma,09/04/2013,Designated,Q5443576,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
1559,Fenretinide,Treatment of neuroblastoma,10/05/2005,Designated,Q5443576,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1560,"ferric hexacyanoferrate (II) ""Prussian Blue""",Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,06/26/2003,Designated,,,patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,,,,,,,
1564,fexinidazole,Treatment of human African trypanosomiasis (HAT) or sleeping sickness,04/04/2016,Designated,Q5446115,,human african trypanosomiasis (hat) or sleeping sickness,,,,,,,
1566,Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34,Treatment of solitary (unicameral) bone cysts,02/01/2007,Designated,,,solitary (unicameral) bone cysts,,,,,,,
1568,Fibronectin (human plasma derived),Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.,09/05/1988,Designated,,,non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated,,,,,,,
1569,Fibronectin (plasma derived),Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated.,12/05/1988,Designated/Withdrawn,,,non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated,,,,,,,
1570,Fibronectin Peptide,"Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.",06/29/2011,Designated,,,"burn injury progression of acute, deep dermal burns in hospitalized patients",,,,,,,
1571,fidaxomicin,Treatment of pediatric Clostridium difficile infection,12/13/2010,Designated,Q5446672,,pediatric clostridium difficile infection,,,,,,,
1572,filanesib,Treatment of multiple myeloma.,05/06/2014,Designated,Q15634095,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1573,filgrastim,Treatment of amyotrophic lateral sclerosis (ALS),01/27/2015,Designated,Q3151081,,amyotrophic lateral sclerosis (als),,,,,,,
1574,filgrastim,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,11/20/2013,Designated/Approved,Q3151081,,subjects at risk of developing myelosuppression after a radiological or nuclear incident,,,,,,,
1576,Filgrastim,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,11/07/1990,Designated/Approved,Q3151081,,patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3),,,,,,,
1577,Filgrastim,Treatment of neutropenia associated with bone marrow transplants.,10/01/1990,Designated/Approved,Q3151081,,neutropenia associated with bone marrow transplants,,,,,,,
1579,Filgrastim,Treatment of myelodysplastic syndrome,08/30/1990,Designated/Withdrawn,Q3151081,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1580,Filgrastim,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir",09/03/1991,Designated/Withdrawn,Q3151081,,"patients with aids who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir",,,,,,,
1581,filociclovir,Treatment of active cytomegalovirus infections,11/29/2010,Designated,Q27277076,,active cytomegalovirus infections,,,,,,,
1582,fingolimod,Treatment of chronic inflammatory demyelinating polyneuropathy,04/30/2010,Designated,Q425137,,chronic inflammatory demyelinating polyneuropathy,,,http://www.orpha.net/ORDO/Orphanet_2932,,,,
1583,firtecan pegol,Treatment of neuroblastoma.,04/18/2011,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1584,fixed dose combination formulation of macitentan and tadalafil,Treatment of pulmonary arterial hypertension,10/19/2016,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1585,fixed dose combination of modafinil and flecainide,Treatment of narcolepsy,09/19/2016,Designated,,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
1586,FliC Flagellin Deletion Variant TLR5 Agonist,Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,11/23/2010,Designated,,,death following a potentially lethal dose of total body irradiation during or after a radiation disaster,,,,,,,
1589,flubendazole,Treatment of onchocerciasis caused by Onchocerca volvulus,10/25/2013,Designated,Q241992,,onchocerciasis caused by onchocerca volvulus,,,,,,,
1590,flubendazole,"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.",01/23/2014,Designated,Q241992,,"lymphatic filariasis caused by nematodes of the family filariodidea, in children and adults",,,,,,,
1592,Fludarabine phosphate,"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.",04/18/1989,Designated/Approved,Q185916,,"chronic lymphocytic leukemia (cll), including refractory cll",,,,,,,
1593,Fludarabine phosphate,Treatment and management of patients with non-Hodgkins lymphoma.,04/18/1989,Designated,Q185916,,management of patients with non-hodgkins lymphoma,,,,,,,
1594,Fludarabine phosphate oral tablets,Treatment of B-cell chronic lymphocytic leukemia,12/18/2007,Designated/Approved,,,b-cell chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,,http://www.orpha.net/ORDO/Orphanet_67038,D015451,Q1088156,Q1088156,Q1088156
1595,Flumecinol,Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.,01/15/1985,Designated/Withdrawn,Q27281410,,hyperbilirubinemia in newborn infants unresponsive to phototherapy,,,,,,,
1596,flunarizine,Treatment of alternating hemiplegia.,01/06/1986,Designated,Q416237,,alternating hemiplegia,,,http://www.orpha.net/ORDO/Orphanet_209978,,,,
1597,flunarizine,Treatment of hemiplegic migraine,07/20/2016,Designated,Q416237,,hemiplegic migraine,,,,,,,
1598,flunarizine,Treatment of alternating hemiplegia,06/24/2013,Designated,Q416237,,alternating hemiplegia,,,http://www.orpha.net/ORDO/Orphanet_209978,,,,
1599,Fluocinolone,Treatment uveitis involving the posterior segment of the eye.,07/31/2000,Designated/Approved,Q27106662,,involving the posterior segment of the eye,,,,,,,
1600,Fluorouracil,Treatment of glioblastoma multiforme.,06/29/2000,Designated,Q238512,GHASVSINZRGABV-UHFFFAOYSA-N,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1604,Fluoxetine,Treatment of autism.,04/30/1999,Designated,Q422244,,autism,http://purl.obolibrary.org/obo/DOID_12849,http://purl.obolibrary.org/obo/HP_0000717,,D001321,Q38404,,Q38404
1605,Fluoxetine,Treatment of body dysmorphic disorder in children and adolescents,04/14/2004,Designated,Q422244,,body dysmorphic disorder in children and adolescents,,,,,,,
1606,fluticasone propionate,Treatment of pediatric and adult eosinophilic esophagitis,01/19/2011,Designated,Q8564098,,pediatric and adult eosinophilic esophagitis,,,,,,,
1607,fluticasone propionate,Treatment of eosinophilic esophagitis,12/29/2015,Designated,Q8564098,,eosinophilic esophagitis,http://purl.obolibrary.org/obo/DOID_13922,,http://www.orpha.net/ORDO/Orphanet_73247,D057765,Q2057356,Q2057356,Q2057356
1608,folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val,Treatment (including prevention of recurrence) of ovarian cancer,06/08/2016,Designated,,,prevention of recurrence) of ovarian cancer,,,,,,,
1609,Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val,Treatment (including prevention of recurrence) of ovarian cancer,06/08/2016,Designated,,,prevention of recurrence) of ovarian cancer,,,,,,,
1611,Fomepizole,Treatment of methanol or ethylene glycol poisoning.,12/22/1988,Designated/Approved,Q416410,,methanol or ethylene glycol poisoning,,,,,,,
1612,fosbretabulin tromethamine,Treatment of glioma,06/08/2016,Designated,Q27279017,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1613,fosbretabulin tromethamine,Treatment of neuroendocrine tumors,12/29/2015,Designated,Q27279017,,neuroendocrine tumors,,,,D018358,,,Q1981276
1614,fosfomycin/tobramycin,Treatment of pulmonary infections associated with cystic fibrosis,11/28/2008,Designated,,,pulmonary infections associated with cystic fibrosis,,,,,,,
1616,fostamatinib disodium,Treatment of immune thrombocytopenic purpura,08/25/2015,Designated,Q27269733,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
1617,fresolimumab,Treatment of primary focal segmental glomerulosclerosis,10/21/2010,Designated/Withdrawn,Q3753116,,primary focal segmental glomerulosclerosis,,,,,,,
1618,"Fructose-1,6-diphosphate",Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,05/29/1998,Designated/Withdrawn,Q27095310,XPYBSIWDXQFNMH-UYFOZJQFSA-N,painful vaso-occlusive episodes associated with sickle cell disease,,,,,,,
1620,Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles,Treatment of Ewing's sarcoma,09/22/2008,Designated,,,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
1621,Fully human anti-interferon gamma monoclonal antibody,Treatment of hemophagocytic lymphohistiocytosis,03/26/2010,Designated,,,hemophagocytic lymphohistiocytosis,http://purl.obolibrary.org/obo/DOID_0050120,,http://www.orpha.net/ORDO/Orphanet_158032,D051359,Q1642170,,Q1642170
1622,fully human IgG2 monoclonal antibody that binds insulin receptors,Treatment of congenital hyperinsulinism,06/09/2015,Designated,,,congenital hyperinsulinism,,,,D044903,,,Q5160437
1623,fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing,Treatment of growth hormone deficiency,10/16/2013,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
1624,Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1,Treatment of X-linked hypohidrotic ectodermal dysplasia,01/11/2006,Designated,,,x-linked hypohidrotic ectodermal dysplasia,,,http://www.orpha.net/ORDO/Orphanet_181,,,,
1625,G17DT Immunogen,Treatment of adenocarcinoma of the pancreas,07/10/2002,Designated,,,adenocarcinoma of the pancreas,http://purl.obolibrary.org/obo/DOID_4074,,,,Q18556189,,
1626,G17DT Immunogen,Treatment of gastric cancer,07/18/2002,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1628,gabapentin,Treatment of amyotrophic lateral sclerosis,07/05/1995,Designated,Q410352,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1629,gabapentin enacarbil,Treatment of postherpetic neuralgia,06/07/2011,Designated/Approved,Q5515257,,postherpetic neuralgia,,,,D051474,,,
1631,Gallium nitrate injection,Treatment of hypercalcemia of malignancy.,12/05/1988,Designated/Approved/Withdrawn,,,hypercalcemia of malignancy,,,,,,,
1634,Gamma hydroxybutyrate,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.",12/03/1987,Designated,,SJZRECIVHVDYJC-UHFFFAOYSA-M,"narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior",,,,,,,
1635,Gamma-hydroxybutyric acid,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.",01/22/1985,Designated/Withdrawn,Q207920,SJZRECIVHVDYJC-UHFFFAOYSA-N,"narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior",,,,,,,
1636,Gammalinolenic acid,Treatment of juvenile rheumatoid arthritis.,07/27/1994,Designated,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
1637,ganaxolone,Treatment of Protocadherin 19 (PCDH19) female epilepsy.,03/24/2015,Designated,Q3758034,,protocadherin 19 (pcdh19) female epilepsy,,,,,,,
1638,Ganaxolone,Treatment of infantile spasms.,05/25/1994,Designated,Q3758034,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
1639,ganaxolone,Treatment of status epilepticus.,04/14/2016,Designated,Q3758034,,status epilepticus,http://purl.obolibrary.org/obo/DOID_1824,http://purl.obolibrary.org/obo/HP_0002133,,D013226,Q980709,,Q980709
1640,ganaxolone,Treatment of Fragile X Syndrome,12/28/2016,Designated,Q3758034,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1641,ganciclovir,Treatment of acute herpetic keratitis (dendritic and geographic ulcers),03/22/2007,Designated/Approved,Q417640,,acute herpetic keratitis (dendritic and geographic ulcers),,,,,,,
1642,Ganciclovir intravitreal implant,Treatment of cytomegalovirus retinitis.,06/07/1995,Designated/Approved,,,cytomegalovirus retinitis,http://purl.obolibrary.org/obo/DOID_0080160,,,D017726,Q26985508,,Q26985508
1643,Ganciclovir sodium,Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.,10/31/1985,Designated/Approved/Withdrawn,Q27231533,,cytomegalovirus retinitis in immunocompromised patients with aids,,,,,,,
1644,Gancyclovir,Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.,06/07/1985,Designated/Withdrawn,Q417640,,severe human cytomegalovirus infections in specific immunosuppressed patient populations,,,,,,,
1645,Gangliosides as sodium salts,Treatment of retinitis pigmentosa.,11/17/1988,Designated/Withdrawn,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1646,ganitumab,Treatment of pancreatic cancer.,11/23/2010,Designated,Q5521322,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1647,Gastrin 17C Diphtheria Toxoid Immunogen,Treatment of pancreatic cancer,07/07/2009,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1649,gefitinib,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,08/26/2014,Designated/Approved,Q417824,,epidermal growth factor receptor mutation-positive non-small cell lung cancer,,,,,,,
1650,gemcabene,Treatment of homozygous familial hypercholesterolemia,02/06/2014,Designated,Q27095571,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
1651,gemcitabine,Treatment of upper tract urothelial carcinoma,12/30/2015,Designated,Q414143,,upper tract urothelial carcinoma,,,,,,,
1652,gemcitabine,Treatment of cholangiocarcinoma.,01/11/2016,Designated,Q414143,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
1653,gemcitabine ready-to-use,Treatment of ovarian cancer,06/24/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1654,gemcitabine ready-to-use,Treatment of pancreatic cancer,06/24/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1655,Gemtuzumab ozogamicin,Treatment of acute myeloid leukemia,11/24/1999,Designated/Approved,Q412685,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1656,gene encoding chimeric CD40 ligand,Treatment of chronic lymphocytic leukemia,02/04/2009,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1657,genetically engineered herpes simplex virus (G207),Treatment of malignant glioma,04/29/2002,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1658,Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha,Treatment of Crohn's disease.,12/11/1997,Designated,,,crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,http://purl.obolibrary.org/obo/HP_0100280,,D003424,Q1472,,Q18553712
1659,Geneticin,Treatment of amoebiasis.,06/06/2005,Designated,Q27104499,,amoebiasis,http://purl.obolibrary.org/obo/DOID_9181,,,D000562,Q949694,,Q949694
1660,gentamicin C2 congener,Treatment of cystic fibrosis,03/29/2016,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1661,Gentamicin impregnated PMMA beads on surgical wire,"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.",01/31/1991,Designated,,,"chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin",,,,,,,
1662,Gentamicin liposome injection,Treatment of disseminated Mycobacterium avium-intracellulare infection.,07/10/1990,Designated,,,disseminated mycobacterium avium-intracellulare infection,,,,,,,
1663,gevokizumab,Treatment of Behcet's disease,07/27/2010,Designated,Q5554924,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
1664,gevokizumab,Treatment of pyoderma gangrenosum,02/21/2014,Designated,Q5554924,,pyoderma gangrenosum,http://purl.obolibrary.org/obo/DOID_8553,,http://www.orpha.net/ORDO/Orphanet_48104,D017511,Q1526459,,Q1526459
1665,gevokizumab,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",08/20/2012,Designated,Q5554924,,"non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",,,,,,,
1666,Girentuximab,Treatment of renal cell carcinoma.,03/22/2001,Designated,Q5564223,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1667,givinostat,Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy,04/12/2013,Designated,Q426257,,duchenne muscular dystrophy and becker muscular dystrophy,,,,,,,
1668,glatiramer acetate,Treatment of amyotrophic lateral sclerosis (ALS).,11/14/2007,Designated,Q418274,,amyotrophic lateral sclerosis (als),,,,,,,
1669,Glatiramer acetate,Treatment of multiple sclerosis.,11/09/1987,Designated/Approved,Q418274,,multiple sclerosis,http://purl.obolibrary.org/obo/DOID_2377,,,D009103,Q8277,,Q8277
1670,Glatiramer acetate for injection,Treatment of primary-progressive multiple sclerosis,06/05/2001,Designated,,,primary-progressive multiple sclerosis,,,,,,,
1671,glecaprevir and pibrentasvir,Treatment of pediatric patients with chronic hepatitis C virus infection,01/09/2017,Designated,,,pediatric patients with chronic hepatitis c virus infection,,,,,,,
1672,glibentek (glibenclamide oral suspension),Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy),06/08/2016,Designated,,,neonatal diabetes (monogenic forms of diabetes that present in infancy),,,,,,,
1673,glioma derived cell lysates and irradiated cells,Treatment of glioma.,01/12/2011,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1674,glucagon,Prevention of hypoglycemia in the congenital hyperinsulinism population,12/05/2012,Designated,Q28163629,,hypoglycemia in the congenital hyperinsulinism population,,,,,,,
1675,glucagon infusion,"Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism",09/25/2014,Designated,,,"chronic, severe hypoglycemia related to congential hyperinsulinism",,,,,,,
1676,glucarpidase,Treatment of patients at risk of methotrexate toxicity,08/19/2003,Designated/Approved,Q5572303,,patients at risk of methotrexate toxicity,,,,,,,
1677,Glucopyranosyl lipid A stable emulsion,Treatment of follicular lymphoma,02/14/2017,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1680,glutathione,Treatment of lung dysfunction following lung transplant,12/12/2016,Designated,Q116907,RWSXRVCMGQZWBV-WDSKDSINSA-N,lung dysfunction following lung transplant,,,,,,,
1681,Glutathione pegylated liposomal doxorubicin hydrochloride,Treatment of glioma,08/16/2010,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1682,glyburide,Treatment of acute subarachnoid hemorrhage,02/08/2016,Designated,Q420626,,acute subarachnoid hemorrhage,,,,,,,
1683,glyburide,Treatment of acute spinal cord injury,09/29/2015,Designated,Q420626,,acute spinal cord injury,,,,,,,
1684,Glyburide,Treatment of severe cerebral edema in patients with acute ischemic stroke,01/12/2017,Designated,Q420626,,severe cerebral edema in patients with acute ischemic stroke,,,,,,,
1685,glycafilin,Prevention of delayed graft function after solid organ transplantation,08/22/2008,Designated,,,delayed graft function after solid organ transplantation,,,,,,,
1688,Glyceryl tri (4-phenylbutyrate),Treatment of spinal muscular atrophy,05/24/2005,Designated,,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
1689,Glyceryl trioleate and glyceryl trierucate,Treatment of adrenoleukodystrophy.,02/14/1995,Designated,,,adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_117677,D000326,Q366964,,Q366964
1690,glycopyrrolate,Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients,06/09/2006,Designated/Approved,Q411917,,pathologic (chronic moderate to severe) drooling in pediatric patients,,,,,,,
1691,glycopyrrolate 2%,Treatment of Frey's syndrome,06/17/2010,Designated,,,frey's syndrome,,,,D013547,,,Q1431371
1692,glycosylated recombinant human interleukin-7,Treatment of progressive multifocal leukoencephalopathy,09/27/2012,Designated,,,progressive multifocal leukoencephalopathy,http://purl.obolibrary.org/obo/DOID_643,,http://www.orpha.net/ORDO/Orphanet_217260,D007968,Q704930,,Q704930
1693,glycyl-L-2-methylprolyl-L-glutamic Acid,Treatment of Fragile X Syndrome,10/23/2013,Designated,,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1694,glycyl-L-2-methylpropyl-L-glutamic acid,Treatment of Rett syndrome,02/11/2015,Designated,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
1695,Glyeraldehyde-3-phosphate dehydrogenase,Treatment of pediatric multiple sclerosis,04/30/2010,Designated,,,pediatric multiple sclerosis,,,,,,,
1696,GNE Lipoplex,Treatment of hereditary inclusion body myopathy-2,11/13/2008,Designated,,,hereditary inclusion body myopathy-2,,,,,,,
1697,GNE plasmid(H001),Treatment of hereditary inclusion body myopathy type 2,03/26/2010,Designated,,,hereditary inclusion body myopathy type 2,,,http://www.orpha.net/ORDO/Orphanet_602,,,Q3331460,
1698,golimumab,Treatment of chronic sarcoidosis,11/02/2004,Designated/Withdrawn,Q413879,,chronic sarcoidosis,,,,,,,
1699,golimumab,Treatment of sarcoidosis,05/21/2012,Designated/Withdrawn,Q413879,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
1700,golimumab,Treatment of pediatric ulcerative colitis,03/16/2012,Designated,Q413879,,pediatric ulcerative colitis,,,,,,,
1701,golimumab,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,04/02/2015,Designated,Q413879,,polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age,,,,,,,
1702,golnerminogene pradenovec,Treatment of pancreatic cancer.,10/28/2009,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1704,Gossypol,Treatment of cancer of the adrenal cortex.,10/22/1990,Designated,Q411882,,cancer of the adrenal cortex,,,,D000306,,,Q18557308
1705,Gp100 adenoviral gene therapy,Treatment of metastatic melanoma.,03/25/1997,Designated,,,metastatic melanoma,,,,,,,
1706,granulocyte macrophage colony stimuling factor,Treatment of cystic fibrosis,08/27/2008,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1707,Granulocyte macrophage-colony stimulating factor,Treatment of chronic lymphocytic leukemia to increase granulocyte count.,05/04/1990,Designated/Withdrawn,,,chronic lymphocytic leukemia to increase granulocyte count,,,,,,,
1708,Granulocyte macrophage-colony stimulating factor,Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.,06/06/1989,Designated/Withdrawn,,,severe thermal injuries in patients with greater than 40% full or partial thickness burns,,,,,,,
1709,Granulocyte macrophage-colony stimulating factor,Treatment of myelodysplastic syndrome.,08/07/1989,Designated/Withdrawn,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1710,Granulocyte macrophage-colony stimulating factor,Treatment of neutropenia due to hairy cell leukemia.,05/03/1990,Designated/Withdrawn,,,neutropenia due to hairy cell leukemia,,,,,,,
1711,Granulocyte macrophage-colony stimulating factor,Treatment of neutropenia associated with bone marrow transplants.,12/12/1989,Designated/Withdrawn,,,neutropenia associated with bone marrow transplants,,,,,,,
1712,"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF",Treatment of soft tissue sarcoma,07/24/2013,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1713,Group B streptococcus immune globulin,Treatment of neonates for disseminated group B streptococcal infection.,05/08/1990,Designated/Withdrawn,,,neonates for disseminated group b streptococcal infection,,,,,,,
1715,"growth hormone releasing hormone, 1-44 human amide",Treatment of growth hormone deficiency,02/23/2016,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
1716,guadecitabine,Treatment of acute myeloid leukemia.,09/29/2015,Designated,Q27254880,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1717,Guanethidine monosulfate,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,01/06/1986,Designated/Withdrawn,Q27122277,,moderate to severe reflex sympathetic dystrophy and causalgia,,,,,,,
1718,guanfacine,Treatment of fragile X syndrome.,08/05/1999,Designated,Q5613599,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1719,guanfacine and amphetamine,Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age),03/17/2016,Designated,,,pediatric patients with tourette's syndrome (0 through 16 years of age),,,,,,,
1720,Gusperimus,Treatment of acute renal graft rejection episodes.,06/27/1996,Designated/Withdrawn,Q10910504,,acute renal graft rejection episodes,,,,,,,
1721,gusperimus trihydrochloride,Treatment of Wegener's granulomatosis,06/29/2011,Designated,Q27287580,,wegener's granulomatosis,http://purl.obolibrary.org/obo/DOID_12132,,,D014890,Q1161568,,Q1161568
1722,GVAX melanoma,Treatment of stage IIb to IV melanoma,12/23/2010,Designated,,,stage iib to iv melanoma,,,,,,,
1724,H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2,Treatment of acromegaly,11/03/2016,Designated,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
1726,H-Leu-Pro-Pro-Ser-Arg-OH,Treatment of Kaposi sarcoma,09/20/2012,Designated,,,kaposi sarcoma,http://purl.obolibrary.org/obo/DOID_8632,,http://www.orpha.net/ORDO/Orphanet_33276,D012514,Q725345,,Q725345
1727,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH,Treatment of subarachnoid hemorrhage,05/14/2013,Designated,,,subarachnoid hemorrhage,,http://purl.obolibrary.org/obo/HP_0002138,,D013345,,,Q693442
1728,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH,Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset,04/11/2014,Designated,,,acute ischemic stroke patients presenting within 3 hours of symptom onset,,,,,,,
1729,Halofantrine,Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.,11/04/1991,Designated/Approved,Q947595,,mild to moderate acute malaria caused by susceptible strains of p. falciparum and p. vivax,,,,,,,
1730,Halofuginone,Treatment of systemic sclerosis.,02/07/2000,Designated,Q4132745,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1731,halofuginone hydrobromide,Treatment of Duchenne Muscular Dystrophy,10/13/2011,Designated,Q27286744,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1732,Hanferon,Treatment of Behcet's disease,03/09/2012,Designated,,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
1733,Hantaan virus and Puumala virus DNA vaccines,Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus,11/13/2012,Designated,,,hemorrhagic fever with renal syndrome caused by hantaan virus and puumala virus,,,,,,,
1734,HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex,Treatment of localized scleroderma.,04/19/2016,Designated,,,localized scleroderma,http://purl.obolibrary.org/obo/DOID_8472,,http://www.orpha.net/ORDO/Orphanet_90289,D012594,Q3324389,,Q3324389
1737,heat killed mycobacterium w immunomodulator,Treatment of non-small cell lung cancers that express desmocollin-3,07/31/2012,Designated,,,non-small cell lung cancers that express desmocollin-3,,,,,,,
1738,heat killed whole cell mycobacterium obuense,Treatment of pancreatic cancer,09/23/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1740,Heat Shock Protein 70,Treatment of amyotrophic lateral sclerosis,03/18/2011,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1742,hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene,Treatment of leukocyte adhesion deficiency Type I,11/09/2016,Designated,,,leukocyte adhesion deficiency type i,,,http://www.orpha.net/ORDO/Orphanet_99842,,,,
1743,Heme arginate,Treatment of symptomatic stage of acute porphyria.,03/10/1988,Designated,Q14035818,,symptomatic stage of acute porphyria,,,,,,,
1744,Heme arginate,Treatment of myelodysplastic syndromes.,03/01/1994,Designated,Q14035818,,myelodysplastic syndromes,,,,D009190,,,Q954625
1746,Hemin and zinc mesoporphyrin,Treatment of acute porphyric syndromes.,12/20/1993,Designated,,,acute porphyric syndromes,,,,,,,
1747,Hemoximer (pyridoxalated hemoglobin polyoxyethylene),Treatment of cardiogenic shock,12/18/2007,Designated,,,cardiogenic shock,,http://purl.obolibrary.org/obo/HP_0030149,,D012770,,,
1748,heparan sulfate mimetic,Treatment of pancreatic cancer,05/29/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1749,Heparin,Treatment of cystic fibrosis,11/03/2005,Designated/Withdrawn,Q190016,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1750,heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device,Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A),10/24/2011,Designated,,,patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(scale a),,,,,,,
1751,Heparin sodium,Treatment of cystic fibrosis,06/29/2006,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1752,Heparin-binding epidermal growth factor-like growth factor,"Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams",09/18/2006,Designated,,,"treatment of necrotizing enterocolitis (nec) in preterm infants with birth weight less than 1,500 grams",,,,,,,
1753,hepatitis B immune globulin (human),Prevention of hepatitis B recurrence following orthotopic liver transplant,03/24/2008,Designated/Approved,,,hepatitis b recurrence following orthotopic liver transplant,,,,,,,
1755,hepatitis B virus neutralizing human monoclonal antibody,Prevention of hepatitis B recurrence following liver transplantation,05/06/2013,Designated,,,hepatitis b recurrence following liver transplantation,,,,,,,
1757,hepcortespenlisimut-L,Treatment of hepatocellular carcinoma,12/17/2014,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1758,herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter,Treatment of pancreatic cancer,12/23/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1759,Herpes simplex virus gene,Treatment of primary and metastatic brain tumors.,10/16/1992,Designated,,,primary and metastatic brain tumors,,,,,,,
1760,heterologous human adult liver derived progenitor cells (HHALPC),Treatment of urea cycle disorders,01/13/2012,Designated,,,urea cycle disorders,,,,D056806,,,Q1585743
1761,heterologous human liver derived progenitor cells,Treatment of Crigler-Najjar syndrome,03/09/2012,Designated,,,crigler-najjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
1762,hexasodium phytate,Treatment of calciphylaxis,12/02/2012,Designated,Q27295268,,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
1763,"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein",Treatment of systemic sclerosis,06/27/2016,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1764,HIRMAb-IDS,Treatment of mucopolysaccharidosis Type II (Hunter Syndrome),05/15/2013,Designated,,,mucopolysaccharidosis type ii (hunter syndrome),,,,,,,
1766,His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2,Treatment of retinal detachment,01/13/2016,Designated,,,retinal detachment,http://purl.obolibrary.org/obo/DOID_5327,http://purl.obolibrary.org/obo/HP_0000541,,D012163,Q625164,,Q625164
1767,His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr,Treatment of retinal detachment,03/11/2013,Designated,,,retinal detachment,http://purl.obolibrary.org/obo/DOID_5327,http://purl.obolibrary.org/obo/HP_0000541,,D012163,Q625164,,Q625164
1770,Histrelin,"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.",05/03/1991,Designated,Q5871149,,"acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria",,,,,,,
1771,Histrelin,Treatment of central precocious puberty,11/18/2005,Designated/Approved,Q5871149,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
1772,Histrelin acetate,Treatment of central precocious puberty.,08/10/1988,Designated/Approved,Q27895770,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
1773,HIV neutralizing antibodies,Treatment of acquired immunodeficiency syndrome.,03/24/1992,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
1774,HLA-A2-selective gp100-specific T cell redirector,Treatment of uveal melanoma.,01/21/2016,Designated,,,uveal melanoma,http://purl.obolibrary.org/obo/DOID_6039,http://purl.obolibrary.org/obo/HP_0007716,http://www.orpha.net/ORDO/Orphanet_39044,,Q356372,Q356372,
1775,HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex,"Treatment of invasive and metastatic melanoma (Stages II, III, and IV).",09/30/1999,Designated,,,"invasive and metastatic melanoma (stages ii, iii, and iv)",,,,,,,
1776,homoharringtonine,Treatment for chronic myelogenous leukemia,02/08/2002,Designated,Q7089373,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
1777,HPV-16 cancer therapeutic trojan peptide vaccine,Treatment of HPV-16 expressing head and neck squamous cell carcinoma.,01/12/2009,Designated,,,hpv-16 expressing head and neck squamous cell carcinoma,,,,,,,
1778,HPV16 E6/E7 synthetic long peptides vaccine,Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.,09/01/2011,Designated,,,epithelial neoplasias of the vulva positive for human papilloma virus type 16,,,,,,,
1780,"Human acid precursor alpha-glucosidase, recombinant",Treatment of glycogen storage disease type II.,09/10/1996,Designated/Withdrawn,,,glycogen storage disease type ii,http://purl.obolibrary.org/obo/DOID_2752,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,Q1365789,,Q1365789
1781,human allogeneic bone marrow derived osteoblastic cells,Treatment of osteonecrosis,01/10/2014,Designated,,,osteonecrosis,http://purl.obolibrary.org/obo/DOID_10159,http://purl.obolibrary.org/obo/HP_0010885,http://www.orpha.net/ORDO/Orphanet_399158,D010020,Q503629,,Q503629
1782,human allogeneic bone marrow derived osteoblastic cells,Treatment of osteogenesis imperfecta.,11/09/2015,Designated,,,osteogenesis imperfecta,http://purl.obolibrary.org/obo/DOID_12347,,http://www.orpha.net/ORDO/Orphanet_666,D010013,Q749409,Q749409,Q749409
1783,"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells",Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.,09/12/2008,Designated,,,insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy,,,,,,,
1784,"Human alpha 2,6 sialyltransferase adenoviral gene therapy","Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.",04/04/2005,Designated,,,"patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase",,,,,,,
1785,Human anti-CD30 monoclonal antibody,Treatment of Hodgkin's disease,09/27/2004,Designated,,,hodgkin's disease,,,http://www.orpha.net/ORDO/Orphanet_98293,D006689,,Q209369,Q18557991
1786,human anti-CD4 monoclonal antibody,Treatment of mycosis fungoides,08/13/2004,Designated,,,mycosis fungoides,http://purl.obolibrary.org/obo/DOID_8691,,,D009182,Q1891209,,Q1891209
1787,human anti-cellular adhesion molecule-1 monoclonal antibody,Treatment of multiple myeloma,07/29/2008,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1788,Human anti-integrin receptor av monoclonal antibody,Treatment of patients with angiosarcoma,05/05/2005,Designated/Withdrawn,,,patients with angiosarcoma,,,,,,,
1789,human anti-integrin receptor avb3/avb5 monoclonal antibody,"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma",12/01/2004,Designated/Withdrawn,,,"patients with high-risk stage ii, stage iii, and stage iv malignant melanoma",,,,,,,
1790,human anti-transforming growth factor beta 1 monoclonal antibody,Treatment of systemic sclerosis,01/11/2002,Designated/Withdrawn,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1791,"human anti-transforming growth factor-B1,2,3",Treatment of idiopathic pulmonary fibrosis,07/09/2004,Designated/Withdrawn,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1792,Human Anti-tumor Necrosis factor alpha monoclonal antibody,"Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy",01/16/2003,Designated/Withdrawn,,,"uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy",,,,,,,
1793,Human autologous bone-forming cell derived from bone marrow stem cells,Treatment of osteonecrosis,03/24/2008,Designated,,,osteonecrosis,http://purl.obolibrary.org/obo/DOID_10159,http://purl.obolibrary.org/obo/HP_0010885,http://www.orpha.net/ORDO/Orphanet_399158,D010020,Q503629,,Q503629
1795,human coagulation factor XI,Treatment of severe congential Factor XI deficiency.,11/08/2007,Designated/Withdrawn,,,severe congential factor xi deficiency,,,,,,,
1796,human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI),Treatment of patients with cystic fibrosis.,11/03/2015,Designated,,,patients with cystic fibrosis,,,,,,,
1797,Human cytomegalovirus immunoglobulin,Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women,12/20/2006,Designated,,,congenital cytomegalovirus (cmv) infection following primary cmv infection in pregnant women,,,,,,,
1799,Human factor X,Treatment of hereditary factor X deficiency,11/08/2007,Designated/Approved,,,hereditary factor x deficiency,,,,,,,
1800,"human fibrinogen concentrate, pasteurized",Treatment of fibrinogen deficient patients.,03/13/2008,Designated/Approved,,,fibrinogen deficient patients,,,,,,,
1801,human fully IgG1 antibody specific for CD33,Treatment of acute myeloid leukemia,06/19/2014,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1802,human gammaglobulin,Treatment for juvenile rheumatoid arthritis,05/25/2001,Designated,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
1803,human gammaglobulin,Treatment of idiopathic inflammatory myopathies,11/14/2003,Designated,,,idiopathic inflammatory myopathies,,,,D009220,,,Q4117658
1804,human gammaglobulin,"Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.",09/16/2002,Designated,,,"gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients",,,,,,,
1805,human glial restricted progenitor cells and their progeny,Treatment of amyotrophic lateral sclerosis,09/11/2013,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1806,human haptoglobin,Treatment of sickle cell disease,11/19/2013,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1807,Human Hemin,Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation,08/06/2013,Designated,,,ischemia reperfusion injury in patients undergoing solid organ transplantation,,,,,,,
1808,human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein,Treatment of acute liver failure,05/11/2011,Designated,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
1809,human heterologous liver cells,Treatment of urea cycle disorders,02/14/2011,Designated,,,urea cycle disorders,,,,D056806,,,Q1585743
1810,human IgG1k monoclonal antibody,Treatment of systemic sclerosis,10/16/2013,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1811,Human IgM monoclonal antibody (C-58) To CMV,Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.,08/07/1989,Designated/Withdrawn,,,cytomegalovirus infections in allogenic bone marrow transplant patients,,,,,,,
1813,Human immune globulin,Treatment of post-polio syndrome,03/29/2006,Designated,,,post-polio syndrome,,,,D016262,,,Q18556566
1814,Human immunodeficiency virus immune globulin,Treatment of HIV-infected pediatric patients.,01/04/1995,Designated/Withdrawn,,,hiv-infected pediatric patients,,,,,,,
1815,Human immunodeficiency virus immune globulin,Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.,03/25/1992,Designated/Withdrawn,,,hiv-infected pregnant women and infants of hiv-infected mothers,,,,,,,
1816,Human immunodeficiency virus immune globulin,Treatment of AIDS.,11/21/1989,Designated/Withdrawn,,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
1817,Human immunoglobin anti-CD30 monoclonal antibody,Treatment of CD30+ T-cell lymphoma,01/10/2006,Designated,,,cd30+ t-cell lymphoma,,,,,,,
1818,human insulin (rDNA),Treatment of short bowel syndrome (SBS).,04/06/2015,Designated,,,short bowel syndrome (sbs),,,,,,,
1819,human insulin beta chain peptide with incomplete Freund's adjuvant vaccine,Treatment of Type 1 diabetes patients with residual beta cell function,02/11/2013,Designated,,,type 1 diabetes patients with residual beta cell function,,,,,,,
1820,human interleukin-3 genetically conjugated to diphtheria toxin protein,Treatment of blastic plasmacytoid dendritic cell neoplasm,06/06/2013,Designated,,,blastic plasmacytoid dendritic cell neoplasm,,,http://www.orpha.net/ORDO/Orphanet_86870,,,,
1821,human interleukin-3 genetically conjugated to diphtheria toxin protein,Treatment of acute myeloid leukemia.,02/18/2011,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1822,human laminin-111,Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.,09/23/2011,Designated,,,merosin (laminin-alpha2) deficient congential muscular dystrophy type 1a,,,,,,,
1823,human leukocyte antigen-A2 restricted peptides,Treatment of glioma.,01/26/2015,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1825,human MHC non-restricted cytotoxic T-cell line,Treatment of ovarian cancer,07/06/2012,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1827,Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F,Treatment of glioblastoma multiforme,05/29/2014,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1829,human monoclonal antibody againt human interleukin 13 (IL-13),Treatment of eosinophilic esophagitis,10/15/2013,Designated,,,eosinophilic esophagitis,http://purl.obolibrary.org/obo/DOID_13922,,http://www.orpha.net/ORDO/Orphanet_73247,D057765,Q2057356,Q2057356,Q2057356
1830,human monoclonal antibody directed against active plasma kallikrein,Treatment of hereditary angioedema (HAE),11/26/2013,Designated,,,hereditary angioedema (hae),,,,,,,
1831,Human monoclonal antibody directed against human Activin A,Treatment of fibrodysplasia ossificans progressiva,01/19/2017,Designated,,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
1832,Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa,Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa,09/18/2006,Designated,,,hospital acquired pneumonia caused by serotype 011 positive pseudomonas aeruginosa,,,,,,,
1833,human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa,Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa,01/06/2010,Designated,,,pneumonia caused by serotype o1 positive pseudomonas aeruginosa,,,,,,,
1834,human monoclonal antibody directed against tissue factor pathway inhibitor,"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients.",05/18/2016,Designated,,,"hemophilia a and hemophilia b patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia a and hemophilia b patients",,,,,,,
1835,Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2),Prevention (inhibition) of complement-mediated thrombotic microangiopathy,12/16/2013,Designated,,,of complement-mediated thrombotic microangiopathy,,,,,,,
1836,Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888),Treatment of ovarian cancer,04/30/2010,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1837,human monoclonal antibody targeting human sclerostin,Treatment of osteogenesis imperfecta.,02/29/2016,Designated,,,osteogenesis imperfecta,http://purl.obolibrary.org/obo/DOID_12347,,http://www.orpha.net/ORDO/Orphanet_666,D010013,Q749409,Q749409,Q749409
1838,Human plasma coagulation Factor VIII and human plasma von Willebrand Factor,Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated,04/18/2007,Designated/Approved,,,von willebrand disease except for surgical and/or invasive procedures in patients with von willebrand disease in whom desmopressin is either ineffective or contraindicated,,,,,,,
1840,human plasminogen,Treatment of ligneous conjunctivitis,06/07/2010,Designated,,,ligneous conjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_97231,,,,
1841,human platelet antigen-1a immunoglobulin (anti-HPA-1a),Prevention of fetal and neonatal alloimmune thrombocytopenia,06/27/2013,Designated,,,fetal and neonatal alloimmune thrombocytopenia,,,http://www.orpha.net/ORDO/Orphanet_853,,,Q2622318,
1843,human recombinant bone morphogenetic protein 4,Treatment of glioblastoma multiforme.,05/04/2016,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1844,"human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor",Treatment of idiopathic pulmonary fibrosis,07/06/2012,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1845,human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A,Treatment of pediatric patients 0 to <18 yrs of age with oligoarticular-course and polyarticular-course juvenile idiopathic arthritis.,02/04/2016,Designated,,,pediatric patients 0 to <18 yrs of age with oligoarticular-course and polyarticular-course juvenile idiopathic arthritis,,,,,,,
1846,"human recombinant mesencephalic, astrocyte derived neurotrophic factor",Treatment of retinitis pigmentosa,12/22/2014,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1847,human retinal progenitor cells,Treatment of retinitis pigmentosa,07/23/2012,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1848,human single domain antibody-like protein inhibitor of the chemokine receptor type 4,Treatment of idiopathic pulmonary fibrosis,01/11/2017,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1849,human soluble receptor-Fc fusion protein that targets human activin A,Treatment of ovarian cancer.,10/14/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1850,human spinal cord derived neural stem cells,Treatment of amyotrophic lateral sclerosis,02/04/2011,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1851,Human T-lymphotropic virus type III Gp160 antigens,Treatment of AIDS.,11/20/1989,Designated,,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
1852,Human telomerase reverse transcriptase peptide vaccine,Treatment of pancreatic cancer,07/20/2006,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1853,"human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)",Treatment of pancreatic cancer,10/22/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1854,human tumor necrosis factor coupled to the C terminus of CNGRCG peptide,Treatment of liver cancer,10/01/2009,Designated,,,liver cancer,http://purl.obolibrary.org/obo/DOID_3571,http://purl.obolibrary.org/obo/HP_0002896,,D008113,Q623031,,Q1671502
1855,human umbilical cord blood-derived mesenchymal stem cells,Prevention of bronchopulmonary dysplasia,11/26/2013,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
1856,human umbilical tissue derived cells (hUTC),Treatment of amyotrophic lateral sclerosis,05/10/2011,Designated/Withdrawn,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1857,Human umbilical tissue-derived cells,Treatment of retinitis pigmentosa,03/13/2006,Designated/Withdrawn,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1858,Human Wilms tumor protein 1 peptides,Treatment of acute myeloid leukemia,12/23/2015,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1859,Human wilms tumor protein 1 peptides,treatment of mesothelioma.,02/23/2016,Designated,,,mesothelioma,,,,D008654,,,Q18555143
1860,Human/Murine Chimeric Monoclonal antibody to Endoglin,Treatment of soft tissue sarcoma.,01/20/2016,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1861,Humanized 3F8-IgG1 monoclonal antibody,Treatment of neuroblastoma,06/24/2013,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1862,"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19",Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,02/10/2016,Designated,,,neuromyelitis optica and neuromyelitis optica spectrum disorders,,,,,,,
1863,Humanized anti-CD2 monoclonal antibody,Treatment of graft-versus-host disease.,11/13/1998,Designated/Withdrawn,,,graft-versus-host disease,,,,D006086,,,Q1194520
1864,humanized anti-human CD16 monoclonal antibody,Treatment of adult idiopathic thrombocytopenic purpura,03/21/2005,Designated/Withdrawn,,,adult idiopathic thrombocytopenic purpura,,,,,,,
1866,humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,06/30/2014,Designated,,,neuromyelitis optica and neuromyelitis optica spectrum disorder,,,,,,,
1867,Humanized anti-tac,Prevention of acute graft-vs-host disease following bone marrow transplantation.,03/05/1993,Designated,,,acute graft-vs-host disease following bone marrow transplantation,,,,,,,
1868,humanized Fc engineered monoclonal antibody against CD19,Treatment of diffuse large B-cell lymphoma.,12/01/2014,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1869,humanized Fc engineered monoclonal antibody against CD19,Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,04/29/2014,Designated,,,patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,,,,,,,
1870,humanized IgG1 anti-serum amyloid A monoclonal antibody,Treatment of AA amyloidosis and AL amyloidosis,02/17/2012,Designated,,,aa amyloidosis and al amyloidosis,,,,,,,
1871,humanized IgG1 monoclonal anti-CD20 antibody,Treatment of follicular lymphoma,05/26/2011,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1872,humanized IgG2 antibody,Treatment of vaso-occlusive crisis in patients with sickle cell disease.,07/22/2008,Designated,,,vaso-occlusive crisis in patients with sickle cell disease,,,,,,,
1873,humanized IgG4 monoclonal antibody,Prevention of ischemia/reperfusion injury associated with solid organ tranplantation,12/12/2011,Designated,,,ischemia/reperfusion injury associated with solid organ tranplantation,,,,,,,
1874,"humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s (C1s)",Treatment of autoimmune hemolytic anemia (AIHA),07/27/2016,Designated,,,autoimmune hemolytic anemia (aiha),,,,,,,
1875,humanized IgG4 monoclonal antibody binding to human C1q,Treatment of Guillain-Barre Syndrome,01/19/2017,Designated,,,guillain-barre syndrome,http://purl.obolibrary.org/obo/DOID_12842,,,D020275,Q205214,,Q205214
1876,humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen,Treatment of Huntington's disease,08/16/2016,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1877,humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2),Treatment of myelodysplastic syndrome,08/30/2016,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1878,humanized immunoglobulin monoclonal antibody against CD38,Treatment of multiple myeloma.,05/22/2014,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1879,Humanized MAb (IDEC-131) to CD40L,Treatment of systemic lupus erythematosus.,02/09/1999,Designated/Withdrawn,,,systemic lupus erythematosus,http://purl.obolibrary.org/obo/DOID_9074,http://purl.obolibrary.org/obo/HP_0002725,,D008180,Q1485,,Q1485
1880,humanized monoclonal antibodies hu1B7 and hu11E6,Treatment of Bordetella pertussis,09/11/2014,Designated,,,bordetella pertussis,,,,D001886,,,
1881,humanized monoclonal antibody against human integrin alphaVbeta6,Treatment of idiopathic pulmonary fibrosis,08/05/2010,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1883,humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47,Treatment of acute myeloid (myelogenous) leukemia.,08/20/2015,Designated,,,acute myeloid (myelogenous) leukemia,,,,,,,
1884,humanized monoclonal antibody that blocks activity of complement component C5,Treatment of paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated,,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1885,humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473),Treatment of acute myeloid leukemia,05/05/2015,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1886,humanized monoclonal antibody to tissue factor,Treatment of pancreatic cancer.,04/26/2011,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1887,Humanized monoclonal antibody to TumorEndothelial Marker-1,Treatment of soft tissue sarcoma,04/29/2011,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1888,humanized monocloncal antibody against human integrin alphaVbeta6,Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.,06/18/2008,Designated,,,fibrosis-associated chronic allograft nephropathy in kidney transplant patients,,,,,,,
1889,humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains),Treatment of chronic lymphocytic leukemia,11/17/2011,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1890,hyaluronic acid,Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency,03/19/2002,Designated,Q27078001,,emphysema in patients due to alpha-1 antitrypsin deficiency,,,,,,,
1891,hyaluronic acid,Treatment of emphysema due to alpha1-antitrypsin deficiency.,01/18/2017,Designated,Q27078001,,emphysema due to alpha1-antitrypsin deficiency,,,,,,,
1892,Hydralazine,Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy,04/09/2004,Designated,Q419987,,severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy,,,,,,,
1893,hydralazine - magnesium valproate,Treatment of cutaneous T-cell lymphoma.,03/17/2011,Designated,,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1894,hydralazine - magnesium valproate,Treatment of myelodysplastic syndrome,03/17/2011,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1895,hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO),Treatment of amyotrophic lateral sclerosis,03/09/2015,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1896,hydrocortisone modified release capsules,Treatment of adrenal insufficiency.,09/03/2015,Designated,,,adrenal insufficiency,,http://purl.obolibrary.org/obo/HP_0000846,,D000309,,,Q2507454
1897,hydrocortisone modified release capsules,Treatment of congenital adrenal hyperpasia,03/18/2015,Designated,,,congenital adrenal hyperpasia,,,,,,,
1898,hydrocortisone modified release tabs,Treatment of adrenal insufficiency,06/18/2008,Designated,,,adrenal insufficiency,,http://purl.obolibrary.org/obo/HP_0000846,,D000309,,,Q2507454
1899,hydrocortisone oral granules,Treatment of pediatric adrenal insufficiency (0 through 16 years of age).,05/13/2015,Designated,,,pediatric adrenal insufficiency (0 through 16 years of age),,,,,,,
1900,hydromorphone hydrochloride (intrathecal infusion),Treatment of complex regional pain syndrome,06/16/2016,Designated,,,complex regional pain syndrome,http://purl.obolibrary.org/obo/DOID_3223,,http://www.orpha.net/ORDO/Orphanet_83452,,Q1066311,,
1901,Hydroxocobalamin,Treatment of acute cyanide poisoning,11/25/2003,Designated/Approved,Q73972,,acute cyanide poisoning,,,,,,,
1902,Hydroxocobalamin,Treatment of acute cyanide poisoning,09/22/2000,Designated,Q73972,,acute cyanide poisoning,,,,,,,
1903,Hydroxy-Propyl-Beta-Cyclodextrin,"Treatment of Niemann Pick Disease, Type C",05/17/2010,Designated,,,"niemann pick disease, type c",,,,D052556,,,Q2067267
1904,hydroxycarbamide (hydroxyurea),Treatment of sickle cell disease in patients under 18 years of age,07/24/2013,Designated,,,sickle cell disease in patients under 18 years of age,,,,,,,
1905,Hydroxycobalamin/sodium thiosulfate,Treatment of severe acute cyanide poisoning.,10/04/1985,Designated/Withdrawn,,,severe acute cyanide poisoning,,,,,,,
1906,hydroxypioglitazone,Treatment of X-linked adrenoleukodystrophy,01/30/2017,Designated,Q27156475,,x-linked adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_43,D000326,Q366964,,Q366964
1907,hydroxyprogesterone caproate,Prevention of preterm birth in singleton pregnancies,01/25/2007,Designated/Approved,Q26963,,preterm birth in singleton pregnancies,,,,,,,
1908,hydroxyurea,Treatment of pediatric patients with sickle cell anemia.,04/15/2005,Designated,Q212272,VSNHCAURESNICA-UHFFFAOYSA-N,pediatric patients with sickle cell anemia,,,,,,,
1909,hydroxyurea,"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.",03/16/2015,Designated,Q212272,VSNHCAURESNICA-UHFFFAOYSA-N,"symptomatic sickle cell disease in pediatric patients, less than 17 years of age",,,,,,,
1910,Hydroxyurea,Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.,10/01/1990,Designated/Approved,Q212272,VSNHCAURESNICA-UHFFFAOYSA-N,patients with sickle cell anemia as shown by the presence of hemoglobin s,,,,,,,
1911,Hypericin,Treatment of cutaneous T-cell lymphoma.,02/07/2000,Designated,Q425409,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1912,Hypericin,Treatment of glioblastoma multiforme.,08/03/2000,Designated,Q425409,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
1913,Hypothiocyanite and lactoferrin,Treatment of cystic fibrosis,11/05/2009,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1914,I(131)-TM-601 (chlorotoxin),Treatment of malignant glioma,02/14/2002,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1915,ibalizumab,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,10/20/2014,Designated,Q3791531,,hiv-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of hiv-1 replication despite ongoing antiretroviral therapy,,,,,,,
1916,Iboctadekin,Treatment of renal cell carcinoma,06/03/2005,Designated/Withdrawn,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1917,ibritumomab tiuxetan,Treatment of B-cell non-Hodgkin's lymphoma.,09/06/1994,Designated/Approved,Q635415,,b-cell non-hodgkin's lymphoma,,,,,,,
1918,ibrutinib,Treatment of chronic lymphocytic leukemia (CLL).,03/27/2012,Designated/Withdrawn,Q5984881,,chronic lymphocytic leukemia (cll),,,,,,,
1919,ibrutinib,Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma),02/02/2016,Designated/Approved,Q5984881,,patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [malt type] lymphoma),,,,,,,
1920,ibrutinib,Treatment of nodal marginal zone lymphoma,02/05/2015,Designated/Approved,Q5984881,,nodal marginal zone lymphoma,,,,,,,
1921,ibrutinib,Treatment of diffuse large B-cell lymphoma,10/23/2013,Designated,Q5984881,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1922,ibrutinib,Treatment of multiple myeloma,05/16/2013,Designated,Q5984881,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1923,ibrutinib,Treatment of Waldenstrom's macroglobulinemia,10/15/2013,Designated/Approved,Q5984881,,waldenstrom's macroglobulinemia,,,,D008258,,,Q4118092
1924,ibrutinib,Treatment of mantle cell lymphoma,12/03/2012,Designated/Approved,Q5984881,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1925,ibrutinib,Treatment of small lymphocytic lymphoma,05/30/2013,Designated/Approved,Q5984881,,small lymphocytic lymphoma,,,http://www.orpha.net/ORDO/Orphanet_67038,D015451,,Q1088156,Q1088156
1926,ibrutinib,Treatment of chronic Graft versus Host disease.,06/23/2016,Designated,Q5984881,,chronic graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_99921,,,,
1927,ibrutinib,Treatment of follicular lymphoma,09/08/2014,Designated,Q5984881,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1928,ibrutinib,Treatment of chronic lymphocytic leukemia (CLL),04/06/2012,Designated/Approved,Q5984881,,chronic lymphocytic leukemia (cll),,,,,,,
1929,ibrutinib,Treatment of splenic marginal zone lymphoma,02/05/2015,Designated/Approved,Q5984881,,splenic marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050750,,http://www.orpha.net/ORDO/Orphanet_86854,,Q3832900,,
1930,ibudilast,Treatment of amyotrophic lateral sclerosis,10/06/2016,Designated,Q261167,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1931,ibudilast,Treatment of Krabbe disease,06/01/2015,Designated,Q261167,,krabbe disease,http://purl.obolibrary.org/obo/DOID_10587,,http://www.orpha.net/ORDO/Orphanet_121995,D007965,Q511372,,Q511372
1932,Ibuprofen i.v. solution,Prevention of patent ductus arteriosus.,10/29/1996,Designated,,,patent ductus arteriosus,http://purl.obolibrary.org/obo/DOID_13832,http://purl.obolibrary.org/obo/HP_0001643,,D004374,Q2072063,,Q2072063
1933,Ibuprofen lysine,Treatment of patent ductus arteriosus,10/29/1996,Designated/Approved,Q27284326,IHHXIUAEPKVVII-ZSCHJXSPSA-N,patent ductus arteriosus,http://purl.obolibrary.org/obo/DOID_13832,http://purl.obolibrary.org/obo/HP_0001643,,D004374,Q2072063,,Q2072063
1934,icatibant,Treatment of angioedema,11/25/2003,Designated/Approved,Q27137008,,angioedema,http://purl.obolibrary.org/obo/DOID_1558,http://purl.obolibrary.org/obo/HP_0100665,,D000799,Q1129007,,Q1129007
1935,icatibant,Treatment of burn patients hospitalized with burn-induced edema,05/05/2004,Designated/Withdrawn,Q27137008,,burn patients hospitalized with burn-induced edema,,,,,,,
1936,Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution,Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.,07/18/1997,Designated/Approved,,,those patients having end stage renal disease and requiring peritoneal dialysis treatment,,,,,,,
1937,Idarubicin,Treatment of chronic myelogenous leukemia.,12/02/1992,Designated/Withdrawn,Q1063862,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
1938,Idarubicin,Treatment of myelodysplastic syndromes.,12/01/1992,Designated/Withdrawn,Q1063862,,myelodysplastic syndromes,,,,D009190,,,Q954625
1939,Idarubicin HCl for injection,Treatment of acute lymphoblastic leukemia in pediatric patients.,02/12/1991,Designated/Withdrawn,,,acute lymphoblastic leukemia in pediatric patients,,,,,,,
1940,Idarubicin HCl for injection,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",07/25/1988,Designated/Approved,,,"acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia",,,,,,,
1942,idebenone,"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)",05/22/2009,Designated,Q4197874,,"mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (melas)",,,,,,,
1943,idebenone,Treatment of Duchenne muscular dystrophy,02/16/2007,Designated,Q4197874,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1944,idebenone,Treatment of Friedreich's ataxia,03/25/2004,Designated,Q4197874,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
1945,idebenone,Treatment of Leber's hereditary optic neuropathy.,10/31/2006,Designated,Q4197874,,leber's hereditary optic neuropathy,http://purl.obolibrary.org/obo/DOID_705,,,D029242,Q1262161,,Q1262161
1946,idelalisib,Treatment of follicular lymphoma,09/26/2013,Designated/Approved,Q5908266,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1947,idelalisib,Treatment of extranodal marginal zone lymphoma,10/15/2013,Designated,Q5908266,,extranodal marginal zone lymphoma,,,,,,,
1948,idelalisib,Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia,09/26/2013,Designated,Q5908266,,lymphoplasmacytic lymphoma with or without walenstrom's macroglobulinemia,,,,,,,
1949,idelalisib,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,10/15/2013,Designated/Approved,Q5908266,,chronic lymphocytic leukemia and small lymphocytic lymphoma,,,,,,,
1950,idelalisib,Treatment of splenic marginal zone lymphoma,10/15/2013,Designated,Q5908266,,splenic marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050750,,http://www.orpha.net/ORDO/Orphanet_86854,,Q3832900,,
1951,idelalisib,Treatment of nodal marginal zone lymphoma.,10/15/2013,Designated,Q5908266,,nodal marginal zone lymphoma,,,,,,,
1952,idelalisib,Treatment of chronic lymphocytic leukemia,08/25/2011,Designated,Q5908266,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1953,Idoxuridine,Treatment of nonparenchymatous sarcomas.,04/08/1996,Designated,Q409765,XQFRJNBWHJMXHO-RRKCRQDMSA-N,nonparenchymatous sarcomas,,,,,,,
1954,IDUA-HIRMAb fusion protein,Treatment of mucopolysaccharidosis Type 1 (MPS),01/10/2008,Designated,,,mucopolysaccharidosis type 1 (mps),,,,,,,
1956,idursulfase beta,Treatment of Hunter Syndrome (mucopolysaccharidoses),02/11/2013,Designated,,,hunter syndrome (mucopolysaccharidoses),,,,,,,
1958,iduvec,Treatment of Mucopolysaccharidosis Type I,01/21/2011,Designated,,,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
1960,Ifosfamide,Treatment of testicular cancer.,01/20/1987,Designated/Approved,Q418560,,testicular cancer,http://purl.obolibrary.org/obo/DOID_2998,,,D013736,Q324464,,Q324464
1961,ifosfamide,Treatment of soft tissue and bone sarcomas,08/07/1985,Designated,Q418560,,soft tissue and bone sarcomas,,,,,,,
1962,IgG1 chimeric monoclonal antibody,Treatment of multiple myeloma.,06/22/2011,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1963,IL-12 secreting dendritic cells loaded with autologous tumor lysate,Treatment of malignant glioma,06/24/2013,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1964,IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL),Treatment of astrocytic glioma.,04/06/2000,Designated,,,astrocytic glioma,,,,D001254,,,Q19000473
1965,IL13-PE38QQR,Treatment of malignant glioma,11/02/2001,Designated/Withdrawn,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
1966,iloprost,Treatment of pulmonary arterial hypertension,04/06/2012,Designated,Q20817139,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1967,Iloprost inhalation solution,Treatment of pulmonary arterial hypertension,08/17/2004,Designated/Approved,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1968,Iloprost solution for infusion,Treatment of heparin-associated thrombocytopenia.,05/14/1990,Designated/Withdrawn,,,heparin-associated thrombocytopenia,,,http://www.orpha.net/ORDO/Orphanet_3325,,,,
1969,Iloprost solution for infusion,Treatment of Raynaud's phenomenon secondary to systemic sclerosis.,09/21/1989,Designated/Withdrawn,,,raynaud's phenomenon secondary to systemic sclerosis,,,,,,,
1970,ilorasertib,Treatment of ovarian cancer,03/16/2012,Designated/Withdrawn,Q27265085,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1971,imatinib,Treatment of Philadelphia-positive acute lymphoblastic leukemia,10/11/2005,Designated/Approved,Q177094,,philadelphia-positive acute lymphoblastic leukemia,,,,,,,
1972,Imatinib,Treatment of chronic myelogenous leukemia,01/31/2001,Designated/Approved,Q177094,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
1973,imatinib,Treatment of pulmonary arterial hypertension,04/07/2010,Designated/Withdrawn,Q177094,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1974,imatinib mesylate,Treatment of gastrointestinal stromal tumors,11/01/2001,Designated/Approved,Q27114666,,gastrointestinal stromal tumors,,http://purl.obolibrary.org/obo/HP_0100723,,D046152,,,Q1495661
1975,Imatinib mesylate,Treatment of systemic mastocytosis without the D816V c-kit mutation,09/09/2005,Designated/Approved,Q27114666,,systemic mastocytosis without the d816v c-kit mutation,,,,,,,
1976,imatinib mesylate,Treatment of progressive multifocal leukencephalopathy,05/06/2014,Designated,Q27114666,,progressive multifocal leukencephalopathy,,,,,,,
1977,Imatinib mesylate,Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,08/25/2005,Designated/Approved,Q27114666,,idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,,,,,,,
1978,Imatinib mesylate,Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,10/05/2005,Designated/Approved,Q27114666,,myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,,,,,,,
1979,imatinib mesylate,Treatment of dermatofibrosarcoma protuberans,12/19/2005,Designated/Approved,Q27114666,,dermatofibrosarcoma protuberans,http://purl.obolibrary.org/obo/DOID_3507,,http://www.orpha.net/ORDO/Orphanet_31112,D018223,Q1200239,,Q1200239
1981,imetelstat,Treatment of myelodysplastic syndrome,12/23/2015,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
1982,imetelstat,Treatment of myelofibrosis,06/11/2015,Designated,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
1983,Imexon,Treatment of metastatic malignant melanoma,08/03/2001,Designated/Withdrawn,Q6003924,,metastatic malignant melanoma,,,,,,,
1984,Imexon,Treatment of pancreatic adenocarcinoma,11/01/2003,Designated/Withdrawn,Q6003924,,pancreatic adenocarcinoma,http://purl.obolibrary.org/obo/DOID_4074,http://purl.obolibrary.org/obo/HP_0006725,,,Q18556189,,
1985,Imexon,Treatment of multiple myeloma.,11/08/1996,Designated,Q6003924,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1986,imexon,Treatment of ovarian cancer.,08/12/2005,Designated,Q6003924,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1988,Imiquimod,Treatment of carcinoma in situ (CIS) of the urinary bladder,12/03/2014,Designated,Q423417,,carcinoma in situ (cis) of the urinary bladder,,,,,,,
1989,Immortalized human liver cells found in the extracorporeal liver assist device,Treatment of fulminant hepatic failure (acute liver failure),07/16/2004,Designated,,,fulminant hepatic failure (acute liver failure),,,,,,,
1990,immune globulin (human),Treatment of Myasthenia Gravis,12/12/2016,Designated,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
1991,immune globulin (human),Treatment of Guillain-Barre syndrome,03/02/2010,Designated,,,guillain-barre syndrome,http://purl.obolibrary.org/obo/DOID_12842,,,D020275,Q205214,,Q205214
1992,Immune Globulin (Human),Treatment of chronic inflammatory demyelinating polyneuropathy,07/27/2004,Designated/Approved,,,chronic inflammatory demyelinating polyneuropathy,,,http://www.orpha.net/ORDO/Orphanet_2932,,,,
1993,Immune Globulin (Human) containing high titers of West Nile virus antibodies,Treatment of the West Nile virus infection,03/17/2004,Designated,,,the west nile virus infection,,,,,,,
1994,immune globulin infusion (human),Treatment of multifocal motor neuropathy,07/20/2006,Designated/Approved,,,multifocal motor neuropathy,,,http://www.orpha.net/ORDO/Orphanet_641,,,Q6934690,
1995,immune globulin infusion 10% (human) with recombinant human hyaluronidase),Treatment of chronic inflammatory demyelinating polyneuropathy,03/31/2016,Designated,,,chronic inflammatory demyelinating polyneuropathy,,,http://www.orpha.net/ORDO/Orphanet_2932,,,,
1996,Immune globulin intravenous (human),Treatment of juvenile rheumatoid arthritis.,12/16/1992,Designated/Withdrawn,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
1997,Immune globulin intravenous (human),Treatment of polymyositis/dermatomyositis.,10/13/1992,Designated/Withdrawn,,,polymyositis/dermatomyositis,,,,,,,
1998,Immune globulin intravenous (human),Treatment of patients with acute myocarditis.,11/22/1993,Designated/Withdrawn,,,patients with acute myocarditis,,,,,,,
1999,Immune Globulin Intravenous (human),Treatment for Guillain Barre Syndrome,05/04/2004,Designated,,,guillain barre syndrome,,,,D020275,,,Q205214
2001,immune globulin intraveous (human),Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia),04/29/2011,Designated/Approved,,,idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia),,,,,,,
2002,Immune Globulin Subcutaneous (Human),Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access,09/22/2004,Designated/Withdrawn,,,patients with primary immune deficiency (pid) that are intolerant to immune globulin intravenous (igiv) due to severe adverse events or poor venous access,,,,,,,
2003,"Immune Globulin Subcutaneous (Human), 20% Liquid",Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP),08/18/2014,Designated,,,chronic inflammatory demyelinating polyneuropathy (cidp),,,,,,,
2004,immunoglobulin G degrading enzyme of Streptococcus pyogenes,Prevention of antibody mediated organ rejection in solid organ transplant patients.,09/10/2015,Designated,,,antibody mediated organ rejection in solid organ transplant patients,,,,,,,
2005,immunologically active synthetic peptides,Treatment of Hemophilia A,06/01/2015,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
2006,Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val,Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.,03/16/1994,Designated,,,chronic active hepatitis b infection in hla-a2 positive patients,,,,,,,
2007,Implitapide,Treatment of patients with Fredrickson type I or V hyperlipoproteinemia,08/19/2004,Designated/Withdrawn,Q27095549,,patients with fredrickson type i or v hyperlipoproteinemia,,,,,,,
2008,Implitapide,Treatment of homozygous familial hypercholesterolemia,08/13/2004,Designated/Withdrawn,Q27095549,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
2010,"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)",Prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies,12/29/2016,Designated,,,rabies virus infection including post-exposure prophylaxis (pep) for rabies,,,,,,,
2011,Inalimarev and falimarev,Treatment of adenocarcinoma of the pancreas,01/10/2006,Designated,,,adenocarcinoma of the pancreas,http://purl.obolibrary.org/obo/DOID_4074,,,,Q18556189,,
2015,Indium-111 pentetreotide,Treatment of neuroendocrine tumors,06/16/2006,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
2016,inebilizumab,Treatment of scleroderma,12/03/2009,Designated,Q25326696,,scleroderma,http://purl.obolibrary.org/obo/DOID_418,http://purl.obolibrary.org/obo/HP_0100324,http://www.orpha.net/ORDO/Orphanet_801,,Q5340515,Q958797,
2017,Inecalcitol,Treatment of chronic lymphocytic leukemia,05/14/2014,Designated,Q27078058,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2018,inecalcitol,Treatment of acute myeloid leukemia.,08/03/2015,Designated,Q27078058,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2019,Infliximab,Treatment of pediatric (0 to 16 years of age) Crohn's Disease,11/12/2003,Designated/Approved,Q415264,,pediatric (0 to 16 years of age) crohn's disease,,,,,,,
2020,infliximab,Treatment of juvenile rheumatoid arthritis,10/23/2002,Designated,Q415264,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
2021,Infliximab,Treatment of chronic sarcoidosis,05/21/2003,Designated,Q415264,,chronic sarcoidosis,,,,,,,
2022,infliximab,Treatment of giant cell arteritis,05/06/2003,Designated/Withdrawn,Q415264,,giant cell arteritis,http://purl.obolibrary.org/obo/DOID_13375,,http://www.orpha.net/ORDO/Orphanet_397,D013700,Q707816,,Q707816
2023,infliximab,Treatment of Crohn's disease,11/14/1995,Designated/Approved,Q415264,,crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,http://purl.obolibrary.org/obo/HP_0100280,,D003424,Q1472,,Q18553712
2024,infliximab,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,11/12/2003,Designated/Approved,Q415264,,pediatric (0 to 16 years of age) ulcerative colitis,,,,,,,
2025,inhibitor of microRNA-451,Treatment of polycythemia vera,02/04/2011,Designated/Withdrawn,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
2026,Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST,Treatment of gastrointestinal stromal tumors (GIST),10/02/2014,Designated,,,gastrointestinal stromal tumors (gist),,,,,,,
2027,Inhibitor of Tissue Factor Pathway Inhibitor (TFPI),Treatment of hemophilia A and hemophilia B.,01/29/2010,Designated,,,hemophilia a and hemophilia b,,,,,,,
2028,inolimomab,Treatment of graft versus host disease,10/23/2002,Designated,Q3799026,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
2029,Inosine pranobex,Treatment of subacute sclerosing panencephalitis.,09/20/1988,Designated,Q3130053,,subacute sclerosing panencephalitis,http://purl.obolibrary.org/obo/DOID_8970,,http://www.orpha.net/ORDO/Orphanet_2806,D013344,Q2475919,,Q2475919
2030,inotuzumab ozogamicin,Treatment of B-cell acute lymphoblastic leukemia,03/25/2013,Designated,Q3799041,,b-cell acute lymphoblastic leukemia,,,,,,,
2031,insecticidal toxin derived from Bacillus thuringiensis,Treatment of soil transmitted helminth infection strongyloidiasis,09/05/2008,Designated,,,soil transmitted helminth infection strongyloidiasis,,,,,,,
2032,Interferon alfa-2a,Treatment of chronic myelogenous leukemia.,06/06/1989,Designated/Approved,Q20801761,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2033,Interferon alfa-2a (recombinant),Treatment of AIDS related Kaposi's sarcoma.,12/14/1987,Designated/Approved,,,aids related kaposi's sarcoma,,,,,,,
2037,Interferon alfa-2a (recombinant),Treatment of renal cell carcinoma.,04/18/1988,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2039,Interferon alfa-2b (recombinant),Treatment of metastatic renal cell carcinoma.,06/22/1987,Designated/Withdrawn,,,metastatic renal cell carcinoma,,,,,,,
2040,Interferon alfa-2b (recombinant),Treatment of chronic myelogenous leukemia.,06/22/1987,Designated/Withdrawn,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2041,Interferon alfa-2b (recombinant),Treatment of chronic delta hepatitis.,05/04/1990,Designated/Withdrawn,,,chronic delta hepatitis,,,,D019701,,,
2042,Interferon alfa-2b (recombinant),Treatment of laryngeal (respiratory) papillomatosis.,08/17/1988,Designated/Withdrawn,,,laryngeal (respiratory) papillomatosis,,,,,,,
2043,Interferon alfa-2b (recombinant),Treatment of acute hepatitis B.,11/17/1988,Designated/Withdrawn,,,acute hepatitis b,,,,,,,
2044,Interferon alfa-2b (recombinant),Treatment of invasive carcinoma of the cervix.,04/18/1988,Designated/Withdrawn,,,invasive carcinoma of the cervix,,,,,,,
2045,Interferon alfa-2b (recombinant),Treatment of primary malignant brain tumors.,05/13/1988,Designated/Withdrawn,,,primary malignant brain tumors,,,,D001932,,,Q18554460
2046,Interferon alfa-2b (recombinant),Treatment of ovarian carcinoma.,08/03/1987,Designated/Withdrawn,,,ovarian carcinoma,http://purl.obolibrary.org/obo/DOID_4001,,,,Q18556145,,
2047,Interferon alfa-2b (recombinant),Treatment of AIDS-related Kaposi's sarcoma.,06/24/1987,Designated/Approved,,,aids-related kaposi's sarcoma,,,,,,,
2048,Interferon alfa-2b (recombinant),Treatment of carcinoma in situ of the urinary bladder.,08/10/1988,Designated/Withdrawn,,,carcinoma in situ of the urinary bladder,,,,,,,
2049,Interferon alfa-nl,Treatment of AIDS related Kaposi's sarcoma.,08/25/1986,Designated/Withdrawn,,,aids related kaposi's sarcoma,,,,,,,
2050,Interferon alfa-nl,Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.,10/16/1987,Designated/Withdrawn,,,human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis,,,,,,,
2051,Interferon beta (recombinant human),Treatment of primary brain tumors.,01/13/1993,Designated/Withdrawn,,,primary brain tumors,,,,D001932,,,Q18554460
2055,"Interferon beta, recombinant human",Treatment of acquired immunodeficiency syndrome.,11/15/1988,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
2056,interferon Beta-1a,Treatment of juvenile rheumatoid arthritis.,10/14/1998,Designated/Withdrawn,Q2450337,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
2057,Interferon beta-1a,Treatment of patients with secondary progressive multiple sclerosis.,03/11/1996,Designated,Q2450337,,patients with secondary progressive multiple sclerosis,,,,,,,
2058,Interferon beta-1a,Treatment of multiple sclerosis.,12/16/1991,Designated/Approved,Q2450337,,multiple sclerosis,http://purl.obolibrary.org/obo/DOID_2377,,,D009103,Q8277,,Q8277
2059,Interferon beta-1a (recombinant human),Treatment of pulmonary fibrosis.,01/07/1999,Designated/Withdrawn,,,pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_3770,http://purl.obolibrary.org/obo/HP_0002206,,D011658,Q32446,,Q1790424
2060,Interferon beta-1a (recombinant human),"Treatment of acute non-A, non-B hepatitis.",07/24/1992,Designated,,,"acute non-a, non-b hepatitis",,,,,,,
2061,Interferon beta-1a (recombinant),Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.,12/02/1992,Designated,,,symptomatic patients with aids including all patients with cd4 t-cell counts less than 200 cells per mm3,,,,,,,
2063,Interferon beta-1b,Treatment of multiple sclerosis.,11/17/1988,Designated/Approved,Q1851162,,multiple sclerosis,http://purl.obolibrary.org/obo/DOID_2377,,,D009103,Q8277,,Q8277
2064,Interferon gamma,Treatment of idiopathic pulmonary fibrosis,10/11/2007,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2065,interferon gamma,Treatment of Friedreich's ataxia,11/04/2011,Designated,,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
2066,Interferon gamma 1-b,Treatment of chronic granulomatous disease.,09/30/1988,Designated/Approved,,,chronic granulomatous disease,http://purl.obolibrary.org/obo/DOID_3265,,http://www.orpha.net/ORDO/Orphanet_379,D006105,Q2165663,Q2165663,Q2165663
2067,Interferon gamma-1b,Treatment of renal cell carcinoma.,12/04/1995,Designated,Q582356,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2068,interferon gamma-1b,Treatment of Friedreich's Ataxia,10/01/2014,Designated,Q582356,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
2069,interferon gamma-1b,Treatment of idiopathic pulmonary fibrosis,09/12/2002,Designated/Withdrawn,Q582356,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2071,Interferon-alfa-1b,Treatment of multiple myeloma,04/17/2001,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2072,interferon-alpha secreting autologous micro-organ tissue converting into a biopump,Treatment of chronic hepatitis D,06/14/2012,Designated,,,chronic hepatitis d,,,,D019701,,,
2075,interleukin-1 receptor antagonist anakinra,Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.,09/15/2015,Designated,,,still's disease including systemic juvenile idiopathic arithritis and adult-onset still's disease,,,,,,,
2076,"Interleukin-1 receptor antagonist, human recombinant",Prevention and treatment of graft versus host disease in transplant recipients.,10/16/1992,Designated,,,treatment of graft versus host disease in transplant recipients,,,,,,,
2077,"Interleukin-1 receptor antagonist, human recombinant",Treatment of juvenile rheumatoid arthritis.,09/23/1991,Designated,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
2078,Interleukin-1 Trap,Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease,04/04/2005,Designated,Q7334300,,still's disease including juvenile rheumatoid arthritis and adult-onset still's disease,,,,,,,
2079,Interleukin-2,Treatment of metastatic malignant melanoma.,02/06/1990,Designated,,,metastatic malignant melanoma,,,,,,,
2081,Interleukin-2,Treatment of metastatic renal cell carcinoma.,02/05/1990,Designated,,,metastatic renal cell carcinoma,,,,,,,
2085,Intraoral fluoride releasing system,Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer,07/31/2001,Designated,,,dental caries due to radiation-induced xerostomia in patients with head and neck cancer,,,,,,,
2086,intravenous carbamazepine,Treatment of epilepsy patients who cannot take anything by mouth (NPO),06/27/2013,Designated/Approved,,,epilepsy patients who cannot take anything by mouth (npo),,,,,,,
2087,Intravenous immune globulin,Treatment of Stage IIB to IV malignant melanoma,07/26/2007,Designated,,,stage iib to iv malignant melanoma,,,,,,,
2088,Intravenous immune globulin (human) 10%,Treatment of stiff-person syndrome,07/31/2008,Designated,,,stiff-person syndrome,http://purl.obolibrary.org/obo/DOID_13366,,,D016750,Q1235785,,Q1235785
2089,intraventricular nimodipine,Treatment of subarachnoid hemorrhage,05/28/2015,Designated,,,subarachnoid hemorrhage,,http://purl.obolibrary.org/obo/HP_0002138,,D013345,,,Q693442
2092,Iobenguane I 131,Treatment of neuroendocrine tumors,01/18/2006,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
2093,iobenguane I 131,Treatment of neuroendocrine tumors,07/05/2007,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
2100,Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody,Treatment of small-cell lung cancer.,02/22/2000,Designated,,,small-cell lung cancer,,,,,,,
2101,Iodine I 131 Lym-1 Monoclonal Antibody,Treatment of B-cell lymphoma.,11/02/1987,Designated/Withdrawn,,,b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_707,http://purl.obolibrary.org/obo/HP_0012191,,D016393,Q4833719,,Q4833719
2102,Iodine I 131 murine monoclonal antibody IgG2a to B cell,Treatment of B-cell leukemia and B-cell lymphoma.,09/18/1989,Designated/Withdrawn,,,b-cell leukemia and b-cell lymphoma,,,,,,,
2104,Iodine I 131 murine monoclonal antibody to hCG,Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.,11/07/1988,Designated/Withdrawn,,,hcg producing tumors such as germ cell and trophoblastic cell tumors,,,,,,,
2105,Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B),Treatment of glioblastoma multiforme and anaplastic astrocytoma.,02/12/1999,Designated,,,glioblastoma multiforme and anaplastic astrocytoma,,,,,,,
2107,ipilimumab,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",06/03/2004,Designated/Approved,Q2459042,,"high risk stage ii, stage iii, and stage iv melanoma",,,,,,,
2108,irofulven,Treatment of renal cell carcinoma.,07/27/1999,Designated/Withdrawn,Q6072197,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2109,irofulven,Treatment of ovarian cancer.,07/06/1999,Designated/Withdrawn,Q6072197,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2110,iron(III)-hexacyanoferrate(II),Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,05/01/2003,Designated/Approved,,,patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,,,,,,,
2111,isavuconazonium sulfate,Treatment of invasive candidiasis/candidemia,10/20/2014,Designated,Q27158829,,invasive candidiasis/candidemia,,,,,,,
2112,isavuconazonium sulfate,Treatment of invasive aspergillosis,05/06/2013,Designated/Approved,Q27158829,,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
2113,isavuconazonium sulfate,Treatment of zygomycosis,10/25/2013,Designated/Approved,Q27158829,,zygomycosis,,,http://www.orpha.net/ORDO/Orphanet_73263,D020096,,,Q5380626
2114,Isobutyramide,Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.,12/18/1992,Designated,Q10859786,WFKAJVHLWXSISD-UHFFFAOYSA-N,beta-hemoglobinopathies and beta-thalassemia syndromes,,,,,,,
2115,Isobutyramide,Treatment of sickle cell disease and beta thalassemia.,05/25/1994,Designated,Q10859786,WFKAJVHLWXSISD-UHFFFAOYSA-N,sickle cell disease and beta thalassemia,,,,,,,
2116,isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor,Treatment of acute myeloid leukemia (AML),06/09/2015,Designated,,,acute myeloid leukemia (aml),,,,,,,
2117,isocitrate dehydrogenase 2-mutant inhibitor,Treatment of acute myelogenous leukemia,06/12/2014,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2118,isofagomine tartrate,Treatment of Gaucher disease,01/10/2006,Designated,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
2119,"Isoindolin-1,3-Di Thione",Treatment of Frontotemporal dementia,11/21/2016,Designated,,CMTSCLKCQBPLSH-UHFFFAOYSA-N,frontotemporal dementia,http://purl.obolibrary.org/obo/DOID_9255,http://purl.obolibrary.org/obo/HP_0002145,http://www.orpha.net/ORDO/Orphanet_282,D057180,Q18592,Q18592,
2120,isotretinoin,Treatment of congenital ichthyosis,04/10/2014,Designated,Q287029,,congenital ichthyosis,,http://purl.obolibrary.org/obo/HP_0007431,,,,,
2121,Itraconazole,Treatment of basal cell carcinoma nevus syndrome.,05/19/2016,Designated,Q411229,,basal cell carcinoma nevus syndrome,,,,,,,
2122,itraconazole inhalation powder,Treatment of pulmonary fungal infections in patients with cystic fibrosis,08/16/2016,Designated,,,pulmonary fungal infections in patients with cystic fibrosis,,,,,,,
2124,ivabradine,Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.,03/23/2016,Designated,Q27158823,,pediatric patients (0 through 16 years of age) with dilated cardiomyopathy,,,,,,,
2125,ivacaftor,Treatment of patients with cystic fibrosis,12/20/2006,Designated/Approved,Q6095693,,patients with cystic fibrosis,,,,,,,
2126,ixazomib citrate,Treatment of multiple myeloma,02/18/2011,Designated/Approved,Q27162929,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2127,"Japanese encephalitis vaccine (live, attenuated)",Prevention of Japanese encephalitis.,05/19/1999,Designated,,,japanese encephalitis,http://purl.obolibrary.org/obo/DOID_10844,,http://www.orpha.net/ORDO/Orphanet_79139,D004672,Q738292,,Q738292
2128,"Japanese encephalitis vaccine, inactivated, adsorbed",Prevention of Japanese encephalitis virus in pediatric patients.,09/25/2012,Designated/Approved,,,japanese encephalitis virus in pediatric patients,,,,,,,
2130,ketotifen,Treatment of mastocytosis,02/25/2015,Designated,Q2458673,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
2131,Kre-Celazine,Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,04/01/2013,Designated,,,juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,,,,,,,
2132,L-2-oxothiazolidine-4-carboxylic acid,Treatment of amyotrophic lateral sclerosis.,07/30/1996,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2133,L-2-oxothiazolidine-4-carboxylic acid,Treatment of adult respiratory distress syndrome.,06/14/1994,Designated,,,adult respiratory distress syndrome,http://purl.obolibrary.org/obo/DOID_11394,,,D012128,Q344873,,Q7315912
2134,L-5 Hydroxytrytophan,Treatment of postanoxic intention myoclonus.,11/01/1984,Designated,,,postanoxic intention myoclonus,,,,,,,
2135,L-5-hydroxytryptophan,Treatment of tetrahydrobiopterin deficiency.,01/20/1999,Designated,,,tetrahydrobiopterin deficiency,,,,D010661,,,Q5958471
2136,"L-amino acids, vitamins and minerals combined with omega-3 fatty acids",Treatment of patients with pediatric Crohn's disease,01/12/2011,Designated,,,patients with pediatric crohn's disease,,,,,,,
2137,L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,Treatment of Duchenne and Becker muscular dystrophy,01/18/2006,Designated,Q27274718,,duchenne and becker muscular dystrophy,,,http://www.orpha.net/ORDO/Orphanet_262,D020388,,,Q1648484
2138,L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide,Treatment of acute radiation syndrome,09/11/2013,Designated,Q27280772,ZUJBBVJXXYRPFS-DYKIIFRCSA-N,acute radiation syndrome,,,,D054508,,,Q275459
2139,L-asparaginase,Treatment of acute myeloid leukemia,03/27/2014,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2140,L-asparaginase encapsulated in red blood cells,Treatment of pancreatic cancer.,07/06/2012,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2141,L-asparaginase encapsulated in red blood cells,Treatment of acute lymphoblastic leukemia,01/06/2010,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2142,L-baclofen,Treatment of intractable spasticity in children with cerebral palsy.,01/30/1992,Designated,,,intractable spasticity in children with cerebral palsy,,,,,,,
2143,L-baclofen,Treatment of spasticity associated with spinal cord injury or multiple sclerosis.,12/17/1991,Designated,,,spasticity associated with spinal cord injury or multiple sclerosis,,,,,,,
2144,L-baclofen,Treatment of trigeminal neuralgia.,07/13/1990,Designated,,,trigeminal neuralgia,http://purl.obolibrary.org/obo/DOID_12098,http://purl.obolibrary.org/obo/HP_0100661,http://www.orpha.net/ORDO/Orphanet_221091,D014277,Q1132120,,Q1132120
2145,L-baclofen,Treatment of trigeminal neuralgia,01/06/1998,Designated,,,trigeminal neuralgia,http://purl.obolibrary.org/obo/DOID_12098,http://purl.obolibrary.org/obo/HP_0100661,http://www.orpha.net/ORDO/Orphanet_221091,D014277,Q1132120,,Q1132120
2146,L-citrulline,Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients,01/09/2017,Designated,Q408641,RHGKLRLOHDJJDR-BYPYZUCNSA-N,clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients,,,,,,,
2147,L-cycloserine,Treatment of Gaucher's disease.,08/01/1989,Designated,,,gaucher's disease,http://purl.obolibrary.org/obo/DOID_1926,,,D005776,Q861645,,Q861645
2149,L-glutamine,Treatment of sickle cell disease,08/01/2001,Designated,Q181619,ZDXPYRJPNDTMRX-VKHMYHEASA-N,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2150,L-glutamyl-L-tryptophan,Treatment of AIDS-related Kaposi's sarcoma.,10/20/1999,Designated,Q4457491,LLEUXCDZPQOJMY-AAEUAGOBSA-N,aids-related kaposi's sarcoma,,,,,,,
2151,L-ornithine phenylacetate,Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase,04/07/2010,Designated,Q27272385,LRSYFEZBIMVWRY-VWMHFEHESA-N,hyperammonemia and resultant hepatic encephalopathy (he) in patients with acute liver failure or acute on chronic liver disase,,,,,,,
2152,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,Prevention of delayed graft function following renal transplant,09/18/2009,Designated,,,delayed graft function following renal transplant,,,,,,,
2153,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,Treatment of neuropathic pain in patients with sarcoidosis.,09/13/2011,Designated,,,neuropathic pain in patients with sarcoidosis,,,,,,,
2154,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,Treatment to increase survival and improve functioning of pancreatic islets following transplantation,06/13/2016,Designated,,,increase survival and improve functioning of pancreatic islets following transplantation,,,,,,,
2155,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,Treatment of sarcoidosis.,06/13/2016,Designated,,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
2156,L-threonine,Treatment of spasticity associated with familial spastic paraparesis.,07/24/1992,Designated/Withdrawn,Q186521,AYFVYJQAPQTCCC-GBXIJSLDSA-N,spasticity associated with familial spastic paraparesis,,,,,,,
2157,L-threonine,Treatment of amyotrophic lateral sclerosis.,02/06/1989,Designated/Withdrawn,Q186521,AYFVYJQAPQTCCC-GBXIJSLDSA-N,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2158,L-threonyl-L-prolyl-L-prolyl-L-threonine,Treatment of neuropathic pain associated with spinal cord injury,04/26/2005,Designated,,DSBPAFWXMCKFIM-BSOLPCOYSA-N,neuropathic pain associated with spinal cord injury,,,,,,,
2159,L-tyrosine-L-serine-L-leucine,Treatment of hepatocellular carcinoma.,09/10/2004,Designated,,ZQDRFSVZWYSZFY-WQTRMNQHSA-N,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2160,L. reuteri,"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",08/01/2013,Designated,,,"necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",,,,,,,
2161,Lactic acid,"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.",06/29/1999,Designated,Q27077083,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,"severe aphthous stomatitis in severely, terminally immunocompromised patients",,,,,,,
2162,"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)",Treatment of active chronic pouchitis,01/15/2002,Designated,,,active chronic pouchitis,,,,,,,
2163,"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)",Prevention of disease relapse in patients with chronic pouchitis,01/15/2002,Designated,,,disease relapse in patients with chronic pouchitis,,,,,,,
2164,Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis,Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams,03/24/2015,Designated,,,necrotizing enterocolitis (nec) in premature infants with very low birth weight less than or equal to 1500 grams,,,,,,,
2165,lactobacillus brevis CD2,Treatment Behcet's disease,10/04/2011,Designated,,,disease,http://purl.obolibrary.org/obo/DOID_4,,,D004194,Q12136,,Q12136
2166,lactobacillus plantarum,Treatment of amyotrophic lateral sclerosis (ALS),11/30/2016,Designated,,,amyotrophic lateral sclerosis (als),,,,,,,
2167,Lactobin,Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.,09/12/1990,Designated/Withdrawn,,,aids-associated diarrhea unresponsive to initial antidiarrheal therapy,,,,,,,
2168,laminin-111 (human),Treatment of Duchenne Muscular Dystrophy,07/21/2011,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2169,Lamotrigine,Treatment of Lennox-Gastaut syndrome.,08/23/1995,Designated/Approved,Q410346,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
2170,Lanreotide,Treatment for acromegly,09/11/2000,Designated/Approved,Q1707877,,acromegly,,,,,,,
2171,lanreotide acetate,Treatment of symptoms associated with carcinoid syndrome,09/08/2011,Designated,,,symptoms associated with carcinoid syndrome,,,,,,,
2172,lanreotide acetate,Treatment of neuroendocrine tumors,08/25/2011,Designated/Approved,,,neuroendocrine tumors,,,,D018358,,,Q1981276
2173,lapatinib,Treatment of ErbB2 positive gastric cancer,05/29/2009,Designated/Withdrawn,Q420323,,erbb2 positive gastric cancer,,,,,,,
2174,lapatinib ditosylate hydrochloride,Treatment of ErbB2 positive esophageal cancer,05/29/2009,Designated/Withdrawn,,,erbb2 positive esophageal cancer,,,,,,,
2175,laquinimod sodium,Treatment of Huntington's Disease,01/31/2017,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
2176,laromustine,Treatment of acute myelogenous leukemia,10/21/2004,Designated,Q26841309,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2177,Laromustine,Treatment of acute myelogenous leukemia,03/27/2014,Designated,Q26841309,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2178,laronidase,Treatment of patients with mucopolysaccharidosis-I.,09/24/1997,Designated/Approved,Q20801774,,patients with mucopolysaccharidosis-i,,,,,,,
2179,late stage human motor neutron progenitors,Treatment of spinal muscular atrophy,11/25/2009,Designated/Withdrawn,,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
2180,Latrodectus immune F(ab)2,Treatment of black widow spider envenomations,06/18/2001,Designated,,,black widow spider envenomations,,,,,,,
2181,lebrikizumab,Treatment of idiopathic pulmonary fibrosis,03/09/2015,Designated,Q3829321,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2182,ledipasvir/sofosbuvir,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,10/12/2016,Designated,Q19597688,,chronic hepatitis c virus (hcv) infection in pediatric patients,,,,,,,
2183,Leflunomide,Prevention of acute and chronic rejection in patients who have received solid organ transplants.,10/18/1996,Designated,Q248550,,acute and chronic rejection in patients who have received solid organ transplants,,,,,,,
2184,lenalidomide,Treatment of nodal marginal zone lymphoma,01/04/2017,Designated,Q425681,,nodal marginal zone lymphoma,,,,,,,
2185,lenalidomide,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,04/29/2015,Designated,Q425681,,extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,,,,,,,
2186,lenalidomide,Treatment of myelodysplastic syndromes,01/29/2004,Designated/Approved,Q425681,,myelodysplastic syndromes,,,,D009190,,,Q954625
2187,lenalidomide,Treatment of chronic lymphocytic leukemia,01/17/2007,Designated,Q425681,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2188,lenalidomide,Treatment of splenic marginal zone lymphoma,01/04/2017,Designated,Q425681,,splenic marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050750,,http://www.orpha.net/ORDO/Orphanet_86854,,Q3832900,,
2189,lenalidomide,Treatment of multiple myeloma,09/20/2001,Designated/Approved,Q425681,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2190,lenalidomide,Treatment of diffuse large B-cell lymphoma,03/28/2011,Designated,Q425681,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
2191,lenalidomide,Treatment of follicular lymphoma,09/17/2013,Designated,Q425681,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
2192,lenalidomide,Treatment of mantle cell lymphoma,04/27/2009,Designated/Approved,Q425681,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
2193,Lentiviral vector containing the human ABCA4 gene,Treatment of Stargardt disease,04/30/2010,Designated,,,stargardt disease,http://purl.obolibrary.org/obo/DOID_0050817,,http://www.orpha.net/ORDO/Orphanet_117623,,Q1317319,,
2194,lentiviral vector containing the human liver and erythroid pyruvate kinase gene,Treatment of pyruvate kinase deficiency.,03/23/2016,Designated,,,pyruvate kinase deficiency,,,,,,,
2195,Lentiviral vector containing the human MY07A gene,Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.,05/17/2010,Designated,,,retinitis pigmentosa associated with usher syndrome 1b gene defect,,,,,,,
2196,Lentiviral vector encoded with a human beta-globin gene plasmid,Treatment of beta-thalassemia major and beta-thalassemia intermedia,01/11/2006,Designated,,,beta-thalassemia major and beta-thalassemia intermedia,,,,,,,
2197,lenvatinib,"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",12/27/2012,Designated/Approved,Q6523413,,"follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",,,,,,,
2198,lenvatinib,Treatment of stage IIB to Stage IV melanoma,03/26/2014,Designated,Q6523413,,stage iib to stage iv melanoma,,,,,,,
2199,lenvatinib,Treatment of hepatocellular carcinoma,03/27/2014,Designated,Q6523413,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2200,Lepirudin,Treatment of heparin-associated thrombocytopenia type II.,02/13/1997,Designated/Approved,Q3271949,,heparin-associated thrombocytopenia type ii,,,,,,,
2201,lestaurtinib,Treatment of Philadelphia-negative classic myeloproliferative disorders,09/03/2009,Designated,Q6531771,,philadelphia-negative classic myeloproliferative disorders,,,,,,,
2202,Lestaurtinib,Treatment of acute myeloid leukemia,03/24/2006,Designated,Q6531771,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2203,letermovir,Prevention of human cytomegalovirus viremia and disease in at risk populations,12/12/2011,Designated,Q15409407,,human cytomegalovirus viremia and disease in at risk populations,,,,,,,
2208,leukotriene A4 hydrolase inhibitor,Treatment of cystic fibrosis,01/26/2015,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2210,Leuprolide acetate,Treatment of central precocious puberty,07/25/1988,Designated/Approved,Q27104908,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
2211,levetiracetam,Treatment of neonatal seizures,04/30/2010,Designated,,,neonatal seizures,,,,,,,
2212,Levocabastine HCl ophthalmic suspension 0.05%,Treatment of vernal keratoconjunctivitis.,02/29/1988,Designated/Withdrawn,,,vernal keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_70476,D003233,,Q4119259,Q18555085
2213,Levocarnitine,Treatment of primary and secondary carnitine deficiency of genetic origin.,07/26/1984,Designated/Approved,Q20735709,,primary and secondary carnitine deficiency of genetic origin,,,,,,,
2214,Levocarnitine,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,11/24/1986,Designated/Withdrawn,Q20735709,,manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis,,,,,,,
2215,Levocarnitine,Treatment of genetic carnitine deficiency.,02/28/1984,Designated/Approved,Q20735709,,genetic carnitine deficiency,,,,,,,
2217,Levocarnitine,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,09/06/1988,Designated/Approved,Q20735709,,manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis,,,,,,,
2218,Levocarnitine,Treatment of zidovudine-induced mitochondrial myopathy.,04/07/1997,Designated,Q20735709,,zidovudine-induced mitochondrial myopathy,,,,,,,
2219,Levocarnitine,Treatment of pediatric cardiomyopathy.,11/22/1993,Designated,Q20735709,,pediatric cardiomyopathy,,,,,,,
2220,Levodopa and carbidopa,Treatment of late stage Parkinson's disease,01/18/2000,Designated/Approved,,,late stage parkinson's disease,,,,,,,
2221,Levofloxacin,Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients,02/27/2008,Designated,Q424193,,pulmonary infections due to pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients,,,,,,,
2224,levomefolate calcium,Treatment of megaloblastic anemia caused by folate deficiency,02/10/2015,Designated,Q27273818,,megaloblastic anemia caused by folate deficiency,,,,,,,
2225,Levomethadyl acetate hydrochloride,Treatment of heroin addicts suitable for maintenance on opiate agonists.,01/24/1985,Designated/Approved,Q27274386,,heroin addicts suitable for maintenance on opiate agonists,,,,,,,
2227,liarozole,Treatment of congenital ichthyosis,06/18/2004,Designated/Withdrawn,Q15633974,,congenital ichthyosis,,http://purl.obolibrary.org/obo/HP_0007431,,,,,
2229,linsitinib,Treatment of adrenocortical carcinoma,03/09/2012,Designated/Withdrawn,Q6554803,,adrenocortical carcinoma,http://purl.obolibrary.org/obo/DOID_3948,http://purl.obolibrary.org/obo/HP_0006744,http://www.orpha.net/ORDO/Orphanet_1501,D018268,Q918285,,Q918285
2230,lintuzumab,Treatment of acute myelogenous leukemia,09/09/2002,Designated/Withdrawn,Q3833129,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2231,lintuzumab,Treatment of acute myeloid leukemia.,01/30/2007,Designated/Withdrawn,Q3833129,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2232,lintuzumab,Treatment of myelodysplastic syndrome,03/20/2007,Designated/Withdrawn,Q3833129,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2233,Liothyronine sodium injection,Treatment of myxedema coma/precoma.,07/30/1990,Designated/Approved,,,myxedema coma/precoma,,,,,,,
2234,"lipase, amylase, and protease",Treatment of pancreatic insufficiency,01/23/2002,Designated/Withdrawn,,,pancreatic insufficiency,,http://purl.obolibrary.org/obo/HP_0001738,,D010188,,,Q641605
2235,Lipid/DNA human cystic fibrosis gene,Treatment of cystic fibrosis.,04/08/1996,Designated/Withdrawn,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2236,liposomal amikacin,Treatment infections caused by non-tuberculous mycobacteria,03/25/2013,Designated,,,caused by non-tuberculous mycobacteria,,,,,,,
2237,liposomal amikacin,Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients,03/09/2006,Designated,,,bronchopulmonary pseudomonas aeruginosa infections in cystic fibrosis patients,,,,,,,
2238,liposomal amikacin,Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens,08/25/2009,Designated,,,bronchiectasis in patients with pseudomonas aeruginosa or other susceptible microbial pathogens,,,,,,,
2239,Liposomal amphotericin B,Treatment of cryptococcal meningitis.,12/10/1996,Designated/Approved,Q412223,,cryptococcal meningitis,http://purl.obolibrary.org/obo/DOID_0080159,,,D016919,Q18967011,,Q18967011
2240,Liposomal amphotericin B,Treatment of histoplasmosis.,12/10/1996,Designated,Q412223,,histoplasmosis,http://purl.obolibrary.org/obo/DOID_1731,,http://www.orpha.net/ORDO/Orphanet_390,D006660,Q627625,,Q627625
2241,Liposomal amphotericin B,Treatment of visceral leishmaniasis.,12/06/1996,Designated/Approved,Q412223,,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
2242,Liposomal annamycin,Treatment of acute myeloid leukemia,06/17/2005,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2243,Liposomal annamycin,Treatment of acute lymphoblastic leukemia,06/17/2005,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2248,Liposomal cisplatin,Treatment of ovarian cancer,05/23/2006,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2250,liposomal cyclosporine,Treatment of bronchiolitis obliterans,05/11/2009,Designated,,,bronchiolitis obliterans,http://purl.obolibrary.org/obo/DOID_2799,http://purl.obolibrary.org/obo/HP_0011946,,D001989,Q614750,,Q614750
2251,liposomal cyclosporine for inhalation,Prevention of bronchiolitis obliterans.,06/24/2008,Designated,,,bronchiolitis obliterans,http://purl.obolibrary.org/obo/DOID_2799,http://purl.obolibrary.org/obo/HP_0011946,,D001989,Q614750,,Q614750
2252,Liposomal doxorubicin hydrochloride,Treatment of soft tissue sarcomas,12/27/2006,Designated,,,soft tissue sarcomas,,http://purl.obolibrary.org/obo/HP_0030448,,D012509,,,Q18975788
2253,liposomal encapsulated paclitaxel,Treatment of ovarian cancer,01/21/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2254,liposomal gadodiamide,Treatment of glioma,11/12/2008,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2255,liposomal glutathione,Treatment of Dengue Virus infection.,05/18/2016,Designated,,,dengue virus infection,,,http://www.orpha.net/ORDO/Orphanet_99828,,,,
2257,liposomal irinotecan,Treatment of pancreatic cancer,07/21/2011,Designated/Approved,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2258,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,Treatment of Ewing's sarcoma.,06/10/1998,Designated,,,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
2259,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,Treatment of osteosarcoma.,06/10/1998,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2260,Liposomal nystatin,Treatment of invasive fungal infections.,06/13/2000,Designated,,,invasive fungal infections,,,,D000072742,,,
2261,liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide,Treatment of acute myeloid leukemia,04/27/2015,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2262,liposomal p-ethoxy growth receptor bound protein-2 antisense product,Treatment of chronic myelogenous leukemia,12/05/2003,Designated,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2263,Liposomal prostaglandin E1 injection,Treatment of acute respiratory distress syndrome.,04/25/1996,Designated/Withdrawn,,,acute respiratory distress syndrome,,,,D012128,,,Q7315912
2264,liposomal topotecan hydrochloride,Treatment of gliomas,10/30/2008,Designated,,,gliomas,,,,D005910,,,Q18556612
2265,liposomal vinorelbine,Treatment of cutaneous t-cell lymphoma (CTCL),10/12/2016,Designated,,,cutaneous t-cell lymphoma (ctcl),,,,,,,
2266,liposomal Ãƒ}Ã‚Â±-galactosylceramide,Prevention of graft-versus-host disease,09/28/2012,Designated,,,graft-versus-host disease,,,,D006086,,,Q1194520
2267,"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)",Treatment of malignant mesothelioma.,09/01/1999,Designated/Withdrawn,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
2268,liposome encapsulated paclitaxel,Treatment of gastric cancer,12/03/2014,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
2269,Liposome encapsulated recombinant interleukin-2,Treatment of cancers of the kidney and renal pelvis,06/20/1994,Designated,,,cancers of the kidney and renal pelvis,,,,,,,
2270,Liposome encapsulated recombinant interleukin-2,Treatment of brain and CNS tumors.,11/25/1991,Designated,,,brain and cns tumors,,,,,,,
2271,lisinopril oral solution,Treatment of hypertension in pediatric patients 0 through 16 years of age.,10/14/2015,Designated/Withdrawn,,,hypertension in pediatric patients 0 through 16 years of age,,,,,,,
2272,lisinopril oral solution,Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age),01/27/2015,Designated/Withdrawn,,,primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age),,,,,,,
2273,Lisofylline,Treatment of patients undergoing induction therapy for acute myeloid leukemia.,06/10/1999,Designated,Q15409404,,patients undergoing induction therapy for acute myeloid leukemia,,,,,,,
2274,listeria monocytogenes,Treatment of pancreatic cancer,09/05/2013,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2275,lisuride,Treatment of pulmonary arterial hypertension,01/17/2013,Designated,Q424446,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
2276,lithium citrate tetrahydrate (in reverse micelle formulation),Treatment of Huntington's disease.,12/13/2010,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
2277,live attenuated bioengineered Listeria monocytogenes immunotherapy,Treatment of human papilloma virus-associated head and neck cancer,11/04/2013,Designated,,,human papilloma virus-associated head and neck cancer,,,,,,,
2278,live attenuated bioengineered Listeria monocytogenes immunotherapy,Treatment of osteosarcoma.,05/21/2014,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2279,live attenuated E. Coli expressing Beta catenin shRNA,Treatment of Familial Adenomatous Polyposis,12/20/2010,Designated,,,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
2280,live E. coli Nissle bacterium modified to assimilate ammonia,Treatment of urea cycle disorders,08/22/2016,Designated,,,urea cycle disorders,,,,D056806,,,Q1585743
2281,Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38,Treatment of mesothelioma.,03/24/2015,Designated,,,mesothelioma,,,,D008654,,,Q18555143
2282,"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL",Treatment of pancreatic cancer,05/04/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2283,Lodoxamide tromethamine,Treatment of vernal keratoconjunctivitis.,10/16/1991,Designated/Approved,Q27260799,,vernal keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_70476,D003233,,Q4119259,Q18555085
2284,lomitapide,Treatment of Familial Chylomicronemia,03/03/2011,Designated,Q1268941,,familial chylomicronemia,,,,D008072,,,Q2349695
2285,lomitapide,Treatment of homozygous familial hypercholesterolemia,10/23/2007,Designated/Approved,Q1268941,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
2286,Lonafarnib,Treatment of Hepatitis Delta Virus (HDV)infection,11/19/2013,Designated,Q3258910,,hepatitis delta virus (hdv)infection,,,,,,,
2287,lonafarnib,Treatment of Hutchinson-Gilford progeria syndrome,04/18/2011,Designated,Q3258910,,hutchinson-gilford progeria syndrome,http://purl.obolibrary.org/obo/DOID_3911,,http://www.orpha.net/ORDO/Orphanet_120620,D011371,Q213098,,Q213098
2288,long acting recombinantFactor VIIa-CTP3,Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX,02/27/2014,Designated,,,prophylaxis of bleeding episodes in patients with hemophilia a or b with inhibitors to factor viii or factor ix,,,,,,,
2289,losartan,Treatment of Marfan Syndrome,12/12/2011,Designated,Q410074,,marfan syndrome,http://purl.obolibrary.org/obo/DOID_14323,,http://www.orpha.net/ORDO/Orphanet_121752,D008382,Q208562,,Q208562
2290,low molecular weight dextran sulfate,Treatment to mobilze progenitor cells prior to stem cell transplantation,07/06/2011,Designated,,,mobilze progenitor cells prior to stem cell transplantation,,,,,,,
2291,low molecular weight dextran sulfate,Prevention of graft rejection during pancreatic islet transplantation,10/20/2009,Designated,,,graft rejection during pancreatic islet transplantation,,,,,,,
2292,Loxoribine,Treatment of common variable immunodeficiency.,02/24/1992,Designated/Withdrawn,Q27081526,,common variable immunodeficiency,http://purl.obolibrary.org/obo/DOID_12177,,http://www.orpha.net/ORDO/Orphanet_1572,D017074,Q1472818,Q1472818,Q1472818
2293,lucerastat,Treatment of Fabry Disease.,10/29/2015,Designated,Q27279309,,fabry disease,http://purl.obolibrary.org/obo/DOID_14499,,http://www.orpha.net/ORDO/Orphanet_324,D000795,Q615645,,Q615645
2294,Lucinactant,Treatment of acute respiratory distress syndrome in adults.,07/17/1995,Designated,Q6697358,,acute respiratory distress syndrome in adults,,,,,,,
2295,Lucinactant,Prevention of bronchopulmonary dysplasia in premature infants,05/23/2006,Designated,Q6697358,,bronchopulmonary dysplasia in premature infants,,,,,,,
2296,Lucinactant,Treatment of meconium aspiration syndrome in newborn infants,07/30/1996,Designated/Withdrawn,Q6697358,,meconium aspiration syndrome in newborn infants,,,,,,,
2297,Lucinactant,Treatment of cystic fibrosis.,10/21/2010,Designated,Q6697358,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2298,Lucinactant,Treatment of bronchopulmonary dysplasia in premature infants.,10/21/2005,Designated,Q6697358,,bronchopulmonary dysplasia in premature infants,,,,,,,
2299,Lucinactant,Treatment of respiratory distress syndrome in premature infants.,10/18/1995,Designated,Q6697358,,respiratory distress syndrome in premature infants,,,,,,,
2300,lumacaftor/ivacaftor,Treatment of cystic fibrosis,06/30/2014,Designated/Approved,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2301,lurbinectedin,Treatment of ovarian cancer,08/20/2012,Designated,Q27254568,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2302,lutetium (177Lu)-edotreotide,Treatment of gastro-entero-pancreatic neuroendocrine tumors,05/21/2015,Designated,,,gastro-entero-pancreatic neuroendocrine tumors,,,,,,,
2303,Lysine acetylsalicylate injectable,Treatment of pain and fever secondary to sickle cell disease crisis.,08/01/1989,Designated/Withdrawn,,,pain and fever secondary to sickle cell disease crisis,,,,,,,
2304,lyso-thermosensitive lipsomal doxorubicin,Treatment of hepatocellular carcinoma,03/17/2009,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2305,lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase,Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome),09/10/2008,Designated,,,mucopolysaccharidosis type iva (morquio syndrome),,,,,,,
2306,MA09-hRPE cells,Treatment of Stargardt's macular dystrophy,02/02/2010,Designated,,,stargardt's macular dystrophy,,,,,,,
2307,macitentan,Treatment of pulmonary arterial hypertension,09/03/2009,Designated/Approved,Q6724151,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
2308,macitentan,Treatment of idiopathic pulmonary fibrosis.,04/14/2009,Designated/Withdrawn,Q6724151,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2310,Mafosfamide,Treatment of neoplastic meningitis,01/21/2003,Designated,Q10322996,,neoplastic meningitis,,,,,,,
2311,MAGE-A3 cancer therapeutic Trojan peptide vaccine,Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma,11/24/2008,Designated,,,mage-a3 expressing head and neck squamous cell carcinoma,,,,,,,
2312,magnesium lysinate bis eicosapentaenoate,Treatment of familial adenomatous polyposis.,12/23/2015,Designated,,FMXOLPIDWYCXAC-BAHCQAMFSA-L,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
2314,Manganese superoxide dismutase mimetic,Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients,02/27/2008,Designated,,,radiation- or chemotherapy-induced oral mucositis in cancer patients,,,,,,,
2316,mannopentaose phosphate sulfate,"Treatment of high-risk Stage II, Stage III, and Stage IV melanoma",04/27/2004,Designated,,,"high-risk stage ii, stage iii, and stage iv melanoma",,,,,,,
2317,maralixibat,Treatment of progressive familial intrahepatic cholestasis,09/04/2013,Designated,Q27291331,,progressive familial intrahepatic cholestasis,,,http://www.orpha.net/ORDO/Orphanet_172,,,Q6058436,
2318,maribavir,Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.,06/07/2011,Designated,Q6762512,,clinically significant cytomegalovirus viremia and disease in at-risk patients,,,,,,,
2319,maribavir,Prevention of cytomegalovirus viremia and disease in the populations at risk.,02/01/2007,Designated,Q6762512,,cytomegalovirus viremia and disease in the populations at risk,,,,,,,
2320,Marijuana,Treatment of HIV-associated wasting syndrome.,05/25/1999,Designated,,,hiv-associated wasting syndrome,,,,,,,
2321,marizomib,Treatment of malignant glioma.,09/21/2015,Designated,Q7404722,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
2322,Marizomib,Treatment of multiple myeloma,12/13/2013,Designated,Q7404722,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2323,MART-1 adenoviral gene therapy for malignant melanoma,Treatment of metastatic melanoma.,03/28/1997,Designated/Withdrawn,,,metastatic melanoma,,,,,,,
2324,masitinib,Treatment of patients with pancreatic cancer,07/21/2009,Designated,Q1907109,,patients with pancreatic cancer,,,,,,,
2325,masitinib,Treatment of malignant gastrointestinal stromal tumors,04/20/2005,Designated,Q1907109,,malignant gastrointestinal stromal tumors,,,,,,,
2326,masitinib,Treatment of mastocytosis,09/14/2005,Designated,Q1907109,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
2327,masitinib mesylate,Treatment of gastric cancer including cancer of the gastroesophageal junction,09/14/2015,Designated,Q27295645,,gastric cancer including cancer of the gastroesophageal junction,,,,,,,
2328,masitinib mesylate,Treatment of amyotrophic lateral sclerosis.,03/18/2015,Designated,Q27295645,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2329,Matrix metalloproteinase inhibitor,Treatment of corneal ulcers.,12/05/1991,Designated,,,corneal ulcers,,,,,,,
2330,MaxAdFVIII,Treatment of Hemophilia A,03/03/2003,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
2331,maytansinoid conjugated humanized monoclonal antibody against FOLRI,Treatment of ovarian cancer,07/14/2014,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2332,Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901,Treatment of small cell lung cancer.,08/17/2010,Designated/Withdrawn,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
2333,maytansinoid DM1-conjugated humanized monoclonal antibody N901,Treatment of Merkel cell carcinoma,03/02/2010,Designated/Withdrawn,,,merkel cell carcinoma,http://purl.obolibrary.org/obo/DOID_3965,,http://www.orpha.net/ORDO/Orphanet_79140,D015266,Q1711744,,
2334,maytansinoid DM1-conjugated humanized monoclonal antibody N901,Treatment of multiple myeloma.,11/29/2010,Designated/Withdrawn,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2335,maytansinoid-conjugated humanized monoclonal antibody against CD37,Treatment of diffuse large B-cell lymphoma,05/12/2016,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
2336,Mazindol,Treatment of Duchenne muscular dystrophy.,12/08/1986,Designated,Q255680,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2337,mazindol,Treatment of narcolepsy,07/06/2016,Designated,Q255680,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
2338,MCMV5322A/MCMV3068A,Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy,11/22/2011,Designated/Withdrawn,,,maternal-fetal transmission of congenital cmv in pregnant women who acquire cmv infection during pregnancy,,,,,,,
2339,mebendazole,"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).",09/03/2014,Designated/Approved,Q422194,,"single or mixed gastrointestinal infestations by trichuris trichiura (whipworm), ascaris lumbricoides (large roundworm), and ancylostoma duodenale and nectar americanus (hookworm)",,,,,,,
2340,Mecamylamine,Treatment of Tourette's syndrome.,10/14/1998,Designated,Q3332124,,tourette's syndrome,,,,D005879,,,Q191779
2341,Mecasermin,Treatment of growth hormone insensitivity syndrome.,12/12/1995,Designated/Approved,Q6804390,,growth hormone insensitivity syndrome,,,http://www.orpha.net/ORDO/Orphanet_181393,D046150,,,Q669822
2342,Mecasermin,Treatment of amyotrophic lateral sclerosis.,08/05/1991,Designated/Withdrawn,Q6804390,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2343,mecasermin,Treatment of myotonic dystrophy,12/03/2007,Designated,Q6804390,,myotonic dystrophy,,,http://www.orpha.net/ORDO/Orphanet_206647,D009223,,,Q1860507
2344,mecasermin rinfabate,Treatment of growth hormone insensitivity syndrome (GHIS),05/17/2002,Designated/Approved,Q6804390,,growth hormone insensitivity syndrome (ghis),,,,,,,
2345,mecasermin rinfabate,Prevention of retinopathy of prematurity in premature infants born at risk for the disease,09/20/2012,Designated,Q6804390,,retinopathy of prematurity in premature infants born at risk for the disease,,,,,,,
2346,mecasermin rinfabate,Treatment of amyotropic lateral sclerosis,07/23/2012,Designated,Q6804390,,amyotropic lateral sclerosis,,,,,,,
2347,"mecasermin, recombinant human insulin-like growth factor-1",Treatment of Rett Syndrome.,09/21/2015,Designated,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
2348,meclorethamine,Treatment of mycosis fungoides,08/17/2004,Designated/Approved,,,mycosis fungoides,http://purl.obolibrary.org/obo/DOID_8691,,,D009182,Q1891209,,Q1891209
2349,Medroxyprogesterone acetate,Treatment of immune thrombocytopenic purpura.,02/22/2001,Designated,Q2823834,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
2350,Mefloquine HCl,Treatment and prevention of chloroquine-resistant Falciparummalaria,07/22/1987,Designated,,,prevention of chloroquine-resistant falciparummalaria,,,,,,,
2352,Megestrol acetate,"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.",04/13/1988,Designated/Approved,Q6808975,,"patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of aids",,,,,,,
2353,Melanoma autologous dendritic cell vaccine,Treatment of stage IIIb through IV metastatic melanoma,09/06/2006,Designated,,,stage iiib through iv metastatic melanoma,,,,,,,
2354,Melanoma cell vaccine,Treatment of invasive melanoma.,10/13/1994,Designated,,,invasive melanoma,,,,,,,
2355,Melanoma peptide vaccine,"Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma",03/29/2005,Designated,,,"hla-a2+ patients with stage iib, iic, iii, and iv malignant melanoma",,,,,,,
2356,Melanoma vaccine,Treatment of stage III - IV melanoma.,12/20/1989,Designated,,,stage iii - iv melanoma,,,,,,,
2357,melarsoprol-hydroxypropylbetadex,Treatment of human African trypanosomiasis (sleeping sickness),09/13/2013,Designated,,,human african trypanosomiasis (sleeping sickness),,,,,,,
2358,Melatonin,Treatment of circadian rhythm sleep disorders in blind people with no light perception.,11/15/1993,Designated,Q180912,,circadian rhythm sleep disorders in blind people with no light perception,,,,,,,
2359,melatonin,Treatment of neonatal hypoxic ischemic encephalopathy,04/12/2013,Designated,Q180912,,neonatal hypoxic ischemic encephalopathy,,,,,,,
2360,melatonin,Treatment of necrotizing enterocolitis,01/25/2017,Designated,Q180912,,necrotizing enterocolitis,http://purl.obolibrary.org/obo/DOID_8677,,,D020345,Q10859678,,Q10859678
2361,melatonin,Treatment of short bowel syndrome,02/14/2017,Designated,Q180912,,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
2362,Melatonin,Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception,07/09/2004,Designated,Q180912,,non-24-hour sleep-wake disorder in blind individuals without light perception,,,,,,,
2363,melatonin,Treatment of smith-magenis syndrome in combination with a beta-blocker,11/03/2016,Designated,Q180912,,smith-magenis syndrome in combination with a beta-blocker,,,,,,,
2364,meloxicam,Treatment of juvenile rheumatoid arthritis,11/22/2002,Designated/Approved,Q414028,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
2365,Melphalan,Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.,02/24/1992,Designated/Approved,Q2298283,,patients with multiple myeloma for whom oral therapy is inappropriate,,,,,,,
2367,melphalan,Treatment of retinoblastoma,11/19/2012,Designated,Q2298283,,retinoblastoma,http://purl.obolibrary.org/obo/DOID_768,http://purl.obolibrary.org/obo/HP_0009919,http://www.orpha.net/ORDO/Orphanet_790,D012175,Q500695,,Q18556413
2368,melphalan,Treatment of cholangiocarcinoma.,07/14/2015,Designated,Q2298283,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
2370,melphalan,Treatment of Stage IIB through IV melanoma,11/19/2012,Designated,Q2298283,,stage iib through iv melanoma,,,,,,,
2371,melphalan flufenamide hydrochloride,"Treatment of plasma cell myeloma, also referred to as multiple myeloma",03/16/2015,Designated,,,"plasma cell myeloma, also referred to as multiple myeloma",,,,,,,
2372,melphalan hydrochloride,Treatment of neuroendocrine tumors,05/22/2009,Designated,Q27252967,,neuroendocrine tumors,,,,D018358,,,Q1981276
2373,melphalan hydrochloride,Treatment of patients with ocular (uveal) melanoma.,11/12/2008,Designated,Q27252967,,patients with ocular (uveal) melanoma,,,,,,,
2374,melphalan hydrochloride,Treatment of patients with cutaneous melanoma.,11/12/2008,Designated,Q27252967,,patients with cutaneous melanoma,,,,,,,
2375,melphalan hydrochloride,Treatment of patients with hepatocellular carcinoma,09/26/2013,Designated,Q27252967,,patients with hepatocellular carcinoma,,,,,,,
2377,menadione sodium bisulfite,Treatment of autosomal dominant polycystic liver disease,05/14/2014,Designated,Q27265674,,autosomal dominant polycystic liver disease,,,http://www.orpha.net/ORDO/Orphanet_2924,,,Q246002,
2378,menaquinone,Treatment of calciphylaxis,09/04/2012,Designated,Q27251438,,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
2379,menatetrenone,Treatment of acute promyelocytic leukemia.,11/02/2010,Designated,Q192354,,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
2380,menatetrenone,Treatment of hepatocellular carcinoma (HCC).,11/02/2010,Designated,Q192354,,hepatocellular carcinoma (hcc),,,,,,,
2381,menatetrenone,Treatment of acute myeloid leukemia,03/17/2011,Designated,Q192354,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2382,menatetrenone,Treatment of myelodysplastic syndrome.,02/04/2011,Designated,Q192354,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2383,menatetrenone and Vitamin D3,Treatment of myelodysplastic syndrome,08/22/2011,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2384,mepivacaine,Treatment of painful HIV-associated neuropathy,10/18/2006,Designated,Q416760,,painful hiv-associated neuropathy,,,,,,,
2385,mepivacaine,Treatment of postherpetic neuralgia,01/08/2007,Designated,Q416760,,postherpetic neuralgia,,,,D051474,,,
2386,mepolizumab,Treatment of Churg-Strauss Syndrome.,07/14/2011,Designated,Q3306175,,churg-strauss syndrome,http://purl.obolibrary.org/obo/DOID_3049,,http://www.orpha.net/ORDO/Orphanet_183,D015267,Q32811,,Q32811
2388,mercaptopurine oral solution,Treatment of acute lymphoblastic leukemia in pediatric patients,08/20/2012,Designated/Approved,,,acute lymphoblastic leukemia in pediatric patients,,,,,,,
2390,mesalamine,Treatment of pediatric ulcerative colitis,01/19/2010,Designated,Q27073969,,pediatric ulcerative colitis,,,,,,,
2391,mesalamine and N-acetycysteine,Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years),09/10/2009,Designated,,,pediatric patients with ulcerative colitis (inclusive through age 16 years),,,,,,,
2392,mesalamine; 5-aminosalicylic acid,Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).,02/27/2008,Designated,,,ulcerative colitis in pediatric patients (revised indication 10/21/2010),,,,,,,
2393,"mesencephalic, astrocyte-derived neurotrophic factor",Treatment of retinal artery occlusion.,09/10/2015,Designated,,,retinal artery occlusion,http://purl.obolibrary.org/obo/DOID_8483,,,D015356,Q18557950,,Q18557950
2394,mesenchymal stromal cells secreting neurotrophic factors,Treatment of Amyotrophic Lateral Sclerosis,02/04/2011,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2397,mesylate synthetic small molecule inhibitor of HDAC and PI3K,Treatment of nuclear protein in testis (NUT) midline carcinoma,09/06/2016,Designated,,,nuclear protein in testis (nut) midline carcinoma,,,,,,,
2398,met-enkephalin; Met-N,Treatment of pancreatic cancer.,02/18/2011,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2399,metadoxine,Treatment of Fragile X Syndrome,12/16/2013,Designated,Q18344013,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
2400,"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide",Treatment of pancreatic cancer,07/06/2016,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2401,metformin,Treatment of pediatric polycystic ovary syndrome,05/29/2014,Designated,Q19484,,pediatric polycystic ovary syndrome,,,,,,,
2402,methimazole and liothyronine sodium,Treatment of glioblastoma multiforme.,06/02/2016,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
2403,Methionine/L-methionine,Treatment of AIDS myelopathy.,08/21/1996,Designated,,,aids myelopathy,,,,,,,
2404,methotrexate,Treatment of acute lymphoblastic leukemia,08/20/2009,Designated,Q422232,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2405,methotrexate,Treatment of juvenile rheumatoid arthritis.,08/23/1993,Designated/Withdrawn,Q422232,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
2406,Methotrexate,Treatment of Myasthenia Gravis,08/28/2014,Designated,Q422232,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
2407,methotrexate oral liquid formulation,Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.,03/18/2015,Designated,,,acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years,,,,,,,
2408,methotrexate oral solution,Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age),05/28/2015,Designated,,,acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age),,,,,,,
2409,methotrexate oral solution,"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age",08/27/2015,Designated,,,"oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age",,,,,,,
2410,Methotrexate sodium,Treatment of osteogenic sarcoma.,10/21/1985,Designated/Approved,Q27122181,,osteogenic sarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2414,"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Ãƒ?Ã‚ÃƒÃƒ?Ãƒ?Ã‚&Ãƒ?ÃƒÃ‚Â½Ãƒ?Ã‚ÃƒÃƒ?Ã‚Ãƒ?ÃƒÃ‚Â±-aspararginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[",Prevention of ischemia reperfusion injury associated wth solid organ transplantation,04/18/2011,Designated,,,ischemia reperfusion injury associated wth solid organ transplantation,,,,,,,
2415,methyldopa,Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function,01/12/2017,Designated,Q412621,QZIWDCLHLOADPK-ZETCQYMHSA-N,type 1 diabetes in dq8 positive patients with residual beta cell function,,,,,,,
2416,methylene blue,Treatment of methemoglobinemia,07/24/2012,Designated,Q422134,,methemoglobinemia,http://purl.obolibrary.org/obo/DOID_10783,http://purl.obolibrary.org/obo/HP_0012119,,D008708,Q748442,,Q748442
2417,methylene blue injection,Treatment of congenital and acquired methemoglobinemia,08/11/2012,Designated,,,congenital and acquired methemoglobinemia,,,,,,,
2418,methylene blue0.5%,Treatment of hereditary and acquired methemoglobinemia,12/18/2012,Designated/Approved,,,hereditary and acquired methemoglobinemia,,,,,,,
2419,Methylnaltrexone,Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.,06/17/1996,Designated/Withdrawn,Q411515,,chronic opioid-induced constipation unresponsive to conventional therapy,,,,,,,
2420,methylparaben suberohydroxamic acid phenyl ester,Treatment of cutaneous T-cell lymphoma,04/15/2013,Designated,,KSPNYRPBKPZYIP-UHFFFAOYSA-N,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
2421,methylprednisolone oral suspension,Treatment of adrenal insufficiency in pediatric patients,09/19/2016,Designated,,,adrenal insufficiency in pediatric patients,,,,,,,
2422,metreleptin,Treatment of metabolic disorders secondary to lipodystrophy,08/22/2001,Designated/Approved,,,metabolic disorders secondary to lipodystrophy,,,,,,,
2423,metreleptin,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,08/22/2001,Designated,,,leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,,,,,,,
2424,metronidazole,Treatment of pouchitis,09/17/2008,Designated,Q169569,,pouchitis,,,,D019449,,,
2425,Metronidazole,Treatment of perioral dermatitis.,10/24/1991,Designated,Q169569,,perioral dermatitis,,http://purl.obolibrary.org/obo/HP_0040181,,D019557,,,
2426,metronidazole,Treatment of pouchitis.,04/26/2011,Designated,Q169569,,pouchitis,,,,D019449,,,
2427,metronidazole,Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).,04/05/2016,Designated,Q169569,,clostridium difficile infection in pediatric patients (0 through 16 years of age),,,,,,,
2428,Metronidazole (topical),Treatment of acne rosacea.,10/22/1987,Designated/Approved,,,acne rosacea,,,,D012393,,,Q831530
2429,Metronidazole (topical),"Treatment of grade III and IV, anaerobically infected, decubitus ulcers.",11/24/1987,Designated/Withdrawn,,,"grade iii and iv, anaerobically infected, decubitus ulcers",,,,,,,
2431,metyrapone,Treatment of Cushing's syndrome,09/25/2012,Designated,Q26840996,,cushing's syndrome,http://purl.obolibrary.org/obo/DOID_12252,,http://www.orpha.net/ORDO/Orphanet_553,D003480,Q219102,,Q219102
2432,metyrosine,Treatment of velocardiofacial syndrome associated psychosis.,07/25/2008,Designated,Q15408417,,velocardiofacial syndrome associated psychosis,,,,,,,
2433,mexiletine,Treatment of nondystrophic myotonia,09/02/2010,Designated,Q420377,,nondystrophic myotonia,,,,,,,
2434,mibefradil,Treatment of glioblastoma multiforme.,08/25/2009,Designated,Q6827783,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
2435,mibefradil,Treatment of pancreatic cancer.,10/16/2008,Designated,Q6827783,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2436,mibefradil,Treatment of ovarian cancer,06/15/2007,Designated,Q6827783,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2437,miconazole,Treatment of fungal otitis externa (otomycosis),05/22/2014,Designated,Q410534,,fungal otitis externa (otomycosis),,,,,,,
2439,Microvesiculated modified glycosylated tissue factor,"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients",01/25/2007,Designated,,,"non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients",,,,,,,
2440,Microvesiculated modified glycosylated tissue factor,"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.",10/11/2007,Designated,,,"non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von willebrand disease",,,,,,,
2441,midazolam,Treatment of nerve agent-induced seizures,07/24/2012,Designated,Q423071,,nerve agent-induced seizures,,,,,,,
2443,midazolam,Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam,05/08/2006,Designated,Q423071,,bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam,,,,,,,
2444,midazolam,Treatment of status epilepticus,02/18/2016,Designated,Q423071,,status epilepticus,http://purl.obolibrary.org/obo/DOID_1824,http://purl.obolibrary.org/obo/HP_0002133,,D013226,Q980709,,Q980709
2445,midazolam,Treatment of status epilepticus,02/04/2016,Designated,Q423071,,status epilepticus,http://purl.obolibrary.org/obo/DOID_1824,http://purl.obolibrary.org/obo/HP_0002133,,D013226,Q980709,,Q980709
2446,midazolam,Treatment of seizures induced by organophosporous insecticide poisoning.,02/08/2016,Designated,Q423071,,seizures induced by organophosporous insecticide poisoning,,,,,,,
2447,Midodrine HCl,Treatment of patients with symptomatic orthostatic hypotension.,06/21/1985,Designated/Approved,Q27114696,,patients with symptomatic orthostatic hypotension,,,,,,,
2448,Midostaurin,Treatment of mastocytosis,04/30/2010,Designated,Q6842945,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
2449,Midostaurin,Treatment of acute myeloid leukemia,07/07/2009,Designated,Q6842945,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2450,mifamuritide,Treatment of osteosarcoma,06/05/2001,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2451,mifepristone,Treatment of the clinical manifestations of endogenous Cushing's syndrone,07/05/2007,Designated/Approved,Q411240,,the clinical manifestations of endogenous cushing's syndrone,,,,,,,
2452,mifepristone,Treatment of ovarian cancer.,01/14/2016,Designated,Q411240,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2453,Mifepristone,Treatment of Cushing's syndrome secondary to ectopic ACTH secretion,02/07/2005,Designated,Q411240,,cushing's syndrome secondary to ectopic acth secretion,,,,,,,
2454,migalastat hydrochloride,Treatment of Fabry Disease,02/25/2004,Designated,Q27275527,,fabry disease,http://purl.obolibrary.org/obo/DOID_14499,,http://www.orpha.net/ORDO/Orphanet_324,D000795,Q615645,,Q615645
2455,miglustat,Treatment of Gaucher disease.,05/29/1998,Designated/Approved,Q425911,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
2456,miglustat,"Treatment of the neurological manifestations of Niemann-Pick disease,type C.",11/12/2008,Designated,Q425911,,"the neurological manifestations of niemann-pick disease,type c",,,,,,,
2457,milatuzumab,Treatment of multiple myeloma,03/10/2008,Designated,Q3857819,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2458,milatuzumab,Treatment of chronic lymphocytic leukemia.,06/24/2008,Designated,Q3857819,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2459,milciclib maleate,Treatment of thymic epithelial tumors.,09/20/2012,Designated,,,thymic epithelial tumors,,,,,,,
2460,miltefosine,Treatment of primary amebic encephalitis (PAM),12/06/2016,Designated,Q411787,,primary amebic encephalitis (pam),,,,,,,
2461,miltefosine,Treatment of leishmaniasis.,10/10/2006,Designated/Approved,Q411787,,leishmaniasis,http://purl.obolibrary.org/obo/DOID_9065,,http://www.orpha.net/ORDO/Orphanet_507,D007896,Q331283,Q2046113,Q331283
2462,miltefosine,Treatment of Acanthamoeba keratitis,12/06/2016,Designated,Q411787,,acanthamoeba keratitis,,,http://www.orpha.net/ORDO/Orphanet_67043,D015823,,,
2464,Minnelide,Treatment of pancreatic cancer,02/18/2013,Designated,Q27252236,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2465,Minocycline HCl,Treatment of chronic malignant pleural effusion.,06/19/1992,Designated/Withdrawn,,,chronic malignant pleural effusion,,,,,,,
2466,Minocycline hydrochloride,Treatment of sarcoidosis,03/28/2006,Designated,Q27104777,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
2467,mipomersen,Treatment of homozygous familial hypercholesterolemia,05/23/2006,Designated/Approved,Q27086456,,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
2468,misoprostol,Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.,01/10/2005,Designated,Q416025,,intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy,,,,,,,
2469,Mitoguazone,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",03/18/1994,Designated,Q6881893,,"diffuse non-hodgkin's lymphoma, including aids-related diffuse non-hodgkin's lymphoma",,,,,,,
2471,Mitolactol,Treatment of invasive carcinoma of the uterine cervix,01/23/1989,Designated,Q27283015,,invasive carcinoma of the uterine cervix,,,,,,,
2472,mitomycin,Prevention of recurrence of pterygium after its surgical excision.,01/13/2011,Designated,Q19856779,,recurrence of pterygium after its surgical excision,,,,,,,
2473,mitomycin,Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy,06/01/2011,Designated,Q19856779,,corneal sub-epithelial haze formation following surface ablation laser keratectomy,,,,,,,
2474,mitomycin,Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter),09/08/2014,Designated,Q19856779,,upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter),,,,,,,
2475,Mitomycin-C,Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.,08/20/1993,Designated,,,refractory glaucoma as an adjunct to ab externo glaucoma surgery,,,,,,,
2476,mitomycin-C,Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.,01/08/2008,Designated/Approved,,,refractory glaucoma as an adjunct to ab externo glaucoma surgery,,,,,,,
2477,Mitoxantrone,Treatment of secondary-progressive multiple sclerosis.,08/13/1999,Designated/Approved,Q239426,,secondary-progressive multiple sclerosis,,,,,,,
2478,Mitoxantrone,Treatment of hormone refractory prostate cancer.,08/21/1996,Designated/Approved,Q239426,,hormone refractory prostate cancer,,,,,,,
2479,Mitoxantrone,Treatment of progressive-relapsing multiple sclerosis.,08/13/1999,Designated/Approved,Q239426,,progressive-relapsing multiple sclerosis,,,,,,,
2480,Mitoxantrone HCl,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",07/13/1987,Designated/Approved,,,"acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia",,,,,,,
2482,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),Treatment of acute myelogenous leukemia.,02/04/2011,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2483,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),Treatment of Myelodysplastic syndrome,02/04/2011,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2484,MN14 monoclonal antibody to carcinoembryonic antigen,Treatment of pancreatic cancer.,11/24/1998,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2485,MN14 monoclonal antibody to carcinoembryonic antigen,Treatment of small cell lung cancer,09/18/1998,Designated,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
2486,mocetinostat,Treatment of diffuse large B-cell lymphoma,08/07/2014,Designated,Q424869,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
2487,Mocetinostat,Treatment of myelodysplastic syndrome,06/12/2014,Designated,Q424869,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2488,MOD-423 hGH analogue,Treatment of growth hormone deficiency,09/29/2010,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
2489,Modafinil,Treatment of excessive daytime sleepiness in narcolepsy.,03/15/1993,Designated/Approved,Q410441,,excessive daytime sleepiness in narcolepsy,,,,,,,
2490,modified a-cobratoxin,Treatment of pediatric multiple sclerosis (0 through 16 years of age).,09/01/2015,Designated,,,pediatric multiple sclerosis (0 through 16 years of age),,,,,,,
2491,Modified cholera toxin,Treatment of Gaucher disease,02/07/2017,Designated,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
2492,modified human papillomavirus capsid protein conjugated to a near infrared dye,Treatment of uveal melanoma,04/08/2015,Designated,,,uveal melanoma,http://purl.obolibrary.org/obo/DOID_6039,http://purl.obolibrary.org/obo/HP_0007716,http://www.orpha.net/ORDO/Orphanet_39044,,Q356372,Q356372,
2493,"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles",Treatment of Crigler-Najjar syndrome,07/05/2016,Designated,,,crigler-najjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
2494,modified recombinant human C-type natriuretic peptide (CNP),Treatment of achondroplasia,01/17/2013,Designated,,,achondroplasia,http://purl.obolibrary.org/obo/DOID_4480,,http://www.orpha.net/ORDO/Orphanet_15,D000130,Q340594,,Q340594
2495,modified recombinant human Factor VIIa (rFVIIa) molecule,Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors,05/30/2013,Designated/Withdrawn,,,bleeding episodes in hemophilia a or b subjects with inhibitors,,,,,,,
2496,modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain,Treatment of inherited mitochondrial respiratory chain disease,08/20/2012,Designated,,,inherited mitochondrial respiratory chain disease,,,,,,,
2497,mogamulizumab,Treatment of peripheral T-cell lymphoma.,11/02/2010,Designated,Q6890447,,peripheral t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
2498,mogamulizumab,Treatment of adult T-cell leukemia/lymphoma (ATLL).,07/14/2011,Designated,Q6890447,,adult t-cell leukemia/lymphoma (atll),,,,,,,
2499,mogamulizumab,Treatment of patients with cutaneous T-cell lymphoma.,11/02/2010,Designated,Q6890447,,patients with cutaneous t-cell lymphoma,,,,,,,
2500,Molgramostim,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",01/24/1989,Designated/Withdrawn,Q6896158,,"aids patients with neutropenia due to the disease, aztor ganciclovir",,,,,,,
2501,Molgramostim,Treatment of aplastic anemia.,09/25/1989,Designated/Withdrawn,Q6896158,,aplastic anemia,http://purl.obolibrary.org/obo/DOID_12449,http://purl.obolibrary.org/obo/HP_0001915,http://www.orpha.net/ORDO/Orphanet_182040,D000741,Q846316,,Q846316
2502,monarsen,Treatment of myasthenia gravis,11/14/2003,Designated/Withdrawn,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
2503,mongersen,Treatment of pediatric Crohn's disease,07/20/2015,Designated,Q27285216,,pediatric crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,,,,Q1472,,
2504,Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen,Treatment of invasive cutaneous melanoma.,09/19/1994,Designated/Withdrawn,,,invasive cutaneous melanoma,,,,,,,
2505,Monoclonal antibodies (murine or human) to B-cell lymphoma,Treatment of B-cell lymphoma.,05/06/1986,Designated/Withdrawn,,,b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_707,http://purl.obolibrary.org/obo/HP_0012191,,D016393,Q4833719,,Q4833719
2507,monoclonal antibody,Prevention of congential cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.,01/21/2011,Designated/Withdrawn,,,congential cytomegalovirus (cmv)infection following primary cmv infection in pregnant women,,,,,,,
2510,Monoclonal antibody 17-1a,Treatment of pancreatic cancer.,04/04/1988,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2511,monoclonal antibody 3F8,Treatment of neuroblastoma,10/16/2008,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
2512,"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus",Treatment of Ebola virus infection,08/25/2014,Designated,,,ebola virus infection,,,,D019142,,,Q8064876
2513,monoclonal antibody directed at hepatitis C virus E2 glycoprotein,Prevention of Hepatitis C recurrence in patients receiving liver transplantation,11/04/2013,Designated,,,hepatitis c recurrence in patients receiving liver transplantation,,,,,,,
2514,Monoclonal antibody for immunization against lupus nephritis,Treatment of lupus nephritis.,01/07/1993,Designated,,,lupus nephritis,http://purl.obolibrary.org/obo/DOID_0080162,,,D008181,Q1621830,,Q1621830
2515,monoclonal antibody Hu3F8,Treatment of osteosarcoma,01/10/2014,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2517,monoclonal antibody targeting eotaxin-2,Treatment of idiopathic pulmonary fibrosis.,10/29/2015,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2518,monoclonal antibody targeting eotaxin-2,Treatment of systemic sclerosis,01/06/2015,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
2520,Monoclonal antibody to cytomegalovirus (human),Treatment of cytomegalovirus retinitis in patients with AIDS.,11/15/1991,Designated/Withdrawn,,,cytomegalovirus retinitis in patients with aids,,,,,,,
2522,Monoclonal antibody-B43.13,Treatment of epithelial ovarian cancer.,11/25/1996,Designated,,,epithelial ovarian cancer,,,,,,,
2523,Monoclonal antiendotoxin antibody XMMEn-0e5,Treatment of patients with gram-negative sepsis which has progressed to shock.,11/04/1985,Designated/Withdrawn,,,patients with gram-negative sepsis which has progressed to shock,,,,,,,
2524,Monolaurin,Treatment of congenital primary ichthyosis.,04/29/1993,Designated,,,congenital primary ichthyosis,,,,,,,
2525,monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C,Treatment of pancreatic cancer.,07/29/2014,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2526,Mononuclear enriched fraction of human umbilical cord blood,Treatment of amyotrophic lateral sclerosis (ALS).,09/15/2015,Designated,,,amyotrophic lateral sclerosis (als),,,,,,,
2531,"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37",Treatment of chronic lymphocytic leukemia (CLL).,03/24/2015,Designated,,,chronic lymphocytic leukemia (cll),,,,,,,
2532,mouse-human chimeric monoclonal anti-GD2 IgG1 antibody,Treatment of neuroblastoma.,09/20/2012,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
2533,moxetumomab pasudotox,Treatment of CD22-positive chronic lymphocytic leukemia,11/15/2007,Designated,Q14605217,,cd22-positive chronic lymphocytic leukemia,,,,,,,
2534,moxetumomab pasudotox,Treatment of hairy cell leukemia,11/15/2007,Designated,Q14605217,,hairy cell leukemia,http://purl.obolibrary.org/obo/DOID_285,,http://www.orpha.net/ORDO/Orphanet_58017,D007943,Q201299,,Q201299
2535,moxetumomab pasudotox,Treatment of acute lymphoblastic leukemia,06/28/2013,Designated,Q14605217,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2536,moxidectin,Treatment of onchocerciasis volvulus in children and adults.,09/29/2010,Designated,Q903824,,onchocerciasis volvulus in children and adults,,,,,,,
2537,moxifloxacin hydrochloride,Treatment of tuberculosis,04/30/2014,Designated/Withdrawn,Q27107395,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
2538,mPEG-r-crisantaspase,Treatment of acute lymphoblastic leukemia.,02/01/2010,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2539,mRNA encoding human ornithine transcarbamylase,Treatment of ornithine transcarbamylase deficiency,11/23/2016,Designated,,,ornithine transcarbamylase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
2540,MTC-DOX for Injection,Treatment of hepatocellular carcinoma,01/03/2001,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2541,mTOR kinase inhibitor (CC-223),Treatment of hepatocellular carcinoma,10/16/2013,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2542,Mucoid exopolysaccharide Pseudomonas hyperimmune globulin,Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.,11/07/1990,Designated/Withdrawn,,,pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis,,,,,,,
2543,Mucoid exopolysaccharide Pseudomonas hyperimmune globulin,Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.,01/09/1991,Designated/Withdrawn,,,pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis,,,,,,,
2544,multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200),Treatment of ovarian cancer.,12/07/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2545,Multi-ligand somatostatin analog,"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.",07/27/2004,Designated,,,"patients with functional gastroenteropancreatic (gep) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, grfoma, vipoma and glucagonoma",,,,,,,
2546,Multi-peptide cancer vaccine,Treatment of multiple myeloma,06/23/2013,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2548,multi-vitamin infusion without vitamin K,Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy,03/08/2004,Designated/Approved,,,vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy,,,,,,,
2550,Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma,Treatment of B-cell non-Hodgkin's lymphoma.,11/27/1998,Designated,,,b-cell non-hodgkin's lymphoma,,,,,,,
2552,murine monoclonal antibody against CD26,Treatment of graft versus host disease,02/18/2011,Designated,,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
2553,"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin",Treatment of Neuroblastoma,09/23/2014,Designated,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
2554,Mx-dnG1,Treatment of soft tissue sarcoma,06/24/2008,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
2555,Mx-dnG1,Treatment of osteosarcoma.,06/24/2008,Designated,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
2556,Mx-dnG1 or Rexin-G retroviral vector,Treatment of pancreatic cancer,08/15/2003,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2558,mycobacterium vaccae,Treatment of tuberculosis,08/20/2010,Designated,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
2559,mycobacterium vaccae,Treatment of pancreatic cancer,08/06/2010,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2560,Mycophenolate mofetil,Treatment of myasthenia gravis,12/19/2005,Designated/Withdrawn,Q4567614,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
2561,Mycophenolate mofetil,Treatment of pemphigus vulgaris,05/26/2006,Designated/Withdrawn,Q4567614,,pemphigus vulgaris,,,http://www.orpha.net/ORDO/Orphanet_704,D010392,,,Q1483214
2562,Myelin,Treatment of multiple sclerosis.,06/27/1991,Designated/Withdrawn,,,multiple sclerosis,http://purl.obolibrary.org/obo/DOID_2377,,,D009103,Q8277,,Q8277
2563,myo-inositol,Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity,04/07/2005,Designated,Q15628176,,retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity,,,,,,,
2564,myristoylated recombinant SCR1-3 of human complement reseptor type I,Prevention of delayed graft function in solid organ transplant,05/21/2003,Designated/Withdrawn,,,delayed graft function in solid organ transplant,,,,,,,
2565,"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine",Treatment of malaria.,10/29/2015,Designated,Q27259831,NCPLTAGJJVCHOW-UHFFFAOYSA-N,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
2566,"N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)",Treatment of mercury toxicity,04/06/2012,Designated,,,mercury toxicity,,,,,,,
2567,"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)",Treatment of gastrointestinal stromal tumors,01/13/2005,Designated/Withdrawn,Q27289746,ONDPWWDPQDCQNJ-UHFFFAOYSA-N,gastrointestinal stromal tumors,,http://purl.obolibrary.org/obo/HP_0100723,,D046152,,,Q1495661
2568,"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide",Treatment of Duchenne muscular dystrophy,11/17/2014,Designated,Q27273902,JQLBBYLGWHUHRW-KUBAVDMBSA-N,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2569,N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide,Treatment of optic neuritis,11/17/2014,Designated,,DLNGCTCNAABWBW-UHFFFAOYSA-N,optic neuritis,http://purl.obolibrary.org/obo/DOID_1210,http://purl.obolibrary.org/obo/HP_0100653,,D009902,Q972514,,Q972514
2570,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,Treatment of Hodgkin's lymphoma,08/08/2007,Designated,,,hodgkin's lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
2571,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,Treatment of acute myeloid leukemia,02/01/2008,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2572,"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide",Treatment of AL Amyloidosis,10/15/2014,Designated,,XIKSEDLKDYKPTO-UHFFFAOYSA-N,al amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85443,,,,
2573,N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate,Treatment of gliomas,11/26/2013,Designated,,,gliomas,,,,D005910,,,Q18556612
2575,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine",Treatment of glioma.,02/18/2016,Designated,,KVMLMFRXRZLEGU-UHFFFAOYSA-N,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2576,N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate,Treatment of ovarian cancer,10/21/2014,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2577,"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt",Treatment of acute myeloid leukemia,03/18/2009,Designated,Q27292691,DHYPGRVMIOATAE-UHFFFAOYSA-N,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2578,N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,Treatment of Friedreich's ataxia.,05/17/2010,Designated/Withdrawn,,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
2579,N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride,"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)",11/17/2014,Designated,,,"acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)",,,,,,,
2580,N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl]amino}pyrimidin-4-yl)benzamide,Treatment of myelofibrosis,08/05/2010,Designated,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
2581,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate,Treatment of multiple myeloma.,10/17/2005,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2582,N-acetyl cysteine amide,Treatment of retinitis pigmentosa,12/31/2013,Designated,,YVDBIXASASLJPM-BYPYZUCNSA-N,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
2583,N-acetyl-glucosamine thiazoline,Treatment of adult Tay-Sachs disease,02/06/2006,Designated,Q27284100,UPCIFQQKHHFBAH-FROKLYQUSA-N,adult tay-sachs disease,,,,,,,
2584,N-acetyl-procainamide,Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.,12/10/1996,Designated,,,life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus,,,,,,,
2585,N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate,Treatment of soft tissue sarcoma,12/09/2003,Designated/Withdrawn,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
2587,N-acetylcysteine,Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers,07/19/2012,Designated,Q375613,PWKSKIMOESPYIA-BYPYZUCNSA-N,ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers,,,,,,,
2588,N-acetylcysteine,Treatment of apnea of prematurity,10/21/2010,Designated/Withdrawn,Q375613,PWKSKIMOESPYIA-BYPYZUCNSA-N,apnea of prematurity,,,http://www.orpha.net/ORDO/Orphanet_99981,,,,
2589,N-acetylcysteine,Treatment of acute liver failure,09/09/2002,Designated,Q375613,PWKSKIMOESPYIA-BYPYZUCNSA-N,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
2590,N-acetylcysteine and sodium thiosulfate,Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).,08/31/2015,Designated,,BVNJVTJUKAWTJM-WJXVXWFNSA-L,platinum-induced toxicities in pediatric patients (0 through 16 years of age),,,,,,,
2591,"N-acetylgalactosamine-4-sulfatase, recombinant human",Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).,02/17/1999,Designated/Approved,,,mucopolysaccharidosis type vi (maroteaux-lamy syndrome),,,,,,,
2592,N-Acetylmannosamine (ManNAc),Treatment of GNE Myopathy (Hereditary Inclusion Body Myopathy Type 2),04/05/2010,Designated,,,gne myopathy (hereditary inclusion body myopathy type 2),,,,,,,
2594,N-adamantanyl-N'-Geranyl-ethylenediamine,Treatment of tuberculosis.,10/16/2007,Designated,,MJOAPUNZUDEDFQ-CNHKJKLMSA-N,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
2595,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,Treatment of Schwannoma of the central nervous system,01/13/2012,Designated,Q27276699,LAMIXXKAWNLXOC-INIZCTEOSA-N,schwannoma of the central nervous system,,,,,,,
2596,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,Treatment of meningioma,01/13/2012,Designated,Q27276699,LAMIXXKAWNLXOC-INIZCTEOSA-N,meningioma,http://purl.obolibrary.org/obo/DOID_3565,http://purl.obolibrary.org/obo/HP_0002858,http://www.orpha.net/ORDO/Orphanet_2495,D008579,Q369157,,Q18557816
2597,N-Methanocarbathymidine,Treatment of neonatal herpes,10/15/2014,Designated,,,neonatal herpes,,,,,,,
2598,N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",05/04/2007,Designated/Withdrawn,,,"follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",,,,,,,
2599,N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride,Treatment of mesothelioma,07/18/2013,Designated,,,mesothelioma,,,,D008654,,,Q18555143
2600,N-t-butylhydroxylamine,Treatment of infantile neuronal ceroid lipofuscinosis.,05/12/2015,Designated,,XWESXZZECGOXDQ-UHFFFAOYSA-N,infantile neuronal ceroid lipofuscinosis,,,http://www.orpha.net/ORDO/Orphanet_79263,D009472,,,Q4358039
2601,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate,Treatment of polycythemia vera,03/21/2013,Designated,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
2602,N-tert-butyl-3-[5-methyl-2-{[4-(2-pryyolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate,Treatment of secondary and primary myelofibrosis,05/18/2009,Designated,,,secondary and primary myelofibrosis,,,,,,,
2603,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride",Treatment of acute myeloid leukemia (AML).,01/12/2011,Designated,,,acute myeloid leukemia (aml),,,,,,,
2604,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride",Treatment of pancreatic cancer,01/29/2010,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2605,"N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt",Treatment of acute myeloid leukemia (AML),02/07/2017,Designated,,WLRWBXFBIJMKHG-CXWNJGBASA-N,acute myeloid leukemia (aml),,,,,,,
2607,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide,Treatment of neuroblastoma,09/30/2004,Designated/Withdrawn,Q27166810,URCVCIZFVQDVPM-UHFFFAOYSA-N,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
2608,"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide",Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.,12/27/2006,Designated,,,philadelphia chromosome-positive chronic myelogenous leukemia,,,,,,,
2609,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea,Treatment of acute myelogenous leukemia,10/23/2007,Designated/Withdrawn,,ACPCMBPQKQTAQY-UHFFFAOYSA-N,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2610,N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea,Treatment of hepatocellular carcinoma,05/23/2007,Designated/Withdrawn,,ACPCMBPQKQTAQY-UHFFFAOYSA-N,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2611,"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",Treatment of stages IIB-IV melanoma,08/13/2004,Designated/Withdrawn,Q27074039,YZOQZEXYFLXNKA-UHFFFAOYSA-N,stages iib-iv melanoma,,,,,,,
2612,"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",Treatment of cutaneous T-cell lymphoma,03/24/2006,Designated/Withdrawn,,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
2613,N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide,Treatment of malignant glioma.,05/25/1995,Designated,Q248550,VHOGYURTWQBHIL-UHFFFAOYSA-N,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
2614,N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide,Treatment of ovarian cancer.,03/12/1996,Designated,Q248550,VHOGYURTWQBHIL-UHFFFAOYSA-N,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2615,"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea",Treatment of sickle cell disease,05/13/2002,Designated/Withdrawn,Q27088062,AEFYFGMSRKDXHZ-UHFFFAOYSA-N,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2616,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer",02/12/2015,Designated,Q27077195,HAYYBYPASCDWEQ-UHFFFAOYSA-N,"trka-positive, trkb-positive, trkc-positive, ros1-positive, or alk-positive colorectal cancer",,,,,,,
2617,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer",02/03/2015,Designated,Q27077195,HAYYBYPASCDWEQ-UHFFFAOYSA-N,"trka-positive, trkb-positive, trkc-positive ros1-positive or alk-positive non-small cell lung cancer",,,,,,,
2618,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",Treatment of tuberculosis.,02/04/2011,Designated,Q15427841,FNDDDNOJWPQCBZ-ZDUSSCGKSA-N,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
2619,"N1,N14,-diethyl-3,12,-dihydroxyhomospermine",Treatment of pancreatic cancer,08/07/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2621,N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody,Treatment of multiple myeloma,02/27/2008,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2622,nabumetone,Treatment of pediatric juvenile rheumatoid arthritis,05/05/2008,Designated,Q425207,,pediatric juvenile rheumatoid arthritis,,,,,,,
2623,Nafarelin acetate,Treatment of central precocious puberty.,07/20/1988,Designated/Approved,Q27270261,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
2625,naltrexone,Treatment of postherpetic neuralgia,02/23/2015,Designated,Q409587,,postherpetic neuralgia,,,,D051474,,,
2626,naltrexone,Treatment of Crohn's disease in pediatric patients,01/19/2010,Designated,Q409587,,crohn's disease in pediatric patients,,,,,,,
2627,naltrexone,Treatment of autoimmune hepatitis,01/13/2015,Designated,Q409587,,autoimmune hepatitis,http://purl.obolibrary.org/obo/DOID_2048,,http://www.orpha.net/ORDO/Orphanet_2137,D019693,Q786844,,Q786844
2629,naltrexone/clonidine combination,Treatment of postherpetic neuralgia,04/14/2014,Designated,,,postherpetic neuralgia,,,,D051474,,,
2630,nano-diamino-tetraiodothyroacetic acid,Treatment of glioblastoma multiforme (GBM),07/09/2015,Designated,,,glioblastoma multiforme (gbm),,,,,,,
2631,nano-diamino-tetraiodothyroacetic acid,Treatment of pancreatic cancer,10/28/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2632,Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.,Treatment of ovarian cancer.,05/23/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2633,NanoDTPA(tm),"Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium",06/17/2011,Designated,,,"known or suspected cases of internal contamination with plutonium, americium, or curium",,,,,,,
2634,nanoparticles containing Zoledronic acid,Treatment of Glioma,11/29/2016,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2635,nanoparticulate paclitaxel,Treatment of ovarian cancer,10/06/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2636,napabucasin,Treatment of gastric cancer including gastroesophageal junction cancer.,06/20/2016,Designated,Q27294876,,gastric cancer including gastroesophageal junction cancer,,,,,,,
2637,napabucasin,Treatment of pancreatic cancer.,10/25/2016,Designated,Q27294876,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2638,naproxcinod,Treatment of Duchenne muscular dystrophy.,03/16/2015,Designated,Q3335996,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2639,Natural human lymphoblastoid interferon-alpha,Treatment of papillomavirus warts in the oral cavity of HIV positive patients.,08/10/2000,Designated,,,papillomavirus warts in the oral cavity of hiv positive patients,,,,,,,
2640,Natural human lymphoblastoid interferon-alpha,Treatment of Behcet's disease,01/18/2000,Designated,,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
2641,natural human lymphoblastoid interferon-alpha,Treatment of polycythemia vera,11/18/2002,Designated,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
2642,NDX-peptides,Treatment of amyotrophic lateral sclerosis,12/14/2010,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2643,Nebacumab,Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,10/01/1986,Designated,Q6984546,,patients with gram-negative bacteremia which has progressed to endotoxin shock,,,,,,,
2644,necitumumab,Treatment of squamous non-small cell lung cancer,11/20/2015,Designated/Approved,Q6985503,,squamous non-small cell lung cancer,,,,,,,
2645,nelarabine,Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,08/10/2004,Designated/Approved,Q1216264,,acute lymphoblastic leukemia and lymphoblastic lymphoma,,,,,,,
2646,nelarabine,Treatment of chronic lymphocytic leukemia.,09/02/1999,Designated,Q1216264,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2647,nelfinavir,Treatment of multiple myeloma,02/14/2017,Designated,Q423366,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2648,neostigmine,Treatment of acute colonic pseudo-obstruction,03/18/2013,Designated,Q410546,,acute colonic pseudo-obstruction,,,,,,,
2649,neostigmine methylsulfate,Treatment of Myasthenia Gravis,02/17/2012,Designated,Q27107519,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
2650,neridronate,"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)",03/25/2013,Designated,,,"complex regional pain syndrome (crps-1, crps-ii, crps-nos)",,,,,,,
2651,Neurotrophin-1,Treatment of motor neuron disease/amyotrophic lateral sclerosis.,09/13/1994,Designated,,,motor neuron disease/amyotrophic lateral sclerosis,,,,,,,
2652,Neutrophil-endothelial interaction inhibitor,Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.,12/22/1993,Designated,,,post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension,,,,,,,
2653,nevirapine,Prevention of HIV infection in pediatric patients under the age of 16 years,11/25/2009,Designated,Q263713,,hiv infection in pediatric patients under the age of 16 years,,,,,,,
2654,NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit),Treatment of chronic myelogenous leukemia (CML),11/09/2016,Designated,,,chronic myelogenous leukemia (cml),,,,,,,
2655,nicotinamide riboside,"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)",01/25/2017,Designated,,,"mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (melas)",,,,,,,
2656,Nifedipine,Treatment of interstitial cystitis.,06/13/1991,Designated,Q39111,,interstitial cystitis,http://purl.obolibrary.org/obo/DOID_13949,,http://www.orpha.net/ORDO/Orphanet_37202,D018856,Q1671412,,Q27675337
2657,nifurtimox,Treatment of Chagas disease,12/31/2013,Designated,Q411582,,chagas disease,http://purl.obolibrary.org/obo/DOID_12140,,http://www.orpha.net/ORDO/Orphanet_3386,D014355,Q649558,,Q649558
2658,nifurtimox,Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi,08/05/2010,Designated,Q411582,,chagas disease (american typanosomiasis)caused by t. cruzi,,,,,,,
2659,Nikkomycin Z,Treatment of coccidioidomycosis,02/14/2006,Designated,,,coccidioidomycosis,http://purl.obolibrary.org/obo/DOID_13450,,http://www.orpha.net/ORDO/Orphanet_228123,D003047,Q868137,,Q868137
2660,nilotinib,Treatment of chronic myelogenous leukemia,04/27/2006,Designated/Approved,Q412327,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2661,nilotinib,Treatment of gastrointestinal stromal tumors.,03/20/2007,Designated/Withdrawn,Q412327,,gastrointestinal stromal tumors,,http://purl.obolibrary.org/obo/HP_0100723,,D046152,,,Q1495661
2662,nimodipine,Treatment of subarachnoid hemorrhage.,09/16/2011,Designated/Approved,Q421429,,subarachnoid hemorrhage,,http://purl.obolibrary.org/obo/HP_0002138,,D013345,,,Q693442
2663,Nimotuzumab,Treatment of glioma,11/17/2004,Designated,Q3877039,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2664,nimotuzumab,Treatment of pancreatic cancer.,09/08/2015,Designated,Q3877039,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2665,Nine amino acid polypeptide derived from proteinase 3,Treatment of myelodysplastic syndromes requiring therapy,09/03/2004,Designated,,,myelodysplastic syndromes requiring therapy,,,,,,,
2666,Nine amino acid polypeptide derived from proteinase 3,Treatment of chronic myelogenous leukemia.,09/03/2004,Designated,,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2667,Nine amino acid polypeptide derived from proteinase 3,Treatment of acute myelogenous leukemia,09/03/2004,Designated,,,acute myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2668,nintedanib,Treatment of patients with idiopathic pulmonary fibrosis.,06/29/2011,Designated/Approved,Q15149723,,patients with idiopathic pulmonary fibrosis,,,,,,,
2669,nintedanib,Treatment of systemic sclerosis (including the associated interstitial lung disease).,07/06/2016,Designated,Q15149723,,systemic sclerosis (including the associated interstitial lung disease),,,,,,,
2670,Nintedanib,Treatment of mesothelioma,12/12/2016,Designated,Q15149723,,mesothelioma,,,,D008654,,,Q18555143
2671,niprisan,Treatment of sickle cell disease,08/15/2003,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2672,niraparib,Treatment of ovarian cancer,04/30/2010,Designated,Q27087937,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2673,nitazoxanide,Treatment of intestinal giardiasis,02/14/2002,Designated/Approved,Q2943789,,intestinal giardiasis,,,,,,,
2674,nitazoxanide,Treatment for intestinal amebiasis,10/23/2001,Designated,Q2943789,,intestinal amebiasis,,,,D004404,,,Q15460254
2675,Nitazoxanide,Treatment of cryptosporidiosis.,12/12/1996,Designated/Approved,Q2943789,,cryptosporidiosis,http://purl.obolibrary.org/obo/DOID_1733,,http://www.orpha.net/ORDO/Orphanet_1549,D003457,Q1359898,,Q1359898
2676,Nitisinone,Treatment of alkaptonuria,10/19/2001,Designated,Q3877355,,alkaptonuria,http://purl.obolibrary.org/obo/DOID_9270,,http://www.orpha.net/ORDO/Orphanet_56,D000474,Q651680,Q651680,Q651680
2677,Nitisinone,Treatment of tyrosinemia type 1.,05/16/1995,Designated/Approved,Q3877355,,tyrosinemia type 1,,,http://www.orpha.net/ORDO/Orphanet_882,D020176,,,Q7861692
2679,Nitric oxide,Treatment of acute respiratory distress syndrome in adults.,07/10/1995,Designated,Q207843,,acute respiratory distress syndrome in adults,,,,,,,
2680,Nitric oxide,Diagnosis of sarcoidosis,02/16/2005,Designated,Q207843,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
2681,nitric oxide,Treatment of cystic fibrosis,09/23/2014,Designated,Q207843,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2682,nitric oxide,Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn,01/25/2017,Designated,Q207843,,pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn,,,,,,,
2683,Nitric oxide,Treatment of cystic fibrosis,09/11/2013,Designated,Q207843,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2685,nitric oxide,Treatment of idiopathic pulmonary fibrosis,01/31/2017,Designated,Q207843,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2686,nitric oxide,Treatment of pulmonary arterial hypertension,12/28/2011,Designated,Q207843,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
2687,Nitric oxide,Treatment of persistent pulmonary hypertension in the newborn.,06/22/1993,Designated/Approved,Q207843,,persistent pulmonary hypertension in the newborn,,,,,,,
2688,nitric oxide,Treatment of persistent pulmonary hypertension in newborns,06/18/2012,Designated,Q207843,,persistent pulmonary hypertension in newborns,,,,,,,
2689,Nitroprusside,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,02/21/2001,Designated,Q420031,,prevention of cerebral vasospasm following subarachnoid hemorrhage,,,,,,,
2690,nivolumab,Treatment of esophageal cancer,08/22/2016,Designated,Q7041828,,esophageal cancer,http://purl.obolibrary.org/obo/DOID_5041,,,D004938,Q372701,,Q372701
2691,nivolumab,Treatment of gastric cancer and gastro-esophageal junction cancer.,12/20/2016,Designated,Q7041828,,gastric cancer and gastro-esophageal junction cancer,,,,,,,
2692,nivolumab,Treatment of Hodgkin lymphoma,08/07/2014,Designated/Approved,Q7041828,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
2693,nivolumab,Treatment of small cell lung cancer.,09/15/2015,Designated,Q7041828,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
2694,nivolumab,Treatment of hepatocellular carcinoma.,09/02/2015,Designated,Q7041828,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2695,nivolumab,Treatment of glioblastoma,08/27/2015,Designated,Q7041828,,glioblastoma,,http://purl.obolibrary.org/obo/HP_0100843,http://www.orpha.net/ORDO/Orphanet_360,D005909,,,Q18555280
2696,nivolumab,Treatment of Stage IIb to IV melanoma,01/23/2013,Designated/Approved,Q7041828,,stage iib to iv melanoma,,,,,,,
2697,Nivolumab and Ipilimumab,Treatment of gastric cancer and gastric-esophageal junction cancer.,12/20/2016,Designated,,,gastric cancer and gastric-esophageal junction cancer,,,,,,,
2698,nolatrexed,Treatment of hepatocellular carcinoma,10/18/2001,Designated/Withdrawn,Q7048249,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2699,non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I,Treatment of hypoparathyroidism,12/15/2014,Designated,,,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
2700,"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene",Treatment of x-linked myotubular myopathy,12/03/2014,Designated,,,x-linked myotubular myopathy,,,,D020914,,,Q18556238
2701,Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene,Treatment of Pompe disease,01/11/2017,Designated,,,pompe disease,,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,,,Q1365789
2702,"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene",Treatment of Crigler Najjar syndrome.,05/24/2016,Designated,,,crigler najjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,,D003414,Q1140000,,Q1140000
2703,non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase,Treatment of Mucopolysaccharidosis Type II,12/08/2015,Designated,,,mucopolysaccharidosis type ii,,,http://www.orpha.net/ORDO/Orphanet_580,D016532,,,Q1529983
2704,non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein,Treatment of retinitis pigmentosa,10/20/2014,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
2705,NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)],Treatment of leakage from the surgical site following penetrating keratoplasty,12/31/2013,Designated,,,leakage from the surgical site following penetrating keratoplasty,,,,,,,
2706,NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)],Treatment of dermal injury due to nuclear/radiation incident,01/31/2014,Designated,,,dermal injury due to nuclear/radiation incident,,,,,,,
2707,noscapine,Treatment of amyotrophic lateral sclerosis.,12/29/2015,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2708,Novel Acting Thrombolytic (NAT),Treatment of peripheral arterial occlusion (PAO),01/26/2001,Designated/Withdrawn,,,peripheral arterial occlusion (pao),,,,,,,
2709,Nucleic acid aptamer binding to tumor cell nucleolin,Treatment of pancreatic cancer,08/17/2004,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2710,Nucleic acid aptamer binding to tumor cell nucleolin,Treatment of acute myeloid leukemia,09/10/2009,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2711,Nucleic acid aptamer binding to tumor cell nucleon,Treatment of renal cell carcinoma,07/28/2005,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2712,nusinersen,Treatment of spinal muscular atrophy,04/18/2011,Designated/Approved,Q25105466,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
2713,O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride,Treatment of Duchenne Muscular Dystrophy,01/15/2013,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2714,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate",Treatment of acute myeloid leukemia,03/16/2012,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2715,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate",Treatment of multiple myeloma,12/13/2013,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2716,Obatoclax mesylate,Treatment of myelofibrosis,12/01/2006,Designated/Withdrawn,Q27256844,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
2717,Obatoclax mesylate,Treatment of myelodysplastic syndrome,11/06/2006,Designated/Withdrawn,Q27256844,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
2718,obatoclax mesylate,Treatment of chronic lymphocytic leukemia,10/08/2004,Designated/Withdrawn,Q27256844,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2719,obeticholic acid,Treatment of primary biliary cirrhosis,04/09/2008,Designated/Approved,Q15708271,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
2720,obiltoxaximab,Treatment of exposure to B. anthracis spores,06/09/2006,Designated/Approved,Q20707498,,exposure to b. anthracis spores,,,,,,,
2721,obinutuzumab,Treatment of chronic lymphocytic leukemia,02/17/2012,Designated/Approved,Q389496,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2722,obinutuzumab,Treatment of splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Q389496,,splenic marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050750,,http://www.orpha.net/ORDO/Orphanet_86854,,Q3832900,,
2723,obinutuzumab,Treatment of diffuse large B cell lymphoma,02/17/2012,Designated,Q389496,,diffuse large b cell lymphoma,,,,,,,
2724,obinutuzumab,Treatment of follicular lymphoma,04/15/2015,Designated/Approved,Q389496,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
2725,oblimersen,Treatment of chronic lymphocytic leukemia,08/28/2001,Designated,Q27269650,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2726,oblimersen,Treatment of multiple myeloma,08/28/2001,Designated,Q27269650,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2727,oblimersen,Treatment of acute myelocytic leukemia,08/28/2001,Designated,Q27269650,,acute myelocytic leukemia,,http://purl.obolibrary.org/obo/HP_0004808,,D015470,,,Q264118
2728,oblimersen,"Treatment of advanced malignant melanoma (Stages II,III, IV).",07/31/2000,Designated,Q27269650,,"advanced malignant melanoma (stages ii,iii, iv)",,,,,,,
2729,octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate,Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis,05/16/2002,Designated/Withdrawn,,,psuedomonas aeruginosa infections in patients with cystic fibrosis,,,,,,,
2730,Octreotide,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,08/24/1998,Designated/Approved,Q27088142,,severe diarrhea and flushing associated with malignant carcinoid tumors,,,,,,,
2731,octreotide,Treatment of neuroendocrine tumors,08/05/2010,Designated,Q27088142,,neuroendocrine tumors,,,,D018358,,,Q1981276
2732,Octreotide,Treatment of acromegaly.,08/24/1998,Designated/Approved,Q27088142,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
2733,Octreotide,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,08/24/1998,Designated/Approved,Q27088142,,diarrhea associated with vasoactive intestinal peptide tumors (vipoma),,,,,,,
2735,octreotide acetate subcutaneous implant,Treatment of acromegaly,12/07/2009,Designated,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
2736,ofatumumab,Treatment of chronic lymphocytic leukemia,03/10/2009,Designated/Approved,Q410656,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2737,Ofloxacin,Treatment of bacterial corneal ulcers.,04/18/1991,Designated/Approved,Q411447,,bacterial corneal ulcers,,,,,,,
2738,oglufanide disodium,Treatment of ovarian cancer,09/24/2001,Designated,Q27287036,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2739,olaparib,Treatment of ovarian cancer,10/16/2013,Designated/Approved,Q7083106,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2740,olaptesed pegol,Treatment of glioblastoma in conjunction with radiotherapy.,08/19/2014,Designated,,,glioblastoma in conjunction with radiotherapy,,,,,,,
2741,olaratumab,Treatment of soft tissue sarcoma,10/09/2014,Designated/Approved,Q7083108,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
2742,oleylphosphocholine,Treatment of leishmaniasis,10/25/2013,Designated,,SLVOKEOPLJCHCQ-SEYXRHQNSA-O,leishmaniasis,http://purl.obolibrary.org/obo/DOID_9065,,http://www.orpha.net/ORDO/Orphanet_507,D007896,Q331283,Q2046113,Q331283
2743,oligodendrocyte progenitor cells,Treatment of acute spinal cord injury,02/02/2016,Designated,,,acute spinal cord injury,,,,,,,
2744,oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH),Treatment of amyotrophic lateral sclerosis,02/27/2014,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2745,olipudase alfa,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),08/03/2000,Designated,,,acid sphingomyelinase deficiency (niemann-pick disease),,,,,,,
2746,omacetaine mepesuccinate,Treatment of myelodysplastic syndromes,01/12/2009,Designated,,,myelodysplastic syndromes,,,,D009190,,,Q954625
2747,omacetaxine mepesuccinate,Treatment of chronic myelogenous leukemia,03/10/2006,Designated/Approved,Q7089373,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2748,Ombitasvir/Paritaprevir/Ritonavir,Treatment of pediatric patients with chronic hepatitis C virus infection,02/24/2016,Designated,,,pediatric patients with chronic hepatitis c virus infection,,,,,,,
2749,ombitasvir/paritaprevir/ritonavir and dasabuvir,Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age),07/16/2015,Designated,,,pediatric patients with hepatitis c virus infection (0 through 16 years of age),,,,,,,
2750,"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride",Treatment of soft tissue sarcoma,03/03/2011,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
2751,Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration,Prevention of organ graft rejection.,11/22/1995,Designated,,,organ graft rejection,,,,,,,
2752,Omega-3 (n-3) polyunsaturated fatty acids,Treatment of IgA nephropathy.,05/04/2000,Designated,,,iga nephropathy,http://purl.obolibrary.org/obo/DOID_2986,http://purl.obolibrary.org/obo/HP_0000794,,D005922,Q1146454,,Q1146454
2753,Omegaven emulsion,Treatment of parenteral nutrition-associated liver disease,02/27/2008,Designated,,,parenteral nutrition-associated liver disease,,,,,,,
2754,omeprazole-lansoprazole with buffer,Treatment of esophageal ulcers,02/10/2015,Designated,,,esophageal ulcers,,,,,,,
2755,omigapil,Treatment of congenital muscular dystrophy.,06/24/2008,Designated,Q7090184,,congenital muscular dystrophy,http://purl.obolibrary.org/obo/DOID_0050557,http://purl.obolibrary.org/obo/HP_0003741,http://www.orpha.net/ORDO/Orphanet_122961,,Q1321884,,
2756,onartuzumab,Treatment of gastric cancer including gastroesophageal cancer,01/23/2013,Designated/Withdrawn,Q7091711,,gastric cancer including gastroesophageal cancer,,,,,,,
2757,onartuzumab (MetMab),Treatment of hepatocellular carcinoma,12/16/2013,Designated/Withdrawn,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2758,Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102),Treatment of malignant mesothelioma,12/22/2014,Designated,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
2759,oncophage,Treatment of glioma,04/14/2009,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2760,ondansetron inhalation powder,Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .,10/14/2015,Designated,,,chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) ,,,,,,,
2761,opioid growth factor,Treatment of liver and intrahepatic bile duct cancer,04/16/2013,Designated,,,liver and intrahepatic bile duct cancer,,,,,,,
2762,opium tincture,Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,12/02/2011,Designated,,,chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,,,,,,,
2763,Oprelvekin,Prevention of severe chemotherapy-induced thrombocytopenia.,12/17/1996,Designated/Approved,Q7098691,,severe chemotherapy-induced thrombocytopenia,,,,,,,
2764,oprozomib,Treatment of Waldenstrom's macroglobulinemia,08/25/2014,Designated,Q27088209,,waldenstrom's macroglobulinemia,,,,D008258,,,Q4118092
2765,oprozomib,Treatment of multiple myeloma,10/28/2014,Designated,Q27088209,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2766,optically pure phenylalanine derivative,Treatment of narcolepsy,08/20/2012,Designated,,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
2767,oral potent and selective antagonist,Treatment of patients with chondrosarcoma.,02/18/2011,Designated/Withdrawn,,,patients with chondrosarcoma,,,,,,,
2768,oral testosterone,Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.,06/02/2016,Designated,,,constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age,,,,,,,
2769,oral unfractionated heparin,Treatment of sickle cell disease,01/29/2004,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2770,Orgotein for injection,"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase.",12/22/1994,Designated/Withdrawn,,,"familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase",,,,,,,
2771,osilodrostat,Treatment of Cushing's disease,09/13/2013,Designated,Q27088216,,cushing's disease,,,,,,,
2772,osimertinib,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,09/04/2014,Designated/Approved,Q21506464,,epidermal growth factor receptor mutation-positive non-small cell lung cancer,,,,,,,
2773,otelixizumab,Treatment of new-onset type I diabetes mellitus,02/06/2006,Designated,Q7108506,,new-onset type i diabetes mellitus,,,,,,,
2775,Oxaliplatin,Treatment of ovarian cancer.,10/06/1992,Designated,Q422327,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2776,oxaloacetate,Treatment of gliomas,07/24/2012,Designated,Q27101912,KHPXUQMNIQBQEV-UHFFFAOYSA-M,gliomas,,,,D005910,,,Q18556612
2777,Oxaloacetic acid,Treatment of amyotrophic lateral sclerosis,11/18/2015,Designated,Q408658,KHPXUQMNIQBQEV-UHFFFAOYSA-N,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2778,Oxalobacter formigenes,Treatment of primary hyperoxaluria,03/29/2006,Designated,,,primary hyperoxaluria,http://purl.obolibrary.org/obo/DOID_2977,,http://www.orpha.net/ORDO/Orphanet_416,D006960,Q7243137,,Q7243137
2780,Oxandrolone,Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.,03/18/1994,Designated/Withdrawn,Q420859,,moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition,,,,,,,
2781,Oxandrolone,Treatment of short stature associated with Turner's syndrome.,07/05/1990,Designated/Withdrawn,Q420859,,short stature associated with turner's syndrome,,,,,,,
2782,Oxandrolone,Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.,04/22/1997,Designated,Q420859,,patients with duchenne's muscular dystrophy and becker's muscular dystrophy,,,,,,,
2783,Oxandrolone,Treatment of constitutional delay of growth and puberty.,10/05/1990,Designated/Withdrawn,Q420859,,constitutional delay of growth and puberty,,,,,,,
2784,oxfendazole,Treatment of cysticercosis (including neurocysticercosis),07/14/2014,Designated,Q7115199,,cysticercosis (including neurocysticercosis),,,,,,,
2785,oxybate,Treatment of narcolepsy.,11/07/1994,Designated/Approved,,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
2787,Oxypurinol,Treatment of hyperuricemia in patients intolerant to allopurinol.,11/09/1998,Designated,Q410588,,hyperuricemia in patients intolerant to allopurinol,,,,,,,
2788,oxytocin,Treatment of Prader-Willi syndrome,11/24/2014,Designated,Q169960,,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
2789,ozanimod,Treatment of pediatric (0 through 16 years of age) ulcerative colitis,12/29/2015,Designated,Q21098986,,pediatric (0 through 16 years of age) ulcerative colitis,,,,,,,
2790,"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt",Treatment of cystic fibrosis.,10/27/1998,Designated/Withdrawn,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2793,p38 mitogen-activated kinase inhibitor,"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations",05/27/2014,Designated,,,"dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin a/c gene mutations",,,,,,,
2794,Paclitaxel,Treatment of AIDS-related Kaposi's sarcoma.,04/15/1997,Designated,Q423762,,aids-related kaposi's sarcoma,,,,,,,
2795,paclitaxel,Treatment of pancreatic cancer,05/01/2009,Designated,Q423762,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2796,paclitaxel,Treatment of non-superficial urothelial cancer,12/22/2004,Designated/Withdrawn,Q423762,,non-superficial urothelial cancer,,,,,,,
2797,Paclitaxel,Treatment of AIDS-related Kaposi's sarcoma.,03/25/1997,Designated/Approved,Q423762,,aids-related kaposi's sarcoma,,,,,,,
2798,paclitaxel aqueous gel,Treatment of esophageal cancer,02/01/2008,Designated,,,esophageal cancer,http://purl.obolibrary.org/obo/DOID_5041,,,D004938,Q372701,,Q372701
2799,paclitaxel aqueous gel,Treatment of brain cancer.,12/23/2008,Designated,,,brain cancer,http://purl.obolibrary.org/obo/DOID_1319,,,D001932,Q18554460,,Q18554460
2800,paclitaxel nanoparticles,Treatment of pancreatic cancer,01/02/2013,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2801,paclitaxel poliglumex,Treatment of glioblastoma multiforme,09/20/2012,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
2802,paclitaxel protein-bound particles,Treatment of pancreatic cancer.,09/03/2009,Designated/Approved,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2803,Paclitaxel protein-bound particles for injection suspension,Treatment of stage IIb to IV melanoma,10/01/2009,Designated/Withdrawn,,,stage iib to iv melanoma,,,,,,,
2804,"paclitaxel, micellar",Treatment of ovarian cancer,04/03/2009,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2806,pacritinib,"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF",03/13/2008,Designated,Q3888693,,"primary myelofibrosis (mf), post-polycythemia vera mf, and post-essential thrombocythemia mf",,,,,,,
2807,pafuramidine maleate,Treatment of pneumocystis jiroveci pneumonia,11/17/2006,Designated,Q27281850,,pneumocystis jiroveci pneumonia,,,,,,,
2808,Pafuramidine maleate,Treatment of malaria,05/14/2007,Designated,Q27281850,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
2809,Pafuramidine maleate,Treatment of human African trypanosomiasis (sleeping sickness),08/31/2007,Designated,Q27281850,,human african trypanosomiasis (sleeping sickness),,,,,,,
2810,Palifosfamide,Treatment of soft tissue sarcomas,05/05/2008,Designated/Withdrawn,Q27149611,,soft tissue sarcomas,,http://purl.obolibrary.org/obo/HP_0030448,,D012509,,,Q18975788
2811,palovarotene,Treatment of fibrodysplasia ossificans progressiva,07/21/2014,Designated,Q15708269,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
2812,Panobinostat,Treatment of cutaneous T-cell lymphoma,09/26/2007,Designated/Withdrawn,Q7131441,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
2813,panobinostat,Treatment of multiple myeloma,08/20/2012,Designated/Approved,Q7131441,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2814,panobinostat,Treatment of Hodgkin's lymphoma,09/18/2009,Designated/Withdrawn,Q7131441,,hodgkin's lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
2815,pantothenate phosphate,Treatment of pantothenate kinase associated neurodegeneration (PKAN).,05/04/2015,Designated,,ZETKRGKBCJQXEN-FJXQXJEOSA-N,pantothenate kinase associated neurodegeneration (pkan),,,,,,,
2816,"Papain, trypsin, and chymotrypsin",Treatment of multiple myeloma.,12/21/1998,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2817,Papaverine topical gel,Treatment of sexual dysfunction in spinal cord injury patients.,02/06/1992,Designated/Withdrawn,,,sexual dysfunction in spinal cord injury patients,,,,,,,
2818,paquinimod,Treatment of systemic sclerosis,01/17/2014,Designated,Q27279838,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
2819,Para-toluenesulfonamide,Treatment of adenoid cystic carcinoma,01/30/2017,Designated,Q23013959,LMYRWZFENFIFIT-UHFFFAOYSA-N,adenoid cystic carcinoma,,,,D003528,,,Q18556510
2820,parathyroid hormone,Treatment of hypoparathyroidism,08/31/2007,Designated/Approved,Q20817243,,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
2821,paricalcitol,Treatment of pediatric hyperparathyroidism,10/27/2015,Designated/Approved,Q155746,,pediatric hyperparathyroidism,,,,,,,
2822,paromomycin,Treatment of cutaneous leishmaniasis (Old World and New World),02/11/2015,Designated,Q415625,,cutaneous leishmaniasis (old world and new world),,,,,,,
2823,paromomycin sulfate/gentamicin sulfate,Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World),01/18/2008,Designated,,,all uncomplicated cutaneous leishmaniasis (both new world and old world),,,,,,,
2824,Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2,Treatment of pulmonary arterial hypertension,10/19/2016,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
2825,Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine,Prevention of transient aplastic crisis in patients with sickle cell anemia.,05/07/1999,Designated,,,transient aplastic crisis in patients with sickle cell anemia,,,,,,,
2826,pasireotide,Treatment of acromegaly,08/25/2009,Designated/Approved,Q3896970,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
2827,pasireotide,Treatment of Cushing's disease,07/24/2009,Designated/Approved,Q3896970,,cushing's disease,,,,,,,
2828,patupilone,Treatment of primary pertitoneal cancer.,02/02/2010,Designated/Withdrawn,Q27093987,,primary pertitoneal cancer,,,,,,,
2829,patupilone,Treatment of primary fallopian tube cancer.,02/02/2010,Designated/Withdrawn,Q27093987,,primary fallopian tube cancer,,,,,,,
2830,Patupilone,Treatment of ovarian cancer.,10/04/2005,Designated/Withdrawn,Q27093987,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2831,pazopanib,Treatment of ovarian cancer.,05/06/2013,Designated,Q7157043,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2832,pazopanib,Treatment of soft tissue sarcomas,10/20/2009,Designated/Approved,Q7157043,,soft tissue sarcomas,,http://purl.obolibrary.org/obo/HP_0030448,,D012509,,,Q18975788
2833,"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)",Treatment of angiosarcoma,04/02/2015,Designated,,,angiosarcoma,http://purl.obolibrary.org/obo/DOID_0001816,http://purl.obolibrary.org/obo/HP_0200058,http://www.orpha.net/ORDO/Orphanet_263413,D006394,Q2619091,,Q2619091
2835,PEG-interleukin-2,Treatment of primary immunodeficiencies associated with T-cell defects.,02/01/1990,Designated,,,primary immunodeficiencies associated with t-cell defects,,,,,,,
2837,pegargiminase,Treatment of mesothelioma.,07/21/2014,Designated,,,mesothelioma,,,,D008654,,,Q18555143
2838,Pegaspargase,Treatment of acute lymphocytic leukemia.,10/20/1989,Designated/Approved,Q7160547,,acute lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2839,Pegfilgrastim,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,11/20/2013,Designated/Approved,Q1592932,,subjects at risk of developing myelosuppression after a radiological or nuclear incident,,,,,,,
2840,Peginterferon alfa-2a,Treatment of renal cell carcinoma.,07/13/1998,Designated,Q420056,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2841,Peginterferon alfa-2a,Treatment of chronic myelogenous leukemia.,09/30/1999,Designated,Q420056,,chronic myelogenous leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2842,peginterferon alfa-2b,Treatment of malignant melanoma stages IIb through IV.,04/09/2008,Designated/Approved,Q7160789,,malignant melanoma stages iib through iv,,,,,,,
2844,pegsitacase,Treatment of Lesch-Nyhan syndrome.,12/03/2009,Designated,,,lesch-nyhan syndrome,http://purl.obolibrary.org/obo/DOID_1919,,http://www.orpha.net/ORDO/Orphanet_122476,D007926,Q727436,,Q727436
2845,Pegvisomant,Treatment of acromegaly.,06/24/1997,Designated/Approved,Q409697,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
2846,Pegylated arginine deiminase,Treatment of invasive malignant melanoma.,04/12/1999,Designated,,,invasive malignant melanoma,,,,,,,
2847,pegylated arginine deiminase,Treatment of hepatocellular carcinoma,03/26/1999,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2848,pegylated carboxyhemoglobin,Treatment of acute painful sickling crises in patients with sickle cell disease,10/21/2010,Designated,,,acute painful sickling crises in patients with sickle cell disease,,,,,,,
2849,pegylated carboxyhemoglobin bovine,Treatment of the comorbidities associated with Sickle Cell Disease,01/15/2015,Designated,,,the comorbidities associated with sickle cell disease,,,,,,,
2850,pegylated granulocyte colony stimulating factor,Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident,04/30/2014,Designated,,,patients at risk of developing myelosuppression following a radiological or nuclear incident,,,,,,,
2851,pegylated human recombinant arginase I,Treatment of arginase I deficiency (hyperargininemia).,03/16/2015,Designated,,,arginase i deficiency (hyperargininemia),,,,,,,
2852,pegylated proline interferon alpha-2b,Treatment of myelofibrosis,04/10/2014,Designated,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
2853,pegylated proline interferon alpha-2b,Treatment of essential thrombocythemia,04/11/2014,Designated,,,essential thrombocythemia,http://purl.obolibrary.org/obo/DOID_2224,,http://www.orpha.net/ORDO/Orphanet_3318,D013920,Q18555037,Q18555037,Q18555037
2854,pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b,Treatment of polycythemia vera,04/02/2012,Designated,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
2855,PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody,Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,10/25/2013,Designated,,,cystic fibrosis patients with pseudomonas aeruginosa lung infections,,,,,,,
2856,PEGylated recombinant human hyaluronidase PH20,Treatment of pancreatic cancer,10/01/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2857,Pegylated recombinant human interleukin-10,Treatment of pancreatic cancer,07/18/2016,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2859,pelareorep,Treatment of gastric cancer,05/04/2015,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
2860,pelareorep,Treatment of pancreatic cancer,02/11/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2861,pelareorep,Treatment of fallopian tube cancer,02/24/2015,Designated,,,fallopian tube cancer,http://purl.obolibrary.org/obo/DOID_1964,,,D005185,Q18968203,,Q18968203
2862,pelareorep,Treatment of malignant glioma,04/15/2015,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
2863,pelareorep,Treatment of ovarian cancer,02/10/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2864,pelareorep,Treatment of primary peritoneal cancer,02/24/2015,Designated,,,primary peritoneal cancer,,,,,,,
2865,Peldesine,Treatment of cutaneous T-cell lymphoma.,10/05/1993,Designated,Q27093544,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
2866,pembrolizumab,Treatment of primary mediastinal B cell lymphoma.,01/14/2016,Designated,Q13896859,,primary mediastinal b cell lymphoma,,,,,,,
2867,pembrolizumab,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",06/16/2015,Designated,Q13896859,,"gastric cancer, including gastroesophageal junction adenocarcinoma",,,,,,,
2868,pembrolizumab,Treatment of Stage IIB through IV malignant melanoma,11/19/2012,Designated/Approved,Q13896859,,stage iib through iv malignant melanoma,,,,,,,
2869,pembrolizumab,Treatment of nasopharyngeal carcinoma,10/11/2016,Designated,Q13896859,,nasopharyngeal carcinoma,http://purl.obolibrary.org/obo/DOID_9261,,http://www.orpha.net/ORDO/Orphanet_150,,Q1693598,Q1693598,
2870,pembrolizumab,Treatment of multiple myeloma.,02/17/2016,Designated,Q13896859,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2871,pembrolizumab,Treatment of Hodgkin lymphoma.,12/30/2015,Designated,Q13896859,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
2872,pembrolizumab,Treatment of Merkel cell carcinoma,12/28/2016,Designated,Q13896859,,merkel cell carcinoma,http://purl.obolibrary.org/obo/DOID_3965,,http://www.orpha.net/ORDO/Orphanet_79140,D015266,Q1711744,,
2873,pemetrexed disodium,Treatment of malignant pleural mesothelioma,08/28/2001,Designated/Approved,,,malignant pleural mesothelioma,http://purl.obolibrary.org/obo/DOID_7474,,,,Q18557602,,
2875,pentamidine,Treatment of liver and intrahepatic bile duct cancer,08/12/2013,Designated/Withdrawn,Q416206,,liver and intrahepatic bile duct cancer,,,,,,,
2876,pentamidine,Treatment of pancreatic cancer.,09/13/2010,Designated/Withdrawn,Q416206,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2877,pentamidine,Treatment of ovarian cancer,08/12/2013,Designated/Withdrawn,Q416206,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2878,Pentamidine isethionate,Treatment of Pneumocystis carinii pneumonia.,02/28/1984,Designated/Approved,Q26841221,,pneumocystis carinii pneumonia,http://purl.obolibrary.org/obo/DOID_11339,,,D011020,Q7205993,,Q7205993
2879,Pentamidine isethionate,Treatment of Pneumocystis carinii pneumonia.,10/29/1984,Designated,Q26841221,,pneumocystis carinii pneumonia,http://purl.obolibrary.org/obo/DOID_11339,,,D011020,Q7205993,,Q7205993
2880,Pentamidine isethionate,Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.,01/12/1988,Designated/Approved,Q26841221,,pneumocystis carinii pneumonia in patients at high risk of developing this disease,,,,,,,
2881,Pentamidine isethionate (inhalation),Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease,10/05/1987,Designated,,,pneumocystis carinii pneumonia in patients at high risk of developing this disease,,,,,,,
2882,pentapeptide with sequence Ac-VSRRR-NH2,Treatment of intracerebral hemorrhage,01/13/2015,Designated,,,intracerebral hemorrhage,,http://purl.obolibrary.org/obo/HP_0001342,,D002543,,,Q6058597
2883,"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit",Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.,07/18/1997,Designated,,,neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions,,,,,,,
2885,pentetate trisodium,"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.",04/12/2004,Designated,,,"patients with known or suspected internal contamination with plutonium, americium, or curium",,,,,,,
2886,pentetrazol,Treatment of idiopathic hypersomnia,09/09/2015,Designated,Q412391,,idiopathic hypersomnia,,,http://www.orpha.net/ORDO/Orphanet_33208,D020177,,Q2730080,Q2730080
2887,Pentosan polysulfate sodium,Treatment of interstitial cystitis.,08/07/1985,Designated/Approved,,,interstitial cystitis,http://purl.obolibrary.org/obo/DOID_13949,,http://www.orpha.net/ORDO/Orphanet_37202,D018856,Q1671412,,Q27675337
2888,pentosan polysulfate sodium,Treatment of sickle cell disease.,11/21/2008,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2889,pentosan polysulfate sodium,Treatment of sickle cell disease.,09/16/2011,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
2890,pentosan polysulfate sodium,Treatment of mucopolysaccharidosis (MPS) type VI,01/05/2015,Designated,,,mucopolysaccharidosis (mps) type vi,,,,,,,
2891,Pentostatin,Treatment of peripheral T-cell lymphomas.,11/24/1999,Designated,Q425470,,peripheral t-cell lymphomas,,,,D016411,,,
2892,Pentostatin,Treatment of cutaneous T-cell lymphoma.,03/27/1998,Designated,Q425470,,cutaneous t-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
2893,Pentostatin,Treatment of patients with chronic lymphocytic leukemia.,01/29/1991,Designated,Q425470,,patients with chronic lymphocytic leukemia,,,,,,,
2894,Pentostatin for injection,Treatment of hairy cell leukemia.,09/10/1987,Designated/Approved,,,hairy cell leukemia,http://purl.obolibrary.org/obo/DOID_285,,http://www.orpha.net/ORDO/Orphanet_58017,D007943,Q201299,,Q201299
2895,pentoxifylline,Treatment of Behcet's disease,06/14/2012,Designated,Q416331,,behcet's disease,http://purl.obolibrary.org/obo/DOID_13241,,,,Q911427,,
2896,Peptide 144 TGF beta-1 inhibitor,Treatment of systemic sclerosis,04/27/2006,Designated,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
2897,Peptide 144 TGF beta-1-inhibitor,Treatment of localized scleroderma,04/26/2006,Designated,,,localized scleroderma,http://purl.obolibrary.org/obo/DOID_8472,,http://www.orpha.net/ORDO/Orphanet_90289,D012594,Q3324389,,Q3324389
2898,Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH,Treatment of pancreatic cancer.,06/29/2016,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
2899,Peptide that inhibits mechanosensitive ion channel (MSC) activity,Treatment of Duchenne Muscular Dystrophy (DMD.),09/15/2010,Designated,,,duchenne muscular dystrophy (dmd.),,,,,,,
2900,peptide YY,Treatment of hepatocellular carcinoma.,04/18/2011,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2901,peptide-based vaccine targeting telomerase reverse transcriptase,Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients,02/20/2009,Designated,,,telomerase reverse transcriptase (tert) positive non-small cell lung cancer in hla-a*0201 positive patients,,,,,,,
2902,peptide-conjugated phosporodiamidate morpholino oligomer (PPMO),"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).",09/03/2009,Designated,,,"duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55)",,,,,,,
2903,peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis,Treatment of myasthenia gravis,02/04/2011,Designated,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
2904,Peptidomimetic analog of hexarelin,Diagnosis of growth hormone deficiency,05/14/2007,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
2905,perampanel,Treatment of Lennox-Gastaut Syndrome,12/07/2012,Designated,Q868658,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
2906,peretinoin,Treatment of hepatocellular carcinoma.,09/23/2011,Designated,Q18326479,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2907,Perflubron,Treatment of acute respiratory distress disease (ARDS) in adults,04/26/2001,Designated,Q2190150,,acute respiratory distress disease (ards) in adults,,,,,,,
2909,Pergolide,Treatment of Tourette's syndrome.,11/20/1997,Designated/Withdrawn,Q415752,,tourette's syndrome,,,,D005879,,,Q191779
2910,perhexiline maleate,Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy,06/14/2012,Designated,Q27282064,,moderate to severe symptomatic hypertrophic cardiomyopathy,,,,,,,
2911,perifosine,Treatment of multiple myeloma.,09/03/2009,Designated/Withdrawn,Q3411917,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2912,perifosine,Treatment of neuroblastoma,07/09/2010,Designated,Q3411917,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
2913,perillyl alcohol,Treatment of glioma,04/18/2011,Designated,Q15391928,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
2914,pertuzumab,"Treatment of gastric cancer, including gastroesophageal junction cancer",07/12/2013,Designated,Q1998021,,"gastric cancer, including gastroesophageal junction cancer",,,,,,,
2915,pertuzumab,Treatment of ovarian cancer,06/08/2009,Designated,Q1998021,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2916,pexastimogene devacirepvec,Treatment of hepatocellular carcinoma,05/06/2013,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
2917,PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus),Treatment of idiopathic thrombocytopenic purpura,07/05/2012,Designated,,,idiopathic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_8924,http://purl.obolibrary.org/obo/HP_0001973,,D016553,Q638729,,Q638729
2918,PGC-C12E-terlipressin,Treatment of ascites due to all etiologies except for cancer,12/27/2012,Designated,,,ascites due to all etiologies except for cancer,,,,,,,
2919,phenobarbitol sodium injection,Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates,10/23/2013,Designated,,,hypoxic-ischemic encephalopathy to prevent siezures in neonates,,,,,,,
2920,"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride",Treatment of Huntington's disease.,03/16/2015,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
2922,Phenylalanine ammonia-lyase,Treatment of hyperphenylalaninemia,03/08/1995,Designated,,,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,,,Q7706537,
2923,Phenylbutyrate,Treatment of acute promyelocytic leukemia.,01/19/2000,Designated,Q27288012,IGVPBCZDHMIOJH-UHFFFAOYSA-N,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
2924,phenylephrine,Treatment of ileal pouch anal anastomosis related fecal incontinence,02/14/2002,Designated,Q421910,,ileal pouch anal anastomosis related fecal incontinence,,,,,,,
2925,phenylephrine,Treatment of Tetralogy of Fallot,01/31/2012,Designated,Q421910,,tetralogy of fallot,http://purl.obolibrary.org/obo/DOID_6419,http://purl.obolibrary.org/obo/HP_0001636,http://www.orpha.net/ORDO/Orphanet_3303,D013771,Q1126831,,Q1126831
2926,"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor",Treatment of chronic lymphocytic leukemia (CLL),11/02/2010,Designated,,,chronic lymphocytic leukemia (cll),,,,,,,
2927,Phosphocysteamine,Treatment of cystinosis.,09/12/1988,Designated/Withdrawn,Q27144789,JHBJEBQVXQFYOL-UHFFFAOYSA-N,cystinosis,http://purl.obolibrary.org/obo/DOID_1064,,http://www.orpha.net/ORDO/Orphanet_213,D003554,Q1149042,Q1149042,Q1149042
2928,phosphoinositide-3-kinase delta inhibitor,Treatment of chronic lymphocytic leukemia,08/23/2016,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2929,phosphorothioate antisense olignucleotide against EWS-Fli-1,Treatment of Ewing's sarcoma,09/22/2008,Designated,,,ewing's sarcoma,,http://purl.obolibrary.org/obo/HP_0012254,,D012512,,,Q18555397
2930,phosphorothioate oligonucleotide,Treatment of amyotrophic lateral sclerosis,11/09/2007,Designated/Withdrawn,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
2932,physostigmine salicylatephysostigmine salicylate,Treatment of Friedreich's and other inherited ataxias.,01/16/1985,Designated/Withdrawn,,,friedreich's and other inherited ataxias,,,,,,,
2933,picibanil,Treatment of lymphatic malformations,03/17/2011,Designated,,,lymphatic malformations,,,,,,,
2934,picibanil,Treatment of patients with lymphatic malformations,05/15/2009,Designated,,,patients with lymphatic malformations,,,,,,,
2935,Picoplatin,Treatment of small cell lung cancer,11/02/2005,Designated,Q7191060,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
2936,Pilocarpine,Treatment of xerostomia induced by radiation therapy for head and neck cancer.,09/24/1990,Designated/Approved,Q411461,,xerostomia induced by radiation therapy for head and neck cancer,,,,,,,
2937,Pilocarpine HCl,Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.,02/28/1992,Designated/Approved,,,xerostomia and keratoconjunctivitis sicca in sjogren's syndrome patients,,,,,,,
2938,Piracetam,Treatment of myoclonus.,10/02/1987,Designated/Withdrawn,Q410069,,myoclonus,,http://purl.obolibrary.org/obo/HP_0001336,,D009207,,,
2939,pirfenidone,Treatment of systemic sclerosis (including the associated interstitial lung disease),11/19/2013,Designated,Q2060696,,systemic sclerosis (including the associated interstitial lung disease),,,,,,,
2940,pirfenidone,Treatment of idiopathic pulmonary fibrosis,03/05/2004,Designated/Approved,Q2060696,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2941,pirfenidone,Treatment of idiopathic pulmonary fibrosis,07/31/2014,Designated,Q2060696,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
2942,Piritrexim isethionate,"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.",06/13/1988,Designated/Withdrawn,Q27291624,,"infections caused by pneumocystis carinii, toxoplasma gondii, and mycobacterium avium-intracellulare",,,,,,,
2943,plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent,Treatment of cystic fibrosis,06/30/2014,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2944,Plasmid DNA vector expressing cystic fibrosis transmembrane gene,Treatment of cystic fibrosis,03/29/2005,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
2945,plasmin (human),Treatment of acute peripheral arterial occlusion,03/30/2009,Designated,,,acute peripheral arterial occlusion,,,,,,,
2946,plasminogen (human),"Treatment of hypoplasminogenemia, or type I plasminogen deficiency",03/05/2013,Designated,,,"hypoplasminogenemia, or type i plasminogen deficiency",,,,,,,
2947,pleconaril,Treatment of symptomatic enteroviral infection in the neonate,12/22/2014,Designated,Q770293,,symptomatic enteroviral infection in the neonate,,,,,,,
2949,plerixafor,Treatment of acute myeloid leukemia,07/28/2011,Designated/Withdrawn,Q905835,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
2950,Plevitrexed,Treatment of ovarian cancer,05/14/2007,Designated/Withdrawn,Q27088412,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2951,Plevitrexed,Treatment of gastric (stomach cancer,05/29/2007,Designated/Withdrawn,Q27088412,,gastric (stomach cancer,,,,,,,
2952,Plitidepsin,Treatment of acute lymphoblastic leukemia,06/18/2004,Designated/Withdrawn,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
2953,Plitidepsin,Treatment of multiple myeloma,09/30/2004,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2954,Polatuzumab vedotin,Treatment of diffuse large B-cell lymphoma,12/12/2016,Designated,Q19946115,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
2955,polidocanol,Treatment of congenital venous malformations,02/19/2015,Designated,,,congenital venous malformations,,,,,,,
2956,polifeprosan 20 with carmustine,Treatment of malignant glioma.,12/13/1989,Designated/Approved,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
2957,Poloxamer 188,Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.,08/05/1997,Designated,,,vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm,,,,,,,
2958,poloxamer 188,Treatment of Acute Limb Ischemia,11/08/2013,Designated,,,acute limb ischemia,,,,,,,
2959,Poloxamer 188,Treatment of severe burns requiring hospitalization.,02/22/1990,Designated,,,severe burns requiring hospitalization,,,,,,,
2960,poloxamer 188 (purified),Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease),06/27/1989,Designated,,,sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease),,,,,,,
2962,poloxamer-188 NF,Treatment of Duchenne muscular dystrophy,01/19/2010,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
2963,Poly I: poly C12U,"Treatment of invasive metastatic melanoma (stage IIb, III, IV).",12/09/1993,Designated,,,"invasive metastatic melanoma (stage iib, iii, iv)",,,,,,,
2964,Poly I: poly C12U,Treatment of renal cell carcinoma.,05/20/1991,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
2965,Poly I: poly C12U,Treatment of chronic fatigue syndrome,12/09/1993,Designated,,,chronic fatigue syndrome,http://purl.obolibrary.org/obo/DOID_8544,,,D015673,Q209733,,Q209733
2966,poly(lactide-co-glycolide) carboxylated microparticle,Treatment of malaria,09/13/2016,Designated,,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
2967,poly(lactide-co-glycolide) carboxylated microparticle,Treatment of acute encephalitis syndrome,10/25/2013,Designated,,,acute encephalitis syndrome,,,,D000071072,,,
2968,poly-CD-PEG-camptothecin,Treatment of ovarian cancer.,05/21/2015,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
2969,Poly-ICLC,Treatment of primary brain tumors.,03/17/1997,Designated,,,primary brain tumors,,,,D001932,,,Q18554460
2970,"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine","Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria",04/05/2016,Designated,,,"pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,burkholderia cepacia and other bacteria",,,,,,,
2971,polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase,Treatment of homocystinuria,03/17/2015,Designated,,,homocystinuria,http://purl.obolibrary.org/obo/DOID_9263,http://purl.obolibrary.org/obo/HP_0002156,,D006712,Q994859,,Q994859
2972,Polyethylene glycol-modified uricase,Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.,12/21/1998,Designated,,,tumor lysis syndrome in cancer patients undergoing chemotherapy,,,,,,,
2973,Polyethylene glycol-modified uricase,Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated,06/06/2005,Designated,,,hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated,,,,,,,
2975,polyinosinic-polycytidilic acid,"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses",03/03/2003,Designated,,,"flavivirus infections including those due to west nile, japanese encephalitis, dengue, st. louis encephalitis, yellow fever, murray valley, and banzai viruses",,,,,,,
2977,polyinosinic-polycytidilic acid (Poly-ICLC),Treatment for orthopox virus infections,11/19/2002,Designated,,,orthopox virus infections,,,,,,,
2978,Polymeric oxygen,Treatment of sickle cell anemia.,03/25/1992,Designated,,,sickle cell anemia,http://purl.obolibrary.org/obo/DOID_10923,,http://www.orpha.net/ORDO/Orphanet_232,D000755,Q185034,,Q185034
2979,polyphenon E,Treatment of chronic lymphocytic leukemia,07/17/2008,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
2980,Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid,Treatment of AIDS,07/19/1988,Designated,,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
2981,"Polyvalent, shed-antigen melanoma vaccine",Treatment of stage IIb to stage IV melanoma,06/09/2006,Designated,,,stage iib to stage iv melanoma,,,,,,,
2982,pomalidomide,Treatment of multiple myeloma,01/15/2003,Designated/Approved,Q7227206,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
2983,pomalidomide,Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.,09/21/2010,Designated/Withdrawn,Q7227206,,persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent,,,,,,,
2984,pomalidomide,Treatment of systemic sclerosis,08/22/2013,Designated/Withdrawn,Q7227206,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
2985,ponatinib,Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL),11/20/2009,Designated/Approved,Q198728,,philadelphia chromosome-positive acute lymphoblastic leukemia (ph+all),,,,,,,
2986,ponatinib,Treatment of chronic myeloid leukemia,11/20/2009,Designated/Approved,Q198728,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
2987,ponatinib,Treatment of gastrointestinal stromal tumors (GIST).,03/12/2015,Designated,Q198728,,gastrointestinal stromal tumors (gist),,,,,,,
2988,Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation,Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.,12/17/1996,Designated,,,hoehn and yahr stage 4 and 5 parkinson's disease,,,,,,,
2989,Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.,Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.,12/17/1996,Designated,,,hoehn and yahr stage 4 and 5 parkinson's disease,,,,,,,
2990,Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation,Treatment of Huntington's disease.,12/10/1996,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
2991,Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.,Treatment of Huntington's disease.,12/10/1996,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
2992,porcine GM1 ganglioside,Treatment of acute spinal cord injury,12/03/2012,Designated,,,acute spinal cord injury,,,,,,,
2993,Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue,Treatment of Hoehn and Yahr stage four and five Parkinson's disease.,06/24/1997,Designated,,,hoehn and yahr stage four and five parkinson's disease,,,,,,,
2996,Porfimer sodium,Treatment of cholangiocarcinoma,11/18/2004,Designated,,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
2998,Porfiromycin,Treatment of cervical cancer.,03/13/1997,Designated,Q27279527,,cervical cancer,http://purl.obolibrary.org/obo/DOID_4362,,,D002583,Q160105,,Q18555233
2999,Porfiromycin,Treatment of head and neck cancer.,09/19/1995,Designated,Q27279527,,head and neck cancer,http://purl.obolibrary.org/obo/DOID_11934,http://purl.obolibrary.org/obo/HP_0012288,,D006258,Q1783924,,Q1783924
3000,Posaconazole,Treatment of invasive aspergillosis,10/04/2016,Designated,Q906453,,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
3001,Posaconazole,Treatment of zygomycosis,07/16/2004,Designated,Q906453,,zygomycosis,,,http://www.orpha.net/ORDO/Orphanet_73263,D020096,,,Q5380626
3002,Potassium citrate,Prevention of uric acid nephrolithiasis.,11/01/1984,Designated/Approved,Q27133400,QEEAPRPFLLJWCF-UHFFFAOYSA-K,uric acid nephrolithiasis,http://purl.obolibrary.org/obo/DOID_580,http://purl.obolibrary.org/obo/HP_0000791,,,Q4677952,,
3008,PR-225 (redox-acyclovir),Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.,05/29/1990,Designated/Withdrawn,,,herpes simplex encephalitis in individuals afflicted with aids,,,,,,,
3009,PR-239 (redox penicillin G),Treatment of AIDS associated neurosyphilis.,05/23/1990,Designated/Withdrawn,,,aids associated neurosyphilis,,,,,,,
3011,pracinostat,Treatment of acute myeloid leulemia,02/27/2014,Designated,Q18344027,,acute myeloid leulemia,,,,,,,
3012,pralatrexate,Treatment of diffuse large B-cell lymphoma,10/20/2008,Designated,Q637059,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
3013,pralatrexate,Treatment of T-cell lymphoma,07/20/2006,Designated/Approved,Q637059,,t-cell lymphoma,,http://purl.obolibrary.org/obo/HP_0012190,,D016399,,,
3014,pralatrexate,Treatment of follicular lymphoma,10/20/2008,Designated,Q637059,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
3015,pralatrexate,Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder,05/03/2010,Designated,Q637059,,advanced or metastatic transitional cell carcinoma of the urinary bladder,,,,,,,
3017,pramipexole,Treatment of Tourette's syndrome in pediatric patients,01/31/2008,Designated,Q421304,,tourette's syndrome in pediatric patients,,,,,,,
3019,prasugrel hydrochloride,Treatment of sickle cell disease,05/26/2015,Designated,Q27278929,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
3020,Praziquantel,Treatment of neurocysticercosis.,04/18/1988,Designated/Withdrawn,Q424145,,neurocysticercosis,http://purl.obolibrary.org/obo/DOID_10079,,,D020019,Q246068,,
3021,Prednimustine,Treatment of malignant non-Hodgkin's lymphomas.,06/17/1985,Designated/Withdrawn,Q7239694,,malignant non-hodgkin's lymphomas,,,,,,,
3023,pritumumab,Treatment of glioma,10/28/2014,Designated,Q7245992,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
3024,pritumumab,Treatment of pancreatic cancer.,04/06/2016,Designated,Q7245992,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3025,Procarbazine HCl,Treatment of malignant glioma,08/08/2006,Designated,Q26840941,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
3026,procaspase-activating compound 1,Treatment of malignant glioma,07/23/2015,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
3027,profimer sodium,Treatment of malignant mesothelioma,12/02/2011,Designated,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
3030,prolactin receptor antagonist,Treatment of ovarian cancer,04/15/2013,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3031,propagermanium and irbesartan,Treatment of focal segmental glomerulosclerosis.,12/09/2015,Designated,,,focal segmental glomerulosclerosis,http://purl.obolibrary.org/obo/DOID_1312,http://purl.obolibrary.org/obo/HP_0000097,,D005923,Q1435223,,Q1435223
3032,Propamidine isethionate 0.1% ophthalmic solution,Treatment of acanthamoeba keratitis.,03/10/1988,Designated/Withdrawn,,,acanthamoeba keratitis,,,http://www.orpha.net/ORDO/Orphanet_67043,D015823,,,
3033,"Propanoic acid, 2,2-dimethyl-,1,1'-[[[[4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphinylidene]bis(oxymethylene)] ester",Treatment of X-linked adrenoleukodystrophy.,12/05/2016,Designated,,,x-linked adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_43,D000326,Q366964,,Q366964
3034,propofol hemisuccinate,Treatment of acute repetitive seizures,08/19/2016,Designated,,,acute repetitive seizures,,,,,,,
3035,propranolol,Treatment of proliferating infantile hemangiomas requiring systemic therapy,09/05/2008,Designated/Approved,Q423364,,proliferating infantile hemangiomas requiring systemic therapy,,,,,,,
3036,propranolol and etodolac,Treatment of pancreatic cancer.,04/27/2015,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3037,propranolol and etodolac,Treatment of malignant glioma.,07/08/2015,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
3038,propranolol hydrochloride and etodolac,Treatment of hepatocellular carcinoma,02/24/2015,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3039,Prostaglandin E1 enol ester (AS-013),Treatment of Fontaine Stage IV chronic critical limb ischemia.,06/12/1998,Designated,,,fontaine stage iv chronic critical limb ischemia,,,,,,,
3040,Prostaglandin E1 in lipid emulsion,Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.,09/10/1996,Designated/Withdrawn,,,ischemic ulceration of the lower limbs due to peripheral arterial disease,,,,,,,
3041,Protaxel,Treatment of ovarian cancer,05/21/2003,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3045,prothrombin complex concentrate (human),Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,12/27/2012,Designated/Approved,,,patients needing urgent reversal of vitamin k antagonist therapy for treatment of major bleeding and/or surgical procedures,,,,,,,
3046,Protirelin,Prevention of infant respiratory distress syndrome associated with prematurity.,08/24/1993,Designated/Withdrawn,Q24726011,,infant respiratory distress syndrome associated with prematurity,,,,,,,
3047,Protirelin injection,Treatment of amyotrophic lateral sclerosis.,01/10/1985,Designated/Withdrawn,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3048,ProTmune (ex vivo Programmed Mobilized Peripheral Blood),Prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation,09/19/2016,Designated,,,graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation,,,,,,,
3049,"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients",Treatment of juvenile rheumatoid arthritis.,01/11/2017,Designated,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
3050,Pulmonary surfactant replacement,Prevention and treatment of infant respiratory distress syndrome.,12/05/1988,Designated/Withdrawn,,,treatment of infant respiratory distress syndrome,,,,,,,
3052,purified autologous type 1 regulatory T lymphocytes specific for human type II collagen,Treatment of chronic non-infectious uveitis,09/01/2015,Designated,,,chronic non-infectious uveitis,,,,,,,
3053,purified bovine type collagen,Treatment of idiopathic pulmonary fibrosis,04/27/2009,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3054,Purified extract of Pseudomonas aeruginosa,Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.,09/22/1997,Designated,,,immune thrombocytopenia purpura where it is required to increase platelet counts,,,,,,,
3055,Purified type II collagen,Treatment of juvenile rheumatoid arthritis.,02/09/1995,Designated,,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
3056,pVGI.1(VEGF2),Treatment of thromboangiitis obliterans.,11/09/1999,Designated/Withdrawn,,,thromboangiitis obliterans,http://purl.obolibrary.org/obo/DOID_12918,,http://www.orpha.net/ORDO/Orphanet_36258,D013919,Q746001,,Q746001
3057,PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3',Treatment of rabies virus infections,11/24/2014,Designated,,,rabies virus infections,,,,,,,
3058,pyridopyrimidinone SMN2 splicing modifier,Treatment of spinal muscular atrophy,01/04/2017,Designated,,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
3059,pyridoxal-5â€™ phosphate monohydrate (P5P),Treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency,01/04/2017,Designated,,,seizures associated with pyridox(am)ine 5'-phosphate oxidase (pnpo) deficiency,,,,,,,
3060,pyridoxine; vitamin B6,Treatment of pyridoxine dependent seizures.,03/03/2011,Designated,,,pyridoxine dependent seizures,,,,,,,
3061,pyrimethamine,Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).,08/16/2011,Designated,Q421072,,gm-2 gangliosidoses (tay-sachs disease and sandhoff disease),,,,,,,
3062,Pyruvate,Treatment of interstitial lung disease.,02/21/2001,Designated,Q27089397,LCTONWCANYUPML-UHFFFAOYSA-M,interstitial lung disease,http://purl.obolibrary.org/obo/DOID_3082,http://purl.obolibrary.org/obo/HP_0006530,http://www.orpha.net/ORDO/Orphanet_182095,D017563,Q1153419,,Q1153419
3063,pyrvinium,Treatment of familial adenomatous polyposis,01/05/2015,Designated,Q264039,,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
3064,quinacrine,Treatment of hepatocellular carcinoma,09/28/2012,Designated,Q417208,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3066,quinine sulfate,Treatment of malaria excluding Plasmodium faliparum,12/02/2008,Designated,Q189522,,malaria excluding plasmodium faliparum,,,,,,,
3067,quinine Sulfate,Treatment of malaria,06/03/2004,Designated/Approved,Q189522,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
3068,R-(-)-gossypol,Treatment of chronic lymphocytic leukemia.,10/24/2006,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3069,"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea",Treatment of gastric carcinoids,09/10/2009,Designated,Q2297773,YDZYKNJZCVIKPP-VWLOTQADSA-N,gastric carcinoids,,,,,,,
3070,R-4-amino-3-(4-chlorophenyl)butanoic acid,Treatment of the behavorial abnormalities associated with fragile X syndrome,11/28/2008,Designated,Q27074844,KPYSYYIEGFHWSV-QMMMGPOBSA-N,the behavorial abnormalities associated with fragile x syndrome,,,,,,,
3071,R-etodolac,Treatment of chronic lymphocytic leukemia,12/09/2002,Designated/Withdrawn,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3072,rAAV2-CB-hRPE65,Treatment of type II Leber's Congential Amaurosis,02/11/2005,Designated,,,type ii leber's congential amaurosis,,,,,,,
3076,raloxifene hydrochloride,Treatment of hereditary hemorrhagic telangiectasia,08/20/2010,Designated,Q27122215,,hereditary hemorrhagic telangiectasia,http://purl.obolibrary.org/obo/DOID_1270,,http://www.orpha.net/ORDO/Orphanet_774,D013683,Q776881,Q776881,Q776881
3077,ramucirumab,Treatment of hepatocellular carcinoma,11/04/2011,Designated,Q7290345,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3078,ramucirumab,Treatment of gastric cancer,02/16/2012,Designated/Approved,Q7290345,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3079,ranagengliotucel-L,Treatment of astrocytic tumors,05/29/2009,Designated,,,astrocytic tumors,,,,,,,
3080,ranprinase,Treatment of malignant mesothelioma,01/25/2007,Designated,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
3081,Rapamycin,Treatment of tuberous sclerosis complex,03/20/2007,Designated,Q26998376,,tuberous sclerosis complex,,,http://www.orpha.net/ORDO/Orphanet_805,D014402,,,Q1362721
3082,rapamycin,Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).,02/24/2016,Designated,Q26998376,,facial angiofibromas (fa) associated with tuberous sclerosis complex (tsc),,,,,,,
3083,rapamycin,Treatment of pulmonary arterial hypertention,10/20/2016,Designated,Q26998376,,pulmonary arterial hypertention,,,,,,,
3084,Rapamycin (mTOR) inhibitor,Treatment of bone sarcoma.,08/09/2005,Designated/Withdrawn,,,bone sarcoma,,,http://www.orpha.net/ORDO/Orphanet_223727,,,,
3085,rasburicase,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,10/11/2000,Designated/Approved,Q3088229,,malignancy-associated or chemotherapy-induced hyperuricemia,,,,,,,
3086,raxibacumab,Treatment of anthrax,11/12/2003,Designated/Approved,Q7297093,,anthrax,,,,D000881,,,Q129104
3087,Re188 P2045 somatostatin analog,Treatment of small cell lung cancer,02/06/2014,Designated,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
3088,Re188 P2045 somatostatin peptide analogue,Treatment of pancreatic cancer.,06/19/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3089,recilisib sodium,Prevention of acute radiation syndrome,06/01/2012,Designated,Q27251123,,acute radiation syndrome,,,,D054508,,,Q275459
3090,recilisib sodium,Treatment of acute radiation syndrome,09/04/2012,Designated,Q27251123,,acute radiation syndrome,,,,D054508,,,Q275459
3092,recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase,Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A),04/29/2014,Designated,,,mucopolysaccharidosis type iii-a (sanfilippo syndrome type a),,,,,,,
3093,recombinant activated Factor X variant,Treatment of intracerebral hemorrhage,03/03/2015,Designated,,,intracerebral hemorrhage,,http://purl.obolibrary.org/obo/HP_0001342,,D002543,,,Q6058597
3095,Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65,Treatment of Leber's congential amaurosis,05/11/2009,Designated,,,leber's congential amaurosis,,,,,,,
3096,recombinant adeno-associated virus alpha 1-antitrypsin vector,Treatment of alpha1-antitrypsin deficiency,01/27/2003,Designated,,,alpha1-antitrypsin deficiency,,,,,,,
3097,recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP),Treatment of Huntington's disease.,08/25/2009,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3098,Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2,Treatment of Leber congenital amaurosis due to RPE65 mutations.,06/24/2008,Designated,,,leber congenital amaurosis due to rpe65 mutations,,,,,,,
3099,recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC),Treatment of glycogen storage disease type Ia (von Gierke Disease),09/28/2016,Designated,,,glycogen storage disease type ia (von gierke disease),,,,,,,
3100,recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP,Treatment of Angelman Syndrome.,10/29/2015,Designated,,,angelman syndrome,http://purl.obolibrary.org/obo/DOID_1932,,http://www.orpha.net/ORDO/Orphanet_120365,D017204,Q535364,,Q535364
3101,recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase,Treatment of ornithine transcarbamylase deficiency,12/29/2015,Designated,,,ornithine transcarbamylase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
3102,"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter",Treatment of Duchenne muscular dystrophy,06/16/2015,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
3103,recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV),Treatment of Limb Girdle Muscular Dystrophy Type 2B,09/19/2016,Designated,,,limb girdle muscular dystrophy type 2b,,,,,,,
3104,recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3),Treatment of achromatopsia caused by mutations in the CNGA3 gene,11/16/2015,Designated,,,achromatopsia caused by mutations in the cnga3 gene,,,,,,,
3105,recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3),Treatment of achromatopsia caused by mutations in the CNGB3 gene.,02/04/2011,Designated,,,achromatopsia caused by mutations in the cngb3 gene,,,,,,,
3106,recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase,"Treatment of mucopolysaccharidosis II, also called Hunter syndrome A.",09/01/2016,Designated,,,"mucopolysaccharidosis ii, also called hunter syndrome a",,,,,,,
3107,recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase,"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A",09/01/2016,Designated,,,"mucopolysaccharidosis type iii a, also called sanfilippo syndrome a",,,,,,,
3108,recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits,Treatment of Tay-Sachs disease,03/25/2013,Designated,,,tay-sachs disease,http://purl.obolibrary.org/obo/DOID_3320,,http://www.orpha.net/ORDO/Orphanet_845,D013661,Q560337,,Q560337
3109,Recombinant anti-CD-40 monoclonal antibody,Treatment of multiple myeloma,01/25/2006,Designated/Withdrawn,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3110,Recombinant anti-CD40 monoclonal antibody,Treatment of chronic lymphocytic leukemia,08/12/2005,Designated/Withdrawn,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3111,Recombinant antibody construct against human CD30 and CD16A,Treatment of Hodgkin lymphoma,08/20/2009,Designated,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
3112,Recombinant bactericidal/permeability-increasing protein,Treatment of severe meningococcal disease.,06/22/1998,Designated/Withdrawn,,,severe meningococcal disease,,,,,,,
3113,Recombinant coagulation factor VIIa,Treatment of diffuse alveolar hemorrhage,04/26/2006,Designated,,,diffuse alveolar hemorrhage,,,http://www.orpha.net/ORDO/Orphanet_90060,,,,
3114,recombinant deriative of C3 transferase,Treatment of acute spinal cord injury,11/18/2005,Designated,,,acute spinal cord injury,,,,,,,
3115,Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs,"Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms.",07/29/2008,Designated,,,"thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms",,,,,,,
3116,Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs,"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms.",07/29/2008,Designated,,,"thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms",,,,,,,
3117,recombinant DNA plasmid,"Treatment of stage IIb, IIc, III and IV melanoma.",01/31/2014,Designated,,,"stage iib, iic, iii and iv melanoma",,,,,,,
3118,recombinant elafin,Prevention of inflammatory complications of transthoracic esophagectomy,03/18/2013,Designated,,,inflammatory complications of transthoracic esophagectomy,,,,,,,
3119,Recombinant Epstein-Barr virus gp350 glycoprotein vaccine,Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation,08/18/2005,Designated,,,post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation,,,,,,,
3120,Recombinant fully human monoclonal antibody to anthrax protective antigen,Treatment of anthrax infection,02/16/2006,Designated,,,anthrax infection,,,,,,,
3121,Recombinant Fusion Protein,Treatment of Myelodysplastic Syndrome,07/24/2012,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
3122,recombinant fusion protein comprising exenatide and XTEN,Treatment of short bowel syndrome.,10/07/2015,Designated,,,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
3123,recombinant fusion protein consisiting of a modified form of extracellular domain of human Activin receptor IIB,Treatment of myelodysplastic syndrome,03/18/2013,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
3124,recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain,Treatment of B-thalassemia,03/11/2013,Designated,,,b-thalassemia,,,,,,,
3125,recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP),Treatment of patients with congenital factor IX deficiency (hemophilia B).,04/27/2012,Designated/Approved,,,patients with congenital factor ix deficiency (hemophilia b),,,,,,,
3126,recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP),Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency,05/06/2013,Designated,,,congenital factor vii deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor vii deficiency,,,,,,,
3127,Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7,Treatment of recurrent respiratory papillomatosis (RRP),03/19/2001,Designated,,,recurrent respiratory papillomatosis (rrp),,,,,,,
3128,recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin,Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck,01/28/2005,Designated,,,ep-cam-positive squamous cell carcinoma of the head and neck,,,,,,,
3129,Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1,Treatment of glioblastoma multiforme,10/13/2009,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
3130,recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase,Treatment of Pompe disease.,08/20/2010,Designated,,,pompe disease,,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,,,Q1365789
3131,recombinant growth hormone fused to hyFc,Treatment of growth hormone deficiency.,11/09/2016,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
3132,Recombinant human acid alpha-glucosidase; alglucosidase alfa,Treatment of glycogen storage disease type II.,08/19/1997,Designated/Approved,,,glycogen storage disease type ii,http://purl.obolibrary.org/obo/DOID_2752,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,Q1365789,,Q1365789
3133,recombinant human acid ceramidase,Treatment of Faber disease,12/24/2013,Designated,,,faber disease,,,,,,,
3134,recombinant human alkaline phosphatase,Treatment of hypophosphatasia.,05/13/2015,Designated,,,hypophosphatasia,http://purl.obolibrary.org/obo/DOID_14213,,http://www.orpha.net/ORDO/Orphanet_436,D007014,Q1313510,,Q1313510
3135,Recombinant human alpha 1-antitrypsin,Prevention of bronchopulmonary dysplasia,04/28/2005,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3136,recombinant human alpha 1-antitrypsin (rAAT),Treatment of cystic fibrosis,11/20/2001,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3137,recombinant human alpha-1 antitrypsin,Treatment of cystic fibrosis.,03/06/1998,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3139,Recombinant Human Alpha-Fetoprotein (rhAFP),Treatment of myasthenia gravis,02/22/2001,Designated,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
3140,recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan,Treatment of Pompe Disease,11/19/2013,Designated,,,pompe disease,,,http://www.orpha.net/ORDO/Orphanet_121987,D006009,,,Q1365789
3141,Recombinant human alpha-mannosidase,Treatment of alpha-mannosidosis,02/02/2006,Designated,,,alpha-mannosidosis,http://purl.obolibrary.org/obo/DOID_3413,,http://www.orpha.net/ORDO/Orphanet_61,D008363,Q250449,,Q250449
3142,recombinant human alpha-N-acetylglucosaminidase,Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome),04/15/2013,Designated,,,mucopolysaccharidosis iiib (sanfilippo b syndrome),,,,,,,
3143,Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody,Treatment of Duchenne and Becker muscular dystrophies,02/16/2005,Designated/Withdrawn,,,duchenne and becker muscular dystrophies,,,,,,,
3144,recombinant human anti-GDF-8 monoclonal antibody,Treatment of Duchenne Muscular Dystrophy.,07/24/2012,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
3145,recombinant human antithrombin,"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",12/07/2007,Designated/Approved,,,"congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",,,,,,,
3146,Recombinant human antithrombin III,Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.,04/06/2000,Designated,,,antithrombin iii dependent heparin resistance requiring anticoagulation,,,,,,,
3147,recombinant human arylsulphatase A,Treatment of metachromatic leukodystrophy (MLD).,04/11/2008,Designated/Withdrawn,,,metachromatic leukodystrophy (mld),,,,,,,
3148,recombinant human beta-glucuronidase,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",02/16/2012,Designated,,,"mucopolysaccharidosis vii (mps vii, sly syndrome)",,,,,,,
3149,recombinant human biglycan,Treatment of Duchenne Muscular Dystrophy,07/13/2016,Designated,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
3150,Recombinant human C1 inhibitor,Treatment of capillary leakage syndrome,06/09/2006,Designated,Q22075742,,capillary leakage syndrome,,,,,,,
3151,Recombinant human C1 inhibitor,Prevention and/or treatment of delayed graft function after solid organ transplantation,06/09/2006,Designated,Q22075742,,treatment of delayed graft function after solid organ transplantation,,,,,,,
3153,recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain,Prevention of graft-versus-host disease,06/09/2015,Designated,,,graft-versus-host disease,,,,D006086,,,Q1194520
3154,Recombinant human CD4 immunoglobulin G,Treatment of AIDS resulting from infection with HIV-1.,08/30/1990,Designated,,,aids resulting from infection with hiv-1,,,,,,,
3155,recombinant human cerebral dopamine neurotrophic factor,Treatment of amyotrophic lateral sclerosis,06/08/2016,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3156,Recombinant human Clara Cell 10kDa protein,Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.,07/13/1998,Designated,,,neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome,,,,,,,
3157,recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7),Treatment of dystrophic epidermolysis bullosa,03/17/2014,Designated,,,dystrophic epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_4959,,http://www.orpha.net/ORDO/Orphanet_303,D016108,Q3589131,,Q3589131
3158,recombinant human deoxyribonuclease I,Treatment of graft-vs-host disease,08/18/2014,Designated,,,graft-vs-host disease,,,,D006086,,,Q1194520
3159,recombinant human deoxyribonuclease I (DNase I),Prevention of graft-vs-host disease,08/18/2014,Designated,,,graft-vs-host disease,,,,D006086,,,Q1194520
3160,Recombinant human endostatin protein,Treatment of neuroendocrine tumors,08/13/2001,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
3161,recombinant human endostatin protein,Treatment of metastatic melanoma,02/21/2002,Designated,,,metastatic melanoma,,,,,,,
3162,recombinant human erythropoietin (rHuEPO),Treatment of mutliple myeloma,05/26/2011,Designated,,,mutliple myeloma,,,,,,,
3164,Recombinant human fibrinogen,Treatment of bleeding in patients deficient in fibrinogen,10/04/2007,Designated,,,bleeding in patients deficient in fibrinogen,,,,,,,
3165,recombinant human fibroblast growth factor-20,Treatment of radiation induced oral mucositis,01/29/2004,Designated/Withdrawn,,,radiation induced oral mucositis,,,,,,,
3167,recombinant human galactocerebrosidase (rhGALC);,Treatment of globoid cell leukodystrophy (Krabbe Disease),12/12/2011,Designated,,,globoid cell leukodystrophy (krabbe disease),,,,,,,
3168,Recombinant human gelsolin,Treatment of acute and chronic respiratory symptoms of bronchiectasis.,03/06/1995,Designated,,,acute and chronic respiratory symptoms of bronchiectasis,,,,,,,
3169,Recombinant human gelsolin,Treatment of the respiratory symptoms of cystic fibrosis.,01/12/1994,Designated,,,the respiratory symptoms of cystic fibrosis,,,,,,,
3170,Recombinant human glutamic acid decarboxylase 65KDa isoform,Treatment of Type I diabetes with residual beta cell function,03/22/2010,Designated,,,type i diabetes with residual beta cell function,,,,,,,
3171,"recombinant human GM-CSF, molgramostim",Treatment of pulmonary alveolar proteinosis,10/31/2012,Designated,,,pulmonary alveolar proteinosis,http://purl.obolibrary.org/obo/DOID_12120,,,D011649,Q448698,,Q448698
3172,recombinant human gowth hormone in an ocular delivery system,Treatment of persistent corneal epithelial defects,12/03/2012,Designated,,,persistent corneal epithelial defects,,,,,,,
3173,Recombinant human granulocyte colony stimulating factor,Prevention of implantation failure and unexplained recurrent miscarriage,07/24/2006,Designated/Withdrawn,,,implantation failure and unexplained recurrent miscarriage,,,,,,,
3176,recombinant human histidyl tRNA synthetase,Treatment of facioscapulohumeral muscular dystrophy,04/22/2015,Designated,,,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
3177,recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3,Treatment of acute myeloid leukemia,10/20/2008,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3178,recombinant human IgG1 monoclonal antibody,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),12/14/2009,Designated,,,x-linked hypophosphatemia (formerly known as vitamin d-resistant rickets),,,,,,,
3179,Recombinant human insulin-like growth factor 1,Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.,06/07/1995,Designated/Withdrawn,,,antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency ia,,,,,,,
3180,Recombinant human insulin-like growth factor 1,Treatment of growth hormone receptor deficiency.,06/07/1995,Designated/Withdrawn,,,growth hormone receptor deficiency,,,http://www.orpha.net/ORDO/Orphanet_633,D046150,,,Q669822
3181,Recombinant human insulin-like growth factor-I,Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.,02/16/2000,Designated,,,short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines,,,,,,,
3182,Recombinant human insulin-like growth factor-I,Treatment of post-poliomyelitis syndrome.,10/13/1995,Designated/Withdrawn,,,post-poliomyelitis syndrome,,,,D016262,,,Q18556566
3183,Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3,Treatment of major burns that require hospitalization.,06/15/1999,Designated,,,major burns that require hospitalization,,,,,,,
3184,Recombinant human interleukin-12,Treatment of renal cell carcinoma.,10/20/1997,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
3185,recombinant human interleukin-12,Treatment of acute radiation syndrome,08/22/2016,Designated,,,acute radiation syndrome,,,,D054508,,,Q275459
3186,Recombinant Human Interleukin-21 (rIL-21),"Treatment of stage II (T4), III or IV malignant melanoma.",10/04/2005,Designated,,,"stage ii (t4), iii or iv malignant melanoma",,,,,,,
3188,recombinant human lecithin:cholesterol acyltransferase (rhLCAT),Treatment of LCAT deficiency syndromes,09/02/2010,Designated,,,lcat deficiency syndromes,,,,,,,
3190,Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase,"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease",07/14/2005,Designated,,,"lipase deficiencies, including wolman disease and cholesteryl ester storage disease",,,,,,,
3191,Recombinant human microplasmin,Treatment of peripheral arterial occlusion,01/23/2006,Designated,,,peripheral arterial occlusion,,,,,,,
3192,recombinant human minibody against complement component,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.,06/07/2011,Designated,,,atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,,,,,,,
3193,recombinant human minibody against complement component C5,Treatment of primary membranoproliferative glomerulonephritis,02/04/2009,Designated,,,primary membranoproliferative glomerulonephritis,,,http://www.orpha.net/ORDO/Orphanet_54370,,,,
3194,recombinant human minibody against complement component C5 fused with RGD-motif,Prevention of ischemia/reperfusion injury associated with solid organ transplantation.,02/04/2009,Designated,,,ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
3195,recombinant human monoclonal antibody against activin receptors type II,Treatment of inclusion body myositis,06/18/2012,Designated,,,inclusion body myositis,http://purl.obolibrary.org/obo/DOID_3429,,http://www.orpha.net/ORDO/Orphanet_611,D018979,Q1848471,,Q1848471
3196,Recombinant human monoclonal antibody against human complement component C5a,Treatment of acute graft versus host disease,10/06/2016,Designated,,,acute graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_99920,,,,
3197,recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor,"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath",08/19/2014,Designated,,,"pigmented villonodular synovitis, including giant cell tumor of the tendon sheath",,,,,,,
3198,recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen,Treatment of pancreatic cancer,12/03/2012,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3199,recombinant human monoclonal antibody to hsp90,Treatment of invasive candidiasis,09/16/2002,Designated,,,invasive candidiasis,,,,D058365,,,
3200,recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1),Treatment of merkel cell carcinoma.,09/21/2015,Designated,,,merkel cell carcinoma,http://purl.obolibrary.org/obo/DOID_3965,,http://www.orpha.net/ORDO/Orphanet_79140,D015266,Q1711744,,
3201,recombinant human monoclonal IgM antibody targeting glucose regulated protein 78,Treatment of multiple myeloma,10/25/2013,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3202,recombinant human Naglu- insulin-like growth factor II,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B),03/05/2013,Designated,,,mucopolysaccharidosis type iiib (sanfilippo syndrome type b),,,,,,,
3203,Recombinant human nerve growth factor,Treatment of HIV-associated sensory neuropathy.,04/16/1999,Designated,,,hiv-associated sensory neuropathy,,,,,,,
3204,recombinant human nerve growth factor,Treatment of retinitis pigmentosa,08/08/2013,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3205,recombinant human nerve growth factor,Treatment of neurotrophic keratitis,06/23/2014,Designated,,,neurotrophic keratitis,,,http://www.orpha.net/ORDO/Orphanet_137596,,,,
3206,recombinant human neutrophil inhibitor (hNE),Treatment of cystic fibrosis,12/09/2003,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3207,recombinant human Pentraxin-2,Treatment of myelofibrosis,08/26/2014,Designated,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
3208,recombinant human Pentraxin-2; recombinant human Serum Amyloid P,Treatment of idiopathic pulmonary fibrosis.,02/17/2012,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3209,Recombinant human platelet derived growth factor BB,Treatment of osteonecrosis of the jaws,02/01/2007,Designated,,,osteonecrosis of the jaws,,,,,,,
3210,recombinant human platelet derived growth factor-BB,Treatment of osteochondritis dissecans,08/06/2010,Designated/Withdrawn,,,osteochondritis dissecans,http://purl.obolibrary.org/obo/DOID_84,http://purl.obolibrary.org/obo/HP_0010886,http://www.orpha.net/ORDO/Orphanet_2764,D010008,Q127556,Q5071123,Q5071123
3211,recombinant human porphobilinogen deaminase,Treatment of acute intermittent porphyria attacks,09/09/2002,Designated,,,acute intermittent porphyria attacks,,,,,,,
3212,"recombinant human porphobilinogen deaminase, erythropoetic form",Treatment of acute intermittent porphyria preventing attacks,07/11/2002,Designated,,,acute intermittent porphyria preventing attacks,,,,,,,
3213,recombinant human proinsulin (Including rhPI-Methionine),Treatment of retinitis pigmentosa,12/10/2008,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3214,Recombinant human relaxin,Treatment of progressive systemic sclerosis.,11/03/1995,Designated/Withdrawn,,,progressive systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,,D045743,Q5340515,,Q18554846
3215,recombinant human rod-derived cone viability factor,Treatment of retinitis pigmentosa,01/07/2008,Designated/Withdrawn,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3216,recombinant human serum albumin human growth hormone,Treatment of growth hormone deficiency,01/13/2016,Designated,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
3217,Recombinant Human soluble Fc-gamma Receptor IIb,Treatment of idiopathic thrombocytopenic purpura,03/22/2010,Designated,,,idiopathic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_8924,http://purl.obolibrary.org/obo/HP_0001973,,D016553,Q638729,,Q638729
3218,Recombinant human superoxide dismutase,Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.,04/18/1991,Designated/Withdrawn,,,bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams,,,,,,,
3219,recombinant human surfactant protein D,Prevention of bronchopulmonary dysplasia,06/23/2014,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3221,recombinant human type I pancreatic elastase,Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis,04/03/2009,Designated,,,arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (ckd) who are receiving hemodialysis or preparing for hemodialysis,,,,,,,
3222,recombinant human type VII collagen,Treatment of hereditary dystrophic epidermolysis bullosa (DEB),06/18/2008,Designated,,,hereditary dystrophic epidermolysis bullosa (deb),,,,,,,
3223,recombinant human vascular endothelial growth factor,Treatment of amyotrophic lateral sclerosis,06/07/2010,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3224,recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody,Treatment of eosinophilic esophagitis,02/11/2015,Designated,,,eosinophilic esophagitis,http://purl.obolibrary.org/obo/DOID_13922,,http://www.orpha.net/ORDO/Orphanet_73247,D057765,Q2057356,Q2057356,Q2057356
3225,Recombinant humanized anti-LOXL2 monoclonal antibody,Treatment of idiopathic pulmonary fibrosis,04/18/2011,Designated/Withdrawn,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3226,"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",Treatment of pancreatic cancer.,05/17/2011,Designated/Withdrawn,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3227,"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",Treatment of myelofibrosis.,06/01/2011,Designated/Withdrawn,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
3228,recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4,Treatment of gastric cancer,07/16/2015,Designated,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3229,recombinant humanized anti-tau antibody,Treatment of progressive supranuclear palsy,01/22/2015,Designated,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
3230,recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR),Treatment of sickle cell disease,04/12/2013,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
3231,recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,01/11/2016,Designated,,,pigmented villonodular synovitis and tenosynovial giant cell tumor,,,,,,,
3232,Recombinant humanized MAb 5c8,Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.,10/14/1998,Designated,,,treatment of factor viii/factor ix inhibitors in patients with hemophilia a or b,,,,,,,
3233,Recombinant humanized MAb 5c8,Prevention of rejection of solid organ transplants.,03/22/1999,Designated,,,rejection of solid organ transplants,,,,,,,
3234,Recombinant humanized MAb 5c8,Prevention of rejection of pancreatic islet cell transplants.,03/22/1999,Designated,,,rejection of pancreatic islet cell transplants,,,,,,,
3235,Recombinant humanized monclonal antibody 5c8,Treatment of immune thrombocytopenic purpura.,02/03/1998,Designated,,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3236,Recombinant humanized monoclonal antibody 5c8,Treatment of systemic lupus erythematosus.,02/18/1998,Designated,,,systemic lupus erythematosus,http://purl.obolibrary.org/obo/DOID_9074,http://purl.obolibrary.org/obo/HP_0002725,,D008180,Q1485,,Q1485
3237,Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor,Treatment of glioblastoma multiforme,02/17/2012,Designated/Withdrawn,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
3238,recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,05/14/2014,Designated,,,pigmented villonodular synovitis and tenosynovial giant cell tumor,,,,,,,
3239,recombinant IgA protease of bacterium Heamophilus influenzae,"Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).",04/18/2011,Designated,,,"immunoglobulin a nephropathy (igan, berger's disease)",,,,,,,
3240,Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin,Treatment of malignant mesothelioma,02/11/2002,Designated,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
3241,Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin,Treatment of epithelial ovarian cancer,02/11/2002,Designated,,,epithelial ovarian cancer,,,,,,,
3242,recombinant kallikrein inhibitor,Treatment of Netherton Syndrome.,11/23/2010,Designated,,,netherton syndrome,http://purl.obolibrary.org/obo/DOID_0050474,,http://www.orpha.net/ORDO/Orphanet_634,D056770,Q9390284,Q9390284,Q9390284
3243,recombinant lens epithelium derived growth factor 1-326,Treatment of retinitis pigmentosa,05/19/2014,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3244,Recombinant methionyl brain-derived neurotrophic factor,Treatment of amyotrophic lateral sclerosis.,11/28/1994,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3245,Recombinant methionyl human stem cell factor,Treatment of primary bone marrow failure.,11/22/1995,Designated/Withdrawn,,,primary bone marrow failure,,,,,,,
3246,recombinant monoclonal antibody to human serum amyloid P component,Treatment of AL amyloidosis,02/10/2015,Designated,,,al amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85443,,,,
3247,recombinant multimerized human IgG1 Fc,Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).,07/14/2015,Designated,,,chronic inflammatory demyelinating polyneuropathy (cidp),,,,,,,
3248,recombinant nematode anticoagulant protein c2 (rNAPc2),Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola),12/08/2014,Designated,,,viral hemorrhagic fever post-exposure to ebola virus (treatment of ebola),,,,,,,
3249,recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S,Treatment of patients with carbon monoxide poisoning,11/17/2014,Designated,,,patients with carbon monoxide poisoning,,,,,,,
3250,recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A,Treatment of soft tissue sarcoma.,01/06/2016,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
3251,recombinant ovine interferon tau,Treatment of pediatric multiple sclerosis,01/25/2005,Designated,,,pediatric multiple sclerosis,,,,,,,
3252,Recombinant P-Selectin glycoprotein ligand,Prevention of delayed graft function in renal transplant patients,03/29/2006,Designated,,,delayed graft function in renal transplant patients,,,,,,,
3253,Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig,Prevention of ischemia reperfusion injury in all solid organ transplants,07/26/2007,Designated,,,ischemia reperfusion injury in all solid organ transplants,,,,,,,
3254,Recombinant protein inhibitor of complement factor 5,Treatment of Guillain-Barre Syndrome.,05/10/2016,Designated,,,guillain-barre syndrome,http://purl.obolibrary.org/obo/DOID_12842,,,D020275,Q205214,,Q205214
3255,Recombinant replication deficient adenovirus vector carrying human p53 gene,Treatment of primary ovarian cancer.,04/12/1999,Designated,,,primary ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,,,Q172341,,
3257,Recombinant secretory leucocyte protease inhibitor,Treatment of congenital alpha-1 antitrypsin deficiency.,03/29/1991,Designated/Withdrawn,,,congenital alpha-1 antitrypsin deficiency,,,,,,,
3258,Recombinant secretory leucocyte protease inhibitor,Treatment of cystic fibrosis.,03/29/1991,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3259,Recombinant soluble human CD4,Treatment of acquired immunodeficiency syndrome.,11/20/1989,Designated/Withdrawn,,,acquired immunodeficiency syndrome,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
3260,Recombinant soluble human CD4 (rCD4),Treatment of AIDS in patients infected with HIV virus.,03/23/1989,Designated,,,aids in patients infected with hiv virus,,,,,,,
3261,Recombinant T-cell receptor ligand,Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55,05/02/2003,Designated,,,multiple sclerosis patients who are both hla-dr2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55,,,,,,,
3262,recombinant thymidine phosphorylase encapsulated with autologous erythrocytes,Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.,12/13/2010,Designated,,,mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency,,,,,,,
3263,Recombinant truncated SPINT2 protease inhibitor,Treatment of cystic fibrosis,06/24/2005,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3265,Recombinant vaccinia (human papillomavirus),Treatment of cervical cancer.,08/24/1994,Designated/Withdrawn,,,cervical cancer,http://purl.obolibrary.org/obo/DOID_4362,,,D002583,Q160105,,Q18555233
3266,recombinant von Willebrand factor (rhVWF),Treatment of von Willebrand disease.,11/23/2010,Designated/Approved,,,von willebrand disease,http://purl.obolibrary.org/obo/DOID_12531,,http://www.orpha.net/ORDO/Orphanet_903,D014842,Q709360,,Q709360
3267,"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA",Treatment of aromatic L-amino acid decarboxylase deficiency.,06/08/2016,Designated,,,aromatic l-amino acid decarboxylase deficiency,,,http://www.orpha.net/ORDO/Orphanet_35708,,,,
3268,"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin",Treatment of Friedreich's Ataxia,07/25/2016,Designated,,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
3269,"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)",Treatment of primary sclerosing cholangitis.,08/25/2016,Designated,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
3270,"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b",Treatment of gastric cancer including cancer of the gastroesophageal junction.,06/29/2016,Designated,,,gastric cancer including cancer of the gastroesophageal junction,,,,,,,
3271,"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2",Treatment of glioma,05/26/2016,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
3272,Reduced L-glutathione,Treatment of AIDS-associated cachexia.,02/14/1994,Designated,,,aids-associated cachexia,,,,,,,
3274,regorafenib,Treatment gastrointestinal stromal tumors,01/12/2011,Designated/Approved,Q3891664,,stromal tumors,,,,,,,
3275,regorafenib,Treatment of hepatocellular carcinoma.,06/04/2015,Designated,Q3891664,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3276,Remacemide,Treatment of Huntington's disease.,03/06/2000,Designated/Withdrawn,Q7311505,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3277,REMUNE HIV 1,Treatment of pediatric HIV/AIDS (age through 16 years),02/14/2014,Designated,,,pediatric hiv/aids (age through 16 years),,,,,,,
3278,reparixin,Prevention of delayed graft function in solid organ transplant,01/27/2003,Designated,Q27088533,,delayed graft function in solid organ transplant,,,,,,,
3279,reparixin,Prevention of graft loss in pancreatic islet transplantation,09/25/2012,Designated,Q27088533,,graft loss in pancreatic islet transplantation,,,,,,,
3280,Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region,Treatment of head and neck cancer,01/27/2003,Designated,,,head and neck cancer,http://purl.obolibrary.org/obo/DOID_11934,http://purl.obolibrary.org/obo/HP_0012288,,D006258,Q1783924,,Q1783924
3281,replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA,Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.,05/03/2013,Designated,,,symptoms of grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity,,,,,,,
3282,Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines,Treatment of acute myeloid leukemia,03/02/2010,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3283,Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines,Treatment of chronic myeloid leukemia,04/30/2010,Designated,,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
3284,Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines,Treatment of pancreatic cancer.,03/01/2010,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3285,repository corticortropin injection,Treatment of amyotrophic lateral sclerosis,06/28/2013,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3286,repository corticotropin or adrenocorticotropic hormone,Treatment of infantile spasms,05/21/2003,Designated/Approved,,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
3287,resiniferatoxin,Treatment of intractable pain at end-stage disease,05/13/2003,Designated,Q3277888,,intractable pain at end-stage disease,,,,,,,
3288,reslizumab,Treatment of hypereosinophilic syndrome,01/12/2011,Designated,Q7315650,,hypereosinophilic syndrome,,,http://www.orpha.net/ORDO/Orphanet_168956,D017681,,,Q2551272
3289,reslizumab,Treatment of children with eosinophilic esophagitis,12/19/2007,Designated,Q7315650,,children with eosinophilic esophagitis,,,,,,,
3290,resminostat,Treatment of hepatocellular carcinoma,06/29/2011,Designated,Q18394103,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3291,resminostat,Treatment of Hodgkin's lymphoma.,09/16/2011,Designated,Q18394103,,hodgkin's lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
3292,Respiratory Syncytial Virus Immune Globulin (human),Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.,09/27/1990,Designated,,,respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children,,,,,,,
3294,retaspimycin,Treatment for gastrointestinal stromal tumor,08/31/2007,Designated/Withdrawn,Q27139837,,gastrointestinal stromal tumor,http://purl.obolibrary.org/obo/DOID_9253,http://purl.obolibrary.org/obo/HP_0100723,http://www.orpha.net/ORDO/Orphanet_44890,D046152,Q1495661,,Q1495661
3295,retaspimycin hydrochloride,Treatment of melanoma stages IIb through IV.,06/24/2008,Designated/Withdrawn,Q27139829,,melanoma stages iib through iv,,,,,,,
3296,Retinol palmitate,Prevention of bronchopulmonary dysplasia.,08/08/2016,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3297,retroviral gamma-c cDNA containing vector,Treatment of X linked severe combined immune deficiency disease,04/29/2002,Designated,,,x linked severe combined immune deficiency disease,,,,,,,
3298,"Retroviral vector, R-GC and GC gene 1750",Treatment of Gaucher disease.,05/06/1997,Designated/Withdrawn,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
3299,Reversal agent linked to chloroquine-like moiety,Treatment of malaria,03/26/2010,Designated,,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
3300,Revimmune,Treatment of autoimmune hemolytic anemia.,02/18/2011,Designated,,,autoimmune hemolytic anemia,http://purl.obolibrary.org/obo/DOID_718,http://purl.obolibrary.org/obo/HP_0001890,http://www.orpha.net/ORDO/Orphanet_98375,D000744,Q28814,,Q28814
3301,Reviparin sodium,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,06/18/2001,Designated,Q7318417,,deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,,,,,,,
3303,revusiran,Treatment of transthyretin amyloidosis,05/18/2015,Designated,,,transthyretin amyloidosis,http://purl.obolibrary.org/obo/DOID_0050638,,,,Q2844603,,
3304,"RGG0853, E1A lipid complex",Treatment of ovarian cancer.,09/15/1995,Designated/Withdrawn,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3306,rhIGF-I/rhIGFBP-3,"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)",12/09/2003,Designated,,,"extreme insulin resistance syndromes (type a, rabson-mendenhall syndrome, leprechaunism, type b syndrome)",,,,,,,
3307,Rho (D) immune globulin intravenous (human),Treatment of immune thrombocytopenic purpura.,11/09/1993,Designated/Approved,,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3308,ribavirin,Treatment of hemorrhagic fever with renal syndrome,04/12/1991,Designated,Q421862,,hemorrhagic fever with renal syndrome,http://purl.obolibrary.org/obo/DOID_11266,,,D006480,Q9002005,,Q9002005
3309,ribavirin,Treatment of chronic hepatitis C in pediatric patients,04/04/2003,Designated/Approved,Q421862,,chronic hepatitis c in pediatric patients,,,,,,,
3310,ribavirin elaidate,"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",09/02/2011,Designated,Q27260032,,"follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",,,,,,,
3311,riboflavin ophthalmic solution & ultraviolet A,Treatment of keratoconus,09/02/2011,Designated/Approved,,,keratoconus,http://purl.obolibrary.org/obo/DOID_10126,http://purl.obolibrary.org/obo/HP_0000563,http://www.orpha.net/ORDO/Orphanet_156071,D007640,Q611984,Q611984,Q611984
3312,riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation,Treatment of corneal ectasia following refractive surgery,12/02/2011,Designated/Approved,,,corneal ectasia following refractive surgery,,,,,,,
3313,riboflavin-vitamin E-TPGS topical solution,Treatment of keratoconus in patients undergoing crosslinking procedure,11/08/2016,Designated,,,keratoconus in patients undergoing crosslinking procedure,,,,,,,
3315,Ricin (blocked) conjugated murine MCA (anti-B4),Treatment of B-cell leukemia and B-cell lymphoma.,11/17/1988,Designated/Withdrawn,,,b-cell leukemia and b-cell lymphoma,,,,,,,
3317,Ricin (blocked) conjugated murine MCA (anti-my9),"Treatment of myeloid leukemia, including AML, and blast crisis of CML.",08/03/1989,Designated/Withdrawn,,,"myeloid leukemia, including aml, and blast crisis of cml",,,,,,,
3318,Ricin (blocked) conjugated murine MCA (n901),Treatment of small cell lung cancer,01/25/1991,Designated/Withdrawn,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
3319,Ricin (blocked) conjugated murine monoclonal antibody (CD6),"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.",09/06/1994,Designated/Withdrawn,,,"cutaneous t-cell lymphomas, acute t-cell leukemia-lymphoma, and related mature t-cell malignancies",,,,,,,
3320,ricin vaccine,Prevention of ricin intoxication.,01/07/2011,Designated,,,ricin intoxication,,,,,,,
3321,ridaforolimus,Treatment of soft tissue sarcoma,08/12/2005,Designated/Withdrawn,Q2151796,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
3322,Rifabutin,Treatment of disseminated Mycobacterium avium complex disease.,12/18/1989,Designated,Q1135705,,disseminated mycobacterium avium complex disease,,,,,,,
3323,Rifabutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,12/18/1989,Designated/Approved,Q1135705,,disseminated mycobacterium avium complex disease in patients with advanced hiv infection,,,,,,,
3324,Rifalazil,Treatment of pulmonary tuberculosis.,04/13/1999,Designated,Q7333206,,pulmonary tuberculosis,http://purl.obolibrary.org/obo/DOID_2957,,,D014397,Q18555243,,Q18555243
3327,Rifapentine,Treatment of pulmonary tuberculosis.,06/09/1995,Designated/Approved,Q3935297,,pulmonary tuberculosis,http://purl.obolibrary.org/obo/DOID_2957,,,D014397,Q18555243,,Q18555243
3328,Rifapentine,Treatment of Mycobacterium avium complex in patients with AIDS.,06/09/1995,Designated,Q3935297,,mycobacterium avium complex in patients with aids,,,,,,,
3330,rifaximin,Treatment of hepatic encephalopathy,02/10/1998,Designated/Approved,Q416073,,hepatic encephalopathy,http://purl.obolibrary.org/obo/DOID_13413,http://purl.obolibrary.org/obo/HP_0002480,,D006501,Q642548,,Q18554341
3331,rigosertib,Treatment of ovarian cancer,03/16/2012,Designated,Q21099552,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3332,rigosertib,Treatment of pancreatic cancer.,03/18/2011,Designated,Q21099552,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3333,rigosertib,Treatment of myelodysplastic syndromes,09/03/2009,Designated,Q21099552,,myelodysplastic syndromes,,,,D009190,,,Q954625
3334,RII retinamide,Treatment of myelodysplastic syndromes.,05/06/1993,Designated,,,myelodysplastic syndromes,,,,D009190,,,Q954625
3335,rilonacept,Treatment of familial Mediterranean fever,01/09/2013,Designated,Q7334300,,familial mediterranean fever,http://purl.obolibrary.org/obo/DOID_2987,,http://www.orpha.net/ORDO/Orphanet_342,D010505,Q1144618,Q1144618,Q1144618
3336,Rilonacept,Treatment of CIAS1-Associated Periodic Syndromes,12/20/2004,Designated/Approved,Q7334300,,cias1-associated periodic syndromes,,,,,,,
3337,rilotumumab,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,06/18/2012,Designated/Withdrawn,Q7334301,,gastric cancer including gastroesophageal junction adenocarcinoma,,,,,,,
3338,Riluzole,Treatment of amyotrophic lateral sclerosis.,03/16/1993,Designated/Approved,Q415744,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3339,riluzole,Treatment of spinocereballar ataxia.,02/23/2016,Designated,Q415744,,spinocereballar ataxia,,,,,,,
3340,Riluzole,Treatment of Huntington's disease.,10/15/1996,Designated,Q415744,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3341,riluzole oral suspension,Treatment of amyotrophic lateral sclerosis (ALS).,09/15/2016,Designated,,,amyotrophic lateral sclerosis (als),,,,,,,
3342,riluzole orally disolving tablet,Treatment of amyotrophic lateral sclerosis (ALS),11/30/2016,Designated,,,amyotrophic lateral sclerosis (als),,,,,,,
3343,rindopepimut,Treatment of EGFRvIII-expressing glioblastoma multiforme,11/19/2007,Designated,,,egfrviii-expressing glioblastoma multiforme,,,,,,,
3344,riociguat,Treatment of pulmonary arterial hypertension.,09/19/2013,Designated/Approved,Q2154494,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3345,riociguat,Treatment of systemic sclerosis,07/24/2014,Designated,Q2154494,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
3346,riociguat,Treatment of chronic thromboembolic pulmonary hypertension,09/19/2013,Designated/Approved,Q2154494,,chronic thromboembolic pulmonary hypertension,,,http://www.orpha.net/ORDO/Orphanet_70591,,,,
3347,risankizumab,Treatment of pediatric Crohn's disease,11/29/2016,Designated,Q25112466,,pediatric crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,,,,Q1472,,
3348,risedronate sodium,Treatment of patients with osteogenesis imperfecta.,12/18/2006,Designated/Withdrawn,Q27285633,,patients with osteogenesis imperfecta,,,,,,,
3350,rituximab,Treatment of non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,Q412323,,non-hodgkin's b-cell lymphoma,,,,,,,
3351,rituximab,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",02/14/2006,Designated/Approved,Q412323,,"patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (wegener's granulomatosis, microscopic polyangiitis, and churg-strauss syndrome)",,,,,,,
3352,rituximab,Treatment of immune thrombocytopenic purpura,03/12/2002,Designated,Q412323,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3353,rituximab,Treatment of pemphigus vulgaris.,02/23/2015,Designated,Q412323,,pemphigus vulgaris,,,http://www.orpha.net/ORDO/Orphanet_704,D010392,,,Q1483214
3354,rituximab,Treatment of chronic lymphocytic leukemia,01/29/2004,Designated/Approved,Q412323,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3355,rituximab,Treatment of Rasmussen's encephalitis,11/09/2016,Designated,Q412323,,rasmussen's encephalitis,,,,,,,
3356,rituximab and recombinant human hyaluronidase,Treatment of chronic lymphocytic leukemia (CLL),08/22/2016,Designated,,,chronic lymphocytic leukemia (cll),,,,,,,
3357,rituximab and recombinant human hyaluronidase,Treatment of follicular lymphoma,08/22/2016,Designated,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
3358,Rituximab/hyaluronidase,Treatment of diffuse large B-cell lymphoma,09/07/2016,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
3359,rociletinib,Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor,05/14/2013,Designated,Q27088606,,non-small cell lung cancer and mutations in the epidermal growth factor receptor,,,,,,,
3360,rofecoxib,Treatment of juvenile rheumatoid arthritis,03/16/2004,Designated,Q411412,,juvenile rheumatoid arthritis,http://purl.obolibrary.org/obo/DOID_676,http://purl.obolibrary.org/obo/HP_0005681,http://www.orpha.net/ORDO/Orphanet_92,D001171,Q861224,Q861224,Q861224
3361,romidepsin,Treatment of non-Hodgkin T-cell lymphomas,09/30/2004,Designated/Approved,Q7363205,,non-hodgkin t-cell lymphomas,,,,,,,
3362,romiplostim,Treatment of thrombocytopenia associated with myelodysplasia syndrome,10/31/2007,Designated,Q1235195,,thrombocytopenia associated with myelodysplasia syndrome,,,,,,,
3363,romiplostim,Treatment of immune thrombocytopenic purpura,03/27/2003,Designated/Approved,Q1235195,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3364,roneparstat,Treatment of multiple myeloma,03/19/2015,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3367,Rose Bengal Disodium,Treatment of metastatic melanoma,12/21/2006,Designated,,,metastatic melanoma,,,,,,,
3368,Roseburia hominis,Treatment of ulcerative colitis in pediatric patients age 0 through 16 years,08/04/2014,Designated,,,ulcerative colitis in pediatric patients age 0 through 16 years,,,,,,,
3369,Rosomidnar,Treatment of diffuse large B-cell lymphoma.,03/10/2016,Designated/Withdrawn,Q27255734,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
3371,rovalpituzumab tesirine,Treatment of small cell lung cancer,12/22/2015,Designated,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
3372,rozrolimupab,Treatment of primary immune thrombocytopenia.,09/13/2010,Designated,Q7375407,,primary immune thrombocytopenia,,,,,,,
3373,rsATP7A cDNA,Treatment of Menkes disease,01/10/2014,Designated,,,menkes disease,http://purl.obolibrary.org/obo/DOID_1838,,http://www.orpha.net/ORDO/Orphanet_565,D007706,Q639203,,Q639203
3374,rSP-C lung surfactant,Treatment of adult respiratory distress syndrome.,04/03/2000,Designated,,,adult respiratory distress syndrome,http://purl.obolibrary.org/obo/DOID_11394,,,D012128,Q344873,,Q7315912
3376,rt-PA,Treatment of plastic bronchitis,10/20/2014,Designated,Q19606349,,plastic bronchitis,,,http://www.orpha.net/ORDO/Orphanet_439881,,,Q28530014,
3377,rubitecan,Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome,07/17/2002,Designated,Q510113,,pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome,,,,,,,
3378,rucaparib,Treatment of ovarian cancer,07/31/2012,Designated/Approved,Q7376558,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3379,rufinamide,Treatment of Lennox-Gastaut Syndrome.,10/08/2004,Designated/Approved,Q408565,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
3380,ruxolitinib,Treatment of graft versus host disease,11/03/2016,Designated,Q7383611,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
3381,Ruxolitinib,Treatment of acute lymphoblastic leukemia.,07/18/2016,Designated,Q7383611,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
3382,ruxolitinib,Treatment of pancreatic cancer,08/16/2013,Designated,Q7383611,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3383,ruxolitinib,Treatment of polycythemia vera,03/26/2010,Designated/Approved,Q7383611,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
3384,ruxolitinib phosphate,Treatment of essential thrombocythemia,03/22/2010,Designated,Q27135517,,essential thrombocythemia,http://purl.obolibrary.org/obo/DOID_2224,,http://www.orpha.net/ORDO/Orphanet_3318,D013920,Q18555037,Q18555037,Q18555037
3385,ruxolitinib phosphate,Treatment of myelofibrosis,09/05/2008,Designated/Approved,Q27135517,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
3386,rVIIa-FP,Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX,12/22/2011,Designated,,,prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor viii or ix,,,,,,,
3387,S(-)-3-[3-amino-phthalimido]-glutaramide,Treatment of multiple myeloma,03/14/2002,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3388,S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light,Treatment of thrombotic thrombocytopenic purpura,02/14/2011,Designated,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
3389,S-adenosylmethionine,Treatment of AIDS-myelopathy.,04/30/1998,Designated,Q27135598,MEFKEPWMEQBLKI-AIRLBKTGSA-O,aids-myelopathy,,,,,,,
3390,S-ethylisothiourea diethylphosphate,"Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period.",08/29/2016,Designated,Q7387060,CSYSULGPHGCBQD-UHFFFAOYSA-N,"symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period",,,,,,,
3392,S-nitrosoglutathione,Treatment of severe preeclampsia,12/28/2012,Designated,Q7387071,HYHSBSXUHZOYLX-WDSKDSINSA-N,severe preeclampsia,http://purl.obolibrary.org/obo/DOID_13129,,,,Q18554442,,
3393,S-nitrosoglutathione reductase inhibitor,Treatment of cystic fibrosis,01/13/2016,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3394,"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK",Treatment of pancreatic cancer,10/20/2009,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3395,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide",Treatment of C3 glomerulopathy.,11/16/2015,Designated,,,c3 glomerulopathy,,,http://www.orpha.net/ORDO/Orphanet_329918,,,,
3396,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",Treatment of paroxysmal nocturnal hemoglobinuria (PNH),10/09/2014,Designated,,,paroxysmal nocturnal hemoglobinuria (pnh),,,,,,,
3397,sacituzumab govitecan,Treatment of small cell lung cancer,11/27/2013,Designated,Q23901469,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
3398,sacituzumab govitecan,Treatment of pancreatic cancer.,05/29/2014,Designated,Q23901469,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3399,Sacrosidase,Treatment of congenital sucrase-isomaltase deficiency,12/10/1993,Designated/Approved,,,congenital sucrase-isomaltase deficiency,,,http://www.orpha.net/ORDO/Orphanet_35122,,,,
3400,salicylic acid 6%,Treatment of rare congenital ichthyoses.,02/17/2012,Designated,,,rare congenital ichthyoses,,,,,,,
3401,salirasib,Treatment of pancreatic cancer.,12/18/2006,Designated,Q27088685,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3402,salmeterol xinafoate/fluticasone propionate,Treatment of symptomatic exophthalmos associated with thyroid related eye disease,10/29/2009,Designated,,,symptomatic exophthalmos associated with thyroid related eye disease,,,,,,,
3403,saposin C,Treatment of glioblastoma multiforme,02/03/2015,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
3404,sapropterin,Treatment of hyperphenylalaninemia,01/29/2004,Designated/Approved,Q419808,,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,,,Q7706537,
3405,"Sar9, Met(O2)11-Substance P",Treatment of idiopathic pulmonary fibrosis,03/16/2011,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3406,sarcosine,Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age),10/12/2011,Designated,Q414157,FSYKKLYZXJSNPZ-UHFFFAOYSA-N,obsessive compulsive disorder in pediatric patients (0 to 16 years of age),,,,,,,
3408,sargramostim,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),11/09/2016,Designated,Q3950557,,individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),,,,,,,
3409,sargramostim,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.",05/03/1990,Designated/Approved,Q3950557,,"neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment",,,,,,,
3410,sarizotan,Treatment of Rett syndrome.,07/07/2015,Designated,Q7424144,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
3411,sarsasapogenin,Treatment of amyotrophic lateral sclerosis (ALS),06/18/2004,Designated/Withdrawn,,,amyotrophic lateral sclerosis (als),,,,,,,
3413,SC-1 monoclonal antibody,Treatment of patients with CD55 (sc-1) positive gastric tumors,11/12/2003,Designated,,,patients with cd55 (sc-1) positive gastric tumors,,,,,,,
3414,SDF-1 (108) Lysine Dlmer,Treatment of osteogenic sarcoma,07/07/2005,Designated,,,osteogenic sarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
3415,sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs,Treatment of pachyonychia congenita,04/15/2013,Designated,,,pachyonychia congenita,http://purl.obolibrary.org/obo/DOID_0050449,,http://www.orpha.net/ORDO/Orphanet_2309,D053549,Q3360152,,Q3360152
3416,sebelipase alfa,Treatment of lysosomal acid lipase deficiency,07/01/2010,Designated/Approved,Q21789862,,lysosomal acid lipase deficiency,,,http://www.orpha.net/ORDO/Orphanet_275761,,,,
3417,Secalciferol,Treatment of familial hypophosphatemic rickets.,07/26/1993,Designated,Q27103914,,familial hypophosphatemic rickets,,,,D053098,,,Q1779987
3418,Secretory leukocyte protease inhibitor,Treatment of bronchopulmonary dysplasia.,06/30/1992,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3420,selective antagonist of the chemokine receptor type 4,Treatment of acute myeloid leukemia,09/05/2013,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3421,selective deacylglycerol acyltransferase 1 inhibitor,"Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome",03/28/2011,Designated,,,"hypertriglyceridemia in te setting of type i hyperlipoproteinemia, also known as familial chylomicronemia syndrome",,,,,,,
3422,selective inhibitor of fungal CYP51,Treatment of coccidioidomycosis.,03/03/2016,Designated,,,coccidioidomycosis,http://purl.obolibrary.org/obo/DOID_13450,,http://www.orpha.net/ORDO/Orphanet_228123,D003047,Q868137,,Q868137
3423,selective inhibitor of fungal lanosterol demethylase,Treatment of cryptococcal meningitis,08/19/2014,Designated,,,cryptococcal meningitis,http://purl.obolibrary.org/obo/DOID_0080159,,,D016919,Q18967011,,Q18967011
3426,selexipag,Treatment of pulmonary arterial hypertension,04/30/2010,Designated/Approved,Q15424759,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3427,"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid",Treatment of Giant Axonal Neuropathy,09/27/2013,Designated,,,giant axonal neuropathy,,,http://www.orpha.net/ORDO/Orphanet_643,D056768,,Q3338682,
3428,selinexor,Treatment of multiple myeloma,01/05/2015,Designated,Q27256082,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3429,selinexor,Treatment of soft tissue sarcoma,07/07/2016,Designated,Q27256082,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
3430,"Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide",Treatment of acute myeloid leukemia,05/14/2014,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3431,selisistat,Treatment of Huntington's disease,12/07/2009,Designated,Q27088776,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3433,selumetinib,Treatment of uveal melanoma.,04/15/2015,Designated/Withdrawn,Q7448840,,uveal melanoma,http://purl.obolibrary.org/obo/DOID_6039,http://purl.obolibrary.org/obo/HP_0007716,http://www.orpha.net/ORDO/Orphanet_39044,,Q356372,Q356372,
3434,Seneca Valley virus,Treatment of neuroendocrine tumors,08/22/2008,Designated,,,neuroendocrine tumors,,,,D018358,,,Q1981276
3436,Sermorelin acetate,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,09/14/1988,Designated/Approved,,,idiopathic or organic growth hormone deficiency in children with growth failure,,,,,,,
3437,Sermorelin acetate,Treatment of AIDS-associated catabolism/weight loss.,12/05/1991,Designated/Withdrawn,,,aids-associated catabolism/weight loss,,,,,,,
3438,Serratia marcescens extract (polyribosomes),Treatment of primary brain malignancies.,09/07/1988,Designated,,,primary brain malignancies,,,,,,,
3439,setmelanotide,Treatment of Prader-Willi Syndrome.,09/21/2015,Designated,Q21098917,,prader-willi syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
3440,setmelanotide,Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene,04/04/2016,Designated,Q21098917,,pro-opiomelanocortin (pomc) deficiency due to mutations in the pomc gene,,,,,,,
3441,sevuparin,Treatment of sickle cell disease,03/17/2015,Designated,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
3442,Short chain fatty acid enema,Treatment of chronic radiation proctitis.,08/19/1997,Designated,,,chronic radiation proctitis,,,,,,,
3443,Short chain fatty acid solution,Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.,05/29/1990,Designated,,,the active phase of ulcerative colitis with involvement restricted to the left side of the colon,,,,,,,
3444,sildenafil,Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,07/28/2011,Designated,Q191521,,pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,,,,,,,
3445,"Silibinin-C-2',3-dihydrogensuccinate, disodium salt",Prevention of recurrent hepatitis C in liver transplant patients,02/17/2012,Designated,,,recurrent hepatitis c in liver transplant patients,,,,,,,
3446,"silibinin-C-2',3-dihydrogensuccinate, disodium salt","Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure",09/11/2014,Designated,,,"amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure",,,,,,,
3447,Silmitasertib,Treatment of cholangiocarcinoma,12/22/2016,Designated,Q27076934,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
3448,siltuximab,Treatment of multiple myeloma,10/11/2005,Designated/Withdrawn,Q3960572,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3449,siltuximab,Treatment of Castleman's disease,05/26/2006,Designated/Approved,Q3960572,,castleman's disease,,,,D005871,,,
3450,Silver sulfadiazine and cerium nitrate,Treatment of patients with severe dermal burns,11/17/1999,Designated,,,patients with severe dermal burns,,,,,,,
3451,simtuzumab,Treatment of primary sclerosing cholangitis,01/05/2015,Designated,Q7521275,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
3452,single chain urokinase plasminogen activator,Treatment of empyema (pleural),09/11/2014,Designated,,,empyema (pleural),,,,,,,
3453,"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21",Treatment of Alport syndrome,07/17/2014,Designated,,,alport syndrome,http://purl.obolibrary.org/obo/DOID_10983,,http://www.orpha.net/ORDO/Orphanet_63,D009394,Q1331116,,Q1331116
3454,siplizumab,Treatment of T-cell lymphomas,07/15/2003,Designated/Withdrawn,Q7525805,,t-cell lymphomas,,,,D016399,,,
3455,Siponimod,Treatment of polymyositis,11/26/2013,Designated,Q27288262,,polymyositis,,,http://www.orpha.net/ORDO/Orphanet_732,D017285,,,
3456,siponimod,Treatment of dermatomyositis,07/10/2014,Designated,Q27288262,,dermatomyositis,http://purl.obolibrary.org/obo/DOID_10223,,http://www.orpha.net/ORDO/Orphanet_221,D003882,Q681160,,Q6318950
3457,sirolimus,Treatment of lymphangioleiomyomatosis,06/25/2014,Designated,Q32089,,lymphangioleiomyomatosis,http://purl.obolibrary.org/obo/DOID_3319,http://purl.obolibrary.org/obo/HP_0012798,http://www.orpha.net/ORDO/Orphanet_538,D018192,Q1878759,,Q1878759
3458,sirolimus,Treatment of lymphangioleiomyomatosis,11/17/2011,Designated,Q32089,,lymphangioleiomyomatosis,http://purl.obolibrary.org/obo/DOID_3319,http://purl.obolibrary.org/obo/HP_0012798,http://www.orpha.net/ORDO/Orphanet_538,D018192,Q1878759,,Q1878759
3459,sirolimus,Treatment of lymphangioleiomyomatosis,10/31/2012,Designated/Approved,Q32089,,lymphangioleiomyomatosis,http://purl.obolibrary.org/obo/DOID_3319,http://purl.obolibrary.org/obo/HP_0012798,http://www.orpha.net/ORDO/Orphanet_538,D018192,Q1878759,,Q1878759
3460,sirolimus,Treatment of pachyonychia congenita,03/18/2013,Designated,Q32089,,pachyonychia congenita,http://purl.obolibrary.org/obo/DOID_0050449,,http://www.orpha.net/ORDO/Orphanet_2309,D053549,Q3360152,,Q3360152
3461,sirolimus,Treatment of beta-thalassemia.,06/21/2016,Designated,Q32089,,beta-thalassemia,,,http://www.orpha.net/ORDO/Orphanet_848,D017086,,Q3616632,Q3616632
3462,sirolimus,"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).",11/04/2011,Designated,Q32089,,"chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (nicups)",,,,,,,
3463,sirolimus,Treatment of tuberous sclerosis complex-related facial angiofibromas,02/13/2017,Designated,Q32089,,tuberous sclerosis complex-related facial angiofibromas,,,,,,,
3464,sirolimus in an implantable collagen matrix,"Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis",05/10/2012,Designated,,,"arteriovenous(av) fistula or av graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis",,,,,,,
3467,skin tissue,Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting,05/21/2012,Designated,,,hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting,,,,,,,
3468,Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor,Treatment of Ewing sarcoma,06/30/2016,Designated,,,ewing sarcoma,http://purl.obolibrary.org/obo/DOID_3369,http://purl.obolibrary.org/obo/HP_0012254,http://www.orpha.net/ORDO/Orphanet_319,D012512,Q18555397,,Q18555397
3469,small molecule FGFR4 inhibitor,Treatment of hepatocellular cancer (HCC).,09/14/2015,Designated,,,hepatocellular cancer (hcc),,,,,,,
3470,small molecule inhibitor of Exon 17 Mutant KIT,Treatment of mastocytosis,01/21/2016,Designated,,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
3471,Small Molecule Inhibitor of Exon 17 mutant KIT,Treatment of gastrointestinal stromal tumors (GIST).,01/06/2016,Designated,,,gastrointestinal stromal tumors (gist),,,,,,,
3472,small molecule inhibitor of histone methyltransferase DOT1L,Treatment of acute lymphoblastic leukemia (ALL),08/08/2013,Designated,,,acute lymphoblastic leukemia (all),,,,,,,
3473,small molecule inhibitor of histone methyltransferase DOT1L,Treatment of Acute Myeloid Leukemia,08/15/2013,Designated,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3474,small molecule inhibitor of phosphodiesterase 10,Treatment of Huntington's disease,09/26/2013,Designated,,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3475,small molecule normalizing the p53 function,Treatment of ovarian cancer,06/12/2014,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3476,smilagenin,Treatment of amyotrophic lateral sclerosis,07/21/2011,Designated,Q27103971,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3477,sobetirome,Treatment of X-linked adrenoleukodystrophy,04/29/2011,Designated,Q27088838,,x-linked adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_43,D000326,Q366964,,Q366964
3478,"sodium 2, 2 dimethylbutyrate",Treatment of sickle cell disease.,07/25/2008,Designated,Q27293882,OOPXYEYPPHJHSE-UHFFFAOYSA-M,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
3479,sodium 2-hydroxylinoleate,Treatment of neuroblastoma.,08/25/2015,Designated,,VFXKYDDSDQXKLC-NBTZWHCOSA-M,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
3480,sodium 2-hydroxylinoleate,Treatment of pancreatic cancer.,11/23/2016,Designated,,VFXKYDDSDQXKLC-NBTZWHCOSA-M,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3481,sodium 4-phenylbutyrate,Treatment of spinal muscular atrophy,10/18/2011,Designated,Q7553358,VPZRWNZGLKXFOE-UHFFFAOYSA-M,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
3482,"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate",Treatment of ovarian cancer,04/03/2009,Designated/Withdrawn,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3483,sodium alginate oligosaccharide,Treatment of cystic fibrosis.,02/24/2016,Designated,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3484,Sodium aluminosilicate,Treatment of chronic hepatic encephalopathy,03/04/2005,Designated,Q724424,,chronic hepatic encephalopathy,,http://purl.obolibrary.org/obo/HP_0007111,,,,,
3485,Sodium ascorbate and menadione sodium bisulfite,Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer),07/31/2007,Designated,,,metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage iii and iv bladder cancer),,,,,,,
3486,sodium ascorbate and menadione sodium bisulfite,Treatment of autosomal dominant polycystic liver disease,04/15/2013,Designated,,,autosomal dominant polycystic liver disease,,,http://www.orpha.net/ORDO/Orphanet_2924,,,Q246002,
3487,sodium ascorbate and menadione sodium bisulfite,Treatment of noninfected painful total joint without mechanical complication,04/09/2015,Designated,,,noninfected painful total joint without mechanical complication,,,,,,,
3488,sodium ascorbate and menadione sodium bisulfite,Treatment of autosomal dominant polycystic kidney disease,04/15/2013,Designated,,,autosomal dominant polycystic kidney disease,,,,,,,
3489,sodium benzoate and clozapine,Treatment of treatment-resistant schizophrenia,12/22/2011,Designated,,,treatment-resistant schizophrenia,,,,,,,
3491,Sodium dichloroacetate,Treatment of homozygous familial hypercholesterolemia.,06/11/1990,Designated,Q27258517,LUPNKHXLFSSUGS-UHFFFAOYSA-M,homozygous familial hypercholesterolemia,,,http://www.orpha.net/ORDO/Orphanet_391665,,,,
3492,Sodium dichloroacetate,Treatment of lactic acidosis in patients with severe malaria.,11/10/1994,Designated,Q27258517,LUPNKHXLFSSUGS-UHFFFAOYSA-M,lactic acidosis in patients with severe malaria,,,,,,,
3493,Sodium dichloroacetate,Treatment of severe head injury.,06/14/1999,Designated/Withdrawn,Q27258517,LUPNKHXLFSSUGS-UHFFFAOYSA-M,severe head injury,,,,,,,
3494,Sodium dichloroacetate,Treatment of congenital lactic acidosis,06/11/1990,Designated,Q27258517,LUPNKHXLFSSUGS-UHFFFAOYSA-M,congenital lactic acidosis,,http://purl.obolibrary.org/obo/HP_0004902,,,,,
3495,Sodium dichloroacetate,Treatment of congenital lactic acidosis.,12/31/1997,Designated/Withdrawn,Q27258517,LUPNKHXLFSSUGS-UHFFFAOYSA-M,congenital lactic acidosis,,http://purl.obolibrary.org/obo/HP_0004902,,,,,
3498,sodium fusidate,Treatment of patients with prosthetic joint infections,10/23/2013,Designated,,,patients with prosthetic joint infections,,,,,,,
3501,sodium nitrite,Treatment of pulmonary arterial hypertension,07/08/2008,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3502,sodium nitrite,Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation,09/03/2009,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation,,,,,,,
3503,Sodium nitrite,Prevention of vasospasm associated with subarachnoid hemorrhage,01/17/2007,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,vasospasm associated with subarachnoid hemorrhage,,,,,,,
3504,Sodium nitrite,Treatment of cyanide poisoning,04/18/2007,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,cyanide poisoning,,,http://www.orpha.net/ORDO/Orphanet_466670,,,,
3505,sodium nitrite,Treatment of chlorine gas poisoning,01/09/2012,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,chlorine gas poisoning,,,,,,,
3506,Sodium nitrite,Treatment of vaso-occlusive crisis associated with sickle cell disease,04/02/2007,Designated,Q339975,LPXPTNMVRIOKMN-UHFFFAOYSA-M,vaso-occlusive crisis associated with sickle cell disease,,,,,,,
3507,sodium nitrite and EDTA,Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis,11/10/2015,Designated,,,pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis,,,,,,,
3508,sodium nitrite and sodium thiosulfate,Treatment of known or suspected cyanide poisoning,04/09/2008,Designated/Approved,,IVDNHJCYDUKMNR-UHFFFAOYSA-L,known or suspected cyanide poisoning,,,,,,,
3509,Sodium nitrite/sodium thiosulfate,Treatment of cyanide poisoning,03/23/2007,Designated,,,cyanide poisoning,,,http://www.orpha.net/ORDO/Orphanet_466670,,,,
3510,Sodium phenylacetate/sodium benzoate 10%/10% Injection,Treatment of grade III and IV hepatic encephalopathy,06/03/2005,Designated,,,grade iii and iv hepatic encephalopathy,,,,,,,
3511,sodium phenylbutyrate,Treatment of maple syrup urine disease,08/19/2014,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,maple syrup urine disease,http://purl.obolibrary.org/obo/DOID_9269,,http://www.orpha.net/ORDO/Orphanet_119002,D008375,Q402575,,Q402575
3512,Sodium phenylbutyrate,Treatment of spinal muscular atrophy,01/25/2007,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
3513,sodium phenylbutyrate,Treatment of urea cycle disorder.,01/19/2010,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,urea cycle disorder,http://purl.obolibrary.org/obo/DOID_9267,,,D056806,Q1585743,,Q1585743
3514,Sodium phenylbutyrate,Treatment of spinal muscular atrophy,03/20/2007,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
3515,sodium phenylbutyrate,"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.",07/02/1992,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,"sickling disorders, which include s-s hemoglobinopathy, s-c hemoglobinopathy, and s-thalassemia hemoglobinopathy",,,,,,,
3516,sodium phenylbutyrate,"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.",11/22/1993,Designated/Approved,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,"urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency",,,,,,,
3517,sodium phenylbutyrate,Treatment of urea cycle disorders,06/06/2013,Designated,Q7553358,XKOHIWVZKSEQHP-UHFFFAOYSA-N,urea cycle disorders,,,,D056806,,,Q1585743
3519,Sodium pyruvate,Treatment of cystic fibrosis,03/31/2003,Designated,Q3905673,DAEPDZWVDSPTHF-UHFFFAOYSA-M,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3520,Sodium stibogluconate,Treatment of cutaneous leishmaniasis,06/16/2006,Designated,Q2757844,YQDGWZZYGYKDLR-UZVLBLASSA-K,cutaneous leishmaniasis,http://purl.obolibrary.org/obo/DOID_9111,,,D016773,Q2590966,,Q2590966
3521,sodium stibogluconate,Treatment of cutaneous leishmaniasis,10/28/2009,Designated,Q2757844,YQDGWZZYGYKDLR-UZVLBLASSA-K,cutaneous leishmaniasis,http://purl.obolibrary.org/obo/DOID_9111,,,D016773,Q2590966,,Q2590966
3524,Sodium tetradecyl sulfate,Treatment of bleeding esophageal varices.,06/10/1986,Designated,Q7553377,UPUIQOIQVMNQAP-UHFFFAOYSA-M,bleeding esophageal varices,http://purl.obolibrary.org/obo/DOID_112,,,,Q298278,,
3525,sodium thiosulfate,Treatment of calciphylaxis,11/19/2012,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
3526,sodium thiosulfate,Prevention of platinum-induced ototoxicity in pediatric patients,10/13/2011,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,platinum-induced ototoxicity in pediatric patients,,,,,,,
3527,Sodium thiosulfate,Prevention of platinum-induced ototoxicity in pediatric patients,03/17/2004,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,platinum-induced ototoxicity in pediatric patients,,,,,,,
3528,sodium thiosulfate,Treatment of dermatomyositis,10/28/2014,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,dermatomyositis,http://purl.obolibrary.org/obo/DOID_10223,,http://www.orpha.net/ORDO/Orphanet_221,D003882,Q681160,,Q6318950
3529,sodium thiosulfate,Treatment of uremic and non-uremic calciphylaxis,11/09/2011,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,uremic and non-uremic calciphylaxis,,,,,,,
3530,sodium thiosulfate,Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.,12/02/2010,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,extravasation of meclorethamine hydrochloride into subcutaneous tissues,,,,,,,
3531,sodium thiosulfate,Treatment of sulfur mustard poisoning,03/03/2011,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sulfur mustard poisoning,,,,,,,
3532,Sodium Thiosulfate,Treatment of uremic and non-uremic calciphylaxis,02/16/2012,Designated,Q410739,AKHNMLFCWUSKQB-UHFFFAOYSA-L,uremic and non-uremic calciphylaxis,,,,,,,
3533,Sodium thiosulfate and sodium nitrite,Treatment of cyanide poisoning,12/18/2006,Designated,,IVDNHJCYDUKMNR-UHFFFAOYSA-L,cyanide poisoning,,,http://www.orpha.net/ORDO/Orphanet_466670,,,,
3534,"Sodium thiosulfate, sodium nitrite, amyl nitrite",Treatment of cyanide poisoning,06/16/2006,Designated,,,cyanide poisoning,,,http://www.orpha.net/ORDO/Orphanet_466670,,,,
3535,sodium valproate,Treatment of Wolfram syndrome,08/05/2015,Designated,Q4347890,AEQFSUDEHCCHBT-UHFFFAOYSA-M,wolfram syndrome,http://purl.obolibrary.org/obo/DOID_10632,,http://www.orpha.net/ORDO/Orphanet_3463,D014929,Q1153641,,Q1153641
3536,sofosbuvir,Treatment of pediatric chronic hepatitis C virus infection,10/25/2016,Designated,Q2502747,,pediatric chronic hepatitis c virus infection,,,,,,,
3538,Solasonine and solamargine,Treatment of renal cell carcinoma,11/02/2005,Designated,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
3539,solnatide,Treatment of primary graft dysfunction following lung transplantation,02/04/2016,Designated,,,primary graft dysfunction following lung transplantation,,,,,,,
3540,solnatide,Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB),02/08/2016,Designated,,,generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive pha-i or pha-ib),,,,,,,
3541,Soluble complement receptor type 1,Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.,03/06/2000,Designated,,,post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass,,,,,,,
3542,Soluble recombinant human complement receptor type 1,Prevention or reduction of adult respiratory distress syndrome.,11/21/1994,Designated,,,reduction of adult respiratory distress syndrome,,,,,,,
3543,solvent/detergent treated non-blood-group specific human coagulation active plasma,Treatment of thrombotic thrombocytopenic purpura,12/12/2005,Designated,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
3544,"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.",Prevention of organ rejection in living donor kidney transplant recipients,02/04/2016,Designated,,,organ rejection in living donor kidney transplant recipients,,,,,,,
3547,Somatostatin,Treatment of bleeding esophageal varices.,12/22/1994,Designated,Q22075835,,bleeding esophageal varices,http://purl.obolibrary.org/obo/DOID_112,,,,Q298278,,
3551,Somatropin,Treatment of patients with HIV-associated adipose redistribution syndrome,03/16/2004,Designated,Q20801765,,patients with hiv-associated adipose redistribution syndrome,,,,,,,
3552,Somatropin,Treatment of short stature associated with Turner syndrome.,05/08/1990,Designated/Approved,Q20801765,,short stature associated with turner syndrome,,,,,,,
3553,Somatropin,Treatment of short stature in patients with Noonan syndrome,08/09/2006,Designated/Approved,Q20801765,,short stature in patients with noonan syndrome,,,,,,,
3554,Somatropin,Treatment of adults with growth hormone deficiency.,09/06/1994,Designated/Approved,Q20801765,,adults with growth hormone deficiency,,,,,,,
3555,Somatropin,Treatment of cachexia associated with AIDS.,02/12/1993,Designated/Withdrawn,Q20801765,,cachexia associated with aids,,,,,,,
3556,Somatropin,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,12/15/2005,Designated/Approved,Q20801765,,short stature in pediatric patients with short stature homeobox-containing gene (shox) deficiency,,,,,,,
3559,Somatropin (r-DNA) for injection,Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.,03/26/1996,Designated,,,children with aids-associated failure-to-thrive including aids-associated wasting,,,,,,,
3561,Somatropin (rDNA origin),Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,03/06/1987,Designated/Approved,,,idiopathic or organic growth hormone deficiency in children with growth failure,,,,,,,
3563,Somatropin for injection,Treatment of growth retardation associated with chronic renal failure.,08/04/1989,Designated/Approved,,,growth retardation associated with chronic renal failure,,,,,,,
3564,Somatropin for injection,Treatment of AIDS-associated catabolism/weight loss.,11/15/1991,Designated/Approved,,,aids-associated catabolism/weight loss,,,,,,,
3565,Somatropin for injection,Treatment of short stature associated with Turner's syndrome.,03/23/1989,Designated/Approved,,,short stature associated with turner's syndrome,,,,,,,
3568,somatropin [rDNA],Treatment of growth failure in children who were born small for gestational age.,12/27/2000,Designated/Approved,,,growth failure in children who were born small for gestational age,,,,,,,
3569,Somatropin [rDNA],Treatment of short stature in patients with Prader-Willi syndrome.,07/06/1999,Designated/Approved,,,short stature in patients with prader-willi syndrome,,,,,,,
3570,sonidegib,Treatment of medulloblastoma,03/23/2015,Designated,Q22075856,,medulloblastoma,http://purl.obolibrary.org/obo/DOID_0050902,http://purl.obolibrary.org/obo/HP_0002885,http://www.orpha.net/ORDO/Orphanet_616,D008527,Q1333608,,Q18556102
3571,Sorafenib,Treatment of renal cell carcinoma.,10/08/2004,Designated/Approved,Q421136,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
3572,sorafenib,"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",12/12/2011,Designated/Approved,Q421136,,"medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",,,,,,,
3573,Sorafenib,Treatment of stage IIB through stage IV melanoma,09/29/2006,Designated/Withdrawn,Q421136,,stage iib through stage iv melanoma,,,,,,,
3574,Sorafenib,Treatment of hepatocellular carcinoma,04/20/2006,Designated/Approved,Q421136,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3575,Sorivudine,Treatment of herpes zoster (shingles) in immunocompromised patients,11/09/1995,Designated/Withdrawn,Q905418,,herpes zoster (shingles) in immunocompromised patients,,,,,,,
3578,sotalol hydrochloride,Treatment of life-threatening ventricular arrhythmias in pediatric patients,02/10/2014,Designated,Q27108309,,life-threatening ventricular arrhythmias in pediatric patients,,,,,,,
3579,sotatercept,Treatment of beta-thalassemia intermedia and major,12/05/2013,Designated,,,beta-thalassemia intermedia and major,,,,,,,
3580,sotatercept,Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,04/28/2014,Designated,,,anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms,,,,,,,
3581,sparsentan,Treatment of Focal Segmental Glomerulosclerosis,01/05/2015,Designated,Q27088845,,focal segmental glomerulosclerosis,http://purl.obolibrary.org/obo/DOID_1312,http://purl.obolibrary.org/obo/HP_0000097,,D005923,Q1435223,,Q1435223
3582,Sperm Protein-17 oral microparticle vaccine,Treatment of ovarian cancer,06/21/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3583,spherical carbon adsorbent,Treatment of chronic pouchitis,12/19/2007,Designated,,,chronic pouchitis,,,,,,,
3586,squalamine lactate,Treatment of ovarian cancer refractory or resistant to standard chemotherapy,05/11/2001,Designated,Q27260597,,ovarian cancer refractory or resistant to standard chemotherapy,,,,,,,
3588,stabilized sulforaphane,Treatment of subarachnoid hemorrhage,08/22/2016,Designated,,,subarachnoid hemorrhage,,http://purl.obolibrary.org/obo/HP_0002138,,D013345,,,Q693442
3589,staphylococcal aureus protein A,Treatment of immune thrombocytopenic purpura,06/10/2015,Designated,,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3593,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,Treatment of myelodysplastic syndrome.,11/13/2014,Designated,,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
3594,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,Treatment of Hodgkin lymphoma.,11/13/2014,Designated,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
3595,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,Treatment of acute lymphoblastic leukemia.,11/13/2014,Designated,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
3596,stemchymal,Treatment of polyqlutamine spinocerebellar ataxia,12/16/2015,Designated,,,polyqlutamine spinocerebellar ataxia,,,,,,,
3598,Sterile talc,Treatment of malignant pleural effusion.,12/08/1997,Designated,,,malignant pleural effusion,,,,D016066,,,
3599,Sterile talc,Treatment of pneumothorax.,12/08/1997,Designated,,,pneumothorax,http://purl.obolibrary.org/obo/DOID_1673,http://purl.obolibrary.org/obo/HP_0002107,,D011030,Q203601,,Q203601
3600,Sterile talc powder,Treatment of malignant pleural effusion.,09/18/1995,Designated/Approved,,,malignant pleural effusion,,,,D016066,,,
3601,stiripentol,Treatment of Dravet syndrome,10/30/2008,Designated,Q412182,,dravet syndrome,http://purl.obolibrary.org/obo/DOID_0060171,,http://www.orpha.net/ORDO/Orphanet_33069,D004831,Q1255956,Q1255956,Q17147280
3602,substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits,Treatment of sickle cell disease.,10/23/1987,Designated/Withdrawn,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
3603,Substituted imidazopyridine amide,Treatment of active tuberculosis (TB).,12/22/2015,Designated,,,active tuberculosis (tb),,,,,,,
3604,Succimer,Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.,11/05/1990,Designated,Q423814,,cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development,,,,,,,
3605,Succimer,Treatment of mercury intoxication.,03/22/1991,Designated,Q423814,,mercury intoxication,,,http://www.orpha.net/ORDO/Orphanet_330021,,,,
3606,Succimer,Treatment of lead poisoning in children.,05/09/1984,Designated/Approved,Q423814,,lead poisoning in children,,,,,,,
3607,Sucralfate,Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.,07/15/1993,Designated/Withdrawn,Q420394,,oral mucositis and stomatitis following radiation therapy for head and neck cancer,,,,,,,
3608,Sucralfate suspension,Treatment of oral complications of chemotherapy in bone marrow transplant patients.,03/12/1990,Designated,,,oral complications of chemotherapy in bone marrow transplant patients,,,,,,,
3609,Sucralfate suspension,Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.,03/04/1991,Designated,,,oral ulcerations and dysphagia in patients with epidermolysis bullosa,,,,,,,
3612,Sulfapyridine,Treatment of dermatitis herpetiformis.,09/10/1990,Designated,Q3976827,,dermatitis herpetiformis,http://purl.obolibrary.org/obo/DOID_8505,,http://www.orpha.net/ORDO/Orphanet_1656,D003874,Q1151507,,Q1151507
3613,sulfonated monophosphorylated mannose oligosaccharide,Treatment of hepatocellular carcinoma,02/17/2012,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3614,sulthiame,Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy,07/25/2013,Designated,Q2364943,,patients with benign epilepsy of childhood with centrotemporal spikes (bects) also known as rolandic epilepsy,,,,,,,
3616,Superoxide dismutase (recombinant human),Prevention of reperfusion injury to donor organ tissue.,05/17/1988,Designated/Withdrawn,,,reperfusion injury to donor organ tissue,,,,,,,
3617,"superoxide dismutase, gliadin",Treatment of amyotrophic lateral sclerosis,04/30/2010,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3618,Suramin,Treatment of hormone-refractory prostate cancer.,05/06/1997,Designated,Q425946,,hormone-refractory prostate cancer,,,,,,,
3619,Surfactant (human) (amniotic fluid derived),Prevention and treatment of neonatal respiratory distress syndrome.,03/25/1987,Designated/Withdrawn,,,treatment of neonatal respiratory distress syndrome,,,,,,,
3620,Synsorb Pk,Treatment of verocytotoxogenic E. coli infections.,07/17/1995,Designated,,,verocytotoxogenic e. coli infections,,,,,,,
3621,Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH,Treatment of ovarian cancer.,02/04/2016,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3622,synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA,Prevention of scarring post glaucoma filtration surgery,06/04/2014,Designated,,,scarring post glaucoma filtration surgery,,,,,,,
3623,"Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide",Treatment of hepatitis D virus infection.,03/31/2015,Designated,,,hepatitis d virus infection,,,,,,,
3625,synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene,Treatment of primary hyperoxaluria type 1,04/22/2015,Designated,,,primary hyperoxaluria type 1,,,http://www.orpha.net/ORDO/Orphanet_119538,,,,
3626,synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA,Treatment of hemophilia A,08/16/2013,Designated,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
3627,synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA,Treatment of hemophilia B,08/12/2013,Designated,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
3628,Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA,Treatment of ischemic optic neuropathy,09/25/2012,Designated,,,ischemic optic neuropathy,http://purl.obolibrary.org/obo/DOID_12010,,,D018917,Q362719,,Q7234207
3630,synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA,Treatment of familial amyloidotic polyneuropathy,06/14/2012,Designated,,,familial amyloidotic polyneuropathy,,,,,,,
3631,synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA,Treatment of primary hyperoxaluria type 1,02/08/2016,Designated,,,primary hyperoxaluria type 1,,,http://www.orpha.net/ORDO/Orphanet_119538,,,,
3632,Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide targeting delta-aminoevulinic acid synthase 1,Treatment of acute hepatic porphyria,08/29/2016,Designated,,,acute hepatic porphyria,,,http://www.orpha.net/ORDO/Orphanet_95157,,,,
3633,Synthetic Human Parathyroid Hormone 1-34,Treatment of hypoparathyroidism,01/26/2001,Designated/Withdrawn,,,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
3639,synthetic oligomer of 16 nucleotides,Treatment of myotonic dystrophy Type I,01/13/2015,Designated,,,myotonic dystrophy type i,,,,,,,
3640,synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH,Treatment of necrotizing soft tissue infections (NSTI),10/12/2011,Designated,,,necrotizing soft tissue infections (nsti),,,,,,,
3641,synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys,Treatment of high altitude pulmonary edema,01/16/2013,Designated,,,high altitude pulmonary edema,,,,,,,
3646,synthetic signal peptide of human mucin-1 (amino acids 1-21),Treatment of multiple myeloma.,06/16/2015,Designated,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3647,"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue",Treatment of preterm neonatal respiratory distress syndrome,03/16/2012,Designated,,,preterm neonatal respiratory distress syndrome,,,,,,,
3648,"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine",Treatment of Pediatric Multiple Sclerosis,02/06/2014,Designated,,,pediatric multiple sclerosis,,,,,,,
3649,T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells,Treatment of chronic granulomatous disease,11/01/2001,Designated,,,chronic granulomatous disease,http://purl.obolibrary.org/obo/DOID_3265,,http://www.orpha.net/ORDO/Orphanet_379,D006105,Q2165663,Q2165663,Q2165663
3651,tabalumab,Treatment of multiple myeloma,11/19/2012,Designated/Withdrawn,Q7672878,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3652,taberminogene vadenovec,Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.,10/24/2000,Designated,,,complications due to neointimal hyperplasia disease in certain vascular anastomoses,,,,,,,
3654,tacrolimus,Treatment of hemorrhagic cystitis,07/06/2012,Designated,Q27130595,,hemorrhagic cystitis,http://purl.obolibrary.org/obo/DOID_0050859,,,,Q5712565,,
3657,tacrolimus,Treatment of pulmonary arterial hypertension,05/04/2015,Designated,Q27130595,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3658,tacrolimus,Treatment of pulmonary arterial hypertension.,03/16/2015,Designated,Q27130595,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3659,Tacrolimus granules for oral suspension,"Prevention of rejection in kidney, liver or heart transplant in pediatric patients.",10/04/2016,Designated,,,"rejection in kidney, liver or heart transplant in pediatric patients",,,,,,,
3660,tadalafil,Treatment of Duchenne Muscular Dystrophy (DMD),05/04/2015,Designated,Q424156,,duchenne muscular dystrophy (dmd),,,,,,,
3661,tadalafil,Treatment of pulmonary arterial hypertension,12/18/2006,Designated/Approved,Q424156,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3662,tadekinig alfa,Treatment of hemophagocytic lymphohistiocytosis.,01/12/2017,Designated,,,hemophagocytic lymphohistiocytosis,http://purl.obolibrary.org/obo/DOID_0050120,,http://www.orpha.net/ORDO/Orphanet_158032,D051359,Q1642170,,Q1642170
3663,tafamidis,Treatment of familial amyloid polyneuropathy,05/23/2006,Designated,Q519447,,familial amyloid polyneuropathy,http://purl.obolibrary.org/obo/DOID_0050638,,,D028227,Q2844603,,
3664,tafamidis meglumine,Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.,02/17/2012,Designated,Q27148396,,symptomatic transthyretin (ttr) amyloid cardiomyopathy,,,,,,,
3665,tafenoquine,Treatment of malaria,01/15/2013,Designated,Q2387553,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
3666,Talactoferrin alfa,Treatment of stage III/IV non-small cell lung cancer,08/08/2007,Designated/Withdrawn,,,stage iii/iv non-small cell lung cancer,,,,,,,
3669,talactoferrin alfa,Treatment of renal cell carcinoma,09/29/2006,Designated/Withdrawn,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
3670,talampanel,Treatment of amyotrophic lateral sclerosis,03/24/2008,Designated/Withdrawn,Q7678869,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
3671,talampanel,Treatment of glioma,02/17/2009,Designated/Withdrawn,Q7678869,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
3672,talarazole,Treatment of congenital ichthyosis,03/16/2012,Designated/Withdrawn,,,congenital ichthyosis,,http://purl.obolibrary.org/obo/HP_0007431,,,,,
3673,Taliglucerase alfa,Treatment of Gaucher's disease,09/03/2009,Designated/Approved,Q7679506,,gaucher's disease,http://purl.obolibrary.org/obo/DOID_1926,,,D005776,Q861645,,Q861645
3674,talimogene laherparepvec,Treatment of stage IIb-stage IV melanoma,03/14/2011,Designated/Approved,Q7679524,,stage iib-stage iv melanoma,,,,,,,
3675,Talotrexin,Treatment of acute lymphoblastic leukemia,05/08/2006,Designated/Withdrawn,Q27273768,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
3676,Tamibarotene,Treatment of acute promyelocytic leukemia (APL).,10/11/2007,Designated,Q7681221,,acute promyelocytic leukemia (apl),,,,,,,
3677,Tanespimycin,Treatment of multiple myeloma,09/09/2004,Designated,Q4552288,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3678,tarextumab,Treatment of pancreatic cancer,01/26/2015,Designated,Q25098812,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3679,tarextumab,Treatment of small cell lung cancer,01/26/2015,Designated,Q25098812,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
3680,Targeted Gastrin 17 Complexed Peptide,Treatment of pancreatic cancer,05/14/2014,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3682,tasimelteon,Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion,04/30/2010,Designated,Q7687250,,sleep-wake disorder in smith-magenis syndrome associated with diurnal melatonin secretion,,,,,,,
3683,tasisulam sodium,Treatment of melanoma stages IIB through IV,09/03/2009,Designated/Withdrawn,Q27285273,,melanoma stages iib through iv,,,,,,,
3684,taurine,Treatment of cystathionine beta-synthase deficient homocystinuria,03/22/2010,Designated,Q207051,XOAAWQZATWQOTB-UHFFFAOYSA-N,cystathionine beta-synthase deficient homocystinuria,,,,,,,
3685,taurolidine,Treatment of pancreatic cancer.,05/16/2016,Designated,Q3981568,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3686,Taxol isolated from Taxus brevifolia,Treatment of ovarian cancer.,10/15/1990,Designated/Withdrawn,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3687,tazemetostat,Treatment of malignant rhabdoid tumors (MRTs),02/04/2016,Designated,Q27088941,,malignant rhabdoid tumors (mrts),,,,,,,
3688,TD-K6a.513a.12,Treatment of pachyonychia congenita,06/15/2006,Designated,,,pachyonychia congenita,http://purl.obolibrary.org/obo/DOID_0050449,,http://www.orpha.net/ORDO/Orphanet_2309,D053549,Q3360152,,Q3360152
3695,Technetium Tc99m rh-Annexin V,"Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.",11/03/2000,Designated,,,"assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants",,,,,,,
3697,tecovirimat,Treatment of orthopoxvirus infections.,09/29/2010,Designated,Q27277828,,orthopoxvirus infections,,,,,,,
3699,tecovirimat,Treatment of smallpox.,12/27/2006,Designated,Q27277828,,smallpox,http://purl.obolibrary.org/obo/DOID_8736,,,D012899,Q12214,,Q18558071
3700,teduglutide [rDNA origin],Treatment of short bowel syndrome.,06/29/2000,Designated/Approved,Q7694156,,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
3701,Tegafur/gimeracil/oteracil,Treatment of gastric cancer,07/20/2006,Designated,Q15410179,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3702,telatinib,Treatment of gastric cancer,05/17/2010,Designated,Q27252023,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3703,telotristat etiprate,Treatment of carcinoid syndrome in patients with neuroendocrine tumors,03/09/2012,Designated,Q27257995,,carcinoid syndrome in patients with neuroendocrine tumors,,,,,,,
3704,temocillin sodium,Treatment of pulmonary infections caused by Burkholderia cepacia,04/21/2004,Designated,Q27123437,,pulmonary infections caused by burkholderia cepacia,,,,,,,
3706,Temozolomide,Treatment of newly diagnosed high grade glioma,10/18/2004,Designated,Q425088,,newly diagnosed high grade glioma,,,,,,,
3707,temozolomide,Treatment of recurrent malignant glioma.,10/05/1998,Designated/Approved,Q425088,,recurrent malignant glioma,,,,,,,
3708,Temozolomide,Treatment of advanced metastatic melanoma.,10/14/1998,Designated,Q425088,,advanced metastatic melanoma,,,,,,,
3709,temozolomide,Treatment glioblastoma multiforme in pediatric patients,11/25/2015,Designated,Q425088,,multiforme in pediatric patients,,,,,,,
3710,Temsirolimus,Treatment of renal cell carcinoma,12/16/2004,Designated/Approved,Q7699074,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
3712,Teniposide,Treatment of refractory childhood acute lymphocytic leukemia.,11/01/1984,Designated/Approved,Q417555,,refractory childhood acute lymphocytic leukemia,,,,,,,
3713,tenofovir,Treatment of pediatric HIV infection.,03/17/2009,Designated/Approved,Q155954,,pediatric hiv infection,,,,,,,
3714,tenofovir disoproxil fumarate,Prevention of mother to child transmission of hepatitis B virus,09/27/2016,Designated,Q27132754,,mother to child transmission of hepatitis b virus,,,,,,,
3715,teplizumab,Treatment of recent-onset Type I diabetes,09/29/2006,Designated,Q7701358,,recent-onset type i diabetes,,,,,,,
3716,teprotumumab,Treatment of active (dynamic) phase Grave's orbitopathy,05/06/2013,Designated,Q7701391,,active (dynamic) phase grave's orbitopathy,,,,,,,
3717,terguride,Treatment of pulmonary arterial hypertension,05/02/2008,Designated/Withdrawn,Q7702355,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3718,terguride,Treatment of systemic sclerosis,05/17/2013,Designated,Q7702355,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
3720,Teriparatide,Treatment of idiopathic osteoporosis.,10/28/1999,Designated,Q411781,,idiopathic osteoporosis,,,,,,,
3721,teriparatide,Treatment of hypoparathyroidism,04/18/2014,Designated,Q411781,,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
3722,terlipressin,Treatment of ascites due to all etiologies except cancer,09/08/2016,Designated,Q324147,,ascites due to all etiologies except cancer,,,,,,,
3723,Terlipressin,Treatment of bleeding esophageal varices.,03/06/1986,Designated,Q324147,,bleeding esophageal varices,http://purl.obolibrary.org/obo/DOID_112,,,,Q298278,,
3724,terlipressin,Treatment of Hepatorenal Syndrome,10/29/2004,Designated,Q324147,,hepatorenal syndrome,http://purl.obolibrary.org/obo/DOID_11823,,,D006530,Q247131,,Q247131
3725,tesetaxel,Treatment of gastric cancer,12/22/2008,Designated,Q7705452,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3726,tesetaxel,"Treatment of stages IIB, IIC, III, and stage IV melanoma",11/21/2008,Designated,Q7705452,,"stages iib, iic, iii, and stage iv melanoma",,,,,,,
3727,Tesevatinib,Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD),03/01/2016,Designated,Q27277731,,patients with autosomal recessive polycystic kidney disease (arpkd),,,,,,,
3728,Testosterone,Treatment of weight loss in AIDS patients with HIV-associated wasting.,02/05/1996,Designated/Withdrawn,Q1318776,,weight loss in aids patients with hiv-associated wasting,,,,,,,
3730,Testosterone propionate ointment 2%,Treatment of vulvar dystrophies.,07/31/1991,Designated,,,vulvar dystrophies,,,,,,,
3731,Testosterone sublingual,Treatment of constitutional delay of growth and puberty in boys.,01/16/1991,Designated/Withdrawn,,,constitutional delay of growth and puberty in boys,,,,,,,
3732,testosterone undecanoate (oral),Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age),02/13/2013,Designated,,,constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age),,,,,,,
3734,tetra-substituted porphyrin derivative containing manganese (III),Treatment of idiopathic pulmonary fibrosis,03/16/2015,Designated,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3735,Tetrabenazine,Treatment of Huntington's disease,12/11/1997,Designated/Approved,Q413050,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3736,Tetrabenazine,Treatment of moderate/severe tardive dyskinesia.,05/12/1998,Designated,Q413050,,moderate/severe tardive dyskinesia,,,,,,,
3737,tetrabenazine,"Treatment of Tourette's Syndrome in school-age children, ages 5-16",07/01/2009,Designated,Q413050,,"tourette's syndrome in school-age children, ages 5-16",,,,,,,
3738,tetracosactide hexaacetate (beta 1-24-corticotrophin),Treatment of infantile spasms,10/31/2012,Designated,,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
3739,"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride",Treatment of infantile spasms,06/20/2016,Designated,Q27252594,FEQOLYDPQKHFTD-UHFFFAOYSA-N,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
3741,tetrandrine,Treatment of chronic myeloid leukemia.,05/19/2016,Designated,Q7706612,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
3742,tetrandrine,Treatment of acute myeloid leukemia.,12/13/2016,Designated,Q7706612,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3743,Tezacitabine,Treatment of adenocarcinoma of the esophagus and stomach,01/27/2003,Designated,Q27291019,,adenocarcinoma of the esophagus and stomach,,,,,,,
3744,Thalidomide,Prevention of graft versus host disease.,03/05/1990,Designated,Q203174,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
3745,Thalidomide,Treatment and maintenance of reactional lepromatous leprosy.,11/15/1988,Designated,Q203174,,maintenance of reactional lepromatous leprosy,,,,,,,
3746,Thalidomide,Treatment of Kaposi's sarcoma.,07/29/1998,Designated,Q203174,,kaposi's sarcoma,http://purl.obolibrary.org/obo/DOID_8632,http://purl.obolibrary.org/obo/HP_0100726,,D012514,Q725345,,Q725345
3747,Thalidomide,Treatment of erythema nodosum leprosum.,07/26/1995,Designated/Approved,Q203174,,erythema nodosum leprosum,,,,,,,
3748,Thalidomide,Treatment of multiple myeloma,10/14/1998,Designated/Approved,Q203174,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3749,Thalidomide,Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.,01/12/1993,Designated,Q203174,,the clinical manifestations of mycobacterial infection caused by mycobacterium tuberculosis and non-tuberculous mycobacteria,,,,,,,
3750,Thalidomide,Treatment of graft versus host disease.,03/05/1990,Designated,Q203174,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
3751,Thalidomide,Treatment of Crohn's disease.,04/06/1999,Designated,Q203174,,crohn's disease,http://purl.obolibrary.org/obo/DOID_8778,http://purl.obolibrary.org/obo/HP_0100280,,D003424,Q1472,,Q18553712
3752,Thalidomide,"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.",05/15/1995,Designated,Q203174,,"prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients",,,,,,,
3753,Thalidomide,Treatment of primary brain malignancies.,02/27/1998,Designated,Q203174,,primary brain malignancies,,,,,,,
3755,Thalidomide,"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.",05/01/1995,Designated,Q203174,,"severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients",,,,,,,
3756,Thalidomide,Treatment of HIV-associated wasting syndrome.,03/11/1996,Designated,Q203174,,hiv-associated wasting syndrome,,,,,,,
3757,Thalidomide,Treatment of myelodysplastic syndrome,09/27/2004,Designated,Q203174,,myelodysplastic syndrome,http://purl.obolibrary.org/obo/DOID_0050908,http://purl.obolibrary.org/obo/HP_0002863,http://www.orpha.net/ORDO/Orphanet_52688,D009190,Q954625,,Q954625
3763,thioureidobutyronitrile,Treatment of pancreatic cancer.,01/20/2016,Designated,,ZODHXFMUSIYFBE-UHFFFAOYSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3764,thioureidobutyronitrile,Treatment of retinoblastoma.,11/17/2015,Designated,,ZODHXFMUSIYFBE-UHFFFAOYSA-N,retinoblastoma,http://purl.obolibrary.org/obo/DOID_768,http://purl.obolibrary.org/obo/HP_0009919,http://www.orpha.net/ORDO/Orphanet_790,D012175,Q500695,,Q18556413
3765,thioureidobutyronitrile,Treatment of ovarian cancer,07/14/2015,Designated,,ZODHXFMUSIYFBE-UHFFFAOYSA-N,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3766,"three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein",Treatment of ebola virus infection,07/14/2016,Designated,,,ebola virus infection,,,,D019142,,,Q8064876
3767,Thymalfasin,Treatment of chronic active hepatitis B.,05/03/1991,Designated,Q20817234,,chronic active hepatitis b,,,,,,,
3768,Thymalfasin,Treatment of DiGeorge anomaly with immune defects.,01/08/1998,Designated,Q20817234,,digeorge anomaly with immune defects,,,,,,,
3769,Thymalfasin,Treatment of hepatocellular carcinoma.,03/06/2000,Designated,Q20817234,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3770,Thymalfasin,Treatment of stage IIb through Stage IV malignant melanoma,03/13/2006,Designated,Q20817234,,stage iib through stage iv malignant melanoma,,,,,,,
3771,thymopentin,Treatment of sarcoidosis.,02/04/2011,Designated,Q7799637,,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
3772,thymosin beta 4,Treatment of patients with neurotrophic keratopathy,12/31/2013,Designated,,,patients with neurotrophic keratopathy,,,,,,,
3773,Thymosin beta 4,Treatment of epidermolysis bullosa.,05/28/2004,Designated,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
3775,Thyrotropin alfa,"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",08/03/2001,Designated/Approved,Q20816877,,"well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",,,,,,,
3777,Tiapride,Treatment of Tourette's syndrome.,04/21/1998,Designated/Withdrawn,Q416414,,tourette's syndrome,,,,D005879,,,Q191779
3779,tigecycline,Treatment of acute myeloid leukemia.,10/23/2013,Designated,Q420595,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3780,Tilarginine acetate,Treatment of cardiogenic shock,04/11/2005,Designated,Q27254685,,cardiogenic shock,,http://purl.obolibrary.org/obo/HP_0030149,,D012770,,,
3781,tin ethyl etiopurpurin,Prevention of access graft disease in hemodialysis patients,11/04/2003,Designated,,,access graft disease in hemodialysis patients,,,,,,,
3782,tinidazole,Treatment of giardiasis,04/18/2002,Designated/Approved,Q1321320,,giardiasis,http://purl.obolibrary.org/obo/DOID_10718,,,D005873,Q326071,,Q326071
3783,Tinidazole,Treatment of amebiasis,08/20/2003,Designated/Approved,Q1321320,,amebiasis,http://purl.obolibrary.org/obo/DOID_9181,,,D000562,Q949694,,Q949694
3784,Tiopronin,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,01/17/1986,Designated/Approved,Q414456,,cystine nephrolithiasis in patients with homozygous cystinuria,,,,,,,
3786,tipelukast,Treatment of idiopathic pulmonary fibrosis,10/20/2014,Designated,Q27236352,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3787,Tipifarnib,Treatment of acute myeloid leukemia,07/06/2004,Designated,Q7808830,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3788,tiprelestat,Treatment of pulmonary arterial hypertension,12/28/2012,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3789,tirapazamine,Treatment of hepatocellular carcinoma,11/30/2015,Designated,Q3529346,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3790,tirapazamine,Treatment of head and neck cancer,10/23/2002,Designated,Q3529346,,head and neck cancer,http://purl.obolibrary.org/obo/DOID_11934,http://purl.obolibrary.org/obo/HP_0012288,,D006258,Q1783924,,Q1783924
3791,tirasemtiv,Treatment of amyotrophic lateral sclerosis (ALS),03/02/2010,Designated,Q27088998,,amyotrophic lateral sclerosis (als),,,,,,,
3793,tisagenlecleucel-T,Treatment of diffuse large B-cell lymphoma,02/03/2015,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
3794,Tissue Plasminogen activator,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,04/18/2011,Designated,,,acute ischemic stroke (ais) in children age 16 years and younger,,,,,,,
3795,Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system,Treatment of osteonecrosis.,03/13/2006,Designated,,,osteonecrosis,http://purl.obolibrary.org/obo/DOID_10159,http://purl.obolibrary.org/obo/HP_0010885,http://www.orpha.net/ORDO/Orphanet_399158,D010020,Q503629,,Q503629
3796,Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system,Treatment of dilated cardiomyopathy,01/25/2007,Designated,,,dilated cardiomyopathy,http://purl.obolibrary.org/obo/DOID_12930,http://purl.obolibrary.org/obo/HP_0001644,http://www.orpha.net/ORDO/Orphanet_217604,D002311,Q283656,Q283656,Q283656
3798,tivantinib,Treatment of hepatocelular carcinoma,10/16/2013,Designated,Q17123902,,hepatocelular carcinoma,,,,,,,
3799,Tizanidine HCl,Treatment of spasticity associated with multiple sclerosis and spinal cord injury.,01/31/1994,Designated,,,spasticity associated with multiple sclerosis and spinal cord injury,,,,,,,
3800,Tobramycin,Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.,06/18/1999,Designated,Q1758380,,bronchiectasis patients infected with pseudomonas aeruginosa,,,,,,,
3801,Tobramycin for inhalation,Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.,10/13/1994,Designated/Approved,,,bronchopulmonary infections of pseudomonas aeruginosa in cystic fibrosis patients,,,,,,,
3802,tobramycin liposomal,Treatment of pulmonary infection due to Burkholderia cepacia complex pathogens in cystic fibrosis patients,05/11/2009,Designated/Withdrawn,,,pulmonary infection due to burkholderia cepacia complex pathogens in cystic fibrosis patients,,,,,,,
3803,tobramycin liposomal for inhalation,Treatment of chronic pulmonary infection due to P. aeruginosa in cystic fibrosis patients,04/14/2009,Designated/Withdrawn,,,chronic pulmonary infection due to p. aeruginosa in cystic fibrosis patients,,,,,,,
3804,tocilizumab,Treatment of systemic sclerosis,04/17/2013,Designated,Q425154,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
3805,tocilizumab,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,07/31/2012,Designated/Approved,Q425154,,pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,,,,,,,
3806,Tocophersolan oral solution (vitamin E-tpgs),Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.,04/15/1988,Designated/Withdrawn,,,vitamin e deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease,,,,,,,
3807,Tolcapone,Treatment of transthyretin amyloidosis,12/24/2013,Designated,Q413840,,transthyretin amyloidosis,http://purl.obolibrary.org/obo/DOID_0050638,,,,Q2844603,,
3808,tolerogen,Treatment of myasthenia gravis,02/05/2015,Designated,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
3809,tolfenamic acid,Treatment of progressive supranuclear palsy,07/13/2016,Designated,Q59412,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
3810,tolfenamic acid,Treatment of Frontotemporal Dementia,07/13/2016,Designated,Q59412,,frontotemporal dementia,http://purl.obolibrary.org/obo/DOID_9255,http://purl.obolibrary.org/obo/HP_0002145,http://www.orpha.net/ORDO/Orphanet_282,D057180,Q18592,Q18592,
3811,tolvaptan,Treatment of autosomal dominant polycystic kidney disease,04/06/2012,Designated,Q426132,,autosomal dominant polycystic kidney disease,,,,,,,
3812,Topiramate,Treatment of Lennox-Gastaut syndrome.,11/25/1992,Designated/Approved,Q221174,,lennox-gastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
3813,topiramate injection,Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate,07/24/2013,Designated,,,partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate,,,,,,,
3814,toralizumab,Treatment of immune thrombocytopenic purpura,03/14/2002,Designated/Withdrawn,Q7825392,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3816,Toremifene,Treatment of desmoid tumors.,08/17/1993,Designated,Q3993743,,desmoid tumors,,http://purl.obolibrary.org/obo/HP_0100245,,,,,
3817,Tosedostat,Treatment of acute myeloid leukemia,12/10/2008,Designated,Q27166812,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3818,Tositumomab and iodine I 131 tositumomab,Treatment of non-Hodgkin's B-cell lymphoma.,05/16/1994,Designated/Approved,,,non-hodgkin's b-cell lymphoma,,,,,,,
3819,trabectedin,Treatment of patients with ovarian cancer,03/29/2005,Designated,Q2637746,,patients with ovarian cancer,,,,,,,
3820,trabectedin,Treatment of soft tissue sarcoma,09/30/2004,Designated/Approved,Q2637746,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
3821,trabedersen,Treatment of malignant glioma,06/05/2002,Designated,,,malignant glioma,http://purl.obolibrary.org/obo/DOID_3070,,,D005910,Q1365309,,Q18556612
3822,trabedersen,Treatment of pancreatic cancer.,07/21/2009,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3823,trabedersen,Treatment of Stage IIB through Stage IV malignant melanoma.,08/22/2011,Designated,,,stage iib through stage iv malignant melanoma,,,,,,,
3824,tralokinumab,Treatment of idiopathic pulmonary fibrosis,07/24/2012,Designated/Withdrawn,Q7833105,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
3826,Tramadol hydrochloride,Treatment of painful HIV-associated neuropathy,01/28/2005,Designated,Q27145507,,painful hiv-associated neuropathy,,,,,,,
3827,trametinib,Treatment of Stage IIb through Stage IV melanoma,12/20/2010,Designated/Approved,Q7833138,,stage iib through stage iv melanoma,,,,,,,
3828,trametinib and dabrafenib,Treatment of Stage IIb through IV melanoma.,09/20/2012,Designated/Approved,,,stage iib through iv melanoma,,,,,,,
3829,tranexamic acid,Treatment of hereditary angioneurotic edema,09/09/1985,Designated/Approved/Withdrawn,Q418666,,hereditary angioneurotic edema,,,http://www.orpha.net/ORDO/Orphanet_91378,D054179,,,Q2096745
3831,tranilast,Prevention of scarring following glaucoma filtration surgery,12/23/2010,Designated,Q2325594,,scarring following glaucoma filtration surgery,,,,,,,
3832,trans sodium crocetinate,Treatment of brain metastasis,12/03/2012,Designated,Q7833703,,brain metastasis,,,,,,,
3833,trans sodium crocetinate,Treatment of glioblastoma in conjunction with radiotherapy,07/21/2011,Designated,Q7833703,,glioblastoma in conjunction with radiotherapy,,,,,,,
3834,Transforming growth factor-beta 2,Treatment of full thickness macular holes.,12/18/1992,Designated,,,full thickness macular holes,,,,,,,
3835,transforming growth factor-beta receptor 1 kinase inhibitor,Treatment of hepatocellular carcinoma,04/01/2013,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3836,transforming growth factor-beta receptor 1 kinase inhibitor,Treatment of glioma,03/11/2013,Designated,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
3837,Transgenic human alpha 1 antitrypsin,Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.,05/19/1999,Designated,,,emphysema secondary to alpha 1 antitrypsin deficiency,,,,,,,
3838,trastuzumab,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction",10/13/2009,Designated/Approved,Q412616,,"her2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction",,,,,,,
3839,trastuzumab,Treatment of patients with pancreatic cancer that overexpress p185HER2.,12/14/1999,Designated,Q412616,,patients with pancreatic cancer that overexpress p185her2,,,,,,,
3841,trebananib,Treatment of ovarian cancer,08/30/2013,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3842,trehalose,Treatment of occulopharyngeal muscular dystrophy,10/25/2013,Designated,Q27109935,,occulopharyngeal muscular dystrophy,,,,,,,
3843,trehalose,Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease),11/17/2014,Designated,Q27109935,,spinal cerebellar ataxia type 3 (also known as sca3 or machado joseph disease),,,,,,,
3844,tremelimumab,Treatment of malignant mesothelioma,03/18/2015,Designated,Q7838098,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
3845,tremelimumab,Treatment of stage IIb to stage IV metastatic melanoma,09/18/2006,Designated,Q7838098,,stage iib to stage iv metastatic melanoma,,,,,,,
3847,Treosulfan,Treatment of ovarian cancer.,05/16/1994,Designated,Q7838652,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3848,treprostinil,Treatment of pulmonary arterial hypertension.,06/04/1997,Designated/Approved,Q3495231,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3849,treprostinil (inhalational),Treatment of pulmonary arterial hypertension,06/17/2010,Designated/Approved,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3850,"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump",Treatment of pulmonary arterial hypertension,12/29/2015,Designated,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3851,Tretinoin,Treatment of acute and chronic leukemia.,01/14/1993,Designated,Q29417,,acute and chronic leukemia,,,,,,,
3852,Tretinoin,Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.,04/15/1985,Designated,Q29417,,squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization,,,,,,,
3853,Tretinoin,Treatment of T-cell non-Hodgkin's lymphoma,04/11/2003,Designated,Q29417,,t-cell non-hodgkin's lymphoma,,,,,,,
3854,Tretinoin,Treatment of acute promyelocytic leukemia.,10/24/1990,Designated/Approved,Q29417,,acute promyelocytic leukemia,http://purl.obolibrary.org/obo/DOID_0060318,http://purl.obolibrary.org/obo/HP_0004836,http://www.orpha.net/ORDO/Orphanet_520,D015473,Q612108,Q612108,Q612108
3855,tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate,Treatment for hepatocellular carcinoma,11/23/2001,Designated,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
3856,triciribine,Treatment of multiple myeloma,02/01/2008,Designated,Q27887003,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3857,triclabendazole,Treatment of fascioliasis.,06/27/2016,Designated,Q419739,,fascioliasis,http://purl.obolibrary.org/obo/DOID_885,,,D005211,Q719656,,Q719656
3858,Trientine HCl,"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.",12/24/1984,Designated/Approved,,,"patients with wilson's disease who are intolerant, or inadequately responsive to penicillamine",,,,,,,
3859,trientine hydrochloride,Treatment of manganism.,11/02/2010,Designated,Q27279855,,manganism,,,http://www.orpha.net/ORDO/Orphanet_306682,,,,
3860,trientine tetrahydrochloride,treatment of Wilsonâ€™s disease,03/10/2016,Designated,Q27266138,,wilsonâ€™s disease,,,,,,,
3861,trifarotene,Treatment of congenital ichthyosis,06/06/2014,Designated,Q27236856,,congenital ichthyosis,,http://purl.obolibrary.org/obo/HP_0007431,,,,,
3862,triheptanoin,Treatment of glucose transporter type-1 deficiency syndrome,10/21/2014,Designated,Q414576,,glucose transporter type-1 deficiency syndrome,,,,,,,
3863,triheptanoin,Treatment of fatty acid oxidation disorders,04/15/2015,Designated,Q414576,,fatty acid oxidation disorders,,,,,,,
3864,Triheptanoin,Treatment of glycogen storage disorder II (Pompe disease),02/01/2008,Designated,Q414576,,glycogen storage disorder ii (pompe disease),,,,,,,
3865,Triheptanoin,Treatment of fatty acid disorders,05/26/2006,Designated,Q414576,,fatty acid disorders,,,,,,,
3866,Trimetrexate,Treatment of metastatic osteogenic sarcoma.,08/10/2000,Designated/Withdrawn,Q7842225,,metastatic osteogenic sarcoma,,,,,,,
3867,Trimetrexate glucuronate,Treatment of pancreatic adenocarcinoma.,07/25/1985,Designated/Withdrawn,Q27282570,,pancreatic adenocarcinoma,http://purl.obolibrary.org/obo/DOID_4074,http://purl.obolibrary.org/obo/HP_0006725,,,Q18556189,,
3868,Trimetrexate glucuronate,Treatment of patients with advanced non-small cell carcinoma of the lung.,01/13/1988,Designated/Withdrawn,Q27282570,,patients with advanced non-small cell carcinoma of the lung,,,,,,,
3869,Trimetrexate glucuronate,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,05/15/1986,Designated/Approved,Q27282570,,pneumocystis carinii pneumonia in aids patients,,,,,,,
3870,triptorelin pamoate,Treatment of central precocious puberty,08/20/2012,Designated,,,central precocious puberty,,,http://www.orpha.net/ORDO/Orphanet_759,,,,
3872,Trisaccharides A and B,Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.,04/12/1987,Designated,,,moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances a and b,,,,,,,
3873,Trisaccharides A and B,Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.,04/15/1988,Designated,,,abo medical hemolytic reactions arising from abo-incompatible bone marrow transplantation,,,,,,,
3874,Trisaccharides A and B,"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives.",08/03/1987,Designated/Withdrawn,,,"moderate to very severe clinical forms of transfusion reactions arising from abo incompatible transfusions of blood, blood products, and blood derivatives",,,,,,,
3877,Trisodium zinc Diethylenetriaminepentaacetate,"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.",02/27/2004,Designated,,,"patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination",,,,,,,
3878,triterpenoid saponin,Treatment of mantle cell lymphoma,07/23/2014,Designated,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
3879,Troleandomycin,Treatment of severe steroid-requiring asthma.,09/21/1989,Designated/Withdrawn,Q1087499,,severe steroid-requiring asthma,,,,,,,
3880,Troxacitabine,Treatment of acute myeloid leukemia,04/04/2005,Designated/Withdrawn,Q7846702,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3882,Tumor necrosis factor-binding protein 1,Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.,01/06/1993,Designated,,,symptomatic patients with aids including all patients with cd4 counts less than 200 cells per mm3,,,,,,,
3883,Tumor necrosis factor-binding protein II,Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.,01/06/1993,Designated,,,symptomatic patients with the aids including all patients with cd4 t-cell counts less than 200 cells per mm3,,,,,,,
3884,tumor-inflitrating lymphocytes; LN-144,Treatment of malignant melanoma Stages IIb to IV,06/09/2015,Designated,,,malignant melanoma stages iib to iv,,,,,,,
3886,Tyloxapol,Treatment of cystic fibrosis.,03/08/1995,Designated,Q7860340,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3887,Type 1 native bovine skin collagen,Treatment of diffuse systemic sclerosis,02/01/2008,Designated,,,diffuse systemic sclerosis,http://purl.obolibrary.org/obo/DOID_1580,,,D045743,Q18554846,,Q18554846
3888,ubenimex,Treatment of pulmonary arterial hypertension.,11/19/2015,Designated,Q27075116,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
3889,ubiquinol,Treatment of Huntington's Disease,04/12/2004,Designated,Q411963,,huntington's disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
3890,"Ubiquinol, coenzyme Q10, ubiquinone",Treatment of pediatric congestive heart failure,04/12/2004,Designated,,,pediatric congestive heart failure,,,,,,,
3891,Ubiquinone,Treatment of mitochondrial cytopathies.,12/14/1999,Designated,Q321285,,mitochondrial cytopathies,,,,,,,
3892,ublituximab,Treatment of chronic lymphocytic leukemia,08/06/2010,Designated,Q7876570,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3893,ublituximab,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,08/25/2016,Designated,Q7876570,,neuromyelitis optica and neuromyelitis optica spectrum disorder,,,,,,,
3894,ublituximab,Treatment of Nodal marginal zone lymphoma,09/05/2013,Designated,Q7876570,,nodal marginal zone lymphoma,,,,,,,
3895,ublituximab,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)",09/05/2013,Designated,Q7876570,,"extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, malt)",,,,,,,
3896,Ublituximab and phosphoinositide-3-kinase delta inhibitor,Treatment of chronic lymphocytic leukemia,01/05/2017,Designated,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3897,Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor,Treatment of diffuse large B-cell lymphoma,01/19/2017,Designated,,,diffuse large b-cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
3898,udenafil,Treatment of single ventricle congenital heart disease with Fontan physiology,08/31/2015,Designated,Q4815980,,single ventricle congenital heart disease with fontan physiology,,,,,,,
3899,ulocuplumab,Treatment of acute myeloid leukemia,01/12/2015,Designated,Q21098907,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3900,unoprostone isopropyl,Treatment of retinitis pigmentosa,09/16/2010,Designated/Withdrawn,Q27089094,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3901,urea,"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).",11/07/2011,Designated,Q48318,XSQUKJJJFZCRTK-UHFFFAOYSA-N,"rare congenital ichthyoses (child syndrome, collodion baby, congenital ichthyosform erythroderma, conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, kid syndrome, lamellar ichthyosis, netherton syndrome, neutral lipid storage disease, sjorgren-larsson syndrome, trichothiodystrophy, x-linked ichthyosis)",,,,,,,
3902,Urea for intravitreal injection,Treatment of retinitis pigmentosa,12/14/2005,Designated,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
3904,Uridine 5'-triphosphate,Treatment of cystic fibrosis.,12/04/1995,Designated/Withdrawn,,PGAVKCOVUIYSFO-XVFCMESISA-N,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
3906,uridine triacetate,Treatment of mitchondrial disease,09/03/2009,Designated,Q22075857,AUFUWRKPQLGTGF-FMKGYKFTSA-N,mitchondrial disease,,,,,,,
3907,uridine triacetate,Treatment of hereditary orotic aciduria,08/09/2013,Designated/Approved,Q22075857,AUFUWRKPQLGTGF-FMKGYKFTSA-N,hereditary orotic aciduria,,,http://www.orpha.net/ORDO/Orphanet_30,,,,
3911,Ursodiol,Treatment of patients with primary biliary cirrhosis,06/20/1991,Designated/Approved,Q241374,,patients with primary biliary cirrhosis,,,,,,,
3913,ursodiol,Treatment of cystic fibrosis liver disease,10/23/2007,Designated,Q241374,,cystic fibrosis liver disease,,,,,,,
3914,ustekinumab,Treatment of chronic sarcoidosis,12/28/2011,Designated/Withdrawn,Q420305,,chronic sarcoidosis,,,,,,,
3915,ustekinumab,Treatment of pediatric Crohn's disease (0 through 16 years of age),05/18/2016,Designated,Q420305,,pediatric crohn's disease (0 through 16 years of age),,,,,,,
3916,ustekinumab,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,11/29/2010,Designated,Q420305,,type 1 diabetes mellitus patients with residual beta-cell function,,,,,,,
3917,ustekinumab; human monocloncal antibody to interkeukin 12p40,Treatment of primary biliary cirrhosis,12/22/2011,Designated/Withdrawn,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
3918,Vaccinia Immune Globulin (Human) Intravenous,Treatment of severe complications from the smallpox vaccine,06/18/2004,Designated/Approved,,,severe complications from the smallpox vaccine,,,,,,,
3919,Vaccinia Immune Globulin (Human) Intravenous,Treatment of complications of vaccinia vaccination,06/18/2004,Designated/Approved,,,complications of vaccinia vaccination,,,,,,,
3920,vadastuximab talirine,Treatment of acute myeloid leukemia.,11/10/2015,Designated,Q17044502,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3921,"Valine, isoleucine and leucine",Treatment of hyperphenylalaninemia,01/05/1996,Designated,,,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,,,Q7706537,
3922,valine-valine-ganciclovir,Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.,05/21/2007,Designated,,,primary keratoconjunctivitis and recurrent epithelial keratitis due to hsv1 and hsv2,,,,,,,
3923,Valproate,Treatment of fragile X syndrome,05/05/2008,Designated,Q27104876,NIJJYAXOARWZEE-UHFFFAOYSA-M,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
3924,"Valproic acid, sodium",Treatment of familial adenomatous polyposis,06/24/2005,Designated/Withdrawn,,RGZUPIWJTSGERU-UHFFFAOYSA-N,familial adenomatous polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
3925,Valrubicin,Treatment of carcinoma in situ of the urinary bladder.,05/23/1994,Designated/Approved,Q7912593,,carcinoma in situ of the urinary bladder,,,,,,,
3926,valsartan oral solution,Treatment of hypertension in pediatric patients 0 through 16 years of age,10/28/2015,Designated/Withdrawn,,,hypertension in pediatric patients 0 through 16 years of age,,,,,,,
3927,vamorolone,Treatment of Duchenne muscular dystrophy,12/02/2011,Designated,Q27089127,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
3928,vancomycin,Treatment of endophthalmitis,12/27/2012,Designated,Q424027,,endophthalmitis,http://purl.obolibrary.org/obo/DOID_4692,,http://www.orpha.net/ORDO/Orphanet_199323,D009877,Q1294912,,Q1294912
3929,Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer,Treatment of periprosthetic joint infection,01/09/2017,Designated,,,periprosthetic joint infection,,,,,,,
3930,vancomycin hydrochloride (inhalational),Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis,09/20/2012,Designated,,,persistent methicillin-resistant s. aureus lung infection in patients with cystic fibrosis,,,,,,,
3931,vandetanib,"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma",10/21/2005,Designated/Approved,Q7914515,,"patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma",,,,,,,
3932,vapreotide,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,01/10/2000,Designated,Q4008670,,esophageal variceal hemorrhage patients with portal hypertension,,,,,,,
3933,vapreotide,Prevention of early postoperative complications following pancreatic resection.,03/06/2000,Designated,Q4008670,,early postoperative complications following pancreatic resection,,,,,,,
3934,Vapreotide,Treatment of symptomatic carcinoid tumors,04/06/2004,Designated,Q4008670,,symptomatic carcinoid tumors,,,,,,,
3935,vapreotide,Treatment of gastrointestinal and pancreatic fistulas.,01/10/2000,Designated,Q4008670,,gastrointestinal and pancreatic fistulas,,,,,,,
3936,vapreotide,Treatment of acromegaly,11/04/2003,Designated,Q4008670,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
3937,Varbulin,Treatment of glioblastoma multiforme.,11/05/2009,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
3938,varespladib sodium,Prevention of acute chest syndrome in at-risk patients with sickle cell disease,11/19/2007,Designated/Withdrawn,Q27277718,,acute chest syndrome in at-risk patients with sickle cell disease,,,,,,,
3940,Varlitinib,Treatment of cholangiocarcinoma.,08/05/2015,Designated,Q27089126,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
3941,varlitinib,Treatment of gastric cancer.,06/20/2016,Designated,Q27089126,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
3942,vascular endothelial growth factor 165b,Treatment of advanced melanoma stages IIb through IV.,06/24/2008,Designated,,,advanced melanoma stages iib through iv,,,,,,,
3943,Vasoactive intestinal peptide,Treatment of Acute Respiratory Distress Syndrome.,03/09/2001,Designated,,,acute respiratory distress syndrome,,,,D012128,,,Q7315912
3944,vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein,"Treatment of pulmonary arterial hypertension, WHO Group 1",05/13/2014,Designated,,,"pulmonary arterial hypertension, who group 1",,,,,,,
3945,Vasoactive intestinal polypeptide,Treatment of acute esophageal food impaction.,06/23/1993,Designated,,,acute esophageal food impaction,,,,,,,
3946,Vasomera,"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP).",11/19/2015,Designated,,,"cardiomyopathy associated with dystrophinopathies; duchenne muscular dystrophy (dmd), becker muscular dystrophy bmd), and x-linked dilated cardiomyopathy (xl-dcmp)",,,,,,,
3947,vatiquinone,Treatment of Friedreich's ataxia,01/31/2014,Designated,Q27265220,,friedreich's ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
3948,vatiquinone,Treatment of Leigh Syndrome,06/04/2014,Designated,Q27265220,,leigh syndrome,http://purl.obolibrary.org/obo/DOID_3652,,http://www.orpha.net/ORDO/Orphanet_506,D007888,Q1815019,Q1815019,Q1815019
3949,vatiquinone,Treatment of Rett syndrome,11/17/2014,Designated,Q27265220,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
3950,vedolizumab,Prevention of graft versus host disease.,08/04/2016,Designated,Q7918002,,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
3951,velaglucerase-alfa,Treatment of Gaucher disease,06/08/2009,Designated/Approved,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
3952,veliparib,Treatment of hepatocellular carcinoma in combination with DNA-damaging agents,11/20/2009,Designated,Q7919041,,hepatocellular carcinoma in combination with dna-damaging agents,,,,,,,
3953,veliparib,Treatment of brain metastases when used in combination with DNA-damaging agents,12/17/2014,Designated,Q7919041,,brain metastases when used in combination with dna-damaging agents,,,,,,,
3954,veliparib,Treatment of epithelial ovarian cancer in combination with DNA-damaging agents,09/03/2009,Designated,Q7919041,,epithelial ovarian cancer in combination with dna-damaging agents,,,,,,,
3955,veliparib,Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents,05/09/2008,Designated,Q7919041,,glioblastoma multiforme when used in combination with dna-damaging agents,,,,,,,
3956,veliparib,Treatment of squamous non-small cell lung cancer,11/03/2016,Designated,Q7919041,,squamous non-small cell lung cancer,,,,,,,
3957,veltuzumab,Treatment of pemphigus,11/17/2014,Designated,Q4009438,,pemphigus,http://purl.obolibrary.org/obo/DOID_9182,,,D010392,Q1483214,,Q1483214
3958,veltuzumab,Treatment of immune thrombocytopenic purpura.,07/28/2015,Designated,Q4009438,,immune thrombocytopenic purpura,,,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
3959,veltuzumab,Treatment of chronic lymphocytic leukemia,08/28/2008,Designated,Q4009438,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3960,vemurafenib,Treatment of Erdheim-Chester Disease,08/02/2016,Designated,Q423111,,erdheim-chester disease,http://purl.obolibrary.org/obo/DOID_4329,,http://www.orpha.net/ORDO/Orphanet_35687,D031249,Q1349259,,Q1349259
3961,vemurafenib,Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation,11/26/2013,Designated,Q423111,,anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a braf v600 mutation,,,,,,,
3962,vemurafenib,Treatment of hairy cell leukemia (HCL).,08/26/2014,Designated,Q423111,,hairy cell leukemia (hcl),,,,,,,
3963,vemurafenib,Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation,12/20/2010,Designated/Approved,Q423111,,patients with iib to stage iv melanoma positive for the braf(v600) mutation,,,,,,,
3964,vemurafenib,Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation,09/08/2014,Designated,Q423111,,patients with non-small cell lung cancer (nsclc) with braf v600 mutation,,,,,,,
3965,Venetoclax,Treatment of multiple myeloma,08/29/2016,Designated,Q23671272,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3966,venetoclax,Treatment of chronic lymphocytic leukemia,09/20/2012,Designated/Approved,Q23671272,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
3967,venetoclax,Treatment of acute myeloid leukemia.,02/04/2016,Designated,Q23671272,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3968,verteporfin,Treatment of chronic or recurrent central serous chorioretinopathy,03/09/2012,Designated,Q782318,,chronic or recurrent central serous chorioretinopathy,,,,,,,
3969,Vibrio alginolyticus collagenase,Treatment of advanced Dupuytren's disease (Dupuytren's contracture),10/12/2016,Designated,,,advanced dupuytren's disease (dupuytren's contracture),,,,,,,
3971,vigabatrin,Treatment of infantile spasms.,06/12/2000,Designated/Approved,Q421663,,infantile spasms,,http://purl.obolibrary.org/obo/HP_0012469,http://www.orpha.net/ORDO/Orphanet_3451,D013036,,,Q18555095
3972,viloxazine HCL,Treatment of cataplexy and narcolepsy,06/11/1984,Designated/Withdrawn,,,cataplexy and narcolepsy,,,,,,,
3973,vinCRIStine sulfate LIPOSOME injection,Treatment of acute lymphoblastic leukemia,01/08/2007,Designated/Approved,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
3974,vincristine sulfate liposomes,Treatment of metastatic uveal melanoma.,06/24/2008,Designated,,,metastatic uveal melanoma,,,,,,,
3975,vintafolide,Treatment of ovarian cancer,12/16/2013,Designated,Q7932801,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
3976,Virulizin,Treatment of pancreatic cancer.,02/01/2001,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
3977,vitamin A palmitate,Prevention of bronchopulmonary dysplasia.,07/14/2015,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3978,"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide",treatment of familial chylomicronemia syndrome,06/23/2015,Designated,,,familial chylomicronemia syndrome,,,http://www.orpha.net/ORDO/Orphanet_444490,,,,
3979,volasertib,Treatment of acute myeloid leukemia,04/14/2014,Designated,Q7939986,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3980,von Willebrand Factor Human Concentrate,Treatment of Von Willebrand Disease,05/29/2014,Designated,,,von willebrand disease,http://purl.obolibrary.org/obo/DOID_12531,,http://www.orpha.net/ORDO/Orphanet_903,D014842,Q709360,,Q709360
3981,vorinostat,Treatment of multiple myeloma,06/12/2003,Designated/Withdrawn,Q905901,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
3982,vorinostat,"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)",10/13/2016,Designated,Q905901,,"advanced melanoma (stages iib, iic, iii, and iv)",,,,,,,
3983,vorinostat,Treatment of mesothelioma,03/17/2004,Designated/Withdrawn,Q905901,,mesothelioma,,,,D008654,,,Q18555143
3984,vorinostat,Treatment of T-cell non-Hodgkin's lymphoma,03/16/2004,Designated/Approved,Q905901,,t-cell non-hodgkin's lymphoma,,,,,,,
3985,vosaroxin,Treatment of acute myeloid leukemia,10/28/2009,Designated,Q18395775,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
3986,Water-miscible vitamin A palmitate,Prevention of bronchopulmonary dysplasia.,03/26/2010,Designated,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
3987,Wharton's jelly mesenchymal stem cells,Treatment of graft-versus-host disease,09/27/2016,Designated,,,graft-versus-host disease,,,,D006086,,,Q1194520
3988,Xenogeneic hepatocytes,Treatment of severe liver failure.,11/27/1998,Designated,,,severe liver failure,,,,,,,
3989,xenon gas,Treatment of hypoxic ischemic encephalopathy,12/03/2014,Designated,,,hypoxic ischemic encephalopathy,,,,D020925,,,
3991,Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide,Prevention of plague (Yersinia pestis),11/30/2016,Designated,,,plague (yersinia pestis),,,,,,,
3992,Yttrium (90Y) antiferritin polyclonal antibodies,Treatment of Hodgkin's disease.,09/18/2006,Designated,,,hodgkin's disease,,,http://www.orpha.net/ORDO/Orphanet_98293,D006689,,Q209369,Q18557991
3993,Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10,Treatment of soft tissue sarcoma,12/03/2012,Designated,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
3994,Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody,Treatment of ovarian carcinoma.,08/03/1999,Designated,,,ovarian carcinoma,http://purl.obolibrary.org/obo/DOID_4001,,,,Q18556145,,
3995,Zalcitabine,Treatment of AIDS.,06/28/1988,Designated/Approved,Q2344582,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
3996,Zalcitabine,Treatment of AIDS.,12/09/1986,Designated,Q2344582,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
3997,zidovudine,Treatment of AIDS,07/17/1985,Designated/Approved,Q198504,,aids,http://purl.obolibrary.org/obo/DOID_635,,,D000163,Q12199,,Q12199
3998,Zinc acetate,Treatment of Wilson's disease.,11/06/1985,Designated/Approved,Q204639,DJWUNCQRNNEAKC-UHFFFAOYSA-L,wilson's disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
3999,Zoledronate,Treatment of tumor induced hypercalcemia.,08/18/2000,Designated/Approved,Q218507,,tumor induced hypercalcemia,,,,,,,
4000,"zoledronate D,L-lysine monohydrate (ZLM)",Treatment of complex regional pain syndrome (CRPS),04/15/2015,Designated,,,complex regional pain syndrome (crps),,,,,,,
4001,zoledronic acid,Treatment of complex regional pain syndrome (CRPS).,05/06/2013,Designated,Q218507,,complex regional pain syndrome (crps),,,,,,,
4002,Zosuquidar trihydrochloride,Treatment of acute myeloid leukemia,12/15/2005,Designated,Q27269191,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
4003,[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide,"Treatment of metastatic melanoma, stages IIB, IIC, III and IV",09/17/2008,Designated,,,"metastatic melanoma, stages iib, iic, iii and iv",,,,,,,
4004,"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride",Treatment of Amyotrophic Lateral Sclerosis,11/04/2003,Designated,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
4005,"[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt",Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath,02/14/2014,Designated,,CJLUYLRKLUYCEK-UHFFFAOYSA-N,pigmented villonodular synovitis/giant cell tumor of the tendon sheath,,,,,,,
4006,"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",Treatment of pancreatic cancer,10/20/2014,Designated,,IJDQETGUEUJVTB-UHFFFAOYSA-N,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
4007,[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,Treatment of glioblastoma multiforme,05/14/2014,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
4008,[AC3-yCD2(V)] and Flucytosine (5-FC XR),Treatment of glioblastoma multiforme,01/12/2011,Designated,,,glioblastoma multiforme,http://purl.obolibrary.org/obo/DOID_3068,http://purl.obolibrary.org/obo/HP_0012174,http://www.orpha.net/ORDO/Orphanet_360,D005909,Q282142,,Q18555280
4011,[Lu-177]-DOTA-Tyr3-Octreotate,Treatment of gastro-entero-pancreatic neuroendocrine tumors,01/12/2009,Designated,,,gastro-entero-pancreatic neuroendocrine tumors,,,,,,,
4012,[met5]-enkephalin,Treatment of pancreatic cancer,01/24/2013,Designated,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
4013,[ÃŽÂ±Ã¢Â¿Â¿N-(2Ã¢Â¿Â¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[ÃŽÂµÃ¢Â¿Â¿N-(2Ã¢Â¿Â¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[ÃŽÂµÃ¢Â¿Â¿N-(2Ã¢Â¿Â¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,Treatment of breast cancer patients with brain metastases,04/15/2015,Designated,,,breast cancer patients with brain metastases,,,,,,,
4014,"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide",Treatment of ovarian cancer,04/10/2014,Designated,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
